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The incidence of cutaneous  melanoma continues to  rise  rapidly.  Problems are faced throughout 
its  management  and  this  thesis  addresses them  as  follows:  secondary  prevention,  prediction  of 
prognosis and early detection of metastatic disease.  Secondary prevention has been shown to be 
an  effective  strategy for improving  survival  in  other cancers.  A  study of the  rapid  access,  early 
detection,  pigmented  lesion  clinic  at  Mount  Vernon  Hospital  demonstrates  for the  first  time  that 
such an approach improves outcome in melanoma.
Refining  current  prognostic  capability  in  melanoma  is  essential  for  improving  disease 
management.  Tissue  microarray  was  used  to  investigate  480  specimens  from  120  primary 
melanomas  for  novel  prognostic  markers.  Several  markers  were  identified,  including  MCAM, 
CD44v3,  Nm23  and  P-cadherin,  which  showed  a  significant  bearing  on  melanoma  patient 
outcome.  Their identification reveals valuable markers for predicting outcome and potential targets 
for therapeutic manipulation.
Immunoscintigraphy  is  the  use  of  radiolabelled  tumour-specific  antibodies  to  detect  disease. 
Previously  the  whole  monoclonal  antibody  LHM2,  directed  against  the  high  molecular  weight 
melanoma-associated  antigen  was  studied.  Whilst  being  highly  melanoma-specific,  its  use  in 
melanoma  detection  is  limited.  Its  large  size  (150  kDa)  results  in  background  accumulation  in 
normal  organs,  reducing  image quality and  hindering  metastasis detection.  The  single chain  Fv 
fragment (scFv) is the smallest part of the whole monoclonal antibody that maintains full antigen- 
binding  capability.  Its  potential  superiority  over  whole  monoclonal  antibodies  has  been 
demonstrated; however it requires further refinement before routine use in patients.  Two methods 
of  improving  tumour  targeting  with  scFvs  were  investigated:  use  of  a  cocktail  of  scFvs  binding 
different  epitopes  and  use  of  scFv  multimers.  The  use  of  a  scFv  cocktail  improved  tumour 
targeting in the spleen and muscle.  Dimeric scFvs were shown to improve tumour retention whilst 
maintaining  rapid  blood  clearance,  leading  to  overall  improved  tumour  targeting  compared  with 
monomers.
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17CHAPTER 1
INTRODUCTION
18Melanoma  continues to present an  increasing  clinical  problem.  Dilemmas  are faced throughout 
the management of melanoma: prevention of the disease, early detection of melanoma, prediction 
of  prognosis,  treatment  of  the  primary  cutaneous  lesion  and  early  detection  and  treatment  of 
metastases.
1.1  THE CLINICAL PROBLEM
1.1.1  History
The earliest published case of melanoma was in 1787, when John Hunter reported a patient with a 
“cancerous, fungous excrescence”,  although  Hunter never described the disease as such.  Rene 
Laennec, the inventor of the stethoscope,  in  1806 was the first to describe the disease entity and 
six years  later  he  coined  the term  “melanosis”,  derived from  the  Greek word  for  black  (Davis  & 
McLeod, 1998).
The first case of melanoma in the English literature is that by William Norris in  1820.  He went on 
to write up a further eight cases in  1857 and can be credited as the first to associate a number of 
features with the disease, such as the association with a fair complexion, a high number of moles 
and  the  recognition  of  various  subtypes.  In  addition,  he  is  probably  the  earliest  advocate  of 
performing wide  local excision for the primary lesion.  Sir James  Paget (1853),  in  his  Lecture on 
Surgical Pathology, identified melanoma as “medullary cancers modified by the formation of black 
pigment  in  their  elemental  structures”.  Sir  Jonathon  Hutchinson  later  reported  on  subungual 
melanoma (1857) and the eponymous Hutchinson’s freckle (1892) (Davis & McLeod,  1998).
The basis of the management of melanoma in the whole of the first half of the last century relied 
on two Hunterian lectures delivered by William Handley in  1907.  On the basis of a single autopsy 
study  he  advocated  wide  local  excision  or  the  primary  lesion,  regional  node  dissection  and 
amputation in selected cases.  Thus it can be seen here that many of the observations made over 
a century ago are still of relevance in the current knowledge and management of melanoma today. 
However,  once  the  disease  had  spread  there  was  no  other  effective  treatment.  Searches  for 
adjuvant or neoadjuvant treatments have been pursued since the early part of the last century are 
still ongoing.
19Interest  in  the  detection,  evaluation  and  treatment  of  melanoma  and  other  cancers  using 
antibodies  has  increased  since  the  pioneering  work  of  Pressman  during  the  1940s  and  1950s 
(Pressman  &  Keighley,  1948;  Pressman  &  Korngold,  1953),  who  used  antibodies  as  carriers  of 
radionuclides.  He  used  1311   labelled  antibodies for the tumour targeting  of  osteogenic  sarcoma. 
Since  then  many  researchers  have  worked  on  improving  the  use  of  antibodies  as  mediators  of 
imaging or treatment modalities for a range of medical conditions.  However, one of the limitations 
endured was the limited production of antibodies with desired antigen specificity.
Then,  in  1975 George  Kohler and  Cesar Milstein of the  Medical  Research  Council  Laboratory of 
Molecular  Biology  in  Cambridge  described  a  way  for  making  cell  lines  that  secreted  a  single 
species  of  antibody  (monoclonal  antibody,  Mab)  with  the  desired  specificity  to  antigen  in  large 
amounts -   hybridoma  technology.  In  the  original  method,  a  mouse  was  immunised  repeatedly 
with  desired  antigen  and the  spleen,  containing  proliferating  B cells,  was  removed.  The  B cells 
were  then  immortalised  by  fusion  with  a  non-secreting  myeloma  cell,  resulting  in  a  hybridoma 
secreting  large  amounts  of  the  desired  antibody.  Supernatants  of  cell  lines  that  survived  the 
selection procedure were then tested for binding to the original antigen.  Alan Williams showed in 
1977 that monoclonal antibodies could be raised against biologically interesting molecules and this 
triggered the development of a stream of useful monoclonal-based diagnostic procedures.  It soon 
became  apparent  however that  rodent  monoclonal  antibodies  were  unsuitable  or  ineffective  for 
treating  humans  because  they  initiate  human  defence  systems  poorly  and  are  themselves  the 
target of an immune response that can greatly shorten their circulating half-life.  This problem was 
addressed  initially  by  using  human  lymphocytes  to  populate  severe  combined  immunodeficient 
(SCID)  mice.  These  mice  could  then  be  immunised  to  make  human  antibodies  (Mosier  et ai, 
1988).  However it was  not  until  1988 when  Skerra and  Pluckthun  developed the phage display 
strategy  for  antibody  production  that  this  problem  was  successfully  overcome.  This  will  be 
discussed in more detail in section 1.7.3.
1.1.2  Epidemiology
The incidence of cutaneous melanoma has continued to rise over the last 50 years (MacKie et ai, 
1997;  Severi  et al.,  2000;  MacKie  et ai, 2002)  (Figure  1.1.2.1).  It is now the  16th  most common 
cancer in the UK in  men and  18th  most common in women  (CRUK 2001).  Using a mathematical 
model,  it  was  predicted  to  become  the  6th   most  common  cancer  in  the  USA  in  the  year  2001
20(Greenlee et ai, 2001) -  due to lack of a national cancer registry in the USA the actual figures are 
not known.  Although arguments exist as to whether the observed increase in incidence is true, or 
whether it is a reflection of improving diagnosis, it is generally acknowledged that a real increase 
does exist (Jemal et a!., 2001).
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Figure 1.1.2.1  Incidence of primary cutaneous melanoma in Scotland 1979-1998 (Adapted from MacKie et 
al. 2002)
Rona  MacKie’s  group  (2002)  found  the  increasing  incidence  was  more  prevalent  in  men  than 
women and occurred in melanomas of all thicknesses in  men.  In women, the trend only seemed 
to be of melanomas thinner than  1.5mm  increasing  in  incidence.  Other studies’  results reflected 
these findings, with a substantial increase in the number of thick lesions in men and thin lesions in 
both  sexes  (MacLennan  et  al.,  1992;  Burton  &  Armstrong  1994).  The  number  of  new  cases 
diagnosed in the UK is illustrated in Figure 1.1.2.2.
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Figure 1.1.2.2  Number of new cases diagnosed and age specific rates per 100,000 population of 
melanoma, by sex, UK, 1999 (Source: Cancer Research UK website)
Overall  mortality from  melanoma  is also  rising;  however this  rise  is  mainly confined to  men  (La 
Vecchia  et al.,  1999;  MacKie  et al.,  2000),  which  would  be  predicted from  the  rising  number of 
thick  lesions  diagnosed  in  men.  Actuarial  survival  for  both  sexes  analysed  by  MacKie  (1997) 
showed a divergence in survival between the sexes (men fairing worse) during the first five years 
after diagnosis and treatment, this difference being maintained over the next five years.  They also 
clearly showed the  steady and continuing  death  rate from  melanoma during follow-up over 5-10 
years, confirming that survival to 5 years is not a guarantee of cure.  Recent UK mortality figures 
are illustrated below (figure 1.1.2.3).
Noting  the  variation  in  incidence  between  countries  (La  Vecchia  et  al.,  1999),  Severi  and  co­
workers  (2000),  using  melanoma  mortality  data  obtained  from  the  World  Health  Organisation 
Cancer  Mortality  Data  Bank,  analysed  the  mortality  trends  between  populations  in  different 
countries.  The overall increase in mortality from melanoma was more pronounced in the older age 
groups (60-79).  Downturns in  mortality,  essentially in women and starting with generations born 
just  before the  Second  World  War,  were found  in  Australia,  the  Nordic countries  and the  USA.
22Small decreases in rates were found in more recent generations in the UK and Canada.  However 
in  France,  Italy and the Czech  Republic mortality rates were still  increasing.  Their data suggests 
that populations are at different places on the melanoma mortality epidemic curve.  The three trend 
patterns observed being  in agreement with time differences between  populations with  respect to 
the promotion of sun protection and the surveillance of pigmented skin lesions.
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Figure 1.1.2.3  Number of deaths and age specific mortality rates per 100,000 population from melanoma, 
by sex, UK, 2001  (Source: Cancer Research UK website)
1.1.3  Aetiology
The process by which  melanocytes are transformed  into melanoma  lies in the interplay between 
genetic factors and the  ultraviolet (UV)  spectrum  of sunlight,  although  the  nature of this  relation 
remains unclear (Jhappan et ai, 2003).  The division of risk factors into genetic and environmental 
is  likely to  be  false,  in  that  multifactorial  genetic features  determine  response  to  environmental 
events,  such  as  severe  sunburn.  It  has  been  calculated  that  inappropriate  sun  exposure  is 
responsible for two thirds of all melanomas (MacKie, 2002).
23The  major genetic feature  increasing  melanoma susceptibility so far identified  is the  presence of 
mutations  of  the  CDKN2A  or  p16  gene  found  on  chromosome  9  (Goldstein  &  Tucker,  2001). 
Around 5% of melanoma patients have a family history of one or more first degree relatives also 
being  affected,  and  of  these  around  25%  have  had  mutations  identified  in  the  CDKN2A  gene. 
Other genetic defects have also been identified including mutations in the  CDK4 gene (Zuo et al., 
1996).
The  strongest  risk  factor  yet  identified  for  sporadic  melanoma  in  several  large  studies  is  the 
presence of large numbers of banal melanocytic naevi, with the presence of dysplastic or atypical 
naevi  as  an  additional  and  independent  risk  factor  (Swerdlow  et  al.,  1986;  Holly  et al.,  1987). 
MacKie et al.  (1989) developed a melanoma risk factor algorithm aimed at quantifying melanoma 
risk  in  patients without a family history.  In  descending  order of significance the  risk factors are: 
total number of banal naevi (less than 20 and 20 and over); degree of freckling; presence of none, 
one or two or three or more clinically atypical naevi; and a history of none, one or two, or three or 
more  episodes  of  blistering  sunburn.  In  addition  a  major  risk  factor  for  developing  a  primary 
melanoma  is  the  presence  of  a  previous  melanoma.  Once  one  primary  melanoma  has  been 
diagnosed the relative risk of a second primary is 70-fold compared with the risk of developing the 
first (MacKie, 2002).
Wallace Clark Jr divided the vertical growth  of melanoma  into 5 anatomic levels of invasion  and 
found these levels to correlate with disease outcome (Table 1.1.4) (Clark,  1969).  However,  it has 
now  been  established  that the  “Breslow thickness”  of the  tumour  in  millimetres  (Breslow,  1970) 
correlates more strongly with prognosis than the Clark’s levels (Balch et al., 2001a).
1.1.4  Prognostic factors
Level of Invasion  Layer of the skin
1   Above the basement membrane
5
2
3
4
Papillary dermis
Between papillary and reticular dermis 
Reticular dermis 
Subcutaneous tissue
Table 1.1.4  Wallace Clark Jr.’s levels of melanoma invasion (1969)
24Various  other  factors  have  since  been  found  to  correlate  with  tumour  progression.  The  most 
comprehensive  publication  to  date  has  analysed  the  various  proposed  prognostic  variables  in 
17,600  patients  resulting  in  the  largest  prognostic  factor  analysis  of  melanoma  ever  conducted 
(Balch  et  al.,  2001a).  The  results  of  this  study  demonstrated  that  the  two  most  powerful 
independent  characteristics  of  the  primary  melanoma  among  all  the  variables  analysed  were 
tumour thickness and ulceration.  Other statistically significant prognostic factors were patient age, 
site of the primary melanoma,  level of invasion  and  sex.  However,  once the  nodal status of the 
patient was taken into account, this became the most significant predictor and level of invasion and 
sex of the patient were no longer independent predictors of outcome.  Clark’s levels still do remain 
important, but only for tumours less than 1mm deep.  Interestingly, there still are patients with thin 
non-ulcerated melanomas who fair badly and those with thick melanomas who fair well  (Elder et 
al.,  1984;  Burton & Armstrong,  1994).  Clearly other factors come in to play in these situations.  If 
high-risk  patients  could  be  better  identified,  treatment  and  follow-up  regimes  could  be  more 
individually tailored.
1.1.5  Staging of patients
On the basis of the study of 17,600 patients from 13 centres,  Balch and co-workers published the 
Final Version of the American Joint Committee on Cancer  (AJCC) Staging System for Cutaneous 
Melanoma  in 2001  (Balch  et al., 2001b).  This was an  evidence-based  system that reflected the 
dominant prognostic factors consistently identified  in  Cox  multivariate  regression  analyses.  The 
actual  categories  and  groupings are  shown  in  Tables  1.1.5.1  and  1.1.5.2.  The  most  significant 
changes to the previous system are the inclusion of pathological staging of the patients by the use 
of sentinel  lymph  node  biopsy and the inclusion  of the presence or absence of ulceration of the 
primary tumour.
25T Classification Thickness Ulceration Status
T1 £ 1.0mm a: without ulceration and level I I/I 1 1  
b: with ulceration or level IV/V
T2 1.01-2.0mm a: without ulceration 
b: with ulceration
T3 2.01  -  4.0mm a: without ulceration 
b: with ulceration
T4 > 4.01mm a: without ulceration 
b: with ulceration
N Classification No. Metastatic Nodes Nodal Metastatic Mass
N1 1   node a: micrometastasis 
b: macrometastasis
N2 2-3 nodes a: micrometastasis 
b: macrometastasis 
c: in transit met(s)/satellite(s) without 
metastatic nodes
N3 4 or more metastatic 
nodes or matted nodes 
or in transit 
met(s)/satellite(s) with 
metastatic node(s)
M Classification Site Serum lactate dehydrogenase
M1a Distant skin, 
subcutaneous or nodal 
metastases
Normal
M1b Lung metastases Normal
M1c All other visceral 
metastases
Normal
Any distant metastasis Elevated
Table 1.1.5.1  Melanoma TNM classification (Adapted from Balch et al., 2001 (b))
26Clinical Staging Pathological staging 5-year survival rates
T N M T N M
0 Tis NO MO Tis NO MO -
IA T1a NO MO T1a NO MO 95%
IB T1b NO MO T1b NO MO 91%
T2a NO MO T2a NO MO 89%
IIA T2b NO MO T2b NO MO 77%
T3a NO MO T3a NO MO 79%
I IB T3b NO MO T3b NO MO 63%
T4a NO MO T4a NO MO 67%
IIC T4b NO MO T4b NO MO 45%
III Any T N1 MO
N2 J  There  are  no stage  III subgroups  for  clinical
N3 staging
IIIA T1-4a N1a MO 67%
T1-4a N2a MO 67%
I MB T1-4b N1a MO 52%
T1-4b N2a MO 52%
T1-4a N1b MO 54%
T1-4a N2b MO 54%
T1- N2c MO -
4a/b
me T1-4b N1b MO 24%
T1-4b N2b MO 24%
Any T N3 MO 23%
IV Any T Any N Any Any T Any N Any N/A
M1 M1
Table 1.1.5.2  Stage groupings for cutaneous melanoma (Adapted from Balch et al., 2001  (b))
271.2  PRIMARY MELANOMA
1.2.1  The growth of melanoma
Cutaneous  melanoma  usually  arises  in  the  epidermis,  where  it  may  be  confined  for  several 
months.  Herlyn  et al.  described  its  proliferation  in  the  epidermis  as  being  in  the  radial  growth 
phase  (Herlyn  et al.,  1987).  If  uninterrupted  by therapy the tumour may progress  into a vertical 
growth phase, whereby it invades the reticular dermis and even the subcutaneous fat (Clark et al., 
1969).  With  the  exception  of  nodular  melanoma,  which  does  not  show  any  significant  radial 
growth  pattern,  all types of melanoma appear to progress through  some degree of radial  growth 
before the vertical growth begins.  The vertical growth phase usually results in a nodule arising in 
the relatively flat radial growth phase lesion.
The radial growth phase represents the melanoma’s capacity for autonomous growth and invasion 
of the papillary dermis,  but not the capacity to metastasise.  The vertical growth  phase is said to 
result from a subpopulation of cells that has a growth advantage over the surrounding  cells,  and 
also possesses the potential to metastasise (Elder et al., 1984, Clark et al., 1989).
1.2.2  Subtypes of melanoma
1.2.2.1  Superficial Spreading Melanoma (SSM)
Superficial spreading  melanoma is the most common subtype of melanoma,  representing around 
70% of all melanomas (Langley et al.,  1998).  SSM frequently arise in a pre-existing naevus or a 
dysplastic  naevus  and  are found  most commonly  on  the  legs  of women  and  the  backs  of  men 
(Mihm et al.,  1975).  Early in their development, these melanomas are often flat or nearly flat, but 
as they become more invasive they may develop one or more nodules.
28Figure 1.2.2.1  Nodule arising within superficial spreading melanoma
1.2.2.2  Nodular Melanoma (NM)
Nodular  melanoma  comprises  10%  to  15%  of  all  melanomas  and  is  solely  made  up  of  cells 
showing  a  tumorigenic,  vertical  growth  pattern  (Langley  et al.,  1998).  It  generally  begins  as  a 
variably pigmented papule that grows rapidly to form a nodule. Because of the rapid growth, these 
lesions are often quite thick at the time of removal, hence have a poor prognosis. However, when 
controlled for thickness, survival is no worse than for other melanomas (Langley et al., 1998).
1.2.2.3  Lentigo Maligna Melanoma (LMM)
Lentigo  maligna  melanoma  was  described  by  Hutchinson  more  than  100  years  ago  and  is  still 
occasionally referred to as Hutchinson’s freckle. This type of melanoma represents about 10% of 
all melanomas. The term "lentigo maligna" is generally used to mean lentigo maligna melanoma in 
situ (confined within the epidermis). This form of melanoma usually  occurs  on the  most  chronically
sun-damaged skin,  usually the face, of older patients (mean  age  65  years).  The  lesion  begins as
an unevenly pigmented macule that slowly grows peripherally, often reaching several centimetres 
in  size.  These  lesions  tend  to  remain  non-invasive  for  a  prolonged  time,  often  many  years.  A 
papule may become apparent when the lesion becomes invasive.
291.2.2.4 Acral  Lentiginous Melanoma (ALM)
Acral  lentiginous melanoma is a distinct subtype of melanoma that arises on the hairless skin  of 
the palms and soles,  in and around the nails and on  mucosal  surfaces (oral,  nasal,  vaginal,  and 
anorectal). Of these, melanoma on the soles is the most common (Langley et al., 1998).  This form 
of  melanoma  is  uncommon  and  of  similar  incidence  in  all  racial  and  ethnic  groups,  but  is  the 
predominant form  in darker skinned  races.  ALM  usually occurs  in older patients  (60 years plus) 
and the survival of patients has traditionally been poor, but this is likely to be due to late diagnosis. 
Subungual melanoma is a rare form of cutaneous melanoma and is often classified as a variant of 
the acral lentiginous type.
Figure 1.2.2.4  a.  acral lentiginous melanoma on the sole of the foot;  b.  lentigo maligna melanoma on the 
cheek.
1.2.3  Problem diagnosis and diagnostic difficulties
Melanomas often present a diagnostic challenge.  In general, malignant pigmented lesions exhibit 
disorganised and chaotic pigment patterns, whereas benign pigmented lesions tend to show order 
in colour, symmetry,  regular borders and uniformity of surface characteristics (Mihm et al.,  1975). 
Important exceptions include small diameter,  amelanotic and  nodular melanomas.  Rona MacKie 
(1986) devised a seven point checklist to aid diagnosis, which has been revised by Du Vivier et al., 
(1991) and is shown  in table  1.2.3.  Lesions with any of the major features or three of the minor 
ones are suspicious of melanoma -  this gives a diagnostic accuracy of around 80% (Du Vivier et 
al., 1991).
a.
30Major Features Minor Features
Change in size 
Change in shape 
Irregular Colour
Largest diameter £ 7mm
Inflammation
Oozing
Change in sensation
Table 1.2.3  The revised 7-point checklist for melanoma diagnosis
1.2.3.1  The effect of early detection
Delays in diagnosis have been shown to result in thicker tumours (Temoshok et al., 1984, Ibbotson 
et al.,  1995).  Various strategies have been used in an attempt to reduce any delays incurred from 
the time of initial consultation to the time of diagnosis and excision of a suspicious lesion.  These 
have included the use of publicity campaigns to raise public awareness of the condition (Doherty & 
MacKie,  1986;  Cassileth  et  al.,  1988;  Rampen  et  al.,  1989)  to  the  existence  of  rapid  access 
pigmented  lesion clinics which have been shown to reduce the mean thickness of melanomas at 
time of presentation (Grover etal., 1996).
1.3.1  Histopathological features
The diagnosis of melanoma is made by the  presence of proliferating atypical  melanocytes along 
the  dermal-epidermal  junction  that  replace  the  basilar  region  and/or  display  a  pagetoid  spread 
within  the  epidermis  (melanoma  in-situ).  The  appearance  of  nests  or  aggregates  of  atypical 
melanocytes  in the  papillary dermis signals an  invasive pattern,  which  in  more advanced  stages
1.3  HISTOPATHOLOGY
31form expansile nodules in the dermis (Slominski  et al., 2001).  The most important determinant of 
prognosis  in  melanoma  is the type of growth:  in the  radial  growth  phase  melanoma  mitoses are 
frequently seen  in  the  epidermis  but  rarely  in  the dermis,  melanoma aggregates do  not become 
expansile and  an  inflammatory lymphocytic  response  is  present  in the  papillary dermis.  Vertical 
growth  phase  melanomas  histologically  show  small  expansile  cell  aggregates  in  the  papillary 
dermis different  in  nature to those exhibited  in the  radial  growth  phase.  They display increased 
cell numbers and occasional mitotic figures (Barnhill & Mihm Jr., 1998).
1.3.2  Histological parameters of prognostic significance in melanoma
Although many studies have been performed on prognostic modelling in melanoma no histological 
prognostic variable has yet been shown to have independent predictive value.  However, a number 
of variables have been reported to modify the predictive meaning of thickness in some databases: 
Clark  et al.,  (1989)  have  suggested  that  it  is the  phase  of tumour  growth  (i.e.  radial  or vertical 
growth)  that  is  more  important than thickness  itself,  although  this  has  not yet  been  validated  by 
other  studies.  It  has  been  proposed  that  histogenetic  subtype  of  tumour  bears  a  relation  to 
prognosis,  however  evidence  suggests  that  prognosis  in  melanoma  subtypes  may  largely  be 
attributed  to  differences  in  tumour  thickness.  For  example  good  prognosis  in  lentigo  maligna 
melanoma may be attributed to the fact that they are usually thin at the time of excision (Koh et al., 
1984).  Other histological factors implicated  in prognosis include:  evidence of tumour regression, 
tumour-infiltrating lymphocyte response and dermal mitotic activity (Carlson et al., 2003).
1.3.3  Immunohistochemistry and melanoma
A variety of immunohistochemical  markers may be used to aid the diagnosis of melanoma.  The 
S100  antigen  is  the  most  commonly  used  immunohistochemical  target,  with  a  high  sensitivity, 
found in almost all cases (Carlson et al., 2003).  However, S100 lacks sufficient specificity because 
it is also expressed in non-melanocytic cells.  Another marker, the HMB-45 melanosomal antigen, 
is  less  sensitive,  but  highly  specific  for  pigmented  cells  (Barnhill  &  Mihm  Jr.,  1998).  The 
melanosomal protein MART-1/Melan-A is a further promising agent for the diagnosis of melanoma 
(Hofbauer etal., 1998).
321.4  BIOLOGY OF MELANOMA METASTASIS
The  molecular  basis  of  human  melanoma  progression  and  the  changes  associated  with  the 
transition  of  melanoma  cells  from  the  radial  growth  phase  to  the  vertical  growth  phase  remain 
unclear.  The  production  of  metastases  depends  on  the  completion  of  a  complex,  multistep 
process  involving  the  survival  and  growth  of  a  unique  subpopulation  of  cells  with  metastatic 
properties (Fidler et aL,  1990).  At the core of this process lie the changing adhesive properties of 
the  tumour  cells,  which  dictate  their  interactions  with  the  surrounding  extracellular  matrix  and 
neighbouring cells.
During metastasis development cell-cell and cell-matrix interactions play a key functional role.  Cell 
adhesion  molecules  are  cell  surface  molecules  which  bind  specifically  to  other  cell  surface 
molecules  (ligands)  on another cell.  Structurally,  many different kinds of molecules can  mediate 
intercellular  adhesion,  but  the  majority  of  cell  adhesion  molecules  known  to  date  fall  into  three 
gene  families:  the  integrins,  the  cadherins  and  the  immunoglobulin  superfamily  (Chothia  et al.,
1997).  Adhesion  molecules  mediate various  interactions  and  modulation  of the expression  of a 
number of adhesion molecules has been associated with metastatic spread in melanoma (Natali et 
al.,  1991;  Bartolazzi  et al.,  1994; Xie etal.,  1997; Johnson,  1999; Christofori & Semb,  1999; Thies 
et al., 2002).
1.4.1  Interrelationships between cell adhesion molecules and their 
relationship to tumour progression
Cell  adhesion  molecules  do  not  simply function  as  a  molecular  glue  organising  cells  into  static 
structural  entities,  but  also  support  and  direct  the  exchange  of  information  between  cells 
(Klymkowsky  et  al.,  1995).  Adhesion  molecules  themselves  actively  participate  in  transducing 
signals  into  the  cells.  Observations  suggest  that  changes  in  the  adhesive  properties  of 
melanocytes and melanomas are involved in the upregulation of MCAM expression (Grimm et al.,
1995).  This will be discussed in detail in the introduction to chapter 4.
331.4.2  Biological prognostic markers for primary melanoma
Some  of  the  most  promising  molecular  markers  of  melanoma  prognosis  include  cell  cycle 
biomarkers  (Karjalainen  et  al.,  1998;  Korabiowska  et  al.,  2000;  Barzilai  et  al.,  1998), 
p16IN K 4a/CDK2NA  (Straume  et al.,  2000;  Straume  et al.,  2002),  MLSN-1  (Duncan  et al.,  2001), 
transcription factor activator protein (AP)-2 (Karjalainen etal.,  1998), matrix metalloprotein (MMP)- 
2  (Vaisanen  et al.,  1998),  DNA  content  (ploidy)  and  fractional  allelic  loss  analysis  (Healy  et al., 
1998;  Umebayashi  &  Otsuka  1997).  Other  independent  molecular  biomarkers  have  prognostic 
significance  in  subgroups  of  melanoma  patients  such  as  c-myc  gene  amplification  in  acral 
lentiginous  melanomas  (Grover  et al.,  1999).  In  addition,  melanomas  possess  a  repertoire  of 
biosynthetic  capacities  represented  by  the  production  of  hormones,  growth  factors  and  their 
receptors that may sustain and accelerate tumour development and progression (Slominski  et al.,
2001).
1.4.2.1  Cell cycle markers
Proliferative  activity  correlates  with  metastatic  potential  and  has  significant  prognostic  value  in 
several  cancers  (Quinn  &  Wright,  1990;  Cross  &  Start,  1996;  Tubiana  &  Courdi,  1989).  For 
melanoma,  five  out  of  eight  studies  on  large  melanoma  collectives  (>450  patients  with  5  years 
mean  follow-up)  have  demonstrated  a  significant  independent  relationship  between  increasing 
mitotic count and decreasing survival (Sondergaard & Schou,  1985;  Kopf et al.,  1987;  Drzewiecki 
et al.,  1990;  MacKie  et al.,  1995;  Barnhill  et al.,  1996;  Ostmeier et al.,  1999;  Retsas  et al., 2002; 
Vossaert  et al.,  1992).  Ki-67/MIB-1  index,  proliferating  nuclear  antigen  (PCNA)  and  others  are 
reliable and  widely used  methods of measuring  proliferative  index  (growth fraction)  (van  Diest  et 
al.,  1998)  and  have been  demonstrated to be  independent prognostic factors  (Karjalainen  et al., 
1998;  Korabiowska  et  al.,  2000;  Barzilai  et  al.,  1998).  Most  studies  in  melanoma  have 
demonstrated that the Ki-67 index is a useful prognostic biomarker for melanoma progression with 
decreased  overall  survival  and  risk for metastatic disease  (Straume  et al.,  2000;  Ramsay  et al., 
1995;  Korabiowska et al., 2000; Vogt et al.,  1997;  Boni  et al.,  1996;  Henrique et al., 2000; Tran et 
al., 1998).  However this correlation appears to be related to melanoma thickness because high Ki- 
67  index  in  melanomas thicker than  1.5mm  are at  risk for  metastases or death from  melanoma 
(Straume  et al.,  2000;  Ramsay  et al.,  1995;  Vogt  et al.,  1997;  Boni  et al.,  1996;  Henrique  et al., 
2000) but this is not the case for thin melanomas (Vogt et al., 1997; Boni et al., 1996).
341.4.2.2  p16IN K 4a
P16IN K 4a, also known as CDK2NA,  inhibits the ability of cyclin-dependent kinases (CDK)-4 and -6  
to activate critical substrates necessary for progression from G1  to the S-phase of the cell cycle 
(Castellano  &  Parmiani,  1999;  Maelandsmo  et al.,  1996;  Bartkova  et al.,  1996).  As  a  tumour 
suppressor  gene,  p16IN K 4a  appears  to  play  a  fundamental  role  in  melanoma  progression 
(Karjalainen, 2001;  Straume  et al., 2002), whereas aberrations (mutations,  homozygous deletion) 
involving  other  products  of  CDK2NA  locus  such  as  p14,  p15  and  p18,  are  extremely  rare  in 
melanoma cell  lines and sporadic melanomas (Castellano &  Parmiani,  1999).  Increasing  loss of 
p1giNK4a expression  is seen with  melanoma progression  (Straume  et al.,  2000;  Funk  et al.,  1998; 
Sparrow  et al.,  1998;  Reed  et al.,  1995;  Talve  et al.,  1997;  Pavey  et al.,  2002).  This  loss  of 
p10iNK4a  protein  expression  correlates  with  increased  cell  proliferation  (Ki-67  index),  advanced 
stage and metastases (Straume et al., 2000).
1.4.2.3  T  ranscription factor AP-2
The  transcription  factor  AP-2  is  a  52kDa  DNA-binding  protein  that  is  thought  to  inhibit  tumour 
growth through the activation of p21.  In a consecutive series of 369 stage I cutaneous melanoma 
patients, loss of AP-2 expression was significantly associated with  low p21  expression,  increased 
tumour  thickness,  high  TNM  category  and  recurrent  disease  (Karjalainen  et al.,  1998).  In  this 
study,  low  AP-2  index  was  an  important  predictor  of  both  recurrence-free  survival  and  overall 
survival.
1.4.2.4  MLSN-1
MLSN-1  is a member of a novel family of at least three distinct putative calcium channel proteins 
that  are  distantly  related  to  the  transient  receptor  (Trp)  calcium  channel  family  (Hunter  et  al., 
1998).  The regulation of intracellular calcium is widely used in biological signalling and appears to 
be a particularly important component of signalling pathways that affects cell cycle regulation and 
cell survival.  By in situ hybridisation techniques on  150 patients with localised melanoma, loss of 
MLSN-1  mRNA independently predicted poor survival (Duncan  et al., 2001).  However,  it has not 
yet  been  demonstrated  that  loss  of  MLSN-1  expression  is  necessary  for  the  acquisition  of 
metastatic potential during the progression of melanoma (Duncan et al., 2001).
351.4.2.5 MMP-2
Proteolytic  enzymes,  such  as  MMPs,  are  instrumental  in  the  degradation  of  extracellular matrix 
components and are crucial in the first step of invasion of normal tissues by cancer cells.  MMP-2, 
also  known  as  Type  4  collagenase,  is  suspected  of  augmenting  the  metastatic  capability  of 
melanoma  cells  by degrading  the  basement  zone  and  surrounding  tissues  (Ferrier  et al.,  1998; 
Vaisanen  et  al.,  1996).  Specifically,  MMP-2  expression  correlates  with  haematogenous 
metastases (Vaisanen  et al.,  1996)  but not tumour thickness  (Vaisanen  et al.,  1998) and in  male 
patients  particularly,  high  MMP-2  expression  independently  predicts  for  poor  5-year  survival 
(Vaisanen etal., 1998).
1.4.2.6  Chromosome analysis and DNA content
Gross  chromosomal  losses  and  gains  characterise  most  human  tumours  including  melanoma 
(Balaban  et  al.,  1986).  Melanoma  exhibits  non-random  chromosomal  break  points,  specific 
aneusomies or specific allelic imbalances and metastasis is suppressed by specific chromosomes, 
implicating  chromosomal  instability  in  melanoma  pathogenesis  (Bastian  et al.,  2000;  Balaban  et 
al., 1986; Nelson etal., 2000; Miele etal., 1996; Udart etal., 2001; Rao etal., 2003).  Furthermore, 
increasing fractional allelic loss correlates with  poor survival and  shortened  disease-free survival 
(Healy  et al.,  1998).  Similarly,  increasing  DNA  index  (aneuploidy)  predicts  for  both  decreased 
disease-free  survival  and  poor overall  survival  (Umebayashi  &  Otsuka,  1997;  Scheistroen  et al., 
1995; Kheir etal., 1988).
1.4.2.7  MIA and S-100B
Melanoma inhibitory activity (MIA) and S-100B are proteins, which can be measured in the serum 
of  melanoma  patients  to  estimate  disease  progression  or  recurrence.  MIA  is  an  11 kd  soluble 
protein, secreted by melanoma cells, that has been suggested to be predictive of disease relapse 
or response to chemotherapy in stage IV disease (Juergensen  et al., 2001).  Recently Martenson 
et  al.,  have  shown  the  independent  prognostic  value  of  serum  S-100B  as  a  marker,  which  is 
associated  with  clinical  stage  I  and  III  disease  (Martenson  et  al.,  2001).  Retsas  et  al.  have 
suggested that in metastatic melanoma S-100 might be a better prognostic factor than LDH, which 
is used in staging of the disease (Retsas et al., 2002).
361-  4.2.8  RT-PCR
Melanoma  antigens  recognised  by  T-cells-1  (MART-1)  and  tyrosinase,  a  key  enzyme  in 
melanogenesis, are specific for melanoma cells.  Circulating  melanoma cells positive for MART-1 
or tyrosinase  can  be  detected  by  reverse-transcriptase  polymerase  chain  reaction  (RT-PCR)  to 
predict disease progression and metastasis (Curry et al.,  1998; Quereux et al., 2001).  Hoon et al. 
utilised a multiple mRNA marker (MM) RT-PCR to detect micrometastases in sentinel lymph nodes 
or the presence of melanoma cells in cerebrospinal fluid to predict disease relapse or development 
of  central  nervous  system  metastases  (Bostick  et al.,  1999;  Hoon  et al.,  2001).  Furthermore 
Curry  et  al.  have  suggested  that  detection  of  MART-1  and  tyrosinase  positive  circulating 
melanoma cells by RT-PCR could help to identify subgroups of patients who develop disseminated 
disease or local recurrence (Curry et al., 1999).
1.4.2.8  Summary of prognostic factors
The  staging  and  survival  expectancy  of  primary  cutaneous  melanoma  is  principally  based  on 
tumour thickness and presence or lack of ulceration as well as on  lymph  node status.  However, 
there is no single biological marker that can reliably predict the outcome of primary melanoma.  As 
described,  a  wide  variety  of  biological  markers  have  been  investigated  and  shown  to  be  of 
importance  in  melanoma  development  and  progression.  However,  as  no  single  one  has  been 
shown  to  accurately  predict  outcome,  further  work  is  required  in  this  field,  including  further 
investigation of markers already studies and discovery of novel prognostic markers.
371.5  HMW-MAA
High-Molecular  Weight  Melanoma-Associated  Antigen  (HMW-MAA),  also  known  as  mCSP 
(melanoma-associated  chondroitin  sulphate  proteoglycan)  and  human  NG2  homologue,  is  an 
established  surface  proteoglycan  consisting  of two  non-covalently  associated  glycopolypeptides 
with molecular weights of 280 and 440 kDa (Wilson et al., 1981; Bumol et al., 1982). HMW-MAA is 
expressed on  cell  surface  microspikes thought to  be  involved  in  migration  and  contact  inhibition 
(Garrigues  et al.,  1986; Schlingemann  et al.,  1990).  It is detected in 80-90% of surgically excised 
melanomas (Buraggi  etal.,  1984; Giacomini etal.,  1984; Natali  et al.,  1984) and expressed in 80- 
100% of primary melanoma cell cultures (Herlyn  et al.,  1980;  Herlyn  et al.,  1985).  Its expression 
levels  in  melanoma  and  normal  tissues  have  been  well  characterised  (Reisfeld  et  al.,  1982). 
Monoclonal antibodies directed against HMW-MAA have been produced by hybridoma techniques 
(Reisfeld etal., 1987; Kupsch etal., 1995; Kupsch etal., 1999) and it has previously been used as 
a target for  radioimmunoscintigraphy and  immunotherapy  (Buraggi  et al.,  1985;  Mittelman  et al., 
1990;  Siccardi  et  al.,  1990).  HMW-MAA  interacts  with  the  extracellular  matrix  a4(31  integrin, 
collagen  V  and  VI,  plasminogen  and  its  fragments  such  as  angiostatin,  MT3  matrix 
metalloproteinase,  bFGF and intracellular signalling  molecules (Garrigues et al.,  1986;  lida et al., 
1998;  Eisenmann et al.,  1999; lida et al., 2001; Staub et al., 2002).  The protein appears to play a 
complex  biological  role  in  angiogenesis  and  cell  spreading,  tissue  invasion  and  metastasis 
formation  by  melanoma.  This  multifunctional  role  may  explain  its  very  limited  expression 
variability.
1.5.1  HMW-MAA Expression in Normal Tissues
Hellstrom  et al.  found  HMW-MAA to  be  expressed  on  cultured  melanocytes  but  not  on  normal 
epidermal melanocytes (Hellstrom et al., 1983).  They did, however, find it expressed at low levels 
on  some small  blood vessels or more specifically,  tumour neovasculature and  in  wound  healing, 
which  would  be  beneficial  for  tumour  targeting.  Guinea  pig  studies  have  shown  low  levels  of 
expression  in  hair  follicles,  sebaceous  glands,  some  basal  keratinocytes  and  several  non­
melanoma tumours  (Liao  et al.,  1987,  Godal  et al.,  1992;  Behm  et al.,  1996;  Smith  et al.,  1996; 
Schrappe  et al.,  1991).  A  minor degree  of  expression  on  human  basal  keratinocytes  has  also 
been reported (Kupsch et al.,  1995,1999). While these data show this antigen to be only relatively 
melanoma-specific,  cross  reactivity  with  normal  tissues  in  these  studies  has  been  very  low. 
Indeed,  Pluschke et al. demonstrated very little HMW-MAA expression  in  normal tissues by RNA
38blot (Pluschke  et al.,  1996).  A low level of binding to blood vessels is unlikely to interfere greatly 
with  melanoma  targeting.  These  data  therefore  suggest  that  a  radioimmunopharmaceutical 
directed  at  HMW-MAA will  bind to melanoma  in  a  reliable fashion  with  very  little cross-reactivity 
with normal tissues.
1.5.2  HMW-MAA Expression on Melanoma Cells
The  level  of  antigen  expression  relates  directly  to  its  efficacy  as  a  target  for 
radioimmunoscintigraphy by determining the amount of antibody that accumulates  in and around 
the tumour.  For  immunoscintigraphy to  be  successful,  uniformity  of  antigen  expression  within  a 
given tumour deposit would  not be absolutely  necessary,  as any “hotspot” would  be considered 
suspicious  and  warrant  further  investigation.  In  contrast,  uniformity  of  expression  would  be 
important for therapeutic studies where it is important to target as many tumour cells as possible.
Fortunately, the degree of antigenic expression for HMW-MAA in metastatic melanoma deposits is 
relatively low in comparison to other tumour-associated antigens (Natali  et al.,  1985;  Kageshita et 
al., 1991). There is also low heterogeneity of HMW-MAA expression in different deposits within the 
same individuals (Natali et al., 1985). The expression is also similar in both primary and metastatic 
cutaneous  melanomas  (Kageshita  et  al.,  1991),  with  the  exception  being  acral  lentiginous 
melanomas,  where  the  difference  in  expression  is  of  prognostic  significance  (Kageshita  et al., 
1992).
In vitro studies on the number of antigenic sites per cell have shown that HMW-MAA is present at 
levels  of  between  2x104  and  1.8x106  molecules  per  melanoma  cell  (Giacomini  et  al.,  1985; 
Shockley  et al.,  1990).  The  density of  HMW-MAA on  a  wide  variety of  both  cultured  melanoma 
cells  and  melanoma  specimens  is comparable to that of other  potential  target antigens  such  as 
p97 (5x104 to 5x106 molecules per melanoma cell) (Houghton et al.,  1992) and gangliosides GM2, 
GD2, GT3 and 9-0-Ac-GD3 (8x106 to 3x10® molecules per melanoma cell) (Hamilton etal.,  1993). 
These data suggest that a  radioimmunopharmaceutical directed at HMW-MAA should  be able to 
bind  melanoma  cells  in  sufficient  amounts  to  be  easily  detected  by  RIS.  This  has  been 
demonstrated  in  extensive  immunoscintigraphic  studies  targeting  HMW-MAA  in  melanoma 
patients (Buraggi etal., 1985; Lotze etal., 1986; Cerny etal.,  1987; Siccardi etal., 1990).
39Correlations have not been found between HMW-MAA staining and survival in for most melanoma 
subtypes (Natali  et al.,  1985; Odili, Thesis 2002), however one group found a correlation between 
its expression and prognosis in primary acral lentiginous melanomas (Kageshita et al.,  1993).  The 
expression of HMW-MAA has been shown to vary according to the stage of disease.  Siccardi  et 
al.  described  a  possible  down-regulation  of  antigen  expression  as  a  cause  for  sub-optimal 
immunoscintigraphic images obtained from patients with stage IV disease (Siccardi et al., 1990).
1.6  DIAGNOSIS OF METASTASES
The  ideal  method  of  detecting  recurrent  disease  would  be  highly  sensitive  and  specific,  whilst 
allowing whole body examination.  A thorough patient history and physical examination have been 
shown  to  be  more  effective  in  detecting  metastatic  disease  than  any  radiological  investigation 
(Weiss  et al.,  1995).  In a German cohort of 661  patients 74% of synchronous  metastases were 
first detected by clinical examination, which proved to be more sensitive than ultrasound and chest 
radiography  (Hofmann  et  al.,  2002).  Currently  the  routine  investigations  for  the  detection  and 
evaluation  of  secondaries  recommended  include:  chest  radiography,  liver  ultrasound,  computed 
tomography of the chest, abdomen and pelvis, lactate dehydrogenase levels and a full blood count 
(Roberts etal., 2002).
1.6.1  Lactate dehydrogenase (LDH)
Serum LDH has been included in the latest AJCC staging classification of melanoma (Balch et al., 
2001b).  It was found to be amongst the most predictive independent factors of diminished survival 
in all published studies when  it was analysed in a multivariate analysis,  even after accounting for 
the site and number of metastases.  Therefore, although not diagnostic of metastasis on its own, if 
elevated, patients with metastases are upstaged to M1c, regardless of the site of metastasis.
401.6.2  Chest radiography (CXR)
Chest x-ray is recommended for stage MB patients and above as a screening tool (Roberts et al., 
2002).  However,  in  the  Geman  study  by  Hofmann  et  al.  only  five  out  of  31  synchronous 
metastases  were  detected  by  CXR  (Hofmann  et al.,  2002).  In  another  study  (Terhune  et al.,
1998)  130  patients  had  a  suspicious  CXR  out  of  a  total  of  876  patients  with  clinically  localised 
melanoma.  Of these, only one had a pulmonary metastasis (0.1%).  These findings suggest that 
CXR is of little value in asymptomatic patients with clinically localised melanoma.
1.6.3  Ultrasound
Ultrasound  B-scan  (brightness-scan)  has  proved  to  be  a  useful  tool  in  the  detection  of  regional 
recurrent and  in-transit disease in melanoma patients (Voit  et al.,  2002).  It is a fast,  reliable and 
inexpensive staging investigation that may be performed regularly.  One advantage is the ability to 
combine  it  with  fine  needle  aspiration  cytology  of  a  suspect  lesion,  thus  obtaining  a  cytological 
sample (Basler et al.,  1997).  Ultrasound may also be used for the marking of metastases in stage 
III and IV patients with solitary lesions to facilitate subsequent surgical removal (Voit et al., 2001).
1.6.4  Computed Tomography
The UK guidelines for the management of cutaneous melanoma, published in 2002 (Roberts et al.,
2002)  suggest  CT  as  a  staging  investigation  for  any  patient  with  intermediate  or  high  risk  of 
recurrence,  i.e.  stage  MB or over.  At MD Anderson  Hospital,  in a group of patients most of who 
had  lesions deeper than  Clark’s  level  III,  17 out of  122  (14%)  CT  scans detected  subcutaneous 
metastases  (Shirkhoda  et  al.,  1987).  CT  is  usually  used  for  looking  for  regional  and  distant 
metastases,  offering  greater resolution than  ultrasound.  However,  high false positive  rates  have 
been reported in asymptomatic patients, suggesting the requirement for cytological confirmation of 
any lesions identified (Buzaid etal., 1995).
411.6.5  Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging avoids the exposure to ionising  radiation.  It produces superior soft 
tissue  resolution  than  CT  and  has  been  shown  to  distinguish  melanoma  from  other  tissues 
(Takahashi  et al.,  1992).  Its downfalls are  its  cost,  the  discomfort to the  patient and  its  lack  of 
availability.
1.6.6  Positron Emission Tomography (PET)
PET  is  a  non-invasive,  high  resolution  imaging  modality  that  is  aimed  at  detecting 
micrometastases  based  on  abnormal  cellular  metabolic  activity,  rather than  relying  on  structural 
changes.  It works on the basis that malignant cells  have a  higher  rate of  utilisation  of glucose 
than normal cells (Warburg et al.,  1930).  PET scanners have been developed that are capable of 
acquiring  whole-body  images  in  a  short timeframe,  combined  with  full  three-dimensional  image 
reconstruction.  Positron-emitting radiopharmaceuticals (commonly 18F-FDG) can be used to target 
malignancy at an early stage.  A review of the literature by Prichard et al. showed the sensitivity of 
PET  in  melanoma to  be  74-100% and  specificity to  be  67-100%  (Prichard  et al.,  2002).  These 
figures were better than CT or MRI for all body regions apart from the thorax.  However, 18F-FDG 
is  a  non-specific  metabolite  agent  that  reflects  increased  glucose  metabolism  and  increased 
anaerobic glycolysis regardless of the underlying cause.  It is therefore liable to high uptake in any 
cell  with  increased  glucose utilisation  or tissue oxygenation,  or when there  is  increased  regional 
blood flow or an inflammatory reaction (Wahl et al., 1990).  In addition, PET scanning is expensive, 
its availability is limited and  imaging is restricted by the size of tumour deposit, which must be at 
least  5mm  in  diameter  (Holder  et  al.,  1998).  It  also  provides  a  less  accurate  anatomical 
localisation  than  other  imaging  modalities  such  as  CT  and  typically  requires  follow-up  with 
conventional imaging.
1.6.7  Sentinel node biopsy
The popularity of sentinel node biopsy stems from the work of Alistair Cochran and Donald Morton 
(Cochran  et al.,  1989;  Morton  et al.,  1992).  It is a process whereby the first draining, or sentinel, 
lymph node from the site of a primary melanoma is removed and studied histopathologically for the 
presence of metastasis.  Should any metastases be present, the patient subsequently undergoes
42a full  lymph  node dissection  of the appropriate area.  No data  have yet shown this  procedure to 
confer any survival benefit.  This along with the associated morbidity of the procedure has resulted 
in  the  technique  not  yet  being  universally  accepted.  However,  it  has  proven  to  be  a  highly 
accurate  method  of  determining  prognosis  (Balch  et  al.,  2001b).  As  regional  metastases  are 
uncommon  in  early  melanoma,  the  procedure  is  not  recommended  until  patients  have  at  least 
stage II disease (Roberts etal., 2002).
Investigation
Advantages Disadvantages Cost (£)
Chest X-ray Cheap, widely Very low sensitivity £34 single film
available £51 multiple views
Ultrasound Widely available, fast, £85 single region
reliable £130 whole abdomen
Computerised Widely available, Low specificity £250 single region
Tomography (CT) sensitive £350
£80
whole body survey 
contrast + rescan
Magnetic Resonance Avoids ionising Expensive, not widely £400 single region
Imaging (MRI) radiation, sensitive available, £650 two or more regions
and relatively specific uncomfortable for 
patients
£100 contrast + rescan
Positron Emission Highly sensitive Not specific, expensive, £500 head
Tomography (PET) limited availability, 
tumours must be > 
5mm
£700 whole body survey
Bone scan Relatively sensitive Not specific, expensive, 
limited availability
£200 whole body survey
Lymphoscintigraphy Sensitive Limited availability, £120 single region
(LSG) non-specific
Immunoscintigraphy (ISG) Sensitive, specific Limited availability £200 single region
Table 1.5  Relative costs of imaging techniques (Costs include interpretation of the images by a radiologist. 
Costs are correct for February 2002. Prices courtesy of Department of Radiology and Department of Nuclear 
Medicine, Mount Vernon Hospital, Northwood, United Kingdom).
431.7  ANTIBODIES
1.7.1  Antibody structure
IgG antibody is a glycoprotein with a molecular weight of 150,000Daltons.  The molecule consists 
of  two  identical  heavy  chain-light  chain  heterodimers  linked  by  disulphide  bridges  to  form  a  Y- 
shaped structure (Figure 1.6.1).  Each heavy chain comprises one variable (V) and three constant 
immunoglobulin  (Ig)  domains,  whereas  light  chains  consist  of  a  single  variable  and  a  single 
constant Ig domain.  Each domain consists of about 110 amino acids.
Antigen binding sites
H = Heavy chain 
L = Light chain 
■  = Disulphide bonds
Figure 1.6.1  Diagram  of whole monoclonal  antibody  IgGi.  VL -  variable  light chain,  VH  -  variable heavy 
chain, CH  -  constant heavy chain.
From a functional perspective the important features are the antigen-binding site (Fab) and the Fc 
region (fragment crystallisable), which is responsible for initiating host-defence mechanisms.  The 
Fc  region  is the  stem  of the  Y-structure  and  the two  antigen  binding  sites  are  at the tip  of the
44outstretched  arms.  The  hinge  region  of the antibody  is flexible  so the  antigen-binding  sites  are 
widely and variably separated, permitting the linking of two identical antigens by the same antibody 
(the avidity effect).  The antigen-binding site  is formed  by the apposition  of two globular variable 
domains, one derived from the heavy chain (VH) and the other from the light chain (VL).  The folds 
of  each  of  the  V  domains  form  three  short  loops  of  amino-acids  -   the  hypervariable  loops  or 
complementarity determining regions (CDRs).
1.7.2  Chemical modification of monoclonal antibodies
1.7.2.1  Genetic modification of monoclonal antibodies
Recombinant  DNA  methodology  has  allowed  production  of  novel  antibody-derived  proteins. 
Antibody  genes  may  be  cut,  joined  to  other  genes,  mutated  randomly  or  non-randomly  and 
expressed  in  various  cell  types.  The  genes can  be  introduced  into  appropriate  plasmid  vectors 
and transfected  into other cells,  including  bacteria,  for protein expression.  Genetic manipulation 
has been used to overcome difficulties in producing human  monoclonal antibodies of the desired 
specificity and affinity.  The result was the production of chimeric antibodies: antibodies with rodent 
variable domains for antigen-binding and human constant regions for recruiting  effector functions 
(Neuberger  et al.,  1985).  Another strategy that has  been  used to  maintain the specificity of the 
rodent  antibody  is  that  of  CDR  grafting,  in  which  the  CDRs  are  transplanted  from  the  rodent 
antibody onto a human framework (Jones et al., 1986).
1.7.2.2  Antibody fusion proteins
Genetic engineering has been used to create chimeric molecules in which the variable domains of 
an  antibody  are  genetically  linked  to  an  unrelated  protein.  In  this  way  enzymes  or  toxins,  for 
example,  may be given  novel binding specificities and can  be produced  in bacteria (Gross  et al., 
1989).  The approach is made easier when the antibody moiety is expressed as a single chain Fv 
(scFv),  an antibody fragment with  variable,  but without constant domains  (see  below).  Previous 
work (Odili, Thesis 2002)  in our laboratory has  involved the fusion of a Staphylococcal  protein A 
molecule  onto  a  single  chain  Fv  antibody  fragment.  This  has  been  used  to  invoke  both  cell- 
mediated  and  antibody  mediated  cytotoxicity against  human  melanoma xenografts  in  nude mice 
(Joshi et al., 2003).
451.7.3  Phage display and antibody libraries
Genetic  engineering  using  antibody  phage  display  techniques  (Skerra  &  Plukthun,  1988)  has 
allowed  rapid  production  of  large  numbers  of  antigen-specific  phage  (McCafferty  et al.,  1990). 
Filamentous bacteriophage attach to the surface of bacteria and  inject their single-stranded  DNA 
through  the  bacterial  wall.  The  infected  bacterium  continues to  divide  distributing  copies  of the 
viral  DNA onto  its  progeny,  which  assemble and  extrude  perfect  replicas of the  infecting  phage. 
After  overnight  incubation,  one  millilitre  of  the  bacterial  culture  supernatant  contains  over  101 1  
progeny  phage  particles.  When  these  phage  DNA  are  used  to  infect  bacteria,  they  produce 
progeny phage particles that not only display the appropriated antibody but also contain a single 
copy of the antibody gene and are still able to infect bacteria almost as efficiently as  unmodified 
phage.  Antibodies displayed  on  the surface of phage are fully functional  and  will  still  bind their 
antigen  specifically.  Phage antibodies with the  desired  specificity can  be  isolated  from  a  mixed 
population because of their ability to bind antigen (McCafferty et al., 1990).
Phage  display  libraries  enable  the  whole  process  of  the  humoral  immune  system  (selection  of 
suitable antibody,  amplification  and affinity maturation)  to be  reproduced  In  vitro,  resulting  in the 
production  of  high  affinity  human  monoclonal  antibodies  and  their fragments  (Winter &  Milstein, 
1991; Chester et al.,  1994).  The bacteriophage with desired antigen reactivity are readily isolated 
by repeated  rounds of selection  using  immobilised antigen  (Clackson  et al.,  1991).  Kretzschmar 
and von  Ruden  have estimated that phage display has provided approximately 30% of all human 
antibodies now in development (Kretzschmar & von Ruden, 2002).
Verhaar et al. were the first to suggest that scFvs isolated by phage display are superior to scFvs 
constructed from Mabs for the in vivo targeting of tumours (Verhaar et al.,  1995).  This idea arose 
from  the  results  of  using  radiolabelled  phage  displayed-isolated  scFv  in  a  mouse  study,  which 
located  tumour  lesions  more  successfully  than  Mab-derived  scFvs.  Richard  Begent’s  group 
(Begent et al.,  1996) obtained better images using phage displayed-isolated scFv in patients than 
Larson  et  al.  with  a  Mab-derived  scFv,  suggesting  that  Verhaar  et  al.’s  mouse  data  might  be 
predictive for the image quality in  patients  (Larson  et al.,  1997).  More  recently,  we  have shown 
that light chain  shuffling  (Clackson  et al.,  1991;  Kang  et al.,  1991)  of a mouse Mab derived anti- 
HMA-MAA scFv can  result in  significant improvements of scFv yield and  melanoma  binding with 
retention of high melanoma specificity in vitro (Kupsch et al., 1995).
461.8  RADIOIMMUNOSCINTIGRAPHY
1.8.1  Introduction
Radio-immunoscintigraphy is the use of radiolabelled tumour-specific antibodies or their fragments 
to detect tumour.  The antibodies act as carriers of radionuclides that enable external  imaging  of 
disease throughout the body by gamma camera imaging  (Larson  et al.,  1984).  Melanoma seems 
ideally suited to antibody-mediated targeting as a number of melanoma antigens have been well 
characterised  (Carrel  et al.,  1980;  Houghton  et al.,  1982;  Reisfeld &  Ferrone,  1982;  Houghton  et 
al.,  1986;  Herlyn  &  Koprowski,  1988).  Monoclonal antibodies  (Mabs)  against melanoma antigens 
have been  labelled with  radioisotopes and shown to localise to melanoma in patients (Buraggi  et 
al.,  1984;  Carrasquillo  et  al.,  1984;  Buraggi,  1986).  The  majority  of  these  studies  used  Mabs 
directed  against  high  molecular  weight  melanoma-associated  proteoglycan  (HMW-MAA).  HMA- 
MAA is a well-characterised melanoma surface antigen with  limited expression  by normal tissues 
(Pluschke et al.,  1996;  Kupsch  etal.,  1999), and low heterogeneous expression between patients 
(Natali  et al.,  1985).  It  has  also  been  used  as a  target for  melanoma therapy  (Mittelman  et al., 
1995a).  It is expressed in up to 90% of cutaneous melanomas, and with similar frequency in both 
primary and metastatic lesions (Kageshita etal., 1991).
1.8.2  Melanoma as a target for RIS
There  are  several  rationales  for  using  RIS  to  image  melanoma  and  as  a  result  melanoma  has 
been the subject of numerous RIS studies in patients.  Metastatic lesions often go undetected by 
physical examination and conventional diagnostic means:  in one study 30% of patients developed 
metastases  despite  negative  findings  on  physical  examination  (Schmelter  et  al.,  1986).  The 
disseminated  distribution  of  metastatic  melanoma  makes  RIS  a  useful  adjunct  offering  a  more 
complete staging of patients before surgery than conventional  imaging and allows the location of 
disease outside the surgical field.  It can be used to identify patients who could benefit from further 
surgery (i.e.  regional lymph node dissection for nodal metastases, or hyperthermic isolated lymph 
node  perfusion  for  patients  with  in-transit  metastases)  or aggressive  biochemotherapy.  Further 
extension  of  radiolabelled  antibodies  towards  treatment  of  disease  would  offer  an  improved 
method of delivering  high doses of radiation to lesions throughout the body.  Finally in one study
47(Bender et al., 1997) it was found that patients who had undergone repeated imaging by means of 
RIS  almost  doubled  their  chances  of  survival  compared  with  patients  imaged  only  once, 
suggesting that RIS itself may have therapeutic potential.
1.8.3  Comparison with Other Imaging Modalities
Current investigations (CT,  MRI,  PET) are not specific for melanoma and biopsy remains the only 
definitive means of identifying the pathology of a lesion.  The sensitivity of  RIS  using anti-HMW- 
MAA  antibody  preparations  for  the  detection  of  known  metastasis  is  around  75%,  comparing 
favourably with standard diagnostic methods (Kang & Yong,  1998). RIS is able to survey the entire 
body  in  a  single  procedure,  detecting  around  25%  of  clinically  occult  metastasis  in  one  study 
(Siccardi etai, 1990).
Advantages  of  antibody-mediated  imaging  over  other  imaging  modalities  have  previously  been 
demonstrated  (Begent  et  al.,  1996).  Antibody  imaging  has  the  potential  to  exceed  the 
performance of CT and  MRI  scans,  because  it depends on  the contrast between  normal tissue, 
tumour and the amount of localised radionuclide and is not limited by size of deposit, whereas CT 
and MRI depend on the resolution of the imaging device.  CT scans also define abnormality based 
on size and site of the pathological lesion.  PET, like immunoscintigraphy provides little anatomic 
information but can be used to scan the entire body.  However, false positive rates with  PET are 
high, and this form of imaging cannot be used to detect microscopic deposits present in the early 
stages of the disease (Tyler et al., 2000).  High sensitivity in  imaging  is important when selecting 
patients  for appropriate  treatment,  as  chemotherapy  appears  to  confer  a  survival  benefit  if  it  is 
administered when tumour deposits are small (Moertel etai, 1994; Glimelius & Pahlman, 1992).
1.8.4  Clinical Experience
The  first  clinical  investigations  with  radiolabeiled  anti-melanoma  antibodies  were  conducted  by 
Larson  et  al.,  who  were  able to visualise  80%  of  lesions  larger than  1.5cm  in  six  patients  with 
metastases (Larson  et al.,  1983).  Siccardi et al.  undertook an  Italian  multicentre study analysing 
the efficacy of " m Tc-  and  1 1 1  In-labelled  F(ab’)2 fragments  reactive against  high  molecular weight 
melanoma  associated  antigen  to  radioimage  254  patients  with  known  melanoma  metastases 
(Siccardi etai, 1986).  Three hundred and seventy seven of the 412 known lesions were identified
48using RIS.  However an additional 127 previously occult lesions were also identified using RIS.  As 
well  as  demonstrating  the  potential  for  the  use  of  RIS  in  melanoma,  Siccardi’s  group  also 
confirmed the reliability of the technique between 10 nuclear medicine departments.
Later Siccardi  carried  out a  large  European  multicentre trial  (Siccardi  et al.,  1990),  in  which 493 
patients were investigated with the murine monoclonal antibody 225.28S recognising  HMW-MAA. 
A  total  of  728  lesions,  70%  including  123  previously  occult  metastases,  were  visualised  by 
radioimmunoscintigraphy.  About 70%  of the  lesions  not visualised  were  less than  2cm  in  size. 
Other radioimmunoscintigraphic studies that have been performed are summarised in table  1.8.4 
below.
Authors Number
patients
of  Sensitivity 
(%)
Specificity
(%)
Accuracy (%)
Siccardi etai. (1990) 493 79 96 84
Siccardi etai. (1986) 254 84 92 86
Feggi etai. (1993) 85a 83 99
Feggi etai. (1993) 50b 62 93
Eary etai. (1989) 27 81 100
Cerny et al. (1987) 25 59
Pyrhonen etai. (1990) 23 68 100
Murray et al. (1987) 21 60
Lamki etai. (1990) 20 79
Blend etai. (1992) 12 91
Larson etai. (1983) 6 80 100
Table  1.8.4  Summary  of  results  from  studies  on  radioimmunodetection  of  cutaneous  melanoma.  The 
performance characteristics of lesion detection. 
a Follow-up patients,b  pre-operative patients
Although  RIS  for  melanoma  appears  attractive,  its  routine  use  has  not yet  become  established 
because it has not yet been refined enough to be superior to existing imaging techniques such as 
PET.  A wide variation in overall sensitivity for melanoma metastases has been reported as shown 
in the table above.  Investigations have mainly focussed on two antigens, HMW-MAA (48 studies) 
and p97 (10 studies).  Sensitivity appears to be largely independent of the antigen studied.
491.8.5  Limitations of RIS with monoclonal antibodies
One  of  the  main  limitations  to  the  routine  use  of  RIS  for  metastatic  melanoma  is  non-specific 
accumulation  of  the  whole  monoclonal  antibody  (IgG)  in  normal  organs.  Binding  of  IgG  to  Fc 
receptors present on normal tissues is a factor resulting in non-specific accumulation (Herlyn et al., 
1983;  Buchegger  et al.,  1986;  Herlyn  et al.,  1986).  The  Fc  receptors  are  naturally  present  on 
macrophages (especially in the lungs, kidneys, and liver) as well as other cells involved in antibody 
metabolism and clearance (Carone etai., 1979; Mizoguchi,  1979; Sancho, 1984).  This results in a 
poorer contrast and reduces the efficacy of the technique.  Therefore, the detection of metastases 
in tissues with  high  non-specific accumulation  is  hampered  (Siccardi  et al.,  1990).  Non-specific 
accumulation would also  result in toxicity to tissues such as the kidneys,  should a toxic agent be 
attached to the antibody for therapy.
In addition, the relatively large size of whole monoclonal antibodies also  leads to long circulatory 
half-lives  and  prolonged antibody  retention  in  the  blood  (Adams,  1998c).  The  large  size  of the 
Mabs  molecules  can  hinder their circulation  into  extra-vascular tumour  sites  and  results  in  poor 
tumour penetration  (Juweid  et al.,  1992).  Clearance from  normal tissues  is slower,  especially  in 
blood-rich  organs  such  as the  liver,  spleen,  or kidneys,  reducing  the  contrast obtained  between 
tumour  and  normal  tissue  (Yokota  et  al.,  1992).  Therefore,  there  is  a  considerable  delay  in 
reaching  high  tumour  to  normal  tissue  ratios  of  antibody  concentration.  Reasonable  contrast 
would  take  6-7  days to  develop  (Siccardi  et al.,  1990)  and  is thus  incompatible  with  the  use  of 
" m Tc-labelling, with a half-life of 6 hours.
Monoclonal antibodies of murine origin elicit immune responses in  human subjects (Rosen  et al., 
1987; Schulz etai., 1988; Van Kroonenburgh etai., 1988).  Multiple administrations of murine Mab 
can result in the development of human-anti-mouse antibodies (HAMA) in > 90% of patients.  This 
results in the formation and deposition of immune complexes in normal tissues (lung, liver, spleen, 
kidney)  (Torres,  1993).  The  HAMA  response  frequently  results  in  the  accelerated  clearance  of 
Mabs from the  blood  (Dillman,  1994).  This  hampers  efficient tumour  localisation  and  limits the 
number of doses that can be administered.  Antibody fragments are less immunogenic (Reynold et 
al.,  1989)  and  the  production  of  humanised  Mabs  and  antibody  fragments  should  eliminate this 
problematic HAMA response characteristic of murine antibodies (Clackson  et al.,  1991; Winter et 
al.,  1994).  Antibody fragments have therefore formed the focal point for improving the tumour to 
normal tissue contrast in  melanoma antibody localisation  studies  (Kang  et al.,  1999,  Kang  et al., 
2000; Pacifico et al., 2003).
501.8.6  Antibody fragments
Antibody  fragments  similar  to  those  generated  by  proteolytic  cleavage  can  be  generated  from 
shortened versions of the heavy and light chains.  The modified genes can then be expressed in 
bacteria (Skerra & Pluckthun,  1988) to produce functional Fv or Fab, which is then easily purified. 
ScFvs are molecules in which the heavy and light chain  V domains are contiguously linked by a 
short peptide between the C-terminus of one V-domain of the Fv fragment and the N-terminus of 
the other that does not seriously affect antigen binding  (Figure  1.8.6).  The antibody can then be 
expressed as a single protein from a single gene rather than as two chains that must subsequently 
associate.  ScFvs  represent the  minimal  portion  of  an  antibody  that  can  still  retain  full  antigen 
binding.  The  scFv  is  a  continuous  polypeptide  molecule  of  approximately 28  kDa.  The  single 
stranded nature of the peptide facilitates production as recombinant protein and increases stability 
of the molecule in comparison to isolated Fvs lacking a linker peptide (Glockshuber etai., 1990).
ScFvs  have  several  further advantages  over their parent  monoclonal  antibodies  (Colcher  et al., 
1990,  Begent  et al.,  1996).  They  have  improved  tumour  penetration,  retain  specific  binding  to 
antigen but have very short half-lives in vivo due to their small size (Pluckthun et al., 1997; Adams 
et al., 1998a; Colcher et al., 1999).  The short residence time in the circulation and normal tissues 
results in good tumour to normal tissue ratios,  but simultaneously limits the maximum amount of 
scFv that can accumulate in the tumour.
Antigen binding site
Figure 1.8.6  Diagram of single chain (Fv) antibody fragment, demonstrating linker peptide between the  C- 
terminus of one V-domain and the N-terminus of the other.
511.8.7  Pharmacokinetics of scFvs
Colcher  et  al.  reported  the  first  pharmacokinetic  study  of  radiolabelled  anti-tumour  scFv  in  a 
tumour bearing immunodeficient mouse model (Colcher et al.,  1990).  They showed that the rapid 
elimination  of  scFv from  the  circulation  followed  a  biexponential  clearance  curve.  A  number  of 
other investigators have since confirmed this observation  (Adams  et al.,  1993;  King  et al.,  1994). 
The rapid elimination of scFv from the circulation facilitates high contrast imaging of radiolabelled 
scFv that remains bound to the target of choice.
1.8.8  Antibody Fragments in Immunoscintigraphy
Reduction  in  background  accumulation  and  improved tumour targeting  has  been  achieved  using 
scFvs  (Colcher  et al.,  1990;  Colcher  et al.,  1998).  The  lower  molecular weight  of  scFvs  allows 
rapid  plasma  clearance  and  improved  tumour  penetration,  resulting  in  higher  tumour-to-normal 
tissue ratios at early time points in vivo (Begent et al.,  1996).  The reasons for the faster dynamics 
are  not  clearly  understood  but  most  probably  relate  both  to  the  smaller  physical  size  of  the 
molecule and to the fact that they lack the Fc portion of the antibody, which promotes uptake and 
metabolism by phagocytic cells (Holliger etai., 1997).
The  problem of  immunogenicity  is  also  reduced  because  immunogenic  protein  domains that are 
not  required for antigen  binding  are absent.  The  human  anti-mouse  antibody  (HAMA)  response 
seen in 50% - 90% of patients administered whole immunoglobulin is reduced as these molecules 
lack the  highly immunogenic  Fc  portion  (Harwood  et al.,  1994;  Moffat  et al.,  1996).  This  HAMA 
response is a direct result of using mice as the hosts to produce Mabs.  It has been suggested that 
production of scFv fragments in bacteria may eliminate this problem altogether.
ScFvs  show  significantly  lower  background  accumulation  in  blood-rich  organs  but  high  renal 
accumulation remains.  The kidney is the principle organ of excretion, and the kidney accumulation 
is  consistent with  glomerular filtration  and  reabsorption  of  scFv  in  the  renal  tubules,  which  is  a 
common  problem  with  proteins  of  similar  molecular  size  (Takakura  et al.,  1990).  Renal  uptake 
does  not  appear  to  interfere  with  tumour  imaging  in  patients  but  would  limit  the  capability  of 
detecting small tumours near the kidney (Begent et al.,  1996).
52In  terms  of  overall  toxicity,  scFvs  are  well  tolerated  in  patients  after  injection.  In  a  clinical  trial 
using  123l-labelled scFv antibody to carcinoembryonic antigen  (CEA)  no serious side effects were 
seen  (Begent  et al.,  1996).  One out of nine patients suffered  hot flushes starting  six hours after 
the  injection  and  lasting  one  hour.  No adverse effects were observed  when  using the Common 
Toxicity Criteria (Operation  Manual, CRC 1986).  In particular there was no evidence of toxicity to 
the  kidneys,  liver  or  bone  marrow,  which  were  the  tissues  exposed  to  the  highest  doses  of 
radioactivity.  Other patient trials have supported this evidence (Mayer et al., 2000).  This contrasts 
with  Mab  therapies  such  as  Mylotarg,  associated  with  relatively  high  incidences  of 
myelosuppression,  hyperbilirubinaemia  and  elevated  hepatic  transaminases  (Sievers  et  al., 
2001a).  A  post-infusion  syndrome  of  fevers  and  chills  was  observed  in  two  thirds  of  patients 
treated with Mylotarg (Sievers etai., 2001b).
1.8.9  Strategies to improve targeting
1.8.9.1  Increasing the dose
Adams  et al.  (1995)  studied  the  intravenous  administration  of  radioiodinated  scFv at  a  range  of 
doses.  The  scFv  bound  in  a  dose-dependent  manner,  but  at  4  and  24  hours  both  doses  gave 
proportionately similar levels of binding, relative to the amount injected.  These results implied that 
injecting large doses at high concentrations could counteract the rapidity of scFv clearance.
1.8.9.2  Use of Multimers
ScFvs  show  rapid  blood  clearance,  excellent  tumour  penetration,  possible  reduced 
immunogenicity and higher tumour-to-normal tissue ratios (except in the kidneys).  However due to 
their  small  size  and  monovalency,  they  clear the  body too  rapidly to  allow for  sufficient tumour 
uptake  and  retention  for  optimal  imaging  and  therapeutic  applications  (Larson  et  al.,  1997; 
Pavlinkova  et  al.,  1999).  Multimerisation  has  been  explored  as  an approach for  increasing  size
and  valency,  two  factors  that  enhance  tumour  targeting.  Higher  molecular  weight fragments
exhibit extended persistence in the serum, resulting in longer availability for binding to tumour cells 
(Goel  et al., 2001).  Increased antibody valency results in an  ‘avidity’  effect,  leading to increased 
retention of antibody by the tumour, thereby improving tumour targeting (Pluckthun etai., 1997).
Recombinant  fragments  with  two  or  more  binding  sites  have  been  made  in  several  ways,  for 
example:  by chemical cross-linking  hinge cysteine  residues (Shalaby  et al.,  1992),  by including a
53C-terminal  peptide that  promotes dimerisation  (Pack  &  Pluckthun,  1992)  or  by varying  the  linker 
length  (Holliger et al.,  1993).  Studies have shown  increasing the valency of the scFv to  improve 
targeting  (Wu  et al.,  1996)  however this  is at the expense  of  increasing  the  size  of the  resultant 
molecule.  The  scFvs  are then  expressed  as  dimers  in  eukaryotic  cells  (FitzGerald  et al.,  1997; 
Pluckthun  et  al.,  1997)  or  produced  as  monomer  in  E.  coli  prior  to  dimerisation  in  vitro 
(Glockshuber et al.,  1990;  Cumber et al.,  1992;  Kipriyanov et al.,  1994).  The dimeric molecule is 
relatively  flexible,  mimics  the  avidity  of  a  whole  monoclonal  antibody  yet  maintains  a  relatively 
small size (~56kDa) (Adams etai., 1993; McCartney et al., 1995).
1.8.9.3  Use of a cocktail of antibodies to different antigenic epitopes
Antibody cocktails have been tested in human melanoma-bearing nude mice and produced a slight 
increase in the specific tracer localisation in melanoma lesions compared with injection of a single 
antibody  (Matzku  et  al.,  1989).  Wahl  et  al.  evaluated  a  lymphoscintigraphic  approach  by 
administering a cocktail of two 1 3 1  l-iabelled monoclonal antibodies to melanoma antigens at the site 
of  the  primary  lesion,  or  its  post-operative  scar  in  11  patients  with  stage  I  or  II  disease, 
demonstrating the potential usefulness of the method (Wahl etai., 1990).
1.8.9.4  Tumour targeting Efficiency
A number of strategies have been shown to affect the efficiency of in vivo tumour targeting.  These 
include affinity,  valency  (avidity),  ko ff,  and antigen  expression  levels  (Adams  et al.,  1999).  Other 
parameters  that  could  be  equally  important  include  the  mouse  model  (tumour  size,  site  of 
implantation),  route  of  antibody  administration,  radiolabelling  method,  in  vivo  stability  of  the 
radiolabel and the antibody itself, or the nature of the target antigen (Adams,  1998c).  It is possible 
that more than one factor could determine the efficiency of in  vivo tumour targeting  in a complex 
manner.  If  this  were  the  case  then  a  single,  generally  applicable  strategy  for  efficient  tumour 
targeting  may  not  exist.  The  importance  of  scFv  thermal  stability  for  the  efficiency  of  in  vivo 
tumour targeting  has  been  demonstrated  in  a  recent  study  (Willuda  et al.,  1999).  The  authors 
showed  a  clear  advantage  in  tumour  targeting  of  two  thermally  stabilised  anti-EGP-2  scFvs  in 
comparison  with  its  parent  scFv  in  spite  of virtually  identical  affinities.  Several  previous  studies 
have considered the  effect of affinity on targeting  but there  is  still  considerable  debate as to the 
impact of affinity maturation (Adams et al.,  1998a; Adams et al.,  1999; Schier et al.,  1996; Nielsen 
et al., 2000).
541.9  MELANOMA THERAPY
1.9.1  Traditional therapies
1.9.1.1  Surgery
Surgery  has  remained  the  mainstay  of  treatment  for  primary  melanoma  since  Hunter’s  day 
(Bodenham,  1968;  Ross  &  Balch,  1998).  The  procedure  involves  en  bloc  removal  of the  entire 
tumour  with  a  margin  of  normal  skin  and  subcutaneous  tissue.  Further  wider  excision  is  then 
carried out depending on the Breslow depth of the tumour (Roberts et al., 2002).  Varying the width 
of excision margins has been shown to effect local disease recurrence however has no impact on 
survival  (Veronesi  et  al.,  1988;  Balch  et  al.,  1993;  Ng  et  al.,  2001;  Lens  et  al.,  2002).  Early 
excision of the primary lesion is the only treatment that is capable of achieving cure (Balch  et al., 
2001a).
Surgical  resection  with  a  generous  margin  may  be  carried  out  for  local  recurrence.  It  is  the 
simplest and most effective form of therapy for local recurrence (Karakousis et al.,  1998).  Lymph 
node  dissection  is  performed  after  a  positive  sentinel  lymph  node  biopsy  or  when  clinically  or 
radiologically detected nodes are found (Balch et al., 1998).
1.9.1.2  Chemotherapy
Melanoma metastases do not respond well to chemotherapies.  Trials are continuously underway 
to seek  novel  agents  or combination  drugs  that  improve  both  survival  and  disease-free  interval. 
Dacarbazine  (DTIC)  is the  most active  single  agent  used  in  patients  with  metastatic  melanoma, 
inducing  a  partial  response  in  <20% of  patients and  a  complete  response  in  <5%  (Legha  et al.,
1996).  Responses however, are usually short-lived,  ranging from 3 to 6 months, although longer- 
term  remission can  occur in  a limited  number of patients who attain  a complete  response.  Multi­
drug regimens containing DTIC have produced higher partial  response rates (20-45%) and similar 
complete response rates than other agents, but none have proven superior to DTIC alone (Legha 
etai., 1989; McClay etai., 1992; Legha etai., 1996).
551.9.1.3  Radiotherapy
Melanoma is a  relatively radio-resistant tumour but palliative  radiation  may alleviate symptoms in 
some patients.  Radiotherapy may also be the treatment of choice for patients who are not surgical 
candidates,  either because of the size or location  of the metastases or other physical  limitations. 
Retrospective studies  have shown that patients with  multiple  brain  metastases,  bone  metastases 
and spinal cord compression may achieve symptom relief and some shrinkage of the tumour with 
radiation  therapy  (Rate  et al.,  1988;  Herbert  et al.,  1991).  The  most  effective  dose-fractionation 
schedule for palliation of melanoma metastasis to bone or spinal cord is unknown,  but high-dose- 
per-fractionation schedules are sometimes used to overcome tumour resistance.
1.9.1.4  Biological Therapies
Work by Kirkwood  et al.  has demonstrated that high  dose alfa-2b  interferon  may improve overall 
survival  in  melanoma  (Kirkwood  et al.,  1996,  2001).  Other studies  have contradicted  Kirkwood’s 
results (Cascinelli  et al., 2001),  even when combining  interferon with chemotherapy (Proebstle  et 
al.,  1998).  Unfortunately  interferon  treatment  is  associated  with  significant  side  effects  and  a 
considerable  proportion  of  patients  who  are  started  on  the  treatment  withdraw  for  this  reason 
(Kirkwood etai., 2001; Cascinelli etai., 2001).
1.9.2  Experimental Therapies
1.9.2.1  Vaccines
The  poor  response  to  chemotherapy  and  the  toxicities  associated  with  biologic  therapy  have 
directed treatment towards forms of immunotherapy with fewer side effects.  Melanoma is the most 
immunogenic  solid  tumour  making  it  an  ideal  target  for  specific  immunotherapy  (Herlyn  et  al., 
1988).  Laboratory  studies  show that  blood from  melanoma  patients contains  antibodies  against 
tumour antigens (Morton  et al.,  1968;  Morton  et al.,  1970) as well as cytotoxic T-lymphocytes that 
can  destroy  melanoma  cells  in  vitro  (Mukherji  et  al.,  1990).  Between  3-15%  of  all  cutaneous 
melanoma are first diagnosed as  lymphatic or visceral  metastases without evidence of a primary 
tumour, suggesting that the immune system may have induced complete regression of the primary 
lesion (Morton etai., 1991).
56Experience with vaccines in melanoma is limited to early clinical trials. Several phase II trials have 
shown  enhanced  disease-free  and  overall  survival  of  patients  who  develop  a  humoral  and/or 
cellular response to a melanoma vaccine but this has not been shown for phase III trials (Ollila et 
al.,  1998b). Two randomised immunotherapy trials with tumour cell-based vaccines failed to show 
a  significant  impact  on  disease-free  survival  (DFS)  or  overall  survival  (OS)  (Eggermont  et  al., 
2000).  A trial  using  GM-CSF  in  stage  II  and  III  melanoma  patients  demonstrated  a  prolonged 
disease-free  survival  compared  with  historical  matched  controls  (Spitler  et al.,  2000).  Only  one 
patient  experienced  side  effects  and  that  was  at  the  injection  site,  suggesting  this  as  a  safe 
therapy suitable for further evaluation in a prospective randomised controlled clinical trial.
Early results combining cytoreductive surgery with CancerVax vaccine (against melanoma) appear 
to  show a  survival  benefit when  compared to  patients  undergoing  surgery alone  or surgery plus 
alternative adjuvant therapy (Morton etai., 1993b; Jones etai., 1996; Morton etai.,  1996; Hsueh et 
al.,  1998).  Resection  of  visible  tumour  masses  is  required  to  remove  the  cells  producing 
immunosuppressive  factors,  thereby allowing  the  vaccine  to  be  effective.  This  suggests  that for 
treatment  of  solid  neoplasms  a  combined  modality  approach  to  metastatic  disease  may  be  the 
best option. However, detection of micrometastases for vaccine therapy holds the most promise.
1.9.2.2  Monoclonal Antibodies and Antibody Fragments in Melanoma Therapy
Antibodies  can  selectively  target  tumour  cells  in  patients,  and  a  number  of  Mabs  are  currently 
tested in advanced clinical trials (Scott et al., 2001;  Phan et al., 2003; Bettinotti et al., 2003), whilst 
some  have  been  approved  for  use  in  cancer  therapy  (Anderson  et  al.,  1997).  Dillman  et  al. 
administered  anti-melanoma  antibodies  producing  regression:  four  of  the  twenty-one  patients 
treated with the anti-GD3 Mab, R24, had objective responses at a variety of dose levels in a phase 
I  trial  (Dillman  et  al.,  1994).  Toxicity  included  pruritis  and  urticaria.  Mittleman  et  al.  used 
antiidiotype  antibodies  that  mirror  the  HMW-MAA  antigen  and  demonstrated  the  induction  of 
endogenous  human  HMW-MAA  antibodies  and  some  tumour  responses  and  improved  patient 
survival  (Mittleman  et al.,  1990).  In  a  later  study,  the  development  of  anti-HMW-MAA  immunity 
preceded  the  reduction  in  the  size  of  metastatic  lesions  suggesting  that  the  anti-HMW-MAA 
immunity  elicited  has  a  beneficial  effect  on  the  clinical  course  of  the  disease  in  patients  with 
melanoma (Mittelman et al., 1994)
57Single  chain  Fv  antibody  fragments  have  also  been  used  for  immunotherapy,  often  used  as 
bispecific scFvs (dual function scFvs, such that one arm of the scFv recognises the tumour whilst 
the  other arm  recognises  either an  effector cell  or a toxic  molecule).  A  number  of  studies  have 
demonstrated  the  ability  of  bispecific  fragments  to  accurate  localise  to  tumours  and  result  in 
tumour destruction (Holliger etai, 1997).
581.10  AIMS
As outlined previously in this introductory chapter, problems are faced in melanoma throughout the 
course  of  the  disease:  from  initial  prevention  and  early  diagnosis  to  the  treatment  of  metastatic 
disease.  Advancements in understanding at any stage of the disease process will be of benefit to 
melanoma  patients.  Bearing  this  in  mind,  this  thesis  aims  to  address  several  of  the  dilemmas 
faced  in  improving  patient  outcome  in  melanoma.  It  deals  with  secondary  prevention  (early 
detection),  estimation  of prognosis and  early detection  of  metastases.  The thesis  is divided  into 
four results chapters.  The aims for each are as follows:
To establish whether an early detection strategy is effective in improving outcome for 
melanoma patients.  Does an early detection clinic lead to better patient survival and disease 
control?
To discover novel prognostic markers for the outcome of primary melanoma with the use of a 
tissue microarray.
To improve targeting of melanoma xenograft-bearing nude mice using a cocktail of single 
chain (Fv) antibody fragments.
•  To determine the improvement in tumour targeting by using single chain (Fv) antibody 
fragment multimers.
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MATERIALS AND METHODS
602.1  MOLECULAR BIOLOGY TECHNIQUES
Unless  otherwise  specified,  all  “standard  methods”,  “established  techniques”  or  “standard 
formulations”  referred  to  in  sections  2.1  and  2.2  were  obtained  from  “Molecular  Cloning:  A 
Laboratory  Manual”  (Sambrook,  1989).  Unless  otherwise  specified,  all  “standard  methods”, 
“established  techniques”  or  “standard  formulations”  referred  to  in  subsequent  sections  were 
obtained from “Antibodies: A Laboratory Manual” (Harlow,  1988).
2.1.1  Bacteria Culture Media
Luria Broth (LB) base (GibcoBRL) was used for all bacterial culture.  25g of broth base was added 
per litre of distilled H20 and autoclaved at 15psi,  120°C for >20 minutes before use.
2.1.2  Technique of Bacterial Culture
Transformed bacteria were stored as glycerol  stocks at -80°C  (500|jl  bacterial  culture with  500|JI 
sterile glycerol  (BDH)).  All  scFvs were isolated from  secreted  proteins  in  bacterial  supernatants. 
For bacterial cultures, the glycerol stocks were stab-sampled with a sterile pipette tip.  The pipette 
tip was ejected into a 50ml polypropylene tube containing  10 - 20mls of LB media + 1  ml  10Opg/ml 
ampicillin  (Boeringer  Mannheim)  +  10mls  40%  D-glucose  (LBG A )  for  large-scale  cultures  (1.5ml 
LBG a for small-scale cultures).  The inoculated culture was placed overnight in a  rotary shaker at 
30°C  and  250rpm.  Temperatures  above  this  resulted  in  poor  bacterial  growth  and  scFv 
expression.
The following  morning  the  overnight  cultures  (ONCs)  were  diluted  1/100  in  LBG a  and  shaken  at 
250rpm for 6 hours at 30°C to an ODeoo of approximately 1.5.  Large-scale inductions involved a 11  
culture produced from 10 - 20ml ONC.  For induction of scFv expression, all bacteria were cultured 
in  LB  media  +  1ml  ampicillin  (100pg/ml)  with  50mls  40%  D-glucose  +  isopropyl-thio-galactoside 
(IPTG)  (LB|A ).  Optimum  conditions  for  induction  of  individual  scFvs  in  large  and  small-scale 
bacterial  culture  have  been  determined  empirically  (Kang,  MD  thesis  1997;  Gundogdu, 
unpublished).
61At  6-8  hours the  cells  were  spun  down  (5000  rpm,  18  minutes)  and  the  supernatant  discarded. 
The  bacteria were  resuspended  in  1-31  of  LB with  1ml  100pg/ml  ampicillin  and  100pM  IPTG  per 
litre.  2.5I  baffled  flask(s)  each  containing  11  broth  were  used.  Cultures  were  then  shaken 
overnight (16-18 hours) at 30°C and 250 rpm.  Further purification was required before subsequent 
use.
2.2  PROTEIN PURIFICATION TECHNIQUES
2.2.1  Storage of Bacterial Clones
As  stated  above,  all  bacterial  clones  were  stored  at  -80°C  as  glycerol  stocks.  500pl  of  an 
overnight  bacterial  culture  was  mixed  with  500pl  of  sterile  glycerol,  vortexed  briefly to  mix,  then 
stored in a Cryovial™ (Nalgene) at -80°C.
2.2.2  Preparation of Bacterial Supernatants
All  the  scFvs were  purified from  bacterial  supernatants.  After a  standard  induction  (see above), 
the cultures were centrifuged at 10,000 rpm (Beckman centrifuge, JLA 10-500 rotor) for 27 minutes 
at  4°C  and  the  supernatant  filtered  (0.2pm  filter  -   Nalgene).  Sodium  azide  (NaN3  0.05%),  a 
bacteriostatic  agent,  was  added  to  the  bacterial  supernatant.  200pM  phenyl-methyl-sulphonyl- 
fluoride (PMSF)  was also added to  reduce proteolysis.  All  supernatants were then  concentrated 
before use (see below).
2.2.3  Protein Concentration
In order to  improve the  recovery of scFv from the  supernatant,  ultrafiltration was  used to  reduce 
the volume  of the supernatants.  This was  achieved  by  using  a  Mini-Ultrasette™ tangential flow 
device  (Filtron)  with  a  10kDa  molecular  weight  cut-off  to  prevent  loss  of  scFv  through  the 
membrane.  The  Mini-Ultrasette™  filter  was  set  up  and  used  according  to  the  manufacturer’s
62instructions.  Using this system the bacterial supernatant was concentrated to a volume of around 
100mls.
2.2.4  Dialysis
The supernatant was transferred to a length of dialysis  membrane tubing,  which was clamped at 
each  end.  The  dialysis  membrane  was  immersed  in  21  PBS  overnight at  4°C,  to  remove  small 
molecular particles from the hypertonic supernatant.
2.2.5  Biologic LP Platform for Column Chromatography
All  liquid  chromatography  was  carried  out  using  a  Biologic  LP  Chromatography  Platform™  (Bio- 
Rad).  This  equipment  included  a  programmable  peristaltic  pump  and  fraction  collector, 
conductivity,  UV  absorbance  meters  and  an  electronic  mixer valve  for  accurate  proportioning  of 
reagents.  All purifications were carried out at room temperature.
2.2.6  Purification of scFvs by Immobilised Metal-ion Affinity 
Chromatography (IMAC)
A  poly-histidine  oligopeptide  (6  histidine  residues)  has  a  high  affinity  for  certain  metal  ions 
including  Zn2+,  Cu2+ and  Ni2+.  Proteins  incorporating  a  poly-histidine  sequence can  therefore  be 
affinity  purified  by  selective  binding  to  metal  ions  immobilised  on  a  solid  medium  (IMAC).  The 
development  of  His-trap  gels  (Amersham  Pharmacia  Biotech)  able  to  chelate  metal  ions  has 
enabled  the  purification  of  numerous  proteins  including  scFv,  in  a  column  system  based  on  this 
principle (Casey 1995).
Three  pre-packed  His-trap  columns  arranged  in  series  were  used  according  to  manufacturer’s 
instructions.  They were washed with distilled water to remove storage buffer.  1  ml of 0.1 M CuS04 
(BDH)  in  distilled  H20   was  loaded  onto  the  top  column  at  1ml/min.  The  top  column  was  then 
washed with distilled H20  to remove any unbound Cu2+.  This was then reconnected to the rest of 
the His-trap columns.  40mls of start buffer was then run through the column.
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Figure 2.2.6  Three pre-packed His trap columns arranged in series
0.5M  sodium  chloride  and  0.01 M  imidazole  were  added  to  the  dialysed  and  concentrated 
supernatant in  PBS,  to  reduce non-specific  binding  of protein to the gel.  The solution was then 
filter sterilised before loading onto the column at 2ml/min.  After loading, the column was washed 
with  a  further  10ml  start  buffer to  remove  any  unbound  protein.  Competitive  elution  was  then 
carried  out  with  a  stepped  gradient  of  imidazole  (Sigma  Aldrich)  in  PBS  at  2ml/min.  20ml  of 
30mM, 50mM and 200mM imidazole in PBS (+0.5M NaCI, pH 7.5) was used.  Fractions containing 
scFv,  as  determined  by  Western  blot  were  pooled  (~  20mls),  concentrated  using  a  centrifugal 
concentrator (Vivascience, Germany) to « 1ml, and then analysed on SDS-PAGE (see below).  To 
regenerate  the  column,  Cu2 +  was  stripped  from  the  column  with  20ml  0.1 M  EDTA  in  PBS  at 
2ml/min.  The column  was then washed with  40mls distilled  H20   at2ml/min.  Following  that,  the 
column was washed through with 20% ethanol and stored at 4°C, ready for re-use.
2.2.7  Analysis of scFv by Gel Filtration
The  monomeric or multimeric nature of the scFv constructs was  investigated  using  low-pressure 
gel  filtration  on  the  Pharmacia  LKB  system,  the  AKTA  FPLC™  system  (Amersham  Pharmacia 
Biotech, Uppsala, Sweden).  A pre-packed HiPrep™ Superdex 75 XK 16/60 (Amersham Pharmacia
64Biotech) was equilibrated  using 2 column volumes of PBS as per the manufacturer’s instructions. 
Molecular weight calibration  was performed  using the  Bio-Rad  Gel  Filtration  Standard  (Hercules, 
USA;  Cat #  1511901)  containing  a  mixture of  proteins  namely thyroglobulin  (670  kDa),  IgG  (158 
kDa),  ovalbumin  (44 kDa),  myoglobin  (17 kDa),  and vitamin  B12  (1.35  kDa).  The  log  (molecular 
weight) of each standard was plotted against the fraction of the stationary gel volume available for 
diffusion  (Kav) to generate a calibration  curve for each  column.  Three  identical calibrations were 
carried  out  and  the  filtration  profile  recorded  on  the  Unicorn™  (Version  3.0)  computer  package 
linked to a UV absorbance sensor set at 280nm.  For use with  scFv,  100 pg of scFv was loaded 
onto  the  column  in  1   ml  of  PBS  at  2  ml/min  and  60-120  2ml  fractions  collected.  The  sample 
corresponding  to the  peaks  were  subjected  to Western  blot  analysis  to  confirm  the  presence  of 
scFv.  The molecular weights were then calculated based on the previously determined calibration 
curve.
2.3 SDS-PAGE AND WESTERN BLOT ANALYSIS
2.3.1  Gels
All  protein  separation  was  performed  using  a  12%  or  15%  Sodium  Dodecyl  Sulphate- 
Polyacrylamide  Gel  (SDS-PAGE)  with  a  4%  stacking  layer,  prepared  from  a  30%  acrylamide 
solution  (Boehringer  Mannheim)  according  to  standard  methods,  unless  otherwise  stated  (see 
table 2.3).
Component Stacking gel Separating gel
4% 12% 15%
Acrylamide/Bis (30%) 1.3ml 4.0ml 5.0ml
Distilled H20 6.1ml 3.4ml 2.4ml
3.0M Tris-HCI, pH 8.8 - 2.5ml 2.5ml
0.5M Tris-HCI, pH 6.8 2.5ml - -
10% SDS 100pl 100pl 100pl
Ammonium persulphate (100mg/ml) 50 pi 50pl 50pl
TEMED 10 pi 10 pi 10 pi
TOTAL VOLUME 10ml 10ml 10ml
Table 2.3  Formulation of SDS-PAGE Gels
652.3.2 Buffers
All  buffers  used  for  Western  blot  and  SDS-PAGE  analysis  followed  standard  formulations.  All 
electrophoresis was carried out in 1  x concentration electrophoresis running buffer, made up from a 
5x  concentration  stock  solution  (235mM  Tris  base  (3g/l),  192mM  glycine  (14.4g/l),  0.1%  SDS 
(1.0g/l) and  1 1  distilled water).  Transfer of protein to nitrocellulose for Western  blot was achieved 
in  1x  concentration  transfer  buffer  (25mM  Tris  base  (3.03g/l),  192mM  glycine  (14.4g/l),  20% 
methanol  (200ml/l)  and  800ml  distilled water).  Blocking buffer for  nitrocellulose filters was  made 
from  skimmed  milk  (Marvel™  supplied  by  Tesco  supermarkets)  made  as  15g  of  skimmed  milk 
(3%) + 2.5ml of 10% NaN3 + 50ml of 10x PBS stock + 447.5 ml distilled water.  Antibodies used to 
stain the nitrocellulose were made up in  incubation buffer composed of 6.6ml of 3% BSA (bovine 
serum albumin) +  10ml of  10% Tween-20 +  100ml of  10x PBS + 883ml of distilled water.  The 5x 
sample  buffer  was  composed  of  1.0ml  of  Tris  HCI  pH  6.8,  1%  glycerol,  2%  SDS,  0.05% 
bromophenol blue with or without a reducing agent (dithiothreitol (DTT) or (3-mercaptoethanol).
2.3.3  SDS-PAGE Analysis
The  method  used  for  SDS-PAGE  analysis  of  protein  was  as  previously  published  (Molecular 
Cloning,  A  Laboratory  Manual,  1989).  Protein  samples  were  prepared  in  1.5ml  microcentrifuge 
tubes.  Volumes of 10 - 20pl of sample were mixed with 7pl of 5x sample buffer ± reducing agent 
and  heated to  95°C for 3  minutes.  25pl  of  each  of the  samples  (total  volume  usually 27pl)  was 
loaded onto the gel.  The Mini-Protean  III™  gel electrophoresis system (BioRad) was used for all 
experiments.  Protein  separation was achieved  by electrophoresis at 250 volts for approximately 
30  minutes.  A protein  stain was prepared according to published  methods.  Approximately  1g of 
Coomassie-brilliant  blue  dye  (Pierce)  was  dissolved  in  200ml  10%  glacial  acetic  acid,  45% 
methanol  and  45%  dH20   (20ml:  90ml:  90ml  respectively).  The  gel  was  allowed  to  stain  for 
approximately 40  minutes and then  de-stained  in the same  mixture of  acetic acid,  methanol  and 
water  without  Coomassie  dye,  for  approximately  24  hours.  Kaleidoscope  protein  standards™ 
(BioRad) or Precision protein standards™  (BioRad) were used in all experiments to show relative 
molecular weights unless otherwise indicated (Figure 2.3.3).  SDS-PAGE was used to quantify the 
yield  of  scFv  at all  stages  of  purification.  A  quantitative  assessment  of  the  protein  loaded  was 
obtained  using  standard  ovalbumin  (Sigma  Aldrich)  samples.  Three  standard  solutions  were 
made: 1pl, 3pl and 5pl in 20pl distilled H20.
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Figure 2.3.3  Protein Standards for Molecular Weight Determination
Western blot analysis of proteins was carried out according to standard methods.  Protein samples 
and gels were prepared as for SDS-PAGE analysis and electrophoresis was performed using the 
Mini-Protean  III™  system (BioRad) at 250 volts for 30 minutes.  However only 1   - 2 pi of sample 
protein was loaded.  Transfer of the separated proteins onto nitrocellulose membrane (Hybond™ 
Amersham  International)  was  achieved  using  a  semi-dry  electroblotting  unit  (Z34,050-2  Sigma 
Aldrich).  Six pieces of Whatman™  3MM filter paper measuring 7 x 9cm were soaked in  transfer 
buffer.  Three  pieces  of  pre-soaked filter paper were  placed  on  the  bottom  (anode)  plate of the 
blotting unit, followed by the nitrocellulose membrane.  The gel was placed onto the nitrocellulose 
membrane and then a further three pieces of filter paper were placed on top of this.  A roller was 
used to  gently ease out any air bubbles from  between the  papers.  The top  (cathode)  electrode 
plate was placed on top of the stack, closing the blotting unit.  Transfer was achieved at 100V and 
200mA for 1   hour.
2.3.4  Western-blot Analysis
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Figure 2.3.4  Semi-Dry Western Blotting Unit (reproduced with permission -  Odili, Thesis, 2002)
The nitrocellulose membrane was place in blocking buffer with NaN3 and left on a shaker overnight 
at  room temperature.  After blocking,  the  nitrocellulose  membrane was washed  briefly with  PBS 
containing 0.5% Tween  (PBS-Tween).  Detection  of all  scFvs possessing  c-myc sequences was 
achieved with the anti-c-myc monoclonal antibody 9E10.  Rabbit anti-human  kappa light chain™ 
(Sigma  Aldrich)  antibody  was  used  to  detect  kappa  light  chains  and  Tetra-His  Mouse  IgG™ 
(Quagen)  was  used  to  detect  the  histidine  (His-6)  tail.  The  antibodies  were  applied  to  the 
nitrocellulose membrane as a hybridoma supernatant (9E10) or in a  1:1000 dilution  in  incubation 
buffer for 4-16 hours at room temperature.
The nitrocellulose membrane was washed  in  PBS-Tween and then  rabbit anti-mouse  Fc-specific 
conjugate (Sigma Aldrich) at 1:1000 dilution in incubation buffer \Nas applied at room temperature 
for  at  least  1   hour.  Rabbit  anti-mouse  Fc-specific  conjugate  was  used  for  most  experiments, 
unless otherwise  stated.  The  nitrocellulose  membrane was  washed  again  in  PBS-Tween.  The 
alkaline  phosphatase  conjugate  substrate  (BioRad)  was  prepared  from  two  components,  which 
were applied to the nitrocellulose membrane, and the colour change allowed to proceed.  Washing 
the nitrocellulose membrane in tap water terminated the reaction.
682.4 TISSUE CULTURE
All  cell  lines  were  maintained  in  RPMI-medium  (Gibco)  containing  10%  FCS  (fetal  calf  serum, 
Gibco)  and  L-glutamine  (2mM,  Gibco)  and  PenStrep  (penicillin  and  streptomycin,  Gibco).  All 
subsequent references to “culture media” refer to this formula, unless otherwise stated.  All media, 
PBS  and  Versene™  (Gibco)  were  pre-warmed  to  37°C  before  use.  All  culture  flasks  were 
incubated at 37°C in a tissue culture incubator (Jencon-PLS)  in an air atmosphere, supplemented 
to 5% C02.  Tissue culture procedures were carried out under a Class II Hood (Greiner).
2.4.1  Maintenance of A375M Cell Line
The human melanoma cell line, A375M, was used for all  in vitro and in vivo experiments involving 
cultured melanoma cells.  A375M is an amelanotic melanoma cell line, derived from a 54-year old 
patient with  metastatic  melanoma.  The  cell  line  was  obtained  from  the  European  Catalogue  of 
Human  and  Animal  Cell  Culture  (ECACC)  and  grown  using  standard  tissue  culture  techniques, 
Briefly,  frozen  stocks  (106  cells)  kept  in  cryosuspension  in  liquid  nitrogen,  in  1ml  dimethyl 
sulphoxide  (Sigma Aldrich)/FCS  (1:9) were thawed  rapidly  in  a 37°C water bath,  resuspended  in 
10ml of culture media and pelleted at 1000rpm for 5min in a bench-top centrifuge.  The pellet was 
resuspended in  1ml culture media and added to a T-25 culture flask (Greiner).  At confluence (3-4 
days at 37°C), the culture media was aspirated off and the cells washed with  10ml PBS.  The cells 
were  released  by  incubation  in  1:5000  Versene  (Gibco)  at  37°C for around  10min.  The A375M 
cells adhere firmly to the flask, and release of the cells usually required a vigorous tap to the side 
of the flask.  An equal amount of culture media was added to stop Versene digestion and the cells 
pelleted at 1000rpm for 5 minutes.  When passaging cells, the pellet was resuspended in a small 
volume  of  culture  media  prior  to  seeding  T-75  flasks  (Greiner)  containing  20ml  culture  media. 
Typically,  cells  were  diluted  1:5  before  seeding  the  flasks.  When  larger  cell  numbers  were 
required, the cells were passaged into T-175 flasks (Greiner) containing 40ml culture media.  Cells 
were allowed to reach confluence (at 3-4 days) at 37°C.
2.4.2 Cell ELISA plate preparation
Since purified HMW-MAA is not readily available,  in vitro analysis of scFv-antigen interaction was 
carried out using cell  ELISA plates seeded with A375M melanoma cells.  Cells from a single T-75
69flask at confluence  (approximately 8x106 cells)  were  harvested  and  resuspended  in  50ml  culture 
media.  This suspension was used to seed ten 96-well flat-bottomed tissue culture plates (Falcon) 
aliquoting 50pl  per well  (around 8x103 cells).  The plates were  incubated for 3-4 days  (37°C,  5% 
C02) until 80% confluent.  The culture media was then aspirated off and the plates dried overnight 
in a 37°C incubator, before storage at 4°C.
2.4.3  Technique of Cell ELISA
Cell  ELISA  plates  were  typically  set  up  using  two-fold  dilutions  of  antibody  or  scFv  in  RPMI 
medium (GibcoBRL) containing  10% FCS and 0.05% sodium azide.  Total volumes of 50pl / well 
were  employed.  Outer  lanes  on  the  plate  were  not  used  due  to  inconsistency  in  the  results 
obtained in these wells.  For scFvs, 90pl 9E10 supernatant was added to each well.  10-50pl of the 
scFv or antibody  was  then  loaded  into  the first well  of  each  row,  titred  out  and  incubated  for 2 
hours at room temperature.  The wells were washed  3 times with 200pl  PBS  per well.  Between 
washes the wells were blotted to remove remaining scFv and media.  50pl of a  1:5000 dilution of 
rabbit anti-mouse horseradish peroxidase (HRP) conjugate (Dako) was added, and after further 1- 
hour  incubation  at  room  temperature,  the  HRP  conjugate  was  washed  off  in  the  same  way. 
Following  this  wash,  all  remaining  media  was  aspirated  from  the  wells  and  100pl  of  OPD™ 
peroxidase  substrate  (Sigma  Aldrich)  prepared  according  to  manufacturer’s  instructions,  was 
added  to  the  wells.  The  plate  was  stored  in  the  dark  for  5-15  minutes,  until  a  colour  reaction 
occurred  which  was  terminated  using  50pl  2M  sulphuric  acid.  All  plates  were  read  using  a 
Microplate Reader™ (BioRad).
2.4.4  Maintenance of 9E10 Hybridoma Cell Lines
The 9E10 monoclonal antibody directed against the c-myc epitope was prepared as a hybridoma 
supernatant.  The cell line was obtained from the American Tissue Culture Collection (ATCC) and 
maintained according to established culture techniques.  Cells were cultured from frozen stocks by 
the same technique employed for melanoma cells (see above).  Cells were passaged from T-25 to 
T-75  and  then  T-175 flasks  containing  100ml  of  culture  media.  The  hybridoma  cells  were  only 
mildly  adherent  and  could  be  detached  from  the  flask  using  gentle  tapping  without  using 
Versene™.  Once  in  T-175 flasks,  the  medium was  harvested  when  depleted  and  replaced  with 
100ml  culture  medium  and  the  process  repeated.  By  this  technique,  many  litres  of  hybridoma
70supernatant was be prepared.  The harvested supernatant was filter-sterilised (0.2pm filter,  Dow- 
Coming) and 0.05% sodium azide added as a bacteriostatic agent before storage at 4°C.
All 96 wells are loaded with 50 id 9E10 hybridoma supernatant.
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Figure 2.4.3  Technique of Cell ELISA (reproduced with permission Hamilton, Thesis, 2001)
712.5  RADIOLABELLING TECHNIQUES
Antibody fragments  were  iodinated  with  iodine-125  (Amersham  International)  using  IODO-GEN® 
(1,3,4,6-tetrachloro-3a,  6a-diphenyl  glycouril)  pre-coated  iodination  tubes  obtained  from  Pierce 
Chemical Company,  USA.  Radioactivity was monitored using a Mini-Monitor™  (Mini-Instruments) 
calibrated for gamma radiation.  Counts were measured as counts per second (cps) at 30 cm from 
the source of radioactivity to obtain an estimate of the iodine-125 activity in MBq.
2.5.1  Buffers
Phosphate buffer (pH 7.5) was used for all iodination reactions.  To make 100 ml of 1M phosphate 
buffer, 81  ml of 1   M Na2P04 was mixed with  19 ml of 1   M NaHP04 and adjusted with NaOH to pH 
7.5.  IODO-GEN® stop buffer was composed of 2.0  mg/ml  D-tyrosine in 0.05  M phosphate buffer 
pH 7.5 + 10% glycerol (BDH) + 0.1% xylene cyanol (BDH).
2.5.2  Iodination of Antibodies
All  reactions  were  carried  out  in  a  dedicated  fume  hood  lined  with  3  mm  of  lead-sheet  and  a 
gamma shield (Scot Lab).  A lead apron, sleeve protectors (Jencon-PLS), facemask, goggles and 
double layers of  latex gloves were worn for all  iodination  reactions.  Standard  safety precautions 
for safe disposal of all  radioactive waste were observed  in accordance with  regulations for Mount 
Vernon Hospital, Northwood, Middlesex.
Radiolabelling  was carried  out using  the direct iodination  method  (Markwell  1978).  All  reactions 
were carried  out at  room temperature.  Approximately  50  -  100  pg  in  100  pi  PBS  antibody was 
placed in a 1.5ml polypropylene Eppendorf tube.  125l  (Amersham) as Nal was added immediately 
to the IODO-GEN® (Pierce) pre-coated tube.  In general, 500 pCi of Na125l was used per 100 pg of 
scFv  for  radiolabelling.  The  reaction  was  allowed  to  proceed  for  around  5-10  minutes.  50  pi 
IODO-GEN® stop buffer was then added to the mixture to stop the reaction.  The scFv and Na125l 
were  then  transferred  to  a  PD10  column  (G-25  Sephadex™  Pharmacia  Biotech)  to  separate 
iodinated protein from unincorporated iodine (see below).
722.5.3 Separation of Unincorporated Iodine-125
A  pre-packed  PD10  column  (Pharmacia  Biotech)  containing  10  ml  of  Sephadex™  G-25  was 
equilibrated with  100 ml of PBS +1% BSA + NaN3.  Equilibration with  1% BSA was carried out to 
reduce the amount of non-specific binding of radiolabelled protein.  The column was washed with 
100  ml  PBS  and  stored  at 4°C  until  use.  To separate  unincorporated  iodine from  the  iodinated 
protein, the mixtures from the iodination reactions were loaded on to the PD10 columns.  A tension 
net at the top of each  PD10 column prevented the gel from drying out and ensured that the same 
volume of fluid loaded onto the top of the column dripped out at the bottom.  300 pi aliquots of PBS 
were used to run the mixture through the PD10 column. A total of 20 fractions were collected from 
each  column  and  the  radioactivity  in  each  fraction  measured.  Ultrafiltration  after  radiolabelling 
(Chapter 6) was performed using VectaSpin  Micro™ centrifuge tube filters (Whatman,  Maidstone, 
Kent) to concentrate the radiolabelled scFv to the original volume used previous to radiolabelling.
2.5.4  Estimation of Incorporation of Iodine-125
The fractions collected from the  PD10 column with the highest counts (usually fractions  10 -   13) 
were  assumed  to  contain  the  radiolabelled  protein  and  were  pooled.  Counts  in  these  fractions 
were  expressed  as  a  percentage  of  the  total  counts  in  all  fractions  +  the  PD10  column.  The 
amount  of  radioactivity  incorporated  into  the  protein  sample  was  assumed  to  be  the  same 
percentage  of  the  total  iodine  used  in  the  reaction  (see  individual  results  chapters  for  values 
obtained).
732.6  DETERMINATION OF ANTIBODY AFFINITY
2.6.1  Preparation of Antibody and Human Melanoma Cells
ScFvs  were  prepared  as  described  in  section  2.2.  The  Mab  LHM2  was  a  gift  of  Prof.  I.  Leigh 
(Queen  Mary  and  Westfield  Medical  College,  London).  Dried  cell  ELISA  plates  made  from  the 
human melanoma cell line A375M were used for all experiments (Section 2.4).
2.6.2  Experimental Technique
Binding affinities were calculated according to the methods of Schodin and Kranz (Schodin,  1993) 
using a competitive inhibition assay. The method used was based on the binding affinity of LHM2 
Mab  and  the  inhibition  of  LHM2  binding  with  various  concentrations  of  scFv  preparations.  The 
wells of cell ELISA plates were initially loaded with 500 ng of LHM2 IgG (parent mouse monoclonal 
antibody) per well and serial dilutions of various scFvs were carried out across the plate from 500 
to  1   ng  per  well.  LHM2  IgG  binding  was  detected  using  rabbit  anti-mouse  IgG-HRP  conjugate 
(Dako), which does not cross-react with scFv. The ELISA was completed as previously described 
(Section 2.4) and the plate read at 490 nm.
2.6.3  Affinity Determination
The affinity constants were calculated on the basis of the equation described by Cheng (Cheng et 
al, 1973).
Cheng equation:  = [l]5 0 %  / (1 + ([LHM2] / K^hm^ ))
Kd[scFv]: binding affinity of scFv (M)
I : unlabelled inhibitor (such as scFv)
[l]5o %  : concentration of inhibitor that yields 50% binding inhibition (nM)
[LHM2]: concentration of 125l-labeled Mab (nM)
K d[LH M 2] : binding affinity of LHM2 Mab (1.6 x 10‘8M)
Affinity  Curves  were  constructed  by  plotting  the  OD  against  scFv  concentration  using  Origin™ 
software (version 4.0, Microcal™).
742.7 ANIMAL MODEL
Localisation  of  radiolabelled  scFv was  carried  out  in  athymic  mice  bearing  xenografts  of  human 
melanoma.  The  human  melanoma  cell  line  A375M  was  used  for  all  experiments  (Section  2.4). 
The  methods  used  for  implantation  were  based  on  the  method  of  McCready  (McCready  et ai, 
1989).
2.7.1  Preparation of Tumour Cells
A375M  tumour cells  were  used for all  animal  experiments.  Cells  were  cultured  as  described  in 
Section  2.4.  Cells  were  harvested  from  confluent  flasks  under  sterile  conditions  at  room 
temperature within 1   hour of inoculation.
2.7.2  Tumour Production in the Mice
Immuno-deficient female Balb/c nu mice were bred from existing animal stocks maintained at the 
Gray Cancer Institute.  The mice were housed in MB1  plastic cages (North Kent Plastics) holding a 
maximum of 20 mice and fed on a diet of standard expanded pellets (B & K Universal).  They were 
implanted  with  tumour  cells  when  they  reached  between  7  to  10  weeks  of  age.  Standard 
precautions were observed  when  handling  immuno-compromised  animals.  Hands and  forearms 
were scrubbed with antiseptic agents before touching the animals.  All  clothing except underwear 
was  removed  before  entering  the  animal  house  and  surgical  hats,  masks,  dedicated  (clean) 
overalls,  latex  gloves  and  operating  boots  were  worn  at  all  times.  A  clean  operative  field  was 
established by laying tissue paper onto the bench-top and spraying this with 70% ethanol.  The cell 
suspension  was  drawn  up  into  a  1   ml  syringe  (NHS  supplies)  and  a  23  G  needle  (Microlance). 
The  mice  were  anaesthetised  in  anaesthetic jars  containing  tissue  soaked  with  Enflurane™.  A 
subcutaneous injection of «100 pi of the cell suspension (-10 million cells) was made into the right 
flank of each  mouse.  Palpable tumours were visible as early as  1   week after injection.  Tumour 
take was successful in 80 - 90% of mice.  Tumours were allowed to grow until they reached 7 mm 
+/-1  mm mean geometric diameter before the mice were used for experiments (Figure 2.7).  Mice 
suffering from abscesses and infection were excluded.
75Figure 2.7.2  Balb/c nu Mouse Bearing Human Melanoma Xenograft 2 weeks after subcutaneous injection 
with A375M melanoma cells into right flank.  The tumour measures 7 mm (+/-1  mm).
2.8  ANTIBODY BIODISTRIBUTION AND 
PHARMACOKINETICS
2.8.1  Design of Experiments
Freshly  radiolabelled  antibody  fragment  was  injected  by  tail  vein  injection.  Each  mouse  was 
injected  with  ~ 0.5  pg  of antibody fragment  at  an  activity of « 3  MBq/pg.  Efforts were  made to 
ensure that the absolute amount of  radiolabelled  antibody  used  in  each  experiment was similar. 
However,  there was  still  some  variation  due to  differences  in  the  specific  activity achieved  with 
each  iodination  reaction.  On average,  each  mouse received  between  0.011-0.037  MBq  (0.3-1.0 
pCi) of radioactivity representing 0.5 pg of antibody fragment.  No specific steps were carried out 
to remove endogenous pyrogen, trace amounts of Cu2 +  or NaN3  in the radiolabelled preparations 
before  injection.  However,  no  adverse  effects  of  any  kind  (directly  attributable  to  the  injected 
solutions) were observed in the mice for the duration of any of the experiments
76For localisation experiments, time points were selected which reflected the expected distribution of 
antibody and  antibody fragments based  on  previously published  data  (Colcher,  1990).  Four time 
points were selected:  1   hour,  3  hours,  6  hours and  18  hours after  injection.  This was to enable 
comparison  of  this  antibody  fragment  with  whole  monoclonal  antibody.  For  pharmacokinetic 
experiments, time points were selected which  reflected the expected blood clearance of antibody 
fragments  based  on  previously  published  data  (Colcher,  1990).  At  these  time  points,  groups  of 
between 4 and 5 mice were sacrificed by cervical dislocation.
2.8.2  Injection of Radio-labelled Antibody
Mice were warmed for 2 to 3 min under a 250 W infrared lamp (Salamander) at 30 cm to increase 
tail vein dilation. Enflurane™ anaesthesia was induced as previously described (Section 2.7.2) and 
tail vein injections carried out using a 26 G  needle (Microlance).  The mice were returned to their 
cages  after  recovering  from  anaesthesia.  In  order to  ensure  reproducibility  of the  administered 
dose, all radiolabelled antibodies/antibody fragments were made up to a volume of 100 //I/mouse. 
After injection, haemostasis of the venepuncture site was achieved by digital pressure applied for 1  
- 2 minutes.  The mice were returned to their cages and left on tissue paper in the prone position to 
recover from the anaesthesia.
2.8.3  Sample Collection
At  the  pre-determined  time  points,  mice  were  sacrificed  by  cervical  dislocation  and  tissue 
specimens  obtained  immediately.  The  whole  tumour,  both  kidneys,  both  lungs,  the  liver,  the 
spleen, both quadriceps muscles and both femurs were collected. A blood sample was obtained by 
cardiac  puncture.  Samples  were  placed  into  scintillation  tubes  (BDH)  and  then  weighed  for 
analysis.
2.8.4  Sample Analysis
Scintillation  tubes  were  loaded  onto  a  gamma  counter  (CompuGamma  CS,  LKB  Wallace)  and 
activity measured in counts per minute (cpm) over 3 minutes with a window set at 111  to 140keV.
77Three calibration samples of the radio-labelled antibody fragment equal to that injected per animal 
were also loaded to allow calculation of the percentage of the injected dose in each sample (%ID).
After counting, the sample weight was determined and the %ID/g of tissue was calculated:
%ID/g  =  com in sample X 100
cpm in calibration sample x sample weight (g)
Tumour to normal tissue ratios were calculated for each mouse as follows:
T:NT  =  %ID/q of tumour
%ID/g of normal tissue
Errors were calculated as standard errors of the mean (SEM) of the measurements obtained from 
groups of 3 or 5 mice, using the computer program JMP™ (version 3.1.5, SAS Institute).
SEM  =  SD / VN  N  = number of measurements 
SD =  standard deviation
Curve  fitting  was  carried  out  using  Origin™  software  (version  4.0,  Microcal™),  and  enabled 
calculation of the circulatory half-lives (t1/2a and t1/2|3).
2.9  PIGMENTED LESION CLINIC AUDIT
2.9.1  The pigmented lesion clinic
A  weekly  PLC  was  started  in  January  1993  at  Mount  Vernon  Hospital.  Consultants  in  plastic 
surgery  as  well  as  two  to  three  plastic  surgery  skin  cancer  research  fellows  staffed  the  weekly 
clinic.  It was run such that general practitioners with a reasonable suspicion of the presence of a 
melanoma or non-melanoma skin cancer may refer patients.  It operated on a “walk-in” basis, with
78no  appointments  made so that  patients  could turn  up to the  clinic  and  as  long  as they provided 
their GP’s letter of  referral, they would be seen.  After consultation,  patients with truly suspicious 
lesions were offered immediate excision under local anaesthesia in an operating theatre that ran in 
parallel  with  the  clinic.  Lesions  that  were  not  suspicious  of  being  skin  cancers,  but  merited 
excision, were given appropriate priority on the hospital waiting list.  If the patient presented with a 
benign lesion they could be reassured and discharged.  All patients seen had a standard proforma 
completed,  which  allowed  immediate feedback to the  patient’s  GP  regarding  the outcome of the 
consultation.  If  surgical  excision  was  performed  the  histology  result  was  forwarded  to the  G.P. 
within seven working days.
2.9.2  Audit Design
An  audit  of  all  melanoma  patients  attending  the  regional  melanoma  centre,  serving  both  a  rural 
and  urban  population  of  1.6  million,  based  at  Mount  Vernon  Hospital,  between  1991-1996  was 
performed.  Before the establishment of the PLC,  referral of such lesions was made by letter from 
the G.P. to the outpatient department of plastic surgery.  Even after introduction of the PLC, many 
referrals  still  continued  via  this  route.  Patients  were  split  into  three  groups:  “pre-PLC”,  those 
diagnosed  before  the  establishment  of  the  PLC  (January  1991  -   December  1992);  “non-PLC” 
patients, those diagnosed January  1993 -  December  1996 via  routine,  existing outpatient clinics; 
and  “PLC”  patients  diagnosed  via  the  PLC  January  1993  -   December  1996.  All  melanomas 
diagnosed by the pathology services at Mount Vernon Hospital over the study period were sought 
on the hospital pathology department computer and from  hand-written  records and  relevant case 
notes  retrieved from  the  hospital’s  medical  records  department.  A  proportion  of  patient  records 
were  incomplete.  Further  details  were  initially  obtained  via  the  Mount  Vernon  Hospital  Cancer 
Registry.  Following that, letters were written to GPs also involved in the patients’ care.  The letters 
included  a questionnaire about the  missing  details from  the  patients’  notes and  a  stamped,  self- 
addressed envelope, to ensure a maximum response rate.  After 5 weeks, those GPs who had not 
replied were contacted via the telephone.
A database was created  using  Microsoft Access™.  Patients’ demographic details were recorded 
as well as information on their primary melanomas and  recurrences.  The end-point for the study 
was  taken  to  be July 2002.  Information  about the  melanomas  included:  Breslow depth,  Clark’s 
level, site of primary melanoma, subtype of melanoma,  information on metastases (both local and 
regional) and disease-free intervals.
792.9.3  Statistical analysis
Kaplan  Meier  univariate  survival  curves were  plotted from  the  database  and  analysed  using  the 
statistical package, JMP®.  Log Rank tests were performed on the data, which was then analysed 
using  Chi-squared  tests  to  obtain  p  values.  The  level  of  statistical  significance  accepted  was 
p<0.05. Graphs were constructed using Origin® and Microsoft Excel®.
2.10  TISSUE ARRAY
Tissue array  is a  high throughput screening technique that may be  used to ascertain  patterns of 
protein  expression  in  a  large  number  of  tissue  specimens  simultaneously.  Using  this  strategy, 
small tumour biopsies are  retrieved from  selected  regions of archival  tissue  blocks,  and  multiple 
such cylindrical samples are then precisely arranged in a new paraffin block, which may be cut and 
stained repeatedly.
2.10.1  Components of the tissue arrayer
The Tissue Arrayer™ (Beecher Instruments, Maryland,  USA) (Fig 2.10.1) consists of a base plate, 
receptacle for the array block,  a  donor block  bridge,  two thin-walled  stainless  steel  hollow borer 
needles and turret for switching between the two borer needles, as well as an X-Y precision guide. 
The X-Y guide  moves  by turning the  knobs on the  ends  of the  steel  arms,  and  the  micrometers 
display either the absolute or relative position of the guide.
2.10.2  Patients
The  records  of  melanoma  patients  with  a  minimum  7-year follow  up  (range  7-10  years)  were 
sought  from  the  pathology  records  of  Mount  Vernon  Hospital.  A  database  of  222  primary 
melanoma  patients  was  created  and  relevant  paraffin-embedded  specimens  retrieved  from  the 
pathology  archives  at  Mount  Vernon  Hospital.  The  database  contained  information  on  patient
80demographics,  melanoma  disease  course  and  patient  outcome.  Details  of  established 
clinicopathological  predictors  of  prognosis  including  Breslow  depth,  Clark’s  level,  site  of 
melanoma,  patient  age,  patient  sex  and  presence  of  ulceration  were  incorporated  into  the 
database.
Figure 2.10.1  Tissue microarrayer™
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2.10.3  Preparation of donor blocks and slides
All  blocks  were  sectioned  and  stained  with  Haematoxylin  and  Eosin  (H&E).  A  consultant 
histopathologist  reviewed  the  slides  for  quality  and  presence  of  melanoma.  Specimens  with 
insufficient  melanoma  or  of  poor  quality  were  not  included  in  the  array.  Areas  of  melanoma, 
distinct from surrounding normal skin, were identified and marked for subsequent sampling.
812.10.4 Preparation of the (recipient) array block
A blank paraffin  block was prepared  as a  recipient for the tissue  samples.  Regular paraffin was 
melted  and  poured  over  a  mould;  a  block  holder was  placed  on  top  of the  melted  paraffin,  the 
complex cooled and the wax removed.  Irregularities were cut from the plastic block holders and it 
was ensured that there were no holes in the paraffin caused by air bubbles during preparation of 
the block.
2.10.5  Construction of the tissue microarray
Four  core  biopsies  were  randomly  obtained  from  the  paraffin-embedded  tissue  within  the 
previously identified and  marked area.  Cores were transferred to a  recipient paraffin block using 
the  technique  described  by  Kononen  et  al.  (1998)  using  a  Tissue  Microarrayer™  (Beecher 
Instruments, Silver Spring, Maryland, USA).  Briefly, the empty recipient paraffin block was placed 
in  the  instrument  and  secured  by  tightening  attachment  screws.  This  complex  was  held  firmly 
against  location  bars  by  magnets  built  into  the  microarrayer.  The  tissue  biopsy  needles  were 
adjusted  to  overlie  the  start  position  and  the  micrometers  set  at  zero.  The  smaller  of  the  two 
hollow needles was used to create holes in the recipient block.  Initially, a depth stop was adjusted 
and a nut tightened to stop the needle at a predetermined depth of 4mm.  The needle was pushed 
downward by hand to the required depth and then,  using a handle on the needle, the needle was 
twisted  back  and  forth  several  times  to  “drill”  out  a  core  of  paraffin.  The  downwards-pushing 
pressure was then  released and springs within the  machine pulled the  needle upwards.  A stylet 
was used to empty the needle of the paraffin core, which was then discarded.
The donor melanoma paraffin block was placed on top of the array block holder, and the turret was 
moved  to  switch  the  larger  needle  into  a  vertical  sampling  position.  The  second,  wider  bore, 
needle  was  then  moved  into  position.  The  H&E  slide  and  the  corresponding  tissue  block  were 
aligned to highlight the previously marked area from which to obtain the biopsy and the slide-block 
complex was  manually  held  in  position  on  top  of the  sampling  bridge.  The  slide-block complex 
was  moved  under the  sampling  needle,  and the  larger bore  needle  used to  retrieve the sample. 
The H&E slide was removed and the needle pushed down to retrieve the biopsy sample.  Once the 
sample  was  retrieved,  the  donor  block  was  removed  and  the  needle  pushed  down  until  its  tip 
reached the hole  in the recipient array block.  Whilst holding this position, the stylet was used to 
insert  the  tissue  core  into  the  hole  created  with  the  smaller  needle.  The  needles  were  then
82advanced using the micrometers, and the process repeated to construct the whole array.  Spacing 
between  adjacent  samples  on  the  array  was  0.8mm,  and  a  sampling  needle  with  a  calibre  of 
0.6mm  was  used.  The four cores from each  specimen were arranged  adjacently.  An  Excel file 
(Microsoft,  USA)  was  simultaneously  constructed  with  the  biopsy  coordinates  during  the 
construction of the array.
Once complete, the array block surface was smoothed and levelled.  This was achieved by placing 
it in a warm  chamber (37°C) for  10-15  minutes.  This served to warm  up the paraffin,  promoting 
adherence of the tissue biopsies to the walls of the holes in the array block, and made the paraffin 
flexible to handle.  After the block was warmed, a glass microscope slide was placed on top of the 
array block, and even pressure applied, to push all tissue cores in the array to the same level.  The 
block was then  ready for sectioning.  Five pm thick sections of the paraffin-embedded specimens 
were mounted on aminopropyl triethoxysilane-coated poly-l-lysine slides, dried for 2 hours at 60°C, 
and used for staining.
2.11  IMMUNOHISTOCHEMISTRY
2.11.1  Immunohistochemistry of tissue array slides
The master block was sectioned and slides of 5pm thickness produced.  Slides were stained using 
the Dako Envision  method  (DAKO Ltd.,  Cambridgeshire,  UK).  Formalin fixed paraffin embedded 
sections  were  dewaxed  in  xylene  for  five  minutes  prior  to  rehydration  through  graded  alcohols 
(100, 90 70% industrial methylated spirits) to water.  Antigen retrieval was performed on the tissue 
by  placing the slide in  a bath of  10mM citric acid or  EDTA according  to Table 2.11.1  below,  in  a 
microwave oven  (2450MHz Panasonic microwave,  800W).  The volume of fluid was topped up to 
its original level and the slides were then  left to stand for 20 minutes at room temperature before 
being  washed  well  in  running  tap  water.  Slides  were  then  transferred  to  a  Dako  Autostainer 
(DAKO,  UK) containing  Peroxidase block (DAKO, S2023) with the detection  reagents (Chemmate 
or Envision  HRP,  DAKO  K4006 and  K5007) and the  relevant antibody added  (see Table 2.11.1). 
The  Autostainer  programme  included  5  minutes  in  peroxidase  block,  1   hour  incubation  with 
primary antibody at various dilutions, 30 minute’s incubation in  Envision polymer and 5 minutes in
83Vector  Labs  SG  horse  radish  peroxidase  (HRP)  or  alkaline  phosphate  (AP)  substrate  (Vector 
Labs,  Peterborough,  UK  SK-4700).  When  the  programme  was  complete  stained  slides  were 
removed from the machine and counterstained with  Nuclear fast red (Vector Labs  UK H3403) for 
60  seconds.  Slides  were then  washed  in  water,  dehydrated  in  graded  alcohols  (70,  90,  100%), 
cleared  in  xylene  and  mounted  in  DPX  (Surgipath  Europe  Ltd  08600E).  Each  staining  run 
incorporated a positive control slide as recommended as a positive control by the primary antibody 
manufactures  (Table 2.11.1).  A negative control was also included with the anti-human antibody 
substituted for an isotype-matched control antibody at the same concentration.
2.11.2  Assessment of staining
The  slides  were  scored  by  two  independent  observers  without  prior  knowledge  of  the  clinical 
outcome for staining positivity and stain intensity.  Cores were scored as positive if any degree of 
antibody staining was evident within the  melanoma cells.  The tissue array was then  scanned  in 
using  an  Axioscope Transillumination  microscope  (Zeiss)  connected to a 2A3ccD  colour camera 
(JBC,  UK) and a semi-quantitative scoring system was constructed for staining intensity based on 
the variation  between the specimens.  Specimens were classified as negative, weak,  moderate or 
strong  positive  staining,  as  compared  with  a  control  section  (Table  2.11.1).  The  stain  intensity 
score  was taken  as  the  strongest  staining  sample from  the four  biopsies  that  represented  each 
tumour.
2.11.3  Statistical analysis
Assessment  of  association  between  markers  and  clinicopathological  features  was  carried  out 
using  Chi-squared  analysis.  Univariate analysis  was  undertaken  using  the  Kaplan  Meier method 
with  the  JMP®  statistical  package  (Version  4.0,  SAS  Institute,  USA).  Log  Rank  tests  were 
performed on the data, which were then analysed using Chi-squared tests to obtain p values.  Cox 
multivariate  analysis  was  performed  using  the  Statistical  Package  for  Social  Sciences  (SPSS) 
(SPSS Inc., Chicago, Illinois, USA).  The level of statistical significance accepted was p<0.05.
84Antibody Positive
control
Pre-treatment Source of antibody Diluti 
on in 
TBS
Method of 
detection
AP-2 Breast
Carcinoma
3x 5min microwave in 
10mM citric acid pH6
Neomarkers 1:50 Envision
HRP
|3-catenin OP/PR +ve 
breast 
carcinoma
3x 5min microwave in 
10mM citric acid pH6
Novacastra, UK 1:100 Envision
HRP
Bcl-2 Tonsil 2x 5min microwave in 
10mM citric acid pH6
Dako, UK 1:40 Chemmate
ALP
CD44v3 Tonsil 3x 5min microwave in 
10mM citric acid pH6
Novacastra, UK 1:25 Envision
HRP
CEACAM 1 Liver 3x 5min microwave in 
10mM citric acid pH6
Novacastra, UK 1:50 Envision
HRP
E-Cadherin Tonsil 3x 4min microwave in 
10mM citric acid pH6
Novacastra, UK 1/35 Envision
HRP
IGF-1R Breast
carcinoma
5x 4min 1mM EDTA 
pH8
Neomarkers UK 1/50 Envision
HRP
Ki-67 Tonsil 3x 4min microwave in 
10mM citric acid pH6
Dako, UK 1/200 Chemmate
ALP
MCAM Appendix 4x 4min microwave in 
10mM citric acid
Dako, UK 1/50 Envision
HRP
MG50 Breast
Carcinoma
3x 4min microwave in 
10mM citric acid
University of Southern 
California, USA
1/100
0
Chemmate
HRP
NCAM Neuro­
blastoma
3x 4min microwave in 
10mM citric acid
Novacastra 1/100 Envision
HRP
Nm23 Breast
Carcinoma
None Novacastra 1/250 Envision
HRP
P-Cadherin Skin 3x 4min microwave in 
10mM citric acid pH6
Novacastra 1/50 Envision
HRP
Table 2.11.1  Antibodies  used for antigen  retrieval and tissue array staining.  Positive control slides were 
obtained from the Mount Vernon Hospital pathology department and treated and stained in parallel
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THE EFFECT OF AN EARLY DETECTION 
PIGMENTED LESION CLINIC ON MELANOMA
PATIENT OUTCOME
863.1  INTRODUCTION
In  an  attempt  to  eliminate  intra-hospital  delays,  as  well  as  delays  in  the  bureaucracy  of  patient 
referral,  pigmented  lesion  clinics  (PLCs)  were  established  across the  UK  in  the  1980s  and  early 
1990s.  The  aim  was  to  diagnose  and  excise  melanomas  while  they  are  thinner,  and  hence  of 
better prognosis.
3.1.1  Trends in incidence of melanoma
Cutaneous  melanoma  is among the  most rapidly increasing cancers among  Caucasians (Ries  et 
al.,  2000;  Jemal  et  al.,  2001),  although  the  rate  of  increase  in  the  incidence  appears  to  be 
declining,  except for  men  over 60  (Severi  et al.,  2000,  Jemal  et al.,  2001).  As the  incidence  of 
melanoma  has  continued  to  rise,  the  number  of  thick  lesions  has  remained  relatively  stable  or 
increased,  and  the  thin  lesions  have  risen  to  an  even  greater  extent  (Doherty  &  MacKie,  1986; 
Burton  et al.,  1993;  Burton & Armstrong,  1994;  MacKie  et al.,  1997; Jemal  et al., 2001).  There is 
no consensus as to whether the observed increase in incidence and pattern of incidence is true or 
artefact and due to other factors.  Arguments cited include the following:
3.1.1.1  An increase in the proportion of excised pigmented skin lesions being 
submitted for histopathological examination
This hypothesis has been addressed in a study by Burton & Armstrong who found that the ratio of 
total  patients  referred  to two  melanoma  units to all  skin  lesions  excised  remained  constant  over 
two  years,  despite  a  dramatic  increase  in  the  number  of  patients  referred  (Burton  &  Armstrong, 
1994).  In addition, the ratio of the number of skin lesions diagnosed histopathologically to the total 
number  of  patients  having  skin  lesions  treated  remained  constant,  even  though  the  number  of 
melanomas diagnosed by the pathologists doubled.  Evidence from this study suggests there has 
been  no  increase  in  the  proportion  of  excised  pigmented  skin  lesions  being  submitted  for 
histopathological examination.
872001).  More importantly,  mortality has increased each decade (Jemal  et al., 2001) and there was 
no  major  change  in  the  International  Causes  of  Death  code  for  melanoma  to  account  for  its 
increase.  On  balance, therefore,  it appears that lead-time bias is unlikely to explain  more than a 
modest part of the observed increase in melanoma incidence.
A further argument that supports the above trends reflecting true increases in incidence is the fact 
that sun exposure, as measured by sun burning and the regular use of solariums, has increased in 
the past decade (Robinson et al.,  1997; Westerdahl et al., 2000); ultraviolet exposure being known 
to be the most important risk factor to melanoma development (Gilchrest et al.,  1999; Jhappan  et 
al., 2003).
Thus  it  would  appear  that  the  observed  increasing  incidence  in  melanoma  is  not  a  result  of 
artefacts.  Melanoma  is  now  the  16th   most  common  cancer  in  the  UK  in  men  and  18th   most 
common in women (CRUK 2001).  Using a mathematical model, it was predicted to become the 6th  
most  common  cancer  in  the  USA  in  the  year  2001  (Greenlee  et  al.,  2001)  -   due  to  lack  of  a 
national  cancer  registry  in  the  USA  the  actual  figures  are  not  known.  The  lifetime  risk  of 
developing  a  melanoma  has  been  predicted  at  one  in  68  (Rogers  et  al.,  2002)  with  some 
authorities predicting a risk of 1   in 20 by the year 2020 (CRUK, 2001).
3.1.2  Melanoma mortality
Overall  mortality from  melanoma  is  also  rising,  however  this  rise  is  mainly  confined  to  men  (La 
Vecchia  et al.,  1999;  MacKie  et al.,  2000,),  which  would  be  predicted  from  the  rising  number of 
thick  lesions diagnosed  in  men.  Actuarial  survival for both  sexes analysed  by MacKie showed a 
divergence  in  survival  between  the  sexes  (men  faring  worse)  during  the  first  five  years  after 
diagnosis  and  treatment  (5-year  survival  for  women  -82%,  men  -78%),  this  difference  being 
maintained  over the  next five years  (MacKie  et al.,  1997).  They also clearly showed the steady 
and  continuing  death  rate  from  melanoma  during  follow-up  over  5-10  years,  confirming  that 
survival  to  5  years  is  not  a  guarantee  of  cure.  A  follow-up  study  by  MacKie  et al.  showed  the 
mortality  of  men  from  melanoma  in  Scotland  to have  been  the  same  in  1998  as  it was  in  1988 
(MacKie  et al.,  2002).  However  there  was  a  rise  in  mortality  over  1993  -   1997,  the  period  of 
interest for this thesis.  Mortality in women  remained fairly constant, although fell from  1.9 to  1.85 
per  100,000  (not  significant)  and  in  women  younger than  65  years  from  1.3  to  1.5/100,000  per 
year.
893.1.3 Improving outcome
On the background of a rising incidence and mortality, various strategies have been investigated in 
an attempt to improve outcome in  melanoma patients.  These have included: varying the width of 
excision, sentinel lymph node biopsy and adjuvant therapies.
3.1.3.1  Varying the Width of Excision
It  has  been  recommended  that  a  lesion  suspected  of  being  a  melanoma  be  excised  as  a  full­
thickness  skin  biopsy to  include  the  whole  tumour with  a  2-5mm  clinical  margin  of  normal  skin 
laterally and with a cuff of subdermal fat (Newton Bishop et al., 2002).  This allows confirmation of 
the diagnosis, such that subsequent definitive treatment can be based on Breslow thickness.  The 
World  Health  Organisation  (WHO)  conducted  a  randomised  control  trial  comparing  excision 
margins  of  1cm  and  3cm  for  melanomas  up  to  2mm  thick  (Veronesi  et  al.,  1988).  No  local 
recurrences  were  seen  in  patients with  melanomas  less than  1mm  in  depth  with  either excision 
margin  and  therefore  a  1cm  margin  was  deemed  safe  and  appropriate for these  lesions.  Four 
patients with tumours between  1   and  2mm thick developed  recurrences with  excision  margins of 
1cm,  leading  the  authors  to  be  cautious  in  recommending  1cm  margins  for  this  group  and 
therefore  suggested  2cm  margins  may  be  more  appropriate  until  further follow-up  is  completed. 
The  Intergroup  Melanoma Trial  compared  2cm  versus 4cm  margins  of excision  for  lesions  of  1- 
4mm in depth (Balch  et al.,  1993).  No difference was seen between the two groups in either local 
recurrence or survival  in  patients with  lesions up to 4mm  in  depth.  No  randomised  studies have 
been  performed  on  patients  with  tumours  deeper  than  4mm.  Despite  improvements  in  local 
recurrence rates,  no published series to date has demonstrated that varying the width of excision 
has an impact on survival.
3.1.3.2  Sentinel Lymph Node Biopsy
Sentinel  lymph  node  (SLN)  biopsy  was  developed  as  a  means  of  identifying  and  excising  the 
lymph  node draining the skin  in which the melanoma arises (Morton  et al.,  1992).  The procedure 
is  usually  carried  out  at  the  same  time  as  definitive  (wider)  excision  of  the  primary  tumour. 
Patients with  positive SLN  proceed to excision of lymph  nodes  in the  relevant nodal  basin.  SLN 
biopsy has been shown to be of importance in the accurate staging and prediction of prognosis of 
melanoma  patients,  so  much  so,  that  it  is  now  recommended  as  a  requirement  to  define
90homogeneous  patient  populations  for  current  clinical  trials  (Balch  et al.,  2001a  &  b).  Although 
elective  lymph  node dissection  has  never  shown  an  improvement  on  survival,  it  may  be  argued 
that  it  would  have  been  difficult  to  show  benefit  because  only  about  20%  of  patients  with 
intermediate thickness melanomas have sub clinical  nodal  metastasis.  Therefore,  80% could  not 
possibly benefit (McMasters et al., 2001).  Furthermore,  in lymph node dissections not directed by 
lymphoscintigraphy, the incorrect nodal  basin could  be chosen for surgery in  up to 32% of cases 
(Norman  et al.,  1991),  making  the  benefit of  node  removal  even  harder to demonstrate.  When 
only  patients  who  had  actual  nodal  metastases  were  considered,  the  5-year  survival  rate  was 
48.2%  in  patients  who  had  immediate  lymph  node  removal  that  showed  occult  metastases, 
compared with 26.6% in those in whom node dissection was delayed until the appearance of overt 
regional  metastases  (Cascinelli  et  al.,  1998).  Therefore,  the  used  of  SLN  biopsy  may  identify 
patients  who  could  benefit  from  lymph  node  dissection.  The  final  evidence  needed  that  SLN 
biopsy may have a bearing on outcome awaits the completion of the large prospective randomised 
control - the Multicentre Selective Lymphadenectomy Trial (MSLT).
3.1.3.3  Adjuvant Therapy
As  discussed  in  the  introduction  to  this  thesis,  there  are  no  conventional  adjuvant  therapies  of 
proven  benefit  for  melanoma  as  yet.  Despite  the  evaluation  of  many  chemotherapy  drugs  in 
metastatic melanoma no single agent demonstrates a response rate of greater than 25% (Lotze et 
al., 2001).  Dacarbazine  (DTIC)  remains the most commonly used  single agent and the standard 
for randomised  studies evaluating  new combinations  (Flaherty  &  Gadgeel,  2002).  Among  1,900 
patients evaluated with  single agent DTIC treatment,  response  rates were in the range of  10% to 
20% with median durations of response of 4-6 months, median survival of 6-9 months and a 5-year 
survival of 2% (Middleton  et al., 2000).  Combination chemotherapy regimes have been  unable to 
reproduce  promising  response  rates  from  single  institution  phase  II  studies  in  larger  multi- 
institutional  studies  and  none  has  demonstrated  a  survival  advantage  over  single  agent  DTIC 
(Flaherty & Gadgeel 2002).
3.1.3.4  Biological therapies
Modulation of the immune response by interferon alpha is based on its ability to stimulate the anti­
tumour  activity  of  natural  killer  cells  and  expression  of  histocompatability  antigens,  leading  to 
increased  susceptibility  of  tumour  cells  to  be  killed  by  immune  effector  cells  (Kirkwood  et  al.,
911991).  In  the  USA,  following  the  ECOG  1684  trial  the  “Kirkwood”  high-dose  alpha  interferon 
regime  is  regarded  as  standard  therapy  for  patients  at  high  risk  of  recurrence  (Kirkwood  et al., 
1996), although the ECOG  1690 trial was non-confirmatory as to the survival advantage achieved 
(Kirkwood  et al.,  2000).  Another study comparing  one year’s treatment with  high-dose  interferon 
with  a vaccine to gangliosides  (anti-GM2) was closed  after interim  analysis  because of apparent 
better  survival  of  the  interferon-treated  group  (Kirkwood  et al.,  2001).  In  metastatic  melanoma, 
interferon  alpha,  as  a  single agent  produces a  response  rate  of approximately  15% and  median 
response durations in the range of 6 to 9 months (Kirkwood 1991).  Although interferon is licensed 
for  use  in  the  UK,  it  is  not  yet  recommended  as  standard  treatment,  on  the  basis  of  a  second 
confirmatory  trial  considered  necessary  and  not  least  because  of  the  side  effects  experienced 
(Roberts etal., 2002).
Apart from  high  dose alpha  interferon  (Kirkwood  et al.,  1996,  2001)  none of the above therefore 
has  yet  been  shown  to  improve  survival  in  melanoma  patients  in  any  prospective  randomised 
controlled  trial.  However,  survival  has  been  improved  in  other  cancers,  such  as  breast  and 
colorectal  cancer  (Moss  et  al.,  1994;  Niv  et  al.,  2002)  by  early  detection  strategies.  With  the 
knowledge  of  the  growth  and  natural  history  of  melanoma  progression,  early  detection  and 
treatment should offer great potential for reducing mortality from melanoma.
3.1.4  Growth of melanoma
Melanoma usually arises in the epidermis, where it may be confined for several months.  Herlyn et 
al. described its proliferation in the epidermis as radial;  hence during this period it is referred to as 
being in the radial or horizontal growth phase (Herlyn  et al.,  1987).  If uninterrupted by therapy the 
tumour  may  progress  into  a  vertical  growth  phase,  whereby  it  invades  the  reticular  dermis  and 
even  the  subcutaneous fat  (Clark  et al.,  1969).  With the  exception  of  nodular melanoma,  which 
does  not  show  any  significant  radial  growth  pattern,  all  types  of  melanoma  appear to  progress 
through some degree of radial growth before the vertical growth begins.  The vertical growth phase 
usually results in a nodule arising in the relatively flat radial growth phase lesion.
It has been  suggested by some authors that the radial  growth  phase  represents the melanoma’s 
capacity  for  autonomous  growth  and  invasion  of  the  papillary  dermis,  but  not  the  capacity  to 
metastasise.  The vertical  growth  phase  is said to  result from a subpopulation of cells that has a 
growth  advantage  over  the  surrounding  cells  and  also  possesses  the  potential  to  metastasise
92(Elder  et al.,  1984,  Clark  et al.,  1989).  This  natural  history  of  melanoma  would  suggest that a 
thicker tumour has been present for longer than a thin tumour and that consequently any delay in 
diagnosis would result in a more advanced tumour and hence a poorer prognosis.  Thus the earlier 
the excision, the more likely the lesion is to be in its radial growth phase and excision at this stage 
should therefore not only improve survival but also has the potential to achieve cure.
3.1.5  Melanoma thickness
It has long been established that patients with thin melanomas have a much improved survival rate 
than those with thick lesions (Breslow 1970) and this remains the single most important prognostic 
indicator of primary melanoma (Barnhill et al.,  1996; Balch et al., 2001;  Ng  et al., 2001; Osborne & 
Hutchinson  2001).  In  a  recent  extensive  study,  Balch  and  colleagues  merged the  data from  13 
prospective  databases  containing  information  on  30,450  melanoma  patients  with  the  aim  of 
updating  the American  Joint Committee on  Cancer  (AJCC)  Melanoma  Staging  System  (Balch  et 
al.,  2001a).  The  data  items  used from  each  group’s  database  were those  already  known  to  be 
independent prognostic factors, were generally available from the databases and were relevant to 
validating the AJCC Melanoma Staging System (Balch  et al.,  2001a & b).  17,600  patients (58%) 
had  information  available  for  all  the  factors  required,  and  13,581  were  patients  with  primary 
localised melanoma.  In a multivariate analysis of the 13,581  patients with localised melanoma, the 
most  powerful  independent  characteristic  of  the  primary  melanoma  among  all  the  prognostic 
variables  was  tumour thickness  (p<0.00001)  -  the  second  most  important  was  ulceration.  Thin 
(<1.0mm),  non-ulcerated  melanoma  has  a  much-improved  outcome  -   the  associated  5-year 
survival probability is better than 95% (Balch et al., 2001a), whereas a patient with a non-ulcerated 
melanoma over 4mm thick has a 5-year survival chance of 67.4% (see Table 1.1.5.2 in chapter 1).
3.1.6  Diagnostic difficulties
Misdiagnosis of  melanoma  is inevitable both  by GPs and  specialists.  In  an Australian  study,  the 
diagnostic accuracy of GPs was found to be around 45% (Paine et al.,  1994) and Cassileth et a/.'s 
study comparing dermatologists with non-dermatologists found the diagnostic accuracy of the non­
dermatologists  to  be  only  38%  (Cassileth  et  al.,  1986).  Morton  and  MacKie  compared  the 
diagnostic  accuracy  of  consultant,  senior  registrar  and  registrar  dermatologists  (Morton  and 
MacKie  1998).  Their diagnostic accuracy was 80%,  62% and 56%,  respectively.  The number of
93false  positives  was  not  significantly  higher amongst the trainees,  indicating  that their decreased 
accuracy could  not be explained by them erring on the side of caution.  These data demonstrate 
the improved diagnostic accuracy of specialists over general practitioners.  The establishment of a 
pigmented  lesion  clinic  staffed  by  specialists  therefore  provides  an  easy-access  specialist 
diagnostic service, as well as a rapid-referral treatment service.
3.1.7  Diagnostic delays
Despite the  unique occurrence of melanoma in often  easily visible sites,  delay on the part of the 
patient in presenting a suspicious lesion to a doctor has been shown to make a major contribution 
to  delay  in  diagnosis.  Delays  by  patients  with  cancer  symptoms  are  most  often  due  to  lack  of 
knowledge  about  the  seriousness  of  the  condition  (Temoshok  et  al.,  1984;  Doherty  &  MacKie 
1986;  Cassileth  et al.,  1988;  Rampen  et al.,  1989),  anatomic site (the upper and  lower back) and 
patient denial (Temoshok et al.,  1984).  The fact that patient lack of knowledge about the condition 
has  been found  to  result  in  delays  in  seeking  medical  attention  has  led  some to  propose that a 
pigmented  lesion  clinic will  not  be  effective  in  improving  survival,  unless  it  is  accompanied  be  a 
publicity campaign (The Southampton Melanoma Group 1986; Severi et al., 2000).  Temoshok and 
colleagues  demonstrated  a  statistically  significant  positive  correlation  between  time  delay  and 
tumour  thickness  (Temoshok  et  al.,  1984),  however  their  results  were  contradicted  by  a  more 
recent study (Richard  et al.,  1999), which found a  negative correlation  between tumour thickness 
and the delay to seek medical attention.  On examination of the data, the authors discovered that 
the  negative  correlation  achieved  was  the  result  of  a  few  patients  with  the  most  aggressive 
tumours presenting  early and when the analysis was  repeated without these,  the delays incurred 
by the patients did have an impact on the rest of the melanoma patient study population.
Diagnostic difficulties and  delays  in  patients seeking  medical  attention  are  often  compounded  by 
delays  due  to  the  bureaucracy  of  referral  to  hospital  and  further  delays  within  the  hospital 
healthcare  system.  In  normal  practice,  GP  letters  of  referral  are  reviewed  by  the  consultant to 
whom  they  were  referred,  and  then  the  patients  are  prioritised  according  to  the  content  of  the 
letter.  Thus,  if  the  GP  suggests  the  possibility  of  a  diagnosis  of  melanoma,  the  patient  will  be 
given  an  urgent  appointment.  If,  however,  it  is  not  clear  that  a  melanoma  is  suspected,  or,  of 
course,  that  the  GP  has  diagnosed  another  lesion  altogether,  a  lower  priority  will  be  given 
(Ibbotson et al., 1995).  Ibbotson has shown that this to leads to severe delays resulting in patients
94with previously unsuspected  melanomas presenting with thicker tumours.  Hence further potential 
delays may occur even after initial GP referral.
3.1.8  Previous work
A previous audit into the PLC at Mount Vernon (Grover et al., 1996) had demonstrated a reduction 
in the  mean thickness  of melanoma  in  patients presenting to the  PLC when  compared with  both 
melanomas diagnosed  before the establishment of the  PLC,  and with  melanomas diagnosed via 
existing  routes  of  referral  in  parallel  with  the  PLC.  However,  the  impact  of the  PLC  on  patient 
outcome, in terms of survival and disease-free interval, was not measured.
3.2  AIMS
This  study  aimed  to  investigate  the  effect  of  a  pigmented  lesion  clinic  on  survival  in  melanoma 
patients. The outcome would be compared with 2 groups: those diagnosed with melanoma before 
the establishment of the PLC (“pre-PLC”) and those diagnosed via normal routes of referral (“non- 
PLC”).  As well as survival, other measures were evaluated,  including differences in tumour depth, 
length to both local and regional recurrence, and disease control.
953.3  METHODS
A weekly  PLC was started  in January  1993 at Mount Vernon  Hospital  in an  attempt to overcome 
the delays in diagnosis and treatment of melanoma.  Consultants in plastic surgery, as well as two 
to three plastic surgery trainees staffed the weekly clinic.  General practitioners with a reasonable 
suspicion  of  melanoma or non-melanoma  skin cancer were  able to  refer patients to the  PLC.  It 
was run on a “walk-in” basis, with no appointments made.  As long as patients had a GP letter of 
referral,  they  are  eligible  to  attend  the  clinic.  After  consultation,  patients  with  truly  suspicious 
lesions were offered immediate excision under local anaesthesia in an operating theatre running in 
parallel with the clinic.  Lesions that were not suspicious of being melanoma, but merited excision, 
were  given  appropriate  priority on  the  hospital waiting  list.  If the  patients  presented with  benign 
lesions they were reassured and discharged.
An  audit  of  all  melanoma  patients  attending  the  regional  melanoma  centre,  serving  both  a  rural 
and  urban  population  of  1.6  million,  based  at  Mount  Vernon  Hospital,  between  1991-1996  was 
performed.  Before  the  establishment  of the  PLC,  referrals  of  such  lesions  were  made  by  letter 
from the GP to the  outpatient department of  plastic surgery.  Even  after introduction  of the  PLC 
many referrals still continued via this route.  Patients were split into three groups: “pre-PLC”, those 
diagnosed  before  the  establishment  of  the  PLC  (January  1991  -   December  1992);  “non-PLC” 
patients, those diagnosed January  1993 -  December  1996 via  routine,  existing outpatient clinics; 
and  “PLC”  patients  diagnosed  via  the  PLC  January  1993  -   December  1996.  All  melanomas 
diagnosed by the pathology services at Mount Vernon  Hospital over the study period were sought 
on  the  hospital  pathology  department  computer  and  from  hand-written  records  and  relevant 
casenotes were retrieved from the hospital’s medical  records department.  A proportion of patient 
records  were  incomplete.  Further  details  were  initially  obtained  via  the  Mount  Vernon  Hospital 
Cancer  Registry.  Following  that,  letters were written  to  GPs  also  involved  in  the  patients’  care. 
The  letters  included  a  questionnaire  about  the  missing  details  from  the  patients’  notes  and  a 
stamped,  self-addressed  envelope,  to  ensure  a  maximum  response  rate.  After  5  weeks,  those 
GPs who had not replied were contacted via the telephone.
A database was created using  Microsoft Access™.  Patients’ demographic details were  recorded 
including patient sex,  patient age at diagnosis and  route of referral.  Details of the primary tumour 
that were recorded were:  subtype of tumour,  site of primary tumour,  Breslow depth,  Clark’s level, 
tumour  ("T")  classification  (see  section  1.1.5)  and  presence  of  ulceration.  Metastatic  tumour 
details  that  were  recorded  were:  site  of  recurrence  (local  or  regional),  disease-free  interval  and 
extent of nodal  involvement.  In addition, date and cause of death were recorded and the time to
96outcome could therefore be calculated.  The end-point of the study for those patients still alive was 
taken to be July 2002.
A significant number of patient records were incomplete.  Further details were initially obtained via 
the Mount Vernon Cancer Registry.  Following that letters were written to GPs also involved in the 
patients’  care.  The  letters  included  a  questionnaire  about the  missing  details from  the  patients’ 
notes.  A stamped,  self-addressed  envelope was also  included,  to  ensure  a  maximum  response 
rate.  After 5 weeks, those GPs who had  not replied contacted via the telephone.  Kaplan  Meier 
univariate  survival  curves  were  plotted  and  analysed  using  the  statistical  package,  JMP®.  Log 
Rank  tests  were  performed  on  the  data,  which  were  then  analysed  using  Chi-squared  tests  to 
obtain  p  values.  The  level  of  statistical  significance  accepted  was  p<0.05.  Graphs  were 
constructed using Origin® and Microsoft Excel®.
973.4  RESULTS
3.4.1  Patients
A total of 290 melanomas were diagnosed over the study period.  One hundred and seventy one 
patient casenotes were  incomplete and  letters were sent to the  relevant  GPs.  After both  letters 
and telephone calls,  a total of  13 patients’ details were incomplete to varying degrees (none to a 
degree that prohibited further analysis).  96% of patients in the study were still with the same GP 
practice  up to  10  years  after  initial  treatment  at the  hospital,  suggesting  a  stable  population  on 
which the study was performed, within an identical catchment area.
The clinicopathological variables of the patients included are shown  in Table 3.4.1.1.  Of the 290 
melanomas diagnosed  in the whole study population  (irrespective of  route of referral),  62% were 
diagnosed  in  women  (n=180),  38%  in  men  (n=110)  (Figure  3.4.1.1).  A  total  of  4399  patients 
attended the PLC over the study period (1993-1996), with an average attendance of 28.2 patients 
per clinic.  The melanomas diagnosed accounted for 2.1% of all referrals.  748 non-melanoma skin 
cancers  were  treated  via  the  PLC.  The  distribution  of  melanoma  patients  between  the  three 
groups  is  illustrated  in  Table  3.4.1.  Seventy-eight  melanomas  were  diagnosed  before  the 
establishment of the PLC (“pre-PLC”),  119 were diagnosed via normal  routes of referral once the 
PLC was established (1993-1996; “non-PLC”), and the remaining 93 melanomas were diagnosed 
via the PLC (Table 3.1.4.2).
Figure 3.4.1.1  Proportion of male and female melanoma patients over study period
98Variable Results
Number of patients in cohort 290
Mean age at diagnosis 58.14 (range 18-97)
?:c? 1.6:1
Site of melanoma (%) [$:$]:
Head & neck 49 (16.9%) [1:1.08]
Trunk 70 (24.14%) [1:1.45]
Upper limb 51  (17.59%) [1.2:1]
Lower limb 120 (41.38%) [5:1]
Tumour subtypes represented (%):
Superficial spreading 157 (54.14%)
Lentigo maligna melanoma 22 (7.59 %)
Nodular melanoma 95 (32.76 %)
Acral lentiginous 7 (2.41  %)
Other 9 (3.1  %)
Mean Clark’s level 3.49 (range 2-5)
Mean tumour thickness 2.56 mm (range 0.1  - 35mm)
Median tumour thickness 1.6 mm
Number of ulcerated melanoma (%) 60 (20.7 %)
Number developing regional recurrence (%) 83 (28.62 %)
Number of patients surviving in cohort (%) 161  (55.5%)
Table 3.4.1.1  Details of patients and melanomas included in the study.
Route of referral
Number of melanomas diagnosed
Pre-PLC 78
PLC 93
Non-PLC 119
Table 3.4.1.2  Distribution of melanomas within study
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Figure 3.4.1.2  Number of melanomas diagnosed each year of the study period
The number of melanomas diagnosed each year varied, but the general trend was of an increasing 
incidence (Figure 3.4.1.2).  The proportion of melanomas diagnosed via the  PLC, compared with 
parallel  routes  of  referral  increased  after  its  establishment,  with  the  highest  proportion  being 
diagnosed in 1995 (Figure 3.4.1.3).
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Figure  3.4.1.3  Proportion  of  melanomas  detected  via  the  PLC  over  the  study  period.  The  PLC  was 
established in 1993.
At  best,  when  the  GP  suspected  a  diagnosis  of  melanoma,  the time from  GP  visit to  specialist 
consultation was two weeks.  After consultation a further delay of around a week was incurred in 
arranging  the  surgery,  resulting  in  a  minimum  delay of three  weeks  between  GP  diagnosis and 
excision.  If there was no suspicion of malignancy by the GP patients waited up to 22 weeks before 
review  by a  specialist.  This  then  translated  into a  delay  of  23  weeks  until  excision.  The  PLC
100however, conferred a maximum time delay of one week and a minimum of same-day consultation 
and excision.
3.4.2  Results according to Breslow depth
Figures 3.4.2.1  and 3.14.2.2 illustrate the trends in melanoma depth according to year of study.  A 
trend  of  increasing  thin  (<1.0mm)  melanomas  with  each  year  was  found,  with  an  exception  in 
1992, in which a very high proportion was thin.
When  comparing  the  percentage  of  thin  melanomas  in  the  pre-PLC  group  with  all  melanomas 
diagnosed  between  1993-1996,  there  were  a  higher  proportion  of  thin  melanomas  seen  in  the 
latter group.  However, this was not statistically significant (x23.76, p=0.2880) (Figure 3.4.2.3).
1991  1992  1993  1994  1995  1996
year
■ % <1.0 melanomas  ■ % 1.01 -2.0 melanomas
H% 2.01-4.0 melanomas IH%>4.01  melanomas
Figure 3.4.2.1  Proportions of melanomas of varying thickness according to year.
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Figure 3A.2.2  Proportions of melanomas of varying thickness according to year.
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Figure 3.4.2.3  Comparison of melanomas detected pre-PLC (1991-1992) and all melanomas detected after 
the inception of the PLC (1993-1996)
There was a significant difference in the thickness of melanomas seen in the PLC when compared 
with both the pre-PLC group and the non-PLC groups (pre-PLC vs. PLC, x217.23, p=0.00063; non- 
PLC vs. PLC, X2  31.9, p=0.00000085) (Figs. 3.4.2.4 & 3.4.2.5).
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Figures 3.4.2.4 & 3.4.2.5  Results according to Breslow depth with respect to route of referral.
3.4.3  Survival analysis
Survival  curves  were  plotted  and  Log  Rank tests  were  performed  on  the  data,  which  was then 
analysed using  Chi-squared tests.  A highly significant improvement in survival was shown when 
comparing  pre-PLC  with  PLC  patients  (x2   18.1924,  p<0.0001)  (Fig.  3.4.3.1).  At  5-years  post­
diagnosis, 62% of pre-PLC patients were alive, compared with 86% of PLC patients.
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Figure 3.4.3.1  Survival  curves  comparing  PLC  (1993-1996)  patients  with  pre-PLC  (1991-1992)  patients. 
Log rank x2  18.1924, p<0.001.  ---------  PLC patients,  pre-PLC patients.
It was possible that this was the result of a “creaming-off” effect, whereby the PLC had purely been 
seeing  better  prognosis  melanomas  for  reasons  discussed  in  section  3.5.3  below.  Taking  this 
potential confounding factor into account, the analysis was repeated, this time comparing the “pre- 
PLC”  group  with  all  those  patients  diagnosed  with  melanoma  after  the  inception  of  the  PLC, 
irrespective of route of referral.  Figure 3.4.3.2 illustrates that even when comparing the “pre-PLC” 
group with all those patients diagnosed with melanoma after the inception of the PLC,  irrespective 
of  route  of  referral,  there  is  still  a  statistically  significant  difference  in  survival  (x2  4.3577, 
p=0.0368).  This suggests that the previous result cannot simply be explained by a “creaming-off” 
effect.  The 5-year survival for the patients seen after the inception of the PLC, irrespective of route 
of referral, is 72% compared with the pre-PLC 5-year survival of 62%.
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Figure 3.4.3.2  Survival curves comparing all melanoma patients 1993-1996, irrespective of route of referral
compared with pre-PLC patients.  Log Rank x2  4.3577, p = 0.0368    pre-PLC  patients
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Figure 3.4.3.3  Survival curves comparing PLC and non-PLC melanoma patients (both 1993-1996).  Log 
Rank x2  21.4185, p<0.0001.    PLC  patients..........non-PLC patients
105When  the  survival  of  non-PLC  patients  is  compared  with  the  survival  of  PLC  patients,  the  PLC 
patients still show an improved survival (x2 21.4185,  p<0.0001) (Fig.  3.4.3.3).  The 5-year survival 
of  non-PLC  patients  is  59%,  compared  with  86%  for  the  PLC  patients.  Figure  3.4.3.4 
demonstrates  that  there  was  no  difference  in  outcome  between  the  pre-PLC  and  non-PLC 
patients.
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Figure 3.4.3.4  Survival curves comparing pre-PLC and non-PLC melanoma patients.  Log Rank x2  0.0074, 
p = 0.9315      non-PLC  patients....pre-PLC patients
3.4.4  Recurrence rates
Both  local  and  regional  recurrence  rates  over  the  study  period  are  summarised  in  Table  3.4.4. 
Patients diagnosed in the PLC developed far fewer regional and local recurrences than those seen 
either before the establishment of the PLC or in routine outpatients in parallel to it.
106Regional recurrence
Number
Number of patients 
in group % Recurrence
pre-PLC 29 78 37.18
non-PLC 47 119 39.50
PLC 13 93 13.98
Total 89 290 30.69
1993-1996 60 212 28.30
Local recurrence
Number
Number of patients 
in group % Recurrence
pre-PLC 10 78 12.82
non-PLC 23 119 19.33
PLC 6 93 6.45
Total 39 290 13.45
1993-1996 29 212 13.68
Table 3.4.4  Rates of regional and local recurrence.
3.4.5  Regional recurrence rates
Each  year  there  were  consistently  fewer  lymph  node  recurrences  in  those  patients  whose 
melanomas had been diagnosed via the  PLC  (Fig.  3.5.1).  However this difference did not reach 
significance  (x2  5.77,  p=0.12),  possibly due  to  the  low  numbers  of  patients  with  recurrences:  in 
1994 and  1995 there were 9 recurrences in the non-PLC group both years compared with 2 and 3 
in the PLC group, respectively.  A comparison of the proportion of recurrences between subgroups 
is shown in Table 3.5.1.
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Fig. 3.4.5.1  Number of lymph node recurrences according to route of referral.
An  increase  in  length  to  lymph  node  recurrence  was  observed  when  comparing  those  patients 
diagnosed “pre-PLC” with those diagnosed via the PLC (x2 13.8487, p=0.0002) (Fig. 3.4.5.2).  In a 
similar  manner  to  that  employed  when  analysing  patients  survival,  to  ensure  that  this  highly 
statistically  significant  improvement  in  regional  recurrence  rates  was  not  a  result  of  having 
creamed  off  the  better  prognosis  melanomas  into  the  PLC  group,  the  analysis  was  repeated 
comparing  the  pre-PLC  patients  with  all  melanoma  patients  diagnosed  between  1993-1996, 
irrespective of route of referral.  Again, a statistically significant difference between the groups was 
observed (x2 5.2773, p=0.0216) (Fig. 3.4.5.3).  When the length to recurrence of non-PLC patients 
was  compared  with  the  PLC  patients,  the  statistically  significant  improvement  in  outcome  of  the 
PLC patients was maintained  (x2 17.0164, p<0.0001) (Fig. 3.4.5.4).
Regional recurrence Chi-squared P-value
PLC - pre-PLC 12.32 0.00045
PLC - non-PLC 16.75 0.000043
Table 3.4.5.1  Comparison of rates of recurrence between subgroups
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Figure 3.4.5.2  Regional recurrence curves comparing PLC and pre-PLC patients.  Log Rank x2 13.8487, p
= 0.0002  ---------  proportion of PLC patients regional recurrence-free    proportion of pre-PLC
patients regional recurrence-free.
1 .0 - t -
0.9-
0.8 -
1
8 c
2
0.7 -
0.6 -
5   0.5 -
C  0.4 - 
.2
I   0.3-
2
0.2 -
0.0
60 40 80 100 120 0 20
Length to recurrence (months)
Fig.  3.4.5.3  Comparison  of  length to  nodal  recurrence  between  pre-PLC  (1991-1992)  and  all  melanoma
patients 1993-1996. Log Rank x2  5.2773, p = 0.0216.      proportion  of  all  1993-1996  patients
regional recurrence-free    proportion of pre-PLC patients regional recurrence-free.
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Figure 3.4.5.4  Comparison of length to nodal  recurrence between  non-PLC and  PLC melanoma patients
(both 1993-1996).  Log Rank x217.0164, p <0.0001  ---------  proportion  of  PLC  patients  regional
recurrence-free,  proportion of non-PLC patients regional recurrence-free.
3.4.6  Local recurrence rates
Analysis of local recurrence rates demonstrated a significant difference between pre-PLC patients 
with  PLC patients (x2 6.4883,  p=0.0109).  On this occasion,  however, the difference between pre- 
PLC  patients  and  all  those  diagnosed  between  1993-1996  was  not  statistically  significantly 
different  (x2  0.8076,  p=0.3688).  However,  a  significant  difference  was  shown  when  comparing 
non-PLC patients with PLC patients (x2 18.4898, p<0.0001) (Results summarised in Table 3.4.6.1).
Analysis performed  Log Rank x2  P value
pre-PLC vs. PLC  6.4883  0.0109
pre-PLC vs. all 1993-1996  0.8076  0.3688
non-PLC vs. PLC  18.4898  0.0001
Table 3.4.6  Comparison of  length to local recurrence between subgroups
1103.4.7 Disease control
The  presence  of  any  recurrence  was  then  analysed  under  the  heading  “disease  control”;  i.e. 
whether the patients developed either a local or regional recurrence.  The groups were compared 
in a similar way to above.  The results are summarised in table 3.4.7.
Groups compared X2 Value P value
pre-PLC vs. PLC 20.1555 <0.0001
pre-PLC vs. all 1993-1996 1.9520 0.1624
non-PLC vs. PLC 88.1080 <0.0001
Table 3.4.7  Comparison of development of disease recurrence between groups.
Ill3.5  DISCUSSION
Pigmented lesion clinics are dedicated to the facilitation of rapid referral to a specialist for clinically 
suspicious lesions.  They have become popular in the last 20 years because of concerns about the 
increasing incidence of melanoma and the need to provide primary care physicians with a form of 
rapid  referral  system.  To date no published study has looked at the effect of a pigmented  lesion 
clinic  on  survival,  recurrence  rates  and  disease-free  interval  in  melanoma.  The  PLC  at  Mount 
Vernon  differs  from  some  other  units  in  that  it  is  run  on  a  “no-appointment”  basis;  other  units 
require appointments to be made prior to attendance.
3.5.1  Demographics and melanomas
In  this  study 290  patients with  melanoma were  reviewed  in  total.  The female to  male  ratio was 
1.6:1,  which  compares with  other data  on  sex distribution  of  melanoma  (1.5:1  in  MacKie  &  Hole 
1992;  1.8:1  in  MacKie  et  al.,  1992;  1.5:1  in  de  Rooij  et  a/.,  1995).  The  site  distribution  of 
melanomas was predominantly the legs in women and the trunk in men.  This pattern followed that 
established  in  the  literature and  corresponds to the  sites  most often  exposed to the  sun  in  each 
sex (Mihm  MC et al.,  1975;  Koh  1991;  MacKie 1998;  Langley et al.,  1998;  Smolinski  et ai, 2001). 
The  variation  in  subtype  of  melanoma  was  similar  to  that  described  elsewhere,  with  a 
predominance  of  superficial  spreading  melanomas  (Mihm  et al.,  1975;  McGovern  et al.,  1973). 
However,  in this series, there were a relatively high  proportion  of nodular melanomas,  at 32.76% 
compared with other series, which describe frequencies of 15% - 30% (Mihm et al.,  1975; Clark et 
al., 1975; McGovern et al.,  1973).
3.5.2  Melanomas diagnosed via the PLC
2.1% of diagnoses made via the PLC over the study period were melanomas.  This compares with 
1.6%  in  Florence  (Carli  et al.,  2002),  2.17%  in  Leicester  (Graham-Brown  et al.,  1990),  2-5%  in 
Edinburgh  (Herd  et al.,  1995), 2.6% at St. George’s Hospital, Tooting  (Mallett et al.  1993,  Bataille 
etal. 1999), 3.1% seen in Dublin’s PLC (O’Connor & Barnes,  1994) and 5.65% in Duff etafs study 
of the PLC at The Frenchay hospital in Bristol (Duff et al., 2001).  An explanation for the relatively 
low proportion of melanomas being diagnosed at early detection  pigmented lesion clinics may be
112the  result  of  GPs  being  less  discriminating  in  their  diagnoses  (i.e.  referring  a  large  number  of 
benign  naevi),  or  not  utilising  the  PLC  appropriately.  Both  of  these  factors  will  be  discussed  in 
depth below.
In terms of other PLC studies, O’Connor and Barnes reported melanoma patients seen at a PLC in 
Dublin.  Eighty per cent of  PLC  patients’  melanomas were  1.5mm  or  less  in  depth  (O’Connor & 
Barnes,  1994).  In  their  analysis,  however,  they  compared  their  PLC  data  with  data  from  other 
studies,  rather than their own non-PLC data.  Thus it is difficult to interpret the significance of this 
finding.  A 9-year retrospective audit of the  PLC at St.  George’s  Hospital,  Tooting  (Bataille  et al., 
1999)  did  not find  any change  in thickness of  melanomas over time.  No comparison  was  made 
with  melanoma  patients  seen  before the  advent of the  PLC  or with  “non-PLC”  patients.  Duff  et 
a/.’s  review  of the  pigmented  lesion  clinic at The  Frenchay  Hospital  in  Bristol  (Duff  et al.,  2001) 
looked  at the trend  of  melanoma thickness over time,  but again  did  not use a  control  group with 
which  to  compare.  There  was  no  significant  reduction  in  mean  Breslow  thickness  with  time, 
although a trend in that direction was observed.
3.5.3  Under-utilisation of PLCs
Of  the  212  melanomas  diagnosed  1993-1996,  only  43.87%  were  diagnosed  via  the  PLC.  The 
maximum proportion of melanomas diagnosed via the PLC over the study period was 57.4% of the 
total,  in  1995.  The  pigmented  lesion  clinic  was  designed  to  be  a  rapid  referral  system  enabling 
melanomas to be diagnosed with as minimal a time delay as possible,  however, this illustrates a 
marked under-utilisation.  Other published series on PLCs have noted similar findings (Melia et al., 
1995, Osborne etal.,  1998, Osborne & Hutchinson 2001).
Reasons for this under utilisation may be because GPs see the PLC as a diagnostic service, rather 
than a treatment or rapid referral system as suggested by Herd  et al.  (Herd et al.,  1995).  There is 
also  an  argument  that  GPs  preferentially  refer  less  suspicious  lesions  to  the  PLC  rather  than 
routine outpatients.  If a GP is certain of the diagnosis of a melanoma, they may be more confident 
of writing  a letter of referral to dermatology or plastic surgery consultants’  outpatient clinics,  such 
as in the case of a nodular melanoma.  Whereas,  if they are unsure of the diagnosis,  as may be 
the  case for thin,  early  melanomas,  they  may  rather  preferentially  refer to the  PLC,  so as  not to 
have to commit themselves to a definitive diagnosis.  In this way,  if they felt the lesion  unlikely to 
be  a  melanoma,  but  were  not  completely  sure,  the  patient  will  nevertheless  be  seen  quickly.
113Therefore, if the lesion did in fact turn out to be a melanoma, they would not be responsible for any 
delays incurred.  In a letter to the Lancet Ibbotson  et al. from Newcastle, whose department does 
not  run  a  PLC,  reviewed  GP  referral  letters  (Ibbotson  et al.,  1995).  Those  patients whose  GPs 
suspected melanoma were seen within a median of 13 days and the melanomas had an average 
thickness of 0.9mm, but in those in which the GPs did not suspect melanoma, the median time to 
be seen was 69 days and the mean thickness was 3mm.  This supports the notion that GPs may 
preferentially refer cases in which they are uncertain of the diagnosis,  as  in  early melanomas, to 
PLCs,  rather than  outpatient departments,  to  minimise  potential  delays  incurred  as  the  result  of 
misdiagnoses.  Finally,  under-use  of the  PLC  could  also  be  due  to  new  GPs  to the  area  being 
unaware of its existence, and those already established forgetting to refer to the PLC,  if not done 
regularly.
The consequence of not using the  PLC,  and  referring to  normal  outpatient clinics,  is of course a 
delay in time to excision of the melanoma.  In order to encourage the use of the PLC as the sole 
referral point for suspicious skin  lesions, annual  reminders could be sent out -  although this may 
encourage  an  increase  in  referral  of  benign  lesions  (Whitehead  et al.,  1989).  To  minimise  the 
referral of benign lesions, regular updates as to the presenting features of melanoma could be sent 
to GPs.  In Scotland the quality of the referral letters rose noticeably after the GPs were updated 
about the  presenting  features  of  melanoma  prior to  a  publicity  campaign.  Most  of their  referral 
letters  now  clearly  indicate  the  degree  of  suspicion  that  the  lesion  is  a  melanoma  and  offer 
appropriate differential diagnosis (MacKie & Hole 1992).
3.5.4  Trends in melanoma incidence
A  general  increase  in  the  total  number of  melanomas  diagnosed  each  year was found,  and  the 
observed trend of increasing proportions of thin melanomas being diagnosed with each year mirror 
results of other studies  (Doherty &  MacKie  1988;  Burton  et al.,  1993;  Burton  &  Armstrong  1994; 
Herd  et al.,  1995;  MacKie  et al.,  1997;  Jemal  et al.,  2001;  MacKie  et al.,  2002).  This effect has 
been put down to an increasing public awareness of the dangers of increased sun exposure, more 
vigilance  in  the  community  and  therefore  earlier  presentation  to  physicians  (Herd  et al.,  1995; 
MacKie etal., 1997).
1143.5.5 Melanoma thickness and survival
The  single  most  important  variable  in  melanoma  prognosis  remains  maximum  tumour thickness 
(Breslow  1970,  1975;  Barnhill  et  al.,  1996;  Balch  et  al.,  2001;  Ng  et  al.,  2001;  Osborne  & 
Hutchinson  2001).  Efforts  focused  on  the  early  detection  of  melanoma  are  based  on  the 
assumption that early melanomas will be thinner, as a result of their natural history, and so have a 
better prognosis.  Thus the aim of a  PLC  is to provide a  method for early detection  and  surgical 
intervention in melanoma thereby contributing to an improved survival and a reduction in mortality 
from  this  condition.  Other  PLC-based  studies  have  therefore  investigated  tumour  depth  as  a 
measure of survival  (Mallett  et al.,  1993;  Herd  et al.,  1995;  Kirkpatrick  et al.,  1995;  Grover et al., 
1996).  In this study, a statistically significant improvement in both tumour depth and survival was 
found  for the  melanoma  patients  diagnosed  via  the  PLC  when  compared  with  those  diagnosed 
before its inception.  The thinner tumours in the PLC group bear out the results of a previous study 
from the PLC at Mount Vernon Hospital that suggested that this might affect improved survival for 
those patients being diagnosed  in the PLC (Grover et al.,  1996).  Other previous studies that also 
found  a  decrease  in  thickness  in  PLC-diagnosed  tumours  include  those  by  Herd,  O’Connor  & 
Barnes  and  Osborne  &  Hutchinson  (Herd  et  al.,  1995;  O’Connor  &  Barnes  1994;  Osborne  & 
Hutchinson  2001).  However,  these studies compared  their  PLC  groups with  patients from other 
studies  (O’Connor  &  Barnes,  1994)  or only those from  other  clinics  that  ran  in  parallel  with  the 
PLC,  rather  than  “pre-PLC”  patients  as  well  (Herd  et  al.,  1995;  Osborne  &  Hutchinson  2001). 
Some  studies  investigating  the  effect  of  a  PLC  on  tumour  depth  have  found  no  statistically 
significant improvement in tumour thickness (Mallett et al.,  1993,  Kirkpatrick et al.,  1995), although 
in one of these studies, trends toward thinner melanomas were seen in the PLC group (Kirkpatrick 
etal.,  1995).
No other study has so far shown an improvement in survival in melanoma patients whose tumours 
were  diagnosed  via  a  PLC.  As  discussed  above,  the  influence  of  this  improvement  being  the 
result of a “creaming off” the better prognosis melanomas into the PLC group was investigated by 
comparing  the  pre-PLC  group  with  all  melanoma  patients  diagnosed  between  1993-1996, 
irrespective of  route of referral.  This comparison  still  showed an  improvement in the  PLC group, 
thereby suggesting that a “creaming off” effect alone could not explain the survival benefit.  As well 
as demonstrating the  better  prognosis  of  PLC  patients when  compared with  pre-PLC  patients,  a 
significant  improvement  in  survival  is  also  shown  when  comparing  them  with  non-PLC  patients, 
which  has  been  shown  in  the two  other  PLC  studies  (Herd  et al.,  1995;  Osborne  &  Hutchinson 
2001).  The present study,  however,  is the first to show an  improvement in survival compared 
with both a parallel control group and an historical one.
1153.5.6 Non-metastasising forms of thin tumours
Some authors have suggested a form of melanoma may exist, which,  if not detected, would either 
regress spontaneously or not progress and would not metastasise (Clark et al.,  1989; Burton et al.,
1993).  Burton  and  Armstrong  compare  it with  the  situation  in  breast cancer  in  which the  recent 
increase in incidence has been attributed to the introduction of screening mammography (Burton & 
Armstrong  1994).  There is concern that many of these cancers would not have become clinically 
apparent during the lifetime of the patient.  This is in accordance with the findings of autopsies on 
women  not previously diagnosed with  breast cancer;  and  autopsy and  biopsy studies on  women 
with breast cancer, which have detected a much higher prevalence of the disease than the known 
incidence of first and  bilateral  breast cancer would  have  predicted  (Neilsen  et al.,  1987).  Burton 
proposes that there  is  a  pathway  of  development  of  cutaneous  melanoma,  which  leads  only  to 
local invasion and precludes the development of metastatic potential  (Burton  et al.,  1993).  If this 
were true, then pigmented lesion clinics and screening of melanoma would lack specificity for fatal 
disease.  This has led some authorities to propose that early excision will  have no real impact on 
survival,  as they argue that thin  lesions may well  remain  static indefinitely,  not undergo a vertical 
growth  phase and  subsequently have  no substantial  effect on  mortality  (Swerlick & Chen  1996). 
In  this  study,  however,  it  appears  that  the  reduction  in  tumour  depth  in  the  PLC-diagnosed 
melanomas does have an impact on survival, contradicting such authors’ arguments.
In addition, the hypothesis that some thin lesions would never have the capacity to metastasise is 
impossible to prove, as the entire lesion must be excised and examined pathologically to establish 
the  diagnosis  and  growth  phase.  Therefore  one  cannot  predict  the  future  behaviour  of  these 
lesions  if  left  in  vivo.  MacKie  suggests  that  long-term  follow-up  of  patients  who  have  had  thin 
primary  tumours  excised  is  needed  to  establish  whether  they  are  truly  cured,  or  whether 
disseminated  tumour  cells  are  present  even  at  an  early  stage  that  will  eventually  develop  into 
metastatic deposits and cause the patient’s death (MacKie 1997).  The fact that patients who have 
such  lesions  excised  whilst  still  in  the  radial  growth  phase  have  later  developed  metastases 
indicates that conventional microscopic examination is not enough to positively exclude metastatic 
potential,  and therefore this alone justifies the  removal  of  early  invasive  (Clark’s  level  2)  primary 
melanomas.  Besides,  even  if  a  proportion  of  melanomas  were  not  to  progress,  the  benefit  of 
increased sensitivity at the expense of specificity,  is undoubtedly worth gaining for those patients 
with the progressive form of the disease.
1163.5.7 Lead-time bias
The evaluation  of screening  programmes such as that for breast cancer has  led to awareness of 
the  confounding  factor of  lead-time  bias.  Patients  who  are diagnosed  at an  early stage  in  their 
illness  may  appear  to  survive  longer  than  those  diagnosed  at  a  later  stage  only  because  the 
diagnosis  is  established  for  a  longer  period  of time.  It  may  be  argued  that  the  improvement  in 
survival  of the  PLC  group  has  arisen  due to  lead-time  bias.  The  melanomas diagnosed via the 
PLC have been  shown to be thinner,  and whether or not this is due to lead-time bias,  excision at 
this stage offers patients the only chance of cure.  Thus any effect of lead-time bias is diluted, as 
the same patients diagnosed at a later stage may have missed the potential of being cured.
In  addition,  if  lead-time  bias  were  to  be  a  factor  in  explaining  the  thinner  melanomas  being 
diagnosed  in  the  PLC,  it  would  be  expected  that  there  would  be  a  decrease  in  the  number  of 
melanomas  being  diagnosed  after  a  sufficient  time  lag  for  the  previously  expected  time  of 
diagnosis.  There would  also  be a decrease  in the  number and  proportion  of thick  lesions  being 
diagnosed  after  a  time  period.  It  has  been  shown  in  this  study that the  number  of  melanomas 
diagnosed each year actually continues on an increasing trend, and there is no overall decrease in 
the thickness of melanoma diagnosed with time (Figure 3.4.1.2).  This reasoning  does assume a 
relatively  stable  incidence  of  melanoma  in  the  population.  Despite  other  studies  (Doherty  & 
MacKie  1988;  Burton  et al.,  1993;  Burton  &  Armstrong  1994;  MacKie  et al.,  1997;  Jemal  et al., 
2001) showing the incidence of melanoma continuing to rise; they also show that this rise is now 
levelling off,  so this argument is still valid.  Thus the impact of lead-time bias is again negated, or 
at least much  reduced.  Finally, discussions on lead time bias also do not allow for the fact that a 
clone  of  cells  with  full  metastatic  potential  might  develop  in  an  untreated  initially  in-situ  primary 
melanoma.  Some  of these  cells  could  move from  the  primary  site  before the  primary tumour  is 
eventually excised.  This justifies the detection  and  excision  of  melanomas as early as  possible, 
however much the influence of lead-time bias.
3.5.8  Length-time bias
Slow-growing tumours are detectable for longer at an early stage than fast-growing  ones and will 
therefore be preferentially identified by any early diagnosis strategy.  Therefore it would seem that 
by  looking  at the  decrease  in  melanoma depth  alone,  there  is  a  chance that the  benefits of the 
PLC are due to an  increased  number of slow-growing  melanomas  being diagnosed.  However,  if
117this  were  the  case,  any  impact  on  survival  would  most  likely  be  minimal,  as  the  slow-growing 
tumours  would  also  be  of  low  metastatic  potential.  It  has  been  shown  here  that  survival  has 
improved  in  those  diagnosed  via  the  PLC  (Figures  3.4.3.1-3).  Therefore,  length-time  bias  is 
unlikely to have occurred.
3.5.8  Recurrent disease
There were fewer  lymph  node  recurrences  in  the  PLC  group when  compared  with  both the  pre- 
PLC  and  the  non-PLC  groups  (x2  12.32,  p  =  0.0005;  x2  16.75,  p  =  0.0005  respectively).  A 
statistically  significant  improvement  was  demonstrated  in  the  length  of time  elapsing  before the 
occurrence of regional metastases in those patients diagnosed with  melanoma via the pigmented 
lesion  clinic  when  compared  with  those  diagnosed  prior  to  its  inception  and  with  patients 
diagnosed via existing  routes of referral.  This was on  a background  of population-based studies 
that have shown overall mortality from melanoma in the UK over the study period to stay constant 
and actually increase for men  (La Vecchia et al.,  1999;  MacKie  et al., 2002).  This would suggest 
that the disease-free interval for the study population would be expected to have at best remained 
stable,  however an improvement in disease-free interval in the PLC patients over the study period 
was  observed.  Metastases  form  once  the  melanoma  has  transformed  from  the  radial  into  the 
vertical  growth  phase  (Elder  et  al.,  1984).  Therefore,  if  excision  is  performed  at  the  earliest 
opportunity  there  is  a  chance  of  cure  as  the  lesion  may  be  excised  before  it  has  reached  the 
vertical growth phase and therefore before it has developed the capacity to metastasise.
Local  recurrence  is  believed  to  be  an  indicator  of  biological  aggressiveness  and  is  also  used 
clinically to assess the adequacy of surgical treatment  (Karakousis  et al.,  1998;  Ng  et al., 2001). 
Despite  the  improved  survival  and  increased  length  to  recurrence  in  the  1993-1996  melanoma 
patients compared with  those diagnosed  prior to the establishment of the  PLC, this improvement 
did  not  reach  significance  (Table  3.4.6).  The  PLC  group  did  however  have  a  significant 
improvement in length to local recurrence when compared with the “pre-PLC” group and the “non- 
PLC” group.  This was probably due to the relatively small number of patients that developed local 
recurrences, thus statistical tests not reaching significance.
1183.5.10 Delays
The  next  point  of  discussion  is  the timing  of  the  excision.  PLCs  work  on  the  rationale  that the 
earlier the tumour  is  excised,  the  better the outcome.  PLCs aim to  minimise  any delays,  but,  of 
course, can  have no impact on patient delay in seeking medical attention, which has been shown 
to be of importance (Temoshok et al., 1984; Doherty & MacKie 1986; Rampen et al., 1989).
Significant  delays  often  occur  after  consultation  of  the  primary  care  physician.  The  delays  are 
often due to a combination of the bureaucracy of the healthcare system and either the failure of the 
primary care physician to recognise a lesion as suspicious (Cassileth  et al.,  1988;  Rampen  et al., 
1989;  Krige  et al.,  1991)  or failure  to  convey  this  point  in  the  letter  of  referral  (Ibbotson  et al., 
1995).  The difference  in  time  between  referral  from  the GP to the consultation  between  routine 
clinics and the PLC in this study also depended upon the suspected diagnosis by the GP.  At best, 
when the GP suspected a diagnosis of melanoma, the time from GP visit to specialist consultation 
was two weeks.  After consultation a further delay of around a week was incurred in arranging the 
surgery, resulting in a minimum delay of three weeks between GP diagnosis and excision.  On the 
other hand, if there was no suspicion of malignancy by the GP patients may have had to wait up to 
22  weeks  before  review  by  a  specialist.  This  then  translated  into  a  delay  of  23  weeks  until 
excision.  The  PLC  however,  conferred  a  maximum  time  delay  of  one  week  and  a  minimum  of 
same-day consultation and excision.  The PLC thus offers a safety net for those instances in which 
previously  unsuspected  lesions  would  be  picked  up  without  the  time  delay  that  would  have 
otherwise  been  incurred.  Osborne  et  al.  examined  the  mean  referral  interval  between  GP  and 
clinic appointment, comparing  PLC and non-PLC patients in Leicester,  UK (Osborne et al.,  1998). 
The  overall  mean  referral  interval for the  11-year  study  period  was  7  days,  compared  with  19.5 
days to  plastic  surgery and  38.4 days to dermatology  routine  outpatient clinics,  showing  a clear 
reduction  in  delay  between  referral  and  appointment.  Of  course  delays  due  to  misdiagnosis  by 
hospital specialists will  not be altered by a pigmented  lesion  clinic.  However,  hospital  specialists 
have an improved diagnostic accuracy when compared with primary care physicians (Paine et al.,
1994)  and trainees (Morton & MacKie 1998).
3.5.11  Publicity campaigns
Tactics  used to  overcome the  patient delay factor are  usually  in  the form  of  publicity campaigns 
involving  local  media,  leaflets  and  posters.  Both  Healsmith  et  al.  and  Graham-Brown  et  al.
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in the proportion  of thin  lesions,  although this did  not  reach  statistical  significance  in  either study 
(Graham-Brown  et al.,  1990;  Healsmith  et al.,  1993).  After a Scottish  publicity campaign  in  1985, 
MacKie  &  Hole  found  a  significant  increase  in  the  numbers  of  melanomas  diagnosed,  mainly 
confined to thin, good prognosis lesions (MacKie & Hole 1992).  There was also a reduction in the 
number  of  thick  melanomas  in  women,  but  not  men,  implying  that  the  campaign  succeeded  in 
delivering the message of early detection to women but not men.  In a later study by MacKie et al, 
a  reduction  in the annual  mortality rate from melanoma was  reported among women  living  in the 
whole of Scotland  (MacKie  et al.,  1997).  This  reduction,  however,  occurred  almost  immediately 
after the start of the intervention.  Given the good survival for melanoma in the first five years,  it is 
debatable whether this was a result of the 1985 campaign.  In contrast, Herd et al., did not find any 
significant change  in the  rate of diagnosis of melanoma in  Edinburgh  after 2  publicity campaigns 
(Herd et al.,  1995).  A later study on melanoma mortality trends between different populations also 
did  not  find  a  correlation  between  improvements  in  mortality  with  local  and  national  melanoma 
prevention campaigns (Severi et al., 2000).
In  conclusion,  studies  into  the  effectiveness  of  publicity  campaigns  are  inconsistent,  and  when 
showing  an  improvement  in  melanoma  diagnosis  it  is  usually  short-lived.  The  downside  of 
publicity campaigns is the massive increase in attendance of pigmented lesion clinics, often with a 
disproportionate  number  of  benign  lesions  (Whitehead  et  al.,  1989).  However,  de  Rooij  and 
colleagues found that by concentrating public awareness and GP education purely on  melanoma, 
rather than  including  non-melanoma  skin  cancer,  increases  in  the  detection  rates  of  melanoma 
and  lesions  suggestive  of  melanoma  (such  as  dysplastic  naevi)  were  achieved  (de  Rooij  et al.,
1995).
3.5.12  PLCs and publicity campaigns
Some  authors  argue  that  PLCs  only  result  in  reducing  the  mean  depth  of  melanoma  at 
presentation  (and  hence  mortality)  if  such  a  publicity  campaign  is  instigated.  Mallett  et  al. 
compared the thickness of melanomas excised in two neighbouring health authorities, only one of 
which  was  served  by  a  PLC  (Mallett  et al.,  1993).  Following  a  Cancer  Research  Campaign  to 
raise public awareness of melanoma, the PLC had an increase in the number of melanomas seen, 
compared with other clinics, in which no increase was seen.  A consistently greater number of thin 
melanomas in patients attending the PLC compared with normal outpatient clinics were also seen,
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this study;  hence its significance is unknown.  The authors concluded that a PLC might only be of 
benefit  if there  is  a  concurrent  publicity campaign,  although  it  does  nevertheless fulfil  a  demand 
from both GPs and patients.  When  Melia’s group studied data collected from 6 UK district health 
authorities’  PLCs  that  took  part  in  the  Cancer  Research  Campaign’s  (CRC)  early  detection 
intervention  (1987-1989)  and  compared  it with  two  districts  that  did  not  take  part,  no  significant 
difference  in  annual  mortality  rates  were  found,  leading  them  to  conclude  that  awareness 
campaigns were not effective in PLCs and other strategies ought to be pursued (Melia et al.,  1995 
& 2001).
In this pigmented lesion study there has been a significant improvement in survival despite the lack 
of a local publicity campaign since the inception of the PLC.  Thus it would appear that although a 
publicity campaign  may be of benefit in  increasing the number of melanomas diagnosed and the 
proportion of thin melanomas,  it is not essential.  With the continued increase in public awareness 
campaigns each  spring  and  summer,  the effects of  individual campaigns are  harder to evaluate. 
The  earlier  study  on  the  pigmented  lesion  clinic  at  Mount  Vernon  Hospital  found  an  increased 
number of attendees over the spring  and  summer  months  (Grover et al.,  1996),  which  has  been 
reflected in the personal experience of the author.
3.5.13  Alternative strategies
In contrast to pigmented lesion clinics that operate in the U.K. and some other European countries, 
in  the  United  States  members  of  the  public  are  encouraged  to  seek  advice  directly,  bypassing 
GPs.  “Skin Cancer Fairs” or “Free Melanoma Diagnostic Clinics” (Koh  et al.,  1996) are set up for 
varying  periods  of time  in  different  States.  These  clinics  are  free,  and  run  on  the  principle that 
diagnosis and advice is offered, but no treatment is carried out.  The screening days have proven 
to  be  popular,  and  it  has  been found that those who take advantage of them  have an  increased 
number of melanoma  risk factors when  compared  with  the  general  population  (fair skin, fair  hair 
and large numbers of naevi).  Melanomas detected at these fairs and subsequently excised have 
been shown to be thinner than those of the population at large.  The structure of these screening 
days does not, however, allow for changes in mean thickness or in melanoma-associated mortality 
to be assessed.
1213.5.14 Further points of discussion
In addition to the detection  of melanomas,  748  non-melanoma skin  cancers were diagnosed and 
treated after presentation to the PLC.  This made the overall excision rate of skin cancer to be 24% 
for all  patients  referred for surgery, although a significant number of benign  lesions were excised 
as  a  result.  The  proportion  of  benign  lesions  excised  compares  with  that  found  in  other  PLC 
studies,  which  have  shown  ranges  of  58%  -  94%  (Bataille  et  al.,  1999;  Mallett  et  al.,  1993; 
Kirkpatrick  et al.,  1995;  Duff  et al.,  2001).  With regard to melanoma,  96% were treated within 2 
weeks of consultation, the majority being excised immediately (76%).
Other  advantages  of  PLCs  that  are  not  immediately  apparent  from  this  study  are  the  non- 
quantifiable  benefits  including  the  patient  satisfaction  from  the  ease  of  access,  GPs  satisfaction 
from  the  ease  and  rapidity  of  referral  and  the  excellent teaching  opportunity for  both  basic  and 
higher surgical trainees, who can  examine patients  under the supervision  of the consultant.  The 
clinic also provided an  invaluable opportunity for data collection,  patient education  and eases the 
burden  on  other clinics.  Disadvantages of the  PLC  include a  potentially  heavy workload  and  an 
increase  in the  number of  benign  lesions excised.  The  number of  patients attending  each week 
was also unpredictable,  although seasonal variation  is encountered,  with  more  patients attending 
in the summer months (Grover et al.,  1996) as described above.  Since the study period there has 
been  a steady increase  in  attendance of the  PLC  in  parallel  with  increasing  public awareness of 
melanoma and the damaging effects of sunlight, such that now an attendance of between 50 and  j 
90 patients is experienced, the maximum number attending over late summer.  I
3.6  CONCLUSION
This  study  has  shown  a  significant  improvement  in  survival  in  those  patients  diagnosed  with 
melanoma  via  the  PLC.  This  same  group  also  had  a  longer  disease-free  interval  before  any 
recurrences developed.  These results support the use of pigmented lesion clinics as a means of 
improving the outcome for patients with  melanoma and  incorporate the  requirements of the  NHS 
Cancer  Plan.  In  addition  the  PLC  confers  a  benefit  on  the  population  it  serves  and  to  GPs  by 
providing rapid access to experts with an interest in melanoma.
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USE OF TISSUE MICROARRAY TECHNOLOGY TO 
DISCOVER PROGNOSTIC MARKERS FOR
MELANOMA
1234.1  INTRODUCTION
4.1.1  Rationale
With  the  development  of  novel  adjuvant  therapies  that  may  alter  the  long-term  survival  of 
melanoma  patients  (Kirkwood  et  al.,  2001),  the  need  for  accurate  prognostic  markers  for  the 
disease  is  greater  than  ever.  Currently  the  establishment  of  prognosis  in  primary  melanomas 
relies on several clinicopathological variables including  Breslow thickness,  Clark’s level,  presence 
of ulceration,  patient age, tumour site and patient sex (Balch  1992;  Chang  et al.,  1998;  Smolinski 
et al.,  2001;  Balch  et al.,  2001a  &  b).  Once  the  cancer  has  metastasised,  the  most  important 
determinant of prognosis is the nodal status of the patient.  Sentinel lymph node biopsy (Morton et 
al.,  1992)  is  now  widely  practiced  as  a  means  of  accurately  staging  patients  and  predicting 
outcome (Balch  et al., 2001) but is associated with significant morbidity (Hettiaratchy  et al., 2000; 
Jakub et al., 2003) and has not yet been shown to have a bearing on overall patient survival.  Non- 
invasive strategies,  if able to provide similar information, would provide a desirable alternative for 
estimating prognosis.
Normal  epidermal  melanocytes  are  found  at  the  dermal-epidermal  border  amongst  the 
keratinocytes.  Their  proliferation  leads  to  nests  of  mature  melanocytes,  known  as  acquired 
melanocytic  naevi.  With  the  development  of a  melanoma,  their  growth  starts  in  a  radial  growth 
phase,  before  progressing  to  a  vertical,  invasive  phase  where  they  acquire  the  potential  to 
metastasise  (Clark  et al.,  1989).  The  underlying  mechanisms  of this  process  are  complex  and 
poorly  understood;  some  patients  with  thin  melanomas  may  suffer  from  early  metastasis  and 
death, whilst other patients with thick melanomas at the time of surgery are cured (Fearfield et al., 
2001;  Salti  et  al.,  2002;  Kalady  et  al.,  2003).  Establishing  an  accurate  prognosis  is  most 
problematical  in the intermediate thickness (1.01-4.0mm)  melanomas.  If high-risk patients could 
be  more  accurately  identified  at  presentation,  adjuvant  therapy  could  be  justified  and  patient 
outcome improved by treatment prior to the onset of metastatic disease.
1244.1.2 Metastasis formation
The  molecular  basis  of  human  melanoma  progression  and  the  changes  associated  with  the 
transition  of  melanoma  cells  from  the  radial  growth  phase  to  the  vertical  growth  phase  remain 
unclear.  The  production  of  metastases  depends  on  the  completion  of  a  complex,  multistep 
process that  involves the  survival  and  growth  of a  unique  subpopulation  of cells with  metastatic 
properties (Fidler et al.,  1990): tumour progression  and  metastasis  involves the separation  of the 
tumour cells from the  primary tumour mass,  migration through the extracellular matrix,  entry and 
survival within the vasculature, extravasation into a foreign environment and the establishment of a 
new  focus  of  growth.  At  the  core  of  this  process  lie  the  changing  adhesive  properties  of  the 
tumour  cells,  which  dictate  their  interactions  with  the  surrounding  extracellular  matrix  and 
neighbouring cells.
4.1.3  Cell adhesion molecules
Cell  adhesion  molecules  are  cell  surface  molecules  which  bind  specifically to  other cell  surface 
molecules  (ligands)  on  other  cells  or  extracellular  matrix  components.  Cell-cell  adhesion  can 
influence cell growth and survival either indirectly through  signalling cascades or through a direct 
interaction  with  growth  factor  receptors.  Structurally,  many  different  kinds  of  molecules  can 
mediate intercellular adhesion,  but the majority of cell adhesion  molecules known to date fall into 
three gene families:  the integrins, the cadherins and the  immunoglobulin  superfamily  (Chothia  et 
al.,  1997).  Cell  adhesion  molecules  do  not simply function  as  a  molecular glue organising  cells 
into static structural entities, but also support and direct the exchange of information between cells 
(Klymkowsky  et  al.,  1995).  Adhesion  molecules  themselves  actively  participate  in  transducing 
signals  into the cells.  Their prime  role seems to be  in  organogenesis and tissue  remodelling  as 
well as the maintenance of tissue organisation and the direction of leukocyte migration throughout 
the body (Johnson 1999).
Alterations in cell adhesion molecule activity in tumour cells can lead to a disruption of normal cell­
cell  and  cell-matrix  contacts  and  to  the  development  of  new  interactions,  both  of  which  are 
important  aspects  of  metastasis formation  (Johnson  et al.,  1999).  Adhesion  molecules  mediate 
these  interactions  and  modulation  of  adhesion  molecules  has  been  associated  with  metastatic 
spread in melanoma (Xie etal., 1997; Hsu eta!., 2000/
1254.1.4  Integrins
Integrins are heterodimeric cell surface receptors formed by non-covalent association  of an alpha 
chain  with  a  beta  chain  (Hynes  1992).  Integrins  mediate  cation-dependent  adhesion  to 
extracellular matrix molecules and to cell surface ligands.  The ligand specificity is determined by 
the combination of alpha and beta chains and since there are a large number of variations of each, 
many  diverse  cell-cell  and  cell-matrix  adhesion  molecules  can  be  expressed  by  a  given  cell. 
Effective  ligand  binding  by  integrins  requires “activation”,  a  change  in  the  avidity of the  receptor 
due to conformational changes.  These are induced by an “inside-out signal” delivered from other 
receptors  on  the  same  cell  (Hynes  1992;  Hughes  &  Raff  1998).  Compared  with  benign 
melanocytic  lesions,  melanomas  demonstrate  loss  of  expression  of  the  laminin  receptor  a6p1 
(Natali  et al.,  1991)  as well  as an  increase  in the expression  of a4p1  (Schadendorf  et al.,  1995) 
and the vitronectin receptor av(33 (van Belle et al.,  1999).  These integrins seem to be functionally 
important since changes in their expression correlate with prognostic parameters and with clinical 
outcome  in  melanoma  patients  (Natali  et al.,  1991;  Schadendorf  et  al.,  1995;  van  Belle  et  al., 
1999).
4.1.5  Cadherins
Cadherins are a family of calcium-dependent surface glycoproteins that mediate cell-cell adhesion. 
Their extracellular domains connect neighbouring cells, and their cytoplasmic tails are linked non- 
covalently to the actin cytoskeleton via catenins (Johnson 1999).  E- (epithelial), N- (neural) and P- 
(placental) cadherins are expressed in a cell-, tissue- and development-specific manner.  E- 
cadherin is the major cadherin in the human epidermis and the major adhesion link between 
epidermal melanocytes and keratinocytes, whereas fibroblasts and endothelial cells (but not 
keratinocytes) or melanocytes express N-cadherin.
There appears to be a shift in the cadherin expression profile of melanoma cells during melanoma 
progression  (Hsu  et al.,  1996).  Progression of melanoma in the radial growth  phase is intimately 
linked  with  loss  of  E-cadherin,  triggering  release  of  cancer  cells  from  the  primary  cell  focus. 
Normally,  keratinocytes  control  cell  growth,  expression  of  melanoma-associated  cell  surface 
molecules  and  other  functions  of  melanocytes.  However,  melanoma  cells  are  refractory  to 
keratinocyte-mediated  regulation,  and  therefore  also  to  decreasing  motility,  proliferation  and 
invasive potential.  This loss of keratinocyte dominance has  been  shown to occur in parallel with
126downregulation of E-cadherin  (Hsu  et al.,  1996).  Once  E-cadherin  has been  lost the melanocytic 
cells  have the ability to escape from  neighbouring  keratinocytes  and  invade the dermis  (Guilford
1999).  Disruption  of  E-cadherin-mediated  cell  adhesion  is  thought to  facilitate  tumour  invasion, 
whereas  restoration  of  E-cadherin  expression  results  in  growth  retardation  and  inhibition  of  the 
invasive and  metastatic behaviour of melanoma cells  (Christofori  &  Semb  1999).  The  loss of  E- 
cadherin  disrupts  protein  traffic  and  cellular architecture which  both  have  been  suggested  to  be 
primary defects resulting in loss of growth regulation and tumour development (Peifer 2000).  The 
signalling of  E-cadherin  is mediated through  (3-catenin and  subsequent activation of target genes 
(Gruss & Herlyn 2001).  Loss of cadherin frees up p-catenin for intracellular interactions.  The loss 
of E-cadherin expression which is observed in the earliest identifiable malignant lesions, i.e.  radial 
growth phase melanoma,  is a critical event in the development of metastatic potential,  leading not 
only to the expression of new adhesion  molecules  but also to broad changes in gene expression 
which contribute to or even constitute the biological behaviour of melanomas (Klymkowsky et al.,
1995).  Melanoma  cells  express  high  levels  of  N-cadherin  that  may  interact  with  N-cadherin- 
positive  fibroblasts  and  endothelial  cells  (Hsu  et  al.,  1996).  The  N-cadherin-mediated  gap 
junctions between melanoma cells allow the transfer of cell signals essential for tissue function and 
homeostasis.
P-cadherin has not been extensively investigated in melanoma.  Experimental studies have linked 
P-cadherin  expression  to the  progression  of  rat tongue carcinogenesis with  the  possibility that  it 
may activate  mechanisms  responsible for cell  proliferation  (Sakaki  et al.,  2003).  P-cadherin  has 
also been implicated in the higher proliferation rates of aggressive breast carcinomas (Paredes et 
al., 2002).  Regarding melanomas,  in an immunohistochemical study by Sanders and colleagues, 
loss  of  P-cadherin  was  demonstrated  in  the  most  aggressive  vertical  growth  phase  melanomas 
compared with thinner melanomas (Sanders etal., 1999).
4.1.6  Immunoglobulin adhesion molecules
Melanomas  express  a  diverse  group  of  cell  adhesion  molecules  of  the  immunoglobulin 
superfamily.  These  include:  neural  adhesion  molecules  (NCAM),  the  endothelial  cell  adhesion 
molecule MCAM (also known as MUC18,  Mel-CAM, CD-146) as well as adhesion molecules such 
as ICAM-1  (CD54) that mediate interaction with leukocytes and CEACAM1.
1274.1.6.1  MCAM
MCAM  (also  known  as  MUC18,  Mel-CAM,  CD146)  is  a  predominant  cell  adhesion  molecule  of 
human  melanomas  that  also  mediates  homotypic  aggregation  of  melanoma  cells  through 
heterophilic adhesion to an as yet unidentified ligand present on melanoma cells (Shih et al., 1997; 
Shih  et al.,  1999; Johnson  1999).  MCAM may be stained using  immunohistochemical techniques 
(Shih  et  al.  1998).  There  is  evidence  to  suggest  that  changes  in  the  adhesive  properties  of 
melanocytes and melanomas are connected with the upregulation of MCAM expression (Grimm et 
al.,  1995).  MCAM  appears  to  be  strongly  upregulated  in  melanomas  compared  with  benign 
lesions and  is expressed  by  more than  80% of  metastatic  lesions  (Lehmann  et al.,  1987).  Most 
work on MCAM has been done using animal models, where its expression seems to play a role in 
the  initiation  of  new  foci  of  growth  of  melanoma  (Luca  et al.,  1993;  Xie  et  al.,  1997).  MCAM 
expression  has  also  been  correlated  with  the  ability  of  human  melanoma  cell  lines  to  form 
metastases  in  nude  mice  (Luca  et  al.,  1993).  More  directly,  Xie  and  colleagues  studied  non- 
metastasising  melanoma  cell  lines  (Xie  et  al.,  1997).  MCAM  expression  was  enforced  by 
transfection  on  the  non-metastatic  MCAM-negative  primary  cutaneous  melanoma  cells,  which 
were  then  injected  into  athymic  nude  mice.  The  enforced  expression  rendered  them  highly 
tumorigenic  and  increased  their  metastatic  potential  in  the  mice  compared  with  parental  and 
control  transfected  cells.  Anti-MCAM  monoclonal  antibody  reversed  these  effects  in  the 
transfected cells.  Similarly,  anti-MCAM  antibodies  have  been  shown to suppress tumour growth 
and formation of metastases in nude mice by Mills and colleagues (Mills et al., 2002).  These data 
provide  indirect  evidence  that  the  development  of  metastatic  capacity  in  melanoma  may  be 
associated with  an  increase  in  MCAM  expression  and that  MCAM  expression  may play a  role  in 
the initiation of new foci of growth of melanoma.
4.1.6.2  CEACAM
CEACAM,  also  known  as  CD66a,  is  a  member  of  the  carcinoembryonic  antigen  family,  also 
belonging to the immunoglobulin superfamily (Thompson et al.,  1991).  It is known to mediate both 
homophilic  and  heterophilic  adhesion  (Thompson  et  al.,  1991)  and  although  expressed  in  a 
number of human tissues, its expression has not been reported in normal melanocytes (Prall et al.,
1996).  CEACAM  is  down-regulated  in  malignant  tissues  derived  from  breast  (Riethdorf  et  al.,
1997),  colon  (Neumaier  et  al.,  1992)  and  prostate  (Luo  et  al.,  1999).  However,  in  an 
immunohistochemical  study of CEACAM 1   in  cutaneous  melanoma,  Thies  et al. found expression 
to correlate with  metastatic disease.  Therefore,  CEACAM  appears  to  play an  alternative  role  in
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with the earlier suggestion that CEACAM1  has a role at the invading front of melanoma, facilitating 
invasion  of  blood  vessels  and  lymphatics  as  well  as  migration  to  distant  sites  (Brummer  et  al.,
2001).
4.1.7  Other adhesion molecules
4.1.7.1  CD44
CD44  is  a  widely  distributed  transmembrane  glycoprotein,  originally  described  as  a  homing 
receptor for  lymphocytes  (Stoolman,  1989).  However  it  has  since  been  found  to  be  involved  in 
such processes as cell-cell adhesion and cell-matrix interaction (Underhill  1992).  Multiple isoforms 
of  CD44  are generated  by alternative  splicing  of transcripts  of this  gene  (Screaton  et al.,  1992). 
CD44 molecules containing the v3 domain are able to bind growth factors and might play a role in 
the control of cell proliferation (Bennett etal.,  1995).  There is increasing evidence that CD44 may 
contribute  to  malignant  progression  and  metastasis  formation  (Bartolazzi  et  al.,  1994).  For 
example,  the  extent  of  CD44  variant  6  (v6)  correlates  with  the  stage  of  tumour  progression  in 
human colorectal adenocarcinomas (Heider et al.,  1993),  bladder carcinoma (Nemec et al.,  1987) 
and non-Hodgkin’s lymphoma (Horst et al.,  1990).  The data suggest that the mechanism involved 
may  be  largely  dependent  on  the  ability  of  CD44  to  mediate  cell  attachment to  hyaluronate,  an 
extracellular polysaccharide (Stamenkovic et al.,  1991).  The interaction of CD44 with hyaluronate 
contributes  to  tumour  cell  proliferation,  migration,  invasion  and  formation  of  metastatic  tumour 
emboli (Catterall et al., 1999).
In  the  case  of  melanoma  cells,  CD44  overexpression  enhances  both  tumorigenicity  and  the 
potential for experimental  metastasis formation  (Birch  et al.,  1991).  One  investigation  examining 
the expression  of several  CD44 variants demonstrated  upregulation  of CD44H  in  benign  lesions, 
dysplastic  lesions  and  melanoma  In  situ,  but  expression  within  melanoma  diminished  with 
increasing  invasiveness,  rather than  Breslow thickness  (Harwood  et al.,  1996).  In this study the 
CD44  splice  variants,  including  v3  were  not  detected  in  any  lesions.  These  results  suggest  a 
possible  role for down regulation  of  CD44H  in  modulating  the  biological  behaviour of  melanoma. 
The  results  are  supported  by  data  from  other  larger  studies  (Karjalainen  et  al.,  2000)  that 
demonstrated downregulation of CD44 with  melanoma progression.  Another study also found no 
CD44v3 expression  in a series of 57 melanoma specimens (Ranuncolo  et al., 2002).  Seiter and
129co-workers,  however,  did  find  splice  variants  v5,  v7,  v8  and  v10  expressed  in  melanomas  to 
varying degrees (Seiter et al.,  1996).  CD44v10 was upregulated  in thick melanomas and v5 was 
upregulated  in  lymph  node  metastases  again  suggesting  that  melanoma  progression  is 
accompanied  by  upregulation  of  distinct  isoforms  of  CD44.  Furthermore,  Seiter  et  al.  found 
CD44v5  expression  at  high  levels  in  cell  lines  known  to  metastasise.  Thus,  there  is  no 
consensus view as to the expression of CD44 splice variants in  melanoma as yet,  particularly the 
involvement of CD44v3.
4.1.7.2  Nm23
nm23 was identified as a gene that is strongly up-regulated in K-1735 melanoma cell lines with low 
metastatic potential compared with variants of this cell line with high metastatic potential (Steeg  et 
al.,  1988).  Follow-up  studies  supported  the  hypothesis  that  the  Nm23  protein  may  act  as  a 
metastasis suppressor in vitro and in vivo (Leone et al.,  1991) and reduced expression was found 
in  patients  with  advanced  hepatocellular  carcinoma  (Nakayama  et  al.,  1992).  However,  other 
studies  demonstrated  high  levels  of  Nm23  in  tumours  such  as  squamous  cell  lung  carcinoma 
(Huwer et al.,  1994).  Reichrath  et al. compared  benign  naevi  and  melanomas and did  not find a 
correlation  with  nm23  expression  challenging  the  hypothesis  that  nm23  is  a  tumour  suppressor 
gene (Reichrath et al.,  1997).  Dome et al. found nm23 expression in melanoma to become “highly 
heterogeneous”  with  increased  tumour  thickness  (Dome  et  al.,  2000).  This  study  found  that 
primary  tumours  characterised  by  lymphatic  progression  had  the  lowest  expression  levels  of 
Nm23.  However,  this  did  not  correlate  with  survival.  Holmes  and  MacKie  also  did  not  find  a 
correlation  between  nm23  expression  and  the  survival  of  melanoma  patients  (Holmes  &  MacKie
1996).  Thus,  no  clear  overall  role  for  nm23  expression  in  melanoma  progression  has  been 
established.
4.1.7.3  Bcl-2
Abnormal expression of bcl-2, an anti-apoptotic regulator gene,  has been shown to be involved in 
the  pathogenesis  of  cancers  (Manning  &  Patierno  1996)  and  might  be  an  important  factor  for 
tumour  progression.  Studies  conducted  on  murine  melanoma  cells  have  shown  that the  down- 
regulation  of  the  bcl-2  gene  is  associated  with  nitric  oxide-mediated  apoptosis  and  that  cells 
transfected with the bcl-2 gene are more resistant to apoptosis (Xie et al.,  1997b).  Moreover, bcl-2 
antisense oligonucleotide treatment of human melanoma resulted in significantly reduced levels of
130Bcl-2 and increased the cellular sensitivity to chemotherapeutic drugs (Jansen  et al.,  1998).  Gene 
expression  of  bcl-2  appears  to  be  increased  with  tumour  progression  of  melanoma,  which  may 
reflect an increased malignant potential caused by inhibition of apoptosis and a growth advantage 
for  metastatic  melanoma  cells  (Leiter  et  al.,  2000).  High  expression  of  bcl-2  in  metastatic 
melanoma compared with primary melanoma has also been found,  supporting the idea that bcl-2 
expression  is  associated  with  advanced  melanoma  and  contributes  to  the  malignant  phenotype 
(Utikal et al., 2002).
4.1.7.4  Ki-67
The  proliferation  rate  of  transformed  cells  is  a  putative  prognostic  indicator,  correlating  with 
metastatic  dissemination  and  long-term  survival  in  various  neoplasms  (Tubiana  &  Courdi  1989; 
Balch et al., 2001a & b).  One of the most reliable methods of assessing the degree of proliferative 
activity  is  the  Ki-67  index  (Gerdes  et al.,  1984).  Ki-67  is  not  expressed  in  resting  cells  but  is 
expressed from the mid-G1  phase of the cell cycle through to S, G2 and M phases (Gerdes et al. 
1984; Guillaud et al.,  1989).  It is therefore considered to be a potential marker of proliferation and 
hence possibly a useful prognostic marker.  The level of proliferative activity, as measured by Ki- 
67 antigen  expression,  has  been  shown  to correlate  with  tumour grade and  patient survival  in  a 
variety of human malignancies (Jochum etal., 1996; Wakimoto eta!., 1996).  Correlations between 
Ki-67  expression  and  tumour thickness are well  documented for melanoma  (Korabiowska  et al., 
1994;  Ramsay  et al.,  1995;  Vogt  et al.,  1997;  Sparrow  et al.,  1998;  Niezabitowski  et al.,  1999; 
Hazan et al., 2002) and a link with patient survival has been established for thick tumours (Ramsay 
et al., 1995; Boni et al., 1996; Henrique et al., 2000).  However, there is no agreement as to its use 
as a prognostic marker for thin tumours or for predicting outcome in melanoma patient cohorts of a 
wide range of depths (Boni  et al.,  1996;  Sparrow et al.,  1998).  Therefore the prognostic value of 
proliferative activity in cutaneous melanoma, as measured by Ki-67 expression, is still a conflicting 
issue.
1314.2  TISSUE MICROARRAY
The  study  of  biological  markers  using  conventional  whole-specimen  sectioning  and 
immunochemical staining can be time-consuming and laborious.  In 1998 Kononen and colleagues 
(Kononen  et al.,  1998)  described  a  method for examining  several  hundred  individual  specimens 
simultaneously by precisely arraying them into a paraffin block.  The investigators designed a robot 
to punch cylinders (0.6mm wide, 3-4mm high) from  1000 individual tumour biopsies embedded in 
paraffin  (see  Figure  4.2).  The  selection  of  cylinders  with  0.6mm  diameters  allowed  the 
preservation  of  histological  information  with  minimal  damage  to  the  original  blocks.  Punch 
biopsies were then arrayed  (at positions with precise coordinates)  in a 45 x 20mm paraffin block. 
Up to 200 consecutive tissue sections (4-8pm) were cut from each block array.  Serial sectioning 
allowed  rapid,  parallel  analysis  of  the  arrayed  tumour  punches  by  immunohistochemistry, 
fluorescence  in  situ  hybridisation  (FISH)  and  RNA/RNA  in  situ  hybridisation.  Kononen  and 
colleagues tested their method by analysing 645 breast tumours for eight markers and the results 
obtained,  using  the  high-throughput  microarray  method,  were  in  good  agreement  with  the 
literature.  The  authors  demonstrated  that  the  tissue  microarray  provided  a  high-throughput 
technique  for  the  molecular  profiling  of  tissue  specimens  by  various  methods,  including 
immunohistochemistry.  The  technique  greatly  facilitates  comprehensive  molecular  profiling  of 
cancer specimens with  minimal tissue requirements.  A further advantage of the technique is that 
all specimens are processed at the same time using identical conditions.  It also markedly reduces 
the amount of archival tissue required, preserving sufficient tissue for other research or diagnostic 
needs (Mills et al., 1995).
4.2.1  Examples of different tissue microarray types
Typical  tissue  microarrays  constructed  in  the  literature  include  multi-tumour  arrays,  progression 
and prognosis arrays.
132Figure 4.2  Tissue Microarrayer™
4.2.1.1  Multi-tumour arrays
Multi-tumour  tissue  microarrays  are  composed  of  samples  from  multiple  tumour  types.  These 
arrays  are  used  to  screen  different  tumour types for  molecular  alterations  of  interest.  The first 
example  of  a  multi-tumour  tissue  array  contained  397  samples  from  17  different  tumour  types 
(Schraml eta!., 1999).
4.2.1.2  Progression arrays
These have been used to study molecular alterations in different stages of one particular tumour, 
such as breast,  urinary,  bladder,  kidney and prostate cancer (Bubendorf et al.,  1999a;  Bubendorf
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133et  al.,  1999b).  For  example,  a  prostate  cancer  progression  tissue  microarray  described  by 
Bubendorf and co-workers contained samples from normal prostate,  benign  prostatic hyperplasia, 
prostatic  intraepithelial  neoplasia,  incidental  carcinomas  (stage  pH ),  organ-confined  carcinomas 
(pT2), carcinomas with extra-prostatic growth (pT3-4), as well as metastases and recurrences after 
androgen withdrawal treatment.
4.1.2.3  Prognostic arrays
Prognostic tissue microarrays contain samples of tumours from patients for whom clinical follow-up 
data and clinical end-points are known  (Moch  et al.,  1999;  Richter  et al.,  2000).  With the  use of 
such a prognosis array,  novel  prognostic parameters can  be identified,  or the value of molecular 
alterations for the prediction of chemotherapy response can be tested.
Currently tissue  microarrays  have  only  been  used  in  cancer  research,  but the technology  is  not 
limited to this field.  The technique may be adapted and used in other fields such as inflammatory, 
cardiovascular and  neurological  diseases.  Similarly,  as for  patient tissues,  tissue arrays  can  be 
used  for  cell  lines  and  other  experimental  tissues  such  as  xenograft  tumours  or  tissues  from 
animal model systems.
4.2.2  The problem of tumour heterogeneity
Because  of  the  small  size  of  tissue  cores  (0.6mm)  taken  from  paraffin-embedded  tumour 
specimens  heterogeneous  expression  patterns  of  investigated  markers  could  lead  to  significant 
differences  in  results  from  tissue  arrays  compared  with  conventional  immunohistochemical 
analysis (Schraml  et al.,  1999).  The number of tissue cores per tumour specimen required on an 
array  to  reduce  the  error  rate  attributable  to  tissue  heterogeneity  and  to  maintain  efficient 
processing  of  tissue  has  been  determined  for a  variety  of  tumour types.  Hoos  et al.  studied  a 
group  of  59  fibroblastic  tumours  with  variable  protein  expression  patterns  by 
immunohistochemistry for  Ki-67,  p53  and  the  retinoblastoma  protein  (pRB)  (Hoos  et al.,  2001). 
Data from conventional full tissue sections were compared with the results from one, two and three 
0.6mm core biopsies on an array.  Concordance for Ki-67 and p53 staining between tissue arrays 
with triplicate cores per tumour and full sections were 96 and 98%,  respectively.  For pRB staining 
concordance was 91 %. The use of three cores per tumour resulted in lower numbers of lost cases
134and  lower  non-concordance  with  standard  full  sections  as  compared  to  one  or  two  cores  per 
tumour.  Correlations  between  phenotypes  and  clinical  outcome  were  not  significantly  different 
between  full  sections versus  array-based  analysis.  Camp  et al.  examined  the  number  of cores 
required  to  adequately  represent  the  expression  of  three  common  antigens  in  invasive  breast 
carcinoma  in  38 cases  (Camp  et al.,  2000).  They compared  the staining  of 2  to  10  microarray 
cores  and  the  whole  tissue  sections  from  which  they  were  derived.  The  results  showed  that 
analysis of two cores was comparable to analysis of a whole tissue section  in  more than 95% of 
cases.  Other validation studies using other tumours have shown that three cores are needed for 
colorectal carcinoma (Jourdan  et al., 2003) and three to four for prostate carcinoma (Rubin  et al.,
2002).  No validation study to date has examined melanoma tissue microarrays.
It  has  been  suggested,  however,  that  tissue  array  technology  has  been  developed  to  examine 
tumour  populations  and  not  to  survey  individual  tumours.  Results  from  tumour  population 
validation studies have borne this out.  For example, Mucci  et a!., compared results from standard 
slides  with  tissue  array  in  50  primary  and  metastatic  prostate  tumours,  without  assessing  the 
number  of  cores  needed  to  achieve  high  concordance  with  individual  specimens  (Mucci  et al.,
2000).  The  data  showed  that focal  neuroendocrine  expression  levels  were  similar between  the 
two groups, supporting the use of high-density tissue arrays to screen for protein expression, even 
when expression  is focal.  Similar studies were performed on breast cancer specimens (Gillett et 
al., 2000),  on peripheral T cell  lymphomas (Rassidakis  et al., 2002)  and on  lymphoid neoplasms 
(Hedvat et al., 2002), all showing high concordance between the tumour populations in the tissue 
arrays and the whole specimens.
The work in this chapter was done by  me apart from the sectioning  and  staining  of the tissue 
microarray and whole tissue specimens.
4.3  AIMS
The aims of this chapter were:
•  To  validate  the  use  of  tissue  array  as  an  investigative  tool  for  melanoma 
immunohistochemical research
•  Assessment of a variety of melanoma associated proteins for use in predicting prognosis
1354.4  MATERIALS AND METHODS
The methodology of the construction and analysis of the tissue microarray are detailed in section 
2.10.  The following constitutes a summary:
A  database  of  222  primary  melanoma  patients,  with  a  minimum  of  seven  year  follow-up,  was 
created and relevant paraffin-embedded specimens retrieved.  The specimens were sectioned and 
stained with  Haematoxylin and  Eosin (H&E) and  reviewed for quality and presence of melanoma. 
Four  core  biopsies  were  randomly  obtained  from  the  paraffin-embedded  tissue  within  the 
previously  identified  and  marked  area  and  transferred  to  a  recipient  paraffin  block  using  the 
technique described by Kononen et al. (Kononen et al.  1998) (figure 4.2).  An Excel file (Microsoft, 
USA)  was  simultaneously constructed  with  the coordinates  of the  specimen  biopsies  during  the 
construction of the array.
The master block was sectioned and slides of 5pm thickness produced, which were stained using 
the  Dako  Envision  method  (DAKO  Ltd.,  Cambridgeshire,  UK).  The  slides  were  scored  by  two 
independent observers without prior knowledge  of the clinical  outcome for staining  positivity and 
stain  intensity.  Cores were  scored  as  positive  if  any  degree  of  staining  was  evident  within  the 
melanoma cells.  The tissue array was then scanned and a semi-quantitative scoring system was 
constructed for staining  intensity based on the variation across the specimens (see figure 4.4.5). 
This  consisted  of  being  classified  as  either  negative,  weak,  moderate  or  strongly  staining,  as 
compared  with  a positive control.  The  stain  intensity  score was taken  as  the  strongest staining 
sample from the four biopsies that represented each tumour.
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Figure 4.3  An example of a completed tissue array master block.
Assessment  of  association  between  markers  and  clinicopathological  features  was  carried  out 
using  Chi-squared analysis.  Univariate analysis was undertaken  using  the  Kaplan  Meier method 
with  the  JMP®  statistical  package  (Version  4.0,  SAS  Institute,  USA).  Log  Rank  tests  were 
performed on the data, which were then analysed using Chi-squared tests to obtain p values.  Cox 
multivariate analysis was performed using SPSS (SPSS Inc., Chicago,  Illinois,  USA).  The level of 
statistical significance accepted was p<0.05.
137Figure  4.4.5  Four  cores  from  the  melanoma  tissue  array,  stained  in  this  example  with  LHM2,  parent 
monoclonal antibody of the RAFT scFvs (magnification x5).  The staining scores were assessed as being (in 
a clockwise direction from the top right) strong, negative, moderate and weak.
1384.5 VALIDATION OF THE MELANOMA TISSUE 
MICROARRAY
4.5.1  Background
It is strongly suggested that tumours with prominent intra-tumour heterogeneity need verification of 
data  generated  by tissue  microarray  analysis  (Kononen  et al.,  1998).  The  issue  of  the  relation 
between  the  immunohistochemical  data  derived  from  tissue  microarray  relative  to  traditional  full 
section  immunohistochemistry has  not yet been  clearly determined for all  tumours.  Currently no 
published  data  exist on  the validation  of tissue  microarray for melanoma.  The  number of tissue 
cores  per  tumour  specimen  required  on  an  array  to  reduce  the  error  rate  attributable  to  tissue 
heterogeneity and  to  maintain  efficient  processing  of tissue  has  previously  been  determined  for 
various tumours  including  breast carcinoma  (Camp  et al.,  2000)  and  human fibroblastic tumours 
(Hoos et al., 2001).  The use of a higher number of cores per tumour results in  lower numbers of 
lost cases and lower non-concordance with full sections as compared with one or two cores.  Most 
standard  immunohistochemistry  stains  result  in  readings  that  distinguish  between  positive  and 
negative categories,  whereas others  have  a  higher degree of complexity  requiring the distinction 
between intensity of staining.
In  an  effort  to  validate  the  use  of  tissue  microarray  for  melanoma  immunohistochemical 
investigation,  a  study  was  conducted  to  define  the  concordance  of  0.6mm  core  biopsies  in 
quadruplicate  on  tissue  microarray  in  comparison  to  full  section  analysis  for  expression  and 
intensity of expression of MCAM.  Although some histological detail is retained in microarray disks, 
it  can  be  difficult  to  distinguish  certain  characteristics  compared  with  examination  of  a  whole 
specimen.  To  reduce the  chances  of  inappropriate  areas  being  included  in  the  array,  areas  of 
invasive melanoma distinct from other tissue were carefully outlined.  The thirty whole specimens 
used for comparison were chosen at random from the  120 specimens that were deemed suitable 
for  inclusion  into  the  final  tissue  microarray  (see  section  4.6.1).  The  whole  specimens  were 
sectioned and stained under the same conditions as the tissue microarray (see section 2.10) and 
the staining then compared between the whole sections and the array.
1394.5.2 Results and discussion
All  paraffin-embedded  specimens were successfully sectioned  and  stained  with  H&E.  Suitable 
areas of tumour were identified and the tissue array was constructed.  The master block suffered 
no loss of tissue cores during  processing and  only one sampling  error was obtained,  which was 
excluded from further analysis.  Details of the melanoma specimens included in the study and the 
results of their analysis are shown  in Table 4.5.2.1.  An example of a part of the tissue array is 
shown in Figure 4.5.2.1  and the corresponding whole section from which it was obtained is shown 
in Figure 4.2.5.2.  Concordance between the tissue array analysis and whole specimen analysis is 
summarised  in  Figures  4.5.2.3.  and  4.5.2.4.  The  results  showed  a  significant  improvement  in 
concordance as the number of cores  increase  up to 4.  For example,  a concordance of  80% or 
greater for both staining positivity and staining intensity is found for a melanoma tissue array when 
three cores per specimen are used.
Figure 4.5.2.1  Two cores from the tissue array staining strongly for MCAM (arrows) (magnification x 5.0).
Figure 4.5.2.2  Whole section from which core biopsies in  Figure 4.5.2.1  were obtained.  Arrows mark the 
areas from which core biopsies were obtained (magnification x 2.5).
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number
Sex  of 
patient
Tumour
subtype
Breslow
thickness
(mm)
Clark’s
level
Positivity score Intensity score
Full
section
Array (4 
cores)
Full
section
Array (4 
cores)
1 F ss 4 1 1 2 2
2 F ss 1.2 4 1 0 1 0
3 M ss 1.6 4 1 1 2 2
4 F ss 2.0 4 1 1 3 3
5 M Im 1.7 4 1 1 1 1
6 M Im 1.0 4 1 1 2 2
7 M Im 7.7 4 1 1 3 3
8 F Im 0.7 2 1 1 1 1
9 F Im 0.5 2 0 0 0 0
10 F Im 3.6 4 1 1 3 3
11 Im 1.9 4 1 1 2 2
12 ss 3.4 4 1 1 2 2
13 F al 2.0 4 1 1 2 2
14 al 3.4 4 1 1 1 1
15 F nm 3.6 4 1 1 1 1
16 F nm 2.3 4 1 1 1 1
17 nm 2.8 4 0 0 0 0
18 nm 0.7 3 0 0 0 0
19 F nm 7.0 5 1 1 3 3
20 nm 3.7 4 0 0 0 0
21 F nm 6.2 5 1 1 2 2
22 F nm 20 5 1 1 3 3
23 ss 0.7 2 0 0 0 0
24 F nm 2.0 3 1 1 3 1
25 ss 0.4 2 0 0 0 0
26 F nm 2.2 4 1 1 2 2
27 F ss 0.3 2 0 0 0 0
28 M nm 15 5 1 1 3 3
29 M ss 0.5 2 1 1 1 1
30 F nm 2.2 4 1 1 2 2
Table 4.5.2.1  Tumour characteristics of specimens used. M = male, F = female; ss = superficial spreading, 
Im = lentigo maligna melanoma, nm = nodular melanoma, al = acral lentiginous melanoma.  Positivity score: 
0 = negative,  1   = positive.  Intensity score:  0 = negative,  1   = weakly positive, 2 = moderately positive, 3 = 
strongly positive.
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Figure  4.5.2.3  Concordance  between  tissue  array  analysis  and  whole  specimen  analysis  for  MCAM 
expression positivity (actual numbers shown in columns).
Concordance 
with whole 
specimen
100%
80%
60%
40%
20%
0 %   -I—
13/30 16/30 24/30 28/30
1   core 2 cores 3 cores 4 cores
Figure  4.5.2.4  Concordance  between  tissue  array  analysis  and  whole  specimen  analysis  for  MCAM 
expression intensity (actual numbers shown in columns).
One  of  the  problems  envisaged  with  the  use  of  tissue  array for  the  examination  of  melanoma 
relates to the variability in depth of melanoma specimens.  Theoretically, this may not only result in 
technical difficulties in the construction of the array,  but also in  loss of cores from the array upon 
sectioning.  No  such  difficulties,  however,  were  encountered  in  this  study.  Clearly though,  the 
depth  of melanomas included  in the array master block will  limit the number of sections that are 
subsequently  cut  and  which  include  all  melanomas  in  the  original  array.  A  study  on  breast
142carcinoma found  that  use  of two cores was comparable to  analysis of  a  whole tissue  section  in 
more than 95% of cases (Camp et al., 2000).  However, use of three cores of a fibroblastic tumour 
was needed to achieve a concordance of 91  - 96%, depending upon immunohistochemical marker 
tested  (Hoos  et al.,  2001).  In  other  studies,  three  cores  were  needed  for  colorectal  carcinoma 
(Jourdan  et al., 2003) and three to four for prostate carcinoma (Rubin  et al., 2002).  In this study 
the  results in  Figures 4.5.2.3 and 4.5.2.4  illustrate that four core  biopsies  seem to  be  needed to 
achieve comparable concordance with studies on other tumours.
The  microarray  was  stained  for  MCAM,  an  antigen  that  is  expressed  in  virtually  all  melanomas 
(Lehmann  et al.,  1989) and  not in  normal  melanocytes.  Indeed,  90% of the  melanomas  used  in 
this study expressed MCAM when analysed using traditional techniques.  This study has shown a 
high  correlation  between  the  analyses  from  the  tissue  array  with  the  traditional 
immunohistochemical staining techniques.  This was highest, as would be expected, when MCAM 
positivity alone was studied, with a concordance of 96.6%.  The correlation when the intensity of 
staining  was  taken  into  account  was  still  high,  achieving  a  value  of  93%.  These  values  were 
achieved using four core biopsies from each paraffin-embedded melanoma.  The concordance is 
comparable to that reached with other tumours studied (Shih  1999;  Lehmann etal.,  1989; Moch et 
al., 2001).
4.5.3  Conclusion
The  results  of  this  study  validate  the  use  of  the  tissue  microarray for  the  immunohistochemical 
study of melanoma.  The data suggest that four cores from each  melanoma specimen should be 
used to reduce the sampling errors,  increase the likelihood of including any heterogeneous areas 
of the tumour and to account for potential core loss during  sectioning and  handling of the master 
block.
1434.6  RESULTS OF SECTIONING AND SCORING 
TISSUE ARRAY
4.6.1  Clinicopathological features of array specimens
Although all 222 paraffin-embedded specimens were successfully sectioned and stained with H&E 
only  120  had  enough  archival  material  available  for  the  present  study  and  were  therefore 
implanted  into the  recipient  block.  Suitable areas of tumour were  identified  and the tissue array 
was constructed.  H&E  staining  of the array  revealed  a further  13%  of specimens  unsuitable for 
analysis due to either lack of melanoma tissue (sampling error) or loss from the block.  This figure 
compares  with  two  previous  studies  using  array  technology  that  found  10-17%  unusable  cores 
(Schraml  et al.,  1999;  Mucci  et al.,  2000).  This meant that 76 specimens were assessed from 4 
cores,  33 from 3 cores and  8 from 2  specimens and  in  3 specimens  no cores were quantifiable. 
Detailed analysis was performed only on the 76 melanomas from which 4 cores were available, as 
this  number was  shown  to  be  accurately  representative  of the  whole  melanoma  specimen  (see 
section 4.5).
Table  4.6.1  illustrates  details  of  all  the  patients  and  the  specimens  included  in  the  tissue 
microarray.  Notably the  median  tumour thickness  is  considerably  lower than  the  mean  tumour 
thickness,  which  was  skewed  by  six  very  thick  tumours  (ranging  between  10mm  and  35mm  in 
thickness).  Without those tumours the  mean tumour thickness was calculated as  1.96mm.  The 
majority  of  tumours  included  in  the  array were  less  than  1  mm  in  thickness.  The  inter-observer 
disagreement when analysing the stained microarray was 5.6%.
144Variable Tissue array
Number of patients in microarray 120
Mean age at diagnosis 59.86 (range 21  -  97)
?: & 1.35:1
Site of melanoma (%):
Head & neck 23(19%)
Trunk 26 (22%)
Upper limb 24 (20%)
Lower limb 47 (39%)
Tumour subtypes represented (%):
Superficial spreading 67 (55.8%)
Lentigo maligna melanoma 11  (9.2%)
Nodular melanoma 35 (29.2%)
Acral lentiginous 5 (4.2%)
Other 2 (1.7%)
Mean Clark’s level 3 (range 1-5)
Mean tumour thickness 2.93mm (range 0.1-35mm)
Median tumour thickness 1.6mm
Number of ulcerated melanoma (%) 26/120 (21.7%)
Number developing regional recurrence (%) 42/120 (35%)
Number of patients surviving in cohort (%) 73/120 (60.8%)
Table 4.6.1  Details of patients and melanomas included in the final tissue microarray.
1454.7  MCAM AND CEACAM: THE 
IMMUNOGLOBULIN SUPERFAMILY
4.7.1  MCAM:  expression and correlation with clinicopathological 
features
Figure 4.7.1  illustrates examples of cores from the array.  There was a high correlation between 
MCAM intensity and both Clark’s level and Breslow thickness (Spearman correlation p < 0.001  for 
both;  Figures 4.7.2 & 4.7.3).  Strongly staining core biopsies (intensity of 3) were all Clark’s levels 
3  to  5.  In  addition,  the  proportion  of  Clark’s  level  2  and  3  tumours  within  each  intensity  group 
decreased  with  intensity.  This  pattern  was  similar  when  compared  with  Breslow  depth.  All 
strongly staining  tumours were  over  1.01mm  thick and the  proportion  of thick tumours  increased 
within  each  intensity set.  A summary of all  correlations  is  shown  in  Table 4.7.1.  Regarding the 
site  of the tumour,  tumours  on the  head  and  neck and the trunk were  more  likely to  be  strongly 
staining for MCAM.
Figure  4.7.1  Core  biopsy  melanoma  specimens  stained  for  MCAM  expression  on  tissue  array  slide 
(magnification  x3.5).  The  cores were  scored  (in  a  clockwise  direction  starting  from  top  right)  as  strong, 
weak, weak and moderate intensity.
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Fig  4.7.2  Figure  illustrating  the  association  of  the  intensity  of  MCAM  expression  with  Clark’s  levels 
(Spearman’s correlation p< 0.001).  Cores were scored from negative (0) to strong (3).
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Figure  4.7.3  Figure  illustrating t he a ssociation b etween t he i ntensity o f M CAM e xpression  and  Breslow 
depth (Spearman’s correlation  p< 0.001).  Breslow depth was grouped according to the “T” staging from the 
AJCC staging classification of melanoma.  Cores were scored from negative (0) to strong (3).
147Variable P value
Clark’s level* < 0.001
Breslow Depth* < 0.001
Site of tumour1 0.03
Agef 0.21
Ulceration1 0.1
Male sexf 0.57
Table 4.7.1  Correlations between MCAM  intensity and established prognostic variables for melanoma.  * 
Spearman test,1  Pearson Chi-squared.
4.7.2  MCAM: expression and clinical outcome
Figure 4.7.2.1  shows univariate survival curves in relation to MCAM expression.  The log rank test 
of  significance  between  Kaplan-Meier  estimates  of  survival  revealed  that  those  patients  whose 
tumours  were MCAM  positive  had  a  significantly  higher  probability  of  poor  outcome  than  those 
whose tumours were scored negative (x2=  18.0082, p<0.0001).  The 5-year survival for the MCAM 
negative melanoma patients (n= 34) was 94%  compared with a  5 -year survival of 46%  for the 
MCAM positive melanoma patients (n= 42).
Subgroup analysis by stratification of the intensity of expression of MCAM  revealed a sequentially 
worsening survival with increasing staining intensity (x2= 22.33, p<0.0001) (Figure 4.7.2.2).  The 5- 
year  survival  of  mildly  positive,  moderately  positive  and  strongly  positive  MCAM  staining 
melanoma patients was 57% (n=  14), 46% (n= 20) and 29% (n= 8) respectively.  Further analysis 
within the  intermediate thickness (1.01-4.0mm) melanomas showed that in this subgroup,  MCAM 
expression also correlated with poor survival  (x2 =5.24, p=0.0221) (Figure 4.7.2.3).
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Figure 4.7.2.1  Survival curves comparing MCAM positive and MCAM negative melanomas.  Log rank x2 = 
18.0082, p<0.0001.      MCAM  negative,    MCAM  positive.
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Figure 4.7.2.2  Survival curves comparing staining intensity of MCAM in primary melanomas.  Log rank x2 =
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Figure 4.7.2.3  Comparison of MCAM expression  in  primary melanomas  1.01-4.Omm thick.  Log  rank x2 = 
5.2413, p = 0.0221.  ---------  MCAM negative,    MCAM positive.
Cox  multivariate  analysis  showed  both  MCAM  expression  positivity  and  intensity  were 
independently predictive of poor outcome (both p <0.001).  In both cases this was over and above 
established markers of  prognosis,  such as Breslow thickness a nd Clark’s Ievel.  For patients 
whose melanomas expressed MCAM, the risk of poor outcome was  16-fold  higher compared with 
those patients whose melanomas did not express this cell adhesion molecule (Table 4.7.1).
95% Cl for the Hazard Risk
Variable Hazard risk Lower Upper P-value
MCAM expression 16.335 3.797 70.280 <0.001
Site 0.524 0.342 0.801 0.003
Clark’s level 3.686 1.330 10.219 0.012
Breslow thickness 1.119 1.006 1.246 0.039
Age 1.020 0.993 1.049 0.154
Ulceration 1.479 0.571 3.829 0.420
Male sex 0.773 0.311 1.918 0.579
Table  4.7.1  Cox  multivariate  analysis  including  MCAM  expression  and  other  established  markers  of 
prognosis.  MCAM expression positivity can be seen to be independently predictive of poor prognosis.4.7.3 Discussion
Conventional  immunohistochemistry  has  shown  that  certain  cancer  phenotypes  correlate  with 
patient  outcome  (Drobnjak  et  ai.,  1994;  Heslin  et  a!.,  1998;  Thies  et  a/.,  2002).  With  the 
introduction of novel therapies to be used in high-risk patients such as interferon alpha (Kirkwood 
et ai,  2001), the  prediction  of patient outcome  is essential  in  the  management of melanoma.  In 
addition to providing the clinician with information  useful  in determining  management,  it facilitates 
appropriate patient follow-up regimes and is of incalculable psychological benefit for the patient.
Previous work  in  vitro  and  in  vivo  suggested  the  potential  of  MCAM  as  a  prognostic  marker  in 
melanoma  (section  4.1.6.1).  The  present  study  was  therefore  designed  to  investigate  the 
expression  of  MCAM  in  melanoma  and  to  correlate  its  expression  positivity  and  intensity  with 
patient  outcome.  The  results  demonstrated  that  expression  of  MCAM  in  primary  cutaneous 
melanoma  was  significantly  associated  with  poor  outcome  (p<0.0001).  Multivariate  Cox 
regression  analysis  showed  that  MCAM  expression  is  an  independent  predictor  of  adverse 
outcome (p<0.0001).  Patients with primary cutaneous melanoma who did not express MCAM had 
a significantly lower risk of dying from the disease than  patients that were  MCAM  positive (RR = 
16;  table  4.7.1).  Thus,  analysis  of  survival  including  MCAM  expression  may  improve  risk 
estimation of survival in melanoma patients.
The  considerable  predictive  power  of  MCAM  expression  is  highlighted  by  incorporating  other 
known  prognostic factors  including  Clark’s  level,  Breslow  thickness,  presence  of  ulceration,  sex 
and age of the patient (Balch et ai, 2001a) in a Cox multivariate analysis.  When this tool is used, 
only  MCAM,  Clark’s  level,  Breslow  thickness  and  site  remained  as  independent  predictors  for 
outcome  in  our study.  The  reason for Clark’s  level  remaining  significant  is  likely to  be  the  high 
proportion of tumours included in the array that were less than 1  mm thick  (34%)  (Balch  eta I., 
2001 a&b).
Furthermore, this investigation has demonstrated that not only MCAM expression,  but also MCAM 
intensity,  was  correlated  with  survival.  This  suggests  that the  degree  of  MCAM  upregulation  is 
associated with the disease course.  This was  revealed  in the  log  rank tests on the Kaplan  Meier 
estimates  analysed  by Chi-squared  tests and  was  corroborated  by  Cox  multivariate analysis.  In 
addition,  univariate  analysis  showed  that  the  survival  of  those  patients  with  tumours  of 
intermediate thickness could be predicted by MCAM expression positivity (Figure 4.7.2.3).  Tumour 
thickness a lone  showed no statistically significant correlation with survival  within this subgroup,
151suggesting that MCAM expression positivity is a more powerful tool for the prediction of prognosis 
for intermediate thickness melanomas.
Currently  tumour  thickness  and  the  presence  of  ulceration  have  been  shown  to  be  the  most 
powerful predictors of outcome in patients with primary cutaneous melanoma, apart from patients 
with  tumours  less than  1mm thick,  in which  the  Clark’s  level  becomes  the  most  important factor 
(Balch  et ai,  2001a  &  b).  Some  patients with  thin  tumours  at the  time  of surgery  may develop 
terminal metastatic disease, whereas other patients with thick melanomas survive (Fearfield et ai, 
2001; Salti et ai, 2002).  This emphasises the need to improve the accuracy of risk estimation.  A 
variety of immunohistochemical markers have been identified as adjunctive prognostic parameters 
in  primary  human  melanomas,  including  loss  of  melastatin  expression  (Duncan  et  ai,  2001), 
expression  of  IJ3  integrin  (Hieken  et  ai,  1996) and  CEACAM1  expression  (Thies  et  ai,  2002). 
These studies are  comparable to the  current study as their cohorts  include  at least  100  patients 
with  follow-up  periods  of  5  to  10  years  and  multivariate  analysis  was  used  to  establish  the 
independent prognostic significance of these markers.
Determination of MCAM expression status  is not only of prognostic interest but may also provide 
insights  into the  mechanisms  of tumour cell  progression and  metastasis formation  in  melanoma. 
No  previous  study  has  used  a  Cox  multivariate  model  in  addition  to  univariate  analysis  to 
demonstrate that upregulation of MCAM expression in a tumour is associated with poor outcome. 
MCAM has previously been tested on a large cohort of melanoma specimens (n= 386) in a study 
by Ostemeier et ai, yet despite showing a correlation with survival in univariate analysis, the study 
failed to show prognostic significance when multivariate analysis was used (Ostmeier et ai, 2001). 
This  study  was  performed  using  melanoma  biopsies  on  cryopreserved  specimens.  Obtaining 
frozen  sections  of primary  melanomas  is  unlikely to  be  practical  and  the  authors  acknowledged 
that studies with  paraffin-embedded  material  had  to  be  performed.  In  addition,  only one  biopsy 
was taken from each tumour specimen  leaving the possibility that non-representative  parts of the 
biopsies may have been tested.  The anti-MCAM antibody used  in Ostemeier’s study was not the 
commercially available  antibody used  in  the  present study.  MCAM  epitopes can  be differentially 
expressed  (Kraus et ai,  1997) and this may further explain  differences in  outcomes between the 
two studies.
MCAM  is  a  predominant  cell  adhesion  molecule  of  human  melanomas  that  also  mediates 
homotypic  aggregation  of  melanoma  cells  (Johnson  1999).  During  progression  of  melanocytic 
lesions  from  benign  to  malignant  forms,  there  is  a  dynamic  shift  in  expression  of  adhesion 
molecules.  This  shift  reflects  the  aggressive  properties  of  melanoma  cells  as  they  invade  the
152dermis from  the  epidermis  (Johnson  1999).  Cell-cell  adhesion  molecules  show  similar changes 
during  melanoma  progression.  For  example,  among  the  cadherins  there  is  a  shift  from  E- 
cadherins to N-cadherin (Hsu et ai, 2000).  In vitro studies have shown that human melanoma cell 
lines adhere to immobilised  MCAM (Shih et ai,  1997) by expressing an as yet unidentified ligand. 
Animal  studies  have  revealed  correlations  between  MCAM  expression  and  the  ability  of  human 
melanoma  cell  lines  to  form  metastases  (Luca  et  ai,  1993).  In  one  study,  enforced  MCAM 
expression  on  non-metastatic  MCAM-negative  primary cutaneous  melanoma  cells  resulted  in  an 
increased  metastatic  capacity  in  nude  mice  (Xie  et ai,  1997).  This  property was  reversible  by 
treatment of mice with anti-MCAM antibody.
On the basis of these findings,  MCAM, as the major adhesion  molecule for melanoma-melanoma 
cell  adhesion,  has  been  suggested  to  play  a  role  in  melanoma  progression,  including  the 
establishment  of  close  cell-cell  communication  that  stimulates  growth,  survival  and  invasion. 
However,  despite  many  assumptions  in  the  literature,  MCAM  expression  positivity  and  intensity 
had not been shown to correlate with outcome in patient studies.
This  study showed  that  MCAM  expression  correlates  significantly with  patient outcome.  MCAM 
expression was upregulated  in those  patients with a  poor prognosis  compared with others.  This 
was still the case in patients with intermediate thickness tumours in whom tumour thickness alone 
could not predict outcome.
4.7.4  CEACAM1:  expression and correlation with clinicopathological 
features
Breslow  depth  was  the  only  clinicopathological  feature  that  was  significantly  correlated  with 
CEACAM1.  A  higher  proportion  of  thick  tumours  expressed  CEACAM1  compared  with  thin 
tumours  (Pearson  Chi-squared  0.013,  p  =  0.012)  (Figure  4.74).  Thin  tumours  (<  2.0mm)  were 
mostly  negative  for  this  marker.  Interestingly,  there  was  no  relationship  between  CEACAM1 
expression and other prognostic indicators tested including Clark’s level.
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Figure 4.7.4  Figure  illustrating  the  association  between  the expression  of CEACAM 1   and  Breslow depth 
(Spearman’s correlation  p = 0.012).  Breslow depth was grouped according to the “T” staging of the AJCC 
staging classification of melanoma.
There was a trend of patients with CEACAM 1   negative tumours  (n =  36) to do better than those 
with  positive  tumours  (n  =  40),  however  CEACAM1  expression  failed  to  show  a  statistically 
significant correlation  with  patient outcome  in  this  series  of patients  (Log  rank x2   =  0.2858,  p  = 
0.59) (Figure 4.7.5.1).  Cox multivariate analysis also failed to show CEACAM1  as an independent 
predictor of prognosis  (p =  0.151) (Table 4.7.5.1).  Breslow thickness and  Clark’s  level  were the 
only two of the other established clinicopathological markers of prognosis that retained significance 
in the Cox model used.
4.7.5  CEACAM1: expression and clinical outcome
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Figure 4.7.5.1  Survival curves comparing CEACAM1  positive and  CEACAM1  negative melanomas.  Log 
rank x2 = 0.2858, p = 0.59.    CEACAM1 negative,--------- CEACAM1  positive.
Variable Hazard risk
95% Cl for the Hazard Risk 
Lower  Upper P-value
Breslow thickness 1.159 1.044 1.287 0.006
Clark’s level 3.189 1.356 7.503 0.008
CEACAM 1 1.899 0.792 4.553 0.151
Age 1.013 0.986 1.040 0.362
Site 0.833 0.586 1.184 0.309
Male sex 0.756 0.309 1.850 0.540
Ulceration 1.247 0.508 3.066 0.630
Table 4.7.5.1  Cox multivariate analysis including CEACAM1  expression and other established markers of 
prognosis.  CEACAM 1   expression is not independently predictive of prognosis.
1554.7.6  Discussion
Having  established  MCAM  as  an  independent  marker  that  may  be  used  to  predict  prognosis, 
CEACAM1  was  studied  using  the tissue  array.  CEACAM1  or  CD66a,  formerly  known  as  biliary 
glycoprotein  I,  is  a  member of the  carcinoembryonic antigen  family and  also,  like  MCAM,  of the 
immunoglobulin  superfamily  (Thompson  et  ai,  1991).  This  study  of  CEACAM1  expression  on 
melanoma,  using  a  tissue  microarray,  did  not show a  statistically  significant  correlation  between 
CEACAM 1   expression  and  outcome,  despite  demonstrating  a  statistically significant  relationship 
between tumour thickness and  marker expression.  Using the log  rank tests on the Kaplan  Meier 
estimates  analysed  by  Chi-squared  tests  a  trend  was  apparent,  suggesting  that  patients  with 
tumours  not expressing  CEACAM 1   fared  better than those with tumours that were  positive.  This 
finding  is supported  by the  results of the  only published  series  examining  CEACAM1  expression 
and its use as a possible prognostic marker.  Thies et al.  used traditional whole specimen staining 
of 100 primary cutaneous melanomas with a 10-year follow up (Thies et ai, 2002).  A total of 28 of 
40 patients with CEACAM1-positive primary melanomas developed  metastatic disease,  compared 
with o nly s ix o f 6 0 p atients w ith C EACAM1 -negative m elanomas.  In  their s tudy, K apian M eier 
analysis  revealed  a  highly  significant  association  between  CEACAM  expression  and  survival  (p 
<0.0001).  Furthermore,  multivariate  Cox  regression  analysis,  including  CEACAM1  expression 
adjusted for tumour thickness, presence of ulceration and mitotic rate showed CEACAM 1   to be an 
independent  predictor  of  prognosis.  However,  in  the  study  by  Thies  and  colleagues,  other 
established  variables  for  predicting  prognosis  were  not  included  in  the  Cox  model  and  no 
comment  is  made  in  the discussion  as to how this would  have affected  the  result.  It is  possible 
that  had  the  present  study  included  a  larger  cohort  of  patients  the  trend  suggested  by  the 
univariate  survival  curves  would  have  reached  significance,  mirroring  the  results  of the  study  by 
Thies et ai
CEACAM1  is down-regulated in malignant tumours originating from glandular tumours, particularly 
in  colorectal  (Neumaier  et  ai,  1993)  and  prostate  cancer  (Luo  et  ai,  1999),  where  its  loss  of 
expression is related to the loss of glandular differentiation (Busch et ai, 2002).  This is especially 
apparent in prostate cancer, where a sharp decline of CEACAM 1   expression is noted when glands 
fuse (Busch et ai, 2002).
The only ligands of the extracellular domain of CEACAM 1   identified so far are CEACAM 1   itself and 
CEACAM6  (Oikawa  et ai,  1992).  Thies  et ai  suggested  that  both  homophilic  and  heterophilic 
interactions of CEACAM 1   may be relevant during glandular differentiation (Thies et ai, 2002).  The 
role of heterophilic i nteractions is a pparent i n endothelial cells, where C EACAM1  expression is
156observed  on  the  albuminal  side  of the  microvessels  (Ergun  et ai,  2000),  suggesting  interaction 
with an unidentified ligand in the surrounding basal lamina.  That these interactions with the basal 
lamina  are  of  physiological  relevance  is  indicated  by  the  fact  that  the  cytoplasmic  domain  of 
CEACAM 1   interacts  with  the  cytoskeleton  (Sadekova  et  ai,  2000)  and  may  therefore  be  an 
important mediator of cell-matrix interactions.  In the study by Thies et ai  CEACAM1  expression 
was shown to be particularly upregulated at the invading front, where cell-matrix interactions play 
an important role, thus implying heterotypic interaction of CEACAM1  with  matrix molecules (Thies 
et ai,  2002).  This  is  in  accordance  with  findings that expression  of CEACAM 1  and  p3  integrin, 
which  has an  established  role  in  the  invasion  and  metastasis of melanoma  (Hsu  et ai,  1998),  is 
found  localised at the invading front (Brummer et ai,  2001).  A potential function of CEACAM 1   in 
invasion  is corroborated by the findings that CEACAM 1   is strongly expressed  by the intermediate 
trophoblast at the  implantation  site,  as  well  as  the  extravillous trophoblast cells with  an  invasive 
phenotype  in  primary  culture,  suggesting  that  CEACAM1  may  be  functionally  involved  in  the 
motility or  invasiveness  of cells  (Bamberger  et ai,  2000).  Thus,  CEACAM1  may  play a  role  in 
melanoma metastasis formation by facilitating the invasion of blood vessels and lymphatics as well 
as migration to distant sites.
In  conclusion,  this study demonstrated  a  correlation  between  CEACAM 1   expression  and tumour 
thickness  and  suggested  that  a  link  between  CEACAM 1   and  outcome  exists,  supporting  the 
findings of Thies et ai  (2002).  However, this was not statistically significant and shows that tissue 
array analysis is not necessarily superior to traditional  immunohistochemistry.  Further studies are 
needed on larger cohorts of patients to determine whether adding  power to the study would result 
in statistically significant results.
1574.8  CADHERINS
4.8.1  P- and E-cadherin: correlation with clinicopathological features
There were  no  correlations  between  P-cadherin  expression  and  any of the established  variables 
for  melanoma prognosis.  The same was found  for E-cadherin in all except for site of tumour, 
which  had  a  highly  significant  relationship  (Pearson  Chi-squared  0.003,  p  =  0.002).  Most 
melanomas strongly-staining for E-cadherin were situated on the legs, whilst most melanomas that 
were negative for E-cadherin were situated on the arms and head and neck regions.
4.8.2  P- and E-cadherin: expression and clinical outcome
Expression o f P -cadherin s howed a  h ighly s tatistically s ignificant c orrelation w ith o utcome ( Log 
rank x2  =  10.1336,  p  =  0.0015)  (Figure 4.8.2.1).  Patients with tumours that were  negative for P- 
cadherin correlated with  poorer outcomes than those whose tumours expressed  P-cadherin.  The 
5-year survival  for  P-cadherin  negative  melanoma  patients was 40%  (n=24)  compared  with  a  5- 
year survival of 75% for the P-cadherin positive patients (n=54).
On further stratification of P-cadherin positive tumours into weak and strong staining, a statistically 
significant  difference  in  staining  intensity with  outcome  was  revealed  (Log  rank x2 =  14.19,  p  =
0.0008) (Figure 4.8.2.2).  Interestingly,  patients with weakly positive  P-cadherin expression  had a 
better prognosis than patients with high P-cadherin expression (see discussion, section 4.8.3).
1580.9-
0.8 -
C J )
C  0.7- 
>
£  0.6- 
u
(f>   0.5- 
c
o  0.4-
o  0.3- 
o
£   0-2-
l-l-H-H-l- l-l- -HI+ -
bi+ h
0.0
20 40 60 80 100 0 120
Length to outcome (months)
Figure 4.8.2.1  Survival curves comparing P-cadherin positive and P-cadherin  negative melanomas.  Log 
rank x2  = 10.1336, p = 0.0015.    P-cadherin negative,    P-cadherin positive.
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Figure 4.8.2.2  Survival curves comparing staining intensity of P-Cadherin in primary melanomas.  Log rank
X2  = 14.19, p = 0.0008.      P-cadherin negative,    P-cadherin 1+ positive,    P-cadherin 2+
positive.
159Cox  multivariate  analysis  on  the  data  showed  that  P-cadherin  expression  did  not  quite  reach 
statistical  significance  as  an  independent  marker  of  prognosis.  In  this  model,  only  Breslow 
thickness  and  Clark’s  level  retained  independence,  over  and  above  other  established 
clinicopathological variables (Table 4.8.2).
Variable Hazard risk
95% Cl for the Hazard Risk 
Lower  Upper P-value
Clark’s level 3.001 1.303 6.910 0.010
Breslow thickness 1.153 1.034 1.285 0.011
P-cadherin 0.440 0.172 1.125 0.087
Site 0.813 0.574 1.151 0.242
Age 1.013 0.986 1.040 0.359
Male sex 0.809 0.337 1.945 0.636
Ulceration 1.170 0.466 2.939 0.738
Table 4.8.2  Cox multivariate analysis  including  P-cadherin  expression  and  other established  markers of 
prognosis.  P-cadherin expression was not shown to be independently predictive of poor prognosis.
Loss  of  E-cadherin  expression,  similar  to  P-cadherin,  was  correlated  with  a  poorer  outcome 
(Figure 4.8.2.3).  However, this result did not reach significance in the log rank test of significance 
between Kaplan-Meier estimates of survival (Log rank x2 = 0.7807, p = 0.3769).
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Figure 4.8.2.3  Survival curves comparing  E-cadherin positive and  E-cadherin  negative melanomas.  Log 
rank x2  = 0.7807, p = 0.377.      E-cadherin negative,    E-cadherin positive.
4.8.3  Discussion
The  results  of this  study  examining  the  relationship  between  P-  and  E-cadherin  and  melanoma 
patient  survival  have  demonstrated  that  loss  of  expression  of  both  markers  appears  to  be 
associated with  poor prognosis.  This  is especially true of P-cadherin, where a  highly statistically 
significant  difference  in  outcome  between  patients  whose  tumours  expressed  P-cadherin  and 
those whose tumours did not, was revealed (x2 = 10.1336, p = 0.0015).  Stratification of P-cadherin 
positive tumours into strong and weak staining again revealed a statistically significant relationship 
between  the  intensity  of  P-cadherin  expression  and  outcome.  Interestingly,  patients  with  the 
weak-staining  tumours fared  best,  those with  strong-staining  tumours did  badly,  but patients with 
P-cadherin  negative  tumours  had  the  poorest outcome;  this will  be  further discussed  below.  P- 
cadherin  expression  did  not  retain  significance  as  an  independent  marker  of  prognosis  when 
analysed in a Cox regression analysis with other established prognostic variables (p = 0.087).
Previous  studies  on  E-cadherin  expression  had  used  cell  culture,  or  compared  benign  with 
malignant lesions.  This  suggested  a  link  between  loss  of E-cadherin  expression  and  melanoma 
progression.  However,  no  study  to  date  had  examined  the  relationship  between  E-cadherin
161expression and melanoma patient outcome.  In this study, loss of E-cadherin expression tended to 
be associated with poor outcome.  However, this did not reach statistical significance (x2 = 0.7807, 
p  =  0.3769)  (Figure  4.8.2.3).  This  result  may  have  been  explained  by  the  difference  in  patient 
numbers in each group (E-cadherin positive n =  19 and negative n = 57).
Loss of E-cadherin is associated with high-grade morphology of tumours and there is a significant 
inverse  relationship  between  E-cadherin  expression  and  survival  in  some  tumour  patients, 
including  colorectal  cancer (Dorudi  et ai,  1993),  breast cancer  (Moll  et ai,  1993;  Siitonen  et ai, 
1996) and  head  and  neck  cancers  (Schipper et ai,  1991).  Normal  cultured  human  melanocytes 
express  both  E-cadherin  and  P-cadherin,  but  it  is  E-cadherin  that  is  primarily  responsible  for 
adhesion of melanocytes to keratinocytes (Tang et ai,  1994, Hsu et ai,  1996).  Danen et ai found 
E-cadherin  to be expressed on cultured normal  melanocytes a nd naevus cells, whilst two non- 
invasive,  non-metastatic melanoma cell lines showed low expression and four invasive, metastatic 
melanoma  cell  lines did  not express  E-cadherin  (Danen  et ai,  1996).  Moreover,  melanoma cells 
transduced with  E-cadherin lost their invasive capacity (Hsu et ai,  2000).  Thus a role for the loss 
of  E-cadherin  expression  in  melanoma  metastasis  has  been  proposed.  Loss  of  E-cadherin 
appears  to  be  one  of the  critical  steps  in  progression  of  melanoma,  because  it  may trigger the 
release of cancer cells from the  primary growth focus (Christifori &  Semb  1999).  This process  is 
not  only  due  to  loss  of  physical  adhesion  but  also  to  multiple  events  that  lead  to  uncontrolled 
proliferation  and  progressive i nvasion  (Guilford  1999).  After  the  loss  of  E-cadherin  expression, 
melanocytic cells can escape from neighbouring keratinocytes and invade the dermis.
Conflicting data  have  been  published on cadherin expression  in  primary melanoma.  Seline et ai 
found  that the  expression  of  both  E-  and  P-cadherin  varied  inversely  with  disease  progression 
(Seline  et  ai,  1996)  and  proposed  that  loss  of  cadherin  expression  is  an  inevitable  feature  of 
tumour progression.  Sanders and colleagues  used  immunohistochemistry and Western blot after 
tissue fractionation  of surgically excised  dysplastic naevi  and  melanoma specimens to determine 
cadherin  expression  (Sanders  et ai,  1999).  Loss of E-cadherin  was  seen  in  a  small  number of 
vertical growth  phase  melanomas only when  metastasis occurred and  E-cadherin was retained  in 
all radial growth phase tumours.  There was,  however, a “dramatic” loss of P-cadherin expression 
in vertical growth  phase  melanomas with  metastasis formation.  These results suggest that shifts 
in  cadherin  profiles  occurred  late  in  the  biological  progression  of melanocytic tumours  and  were 
similar to a  study  by  Danen  et ai  who found  higher E-cadherin  expression  in  advanced  primary 
melanomas  than  in  early  primaries  (Danen  et ai,  1996).  The  study  by  Danen  and  colleagues, 
however,  used  only small  sample sizes:  7  early  primary  melanomas  and  20  "advanced  primary" 
(>1.5mm),  of which only 4 advanced  primary melanomas stained  positively.  Conversely,  Silye et
162al.  showed  E-cadherin expression to be absent in  melanomas in their radial growth  phase and  in 
Clark’s  level  II  and  III  lesions,  whereas  E-cadherin  was  expressed  in  a  high  proportion  of 
melanomas  in  the  vertical  growth  phase,  in  Clark’s  level  IV  and  V  lesions  and  in  metastasising 
melanomas  (Silye  et al.,  1998).  These  results were  in  agreement with  a  study  by  Cowley et al. 
who found that E-cadherin expression tended to be higher in melanomas than in naevi (Cowley et 
al.,  1996),  but  again  this  study  used  relatively  small  sample  sizes  (11  benign  lesions  and  14 
melanomas).
In  the  present study the association  of poor outcome with  loss  of  E-cadherin  expression  did  not 
reach  significance.  It  has  been  proposed  that  although  E-cadherin  expression  in  melanomas 
implies  potential  preservation  of adhesive function,  normal  cadherin  expression  does  not always 
equate to normal function,  because cadherin function  can  be modified  by both the specificity and 
amount  of  different  cadherins  on  cell  surfaces  (Steinberg  &  Takeichi  1994)  and  cadherin 
glycosylation  (Yoshimura  et al.,  1996).  This  may explain why retention of E-cadherin  expression 
did  not  confer  a  survival  advantage  to  patients  whose  tumours  expressed  this  marker  in  the 
present  study.  The  conflicting  evidence  presented  as  to  the  shift  in  cadherin  profiles  with 
melanoma  progression  may  be  explained  by  a  loss  of  cadherin  in  early  melanoma  disease 
progression,  followed  by  re-expression  in  more  advanced  forms  of  the  disease,  (Seline  et  al., 
1996; Danen  eta I.,  1  996; Silye  eta I.,  1 998; Sanders  eta I.,  1  999).  This t heory p roposes t hat 
melanoma  cells  initially  escape  keratinocyte  control  or  dominance  with  the  loss  of  cadherin 
expression.  Once the melanoma cells have developed a metastatic phenotype the cadherins may 
be re-expressed enabling the cells to reattach and form new foci of growth.  This model would also 
explain the results of the i nvestigation examining  the i ntensity of expression of P-cadherin a nd 
patient outcome.  Patients with tumours with the weakest P-cadherin expression fared best, those 
whose tumours had complete loss of P-cadherin fared worst and the outcome of those with strong 
P-cadherin expression was in-between.
1634.9  CD44V3 AND NM23
4.9.1  CD44v3 and Nm23:  expression and correlation with 
clinicopathological features
The expression of CD44v3 was highly correlated with Clark’s level,  Breslow thickness and patient 
age (Table 4.9.1.1).  The strong correlation  between  CD44v3 intensity and  both Clark’s  level and 
Breslow  thickness  (Spearman  correlation  p  <  0.001  for  both)  is  illustrated  in  Figures  4.9.1.1  & 
4.9.1.2.  Melanomas w ith t he s trongest C D44v3 s taining i ntensity w ere  all I ess t han 4.0 m m i n 
depth.  Similarly,  the  proportion  of Clark’s  level  5  tumours was  highest  in  the  negatively stained 
group,  and  decreased  in  proportion  with  increasing  intensity of staining.  The  observed  staining 
pattern is consistent with a role of CD44v3 expression early in melanoma progression.
Variable  P value
Clark’s level*”   < 0.001
Breslow Depth*  <0.001
Agef  < 0.001
Ulceration1  0.113
Site of turnout  0.31
Male sexf  0.833
Table  4.9.1.1  Correlations  between  CD44v3  staining  intensity  and  established  prognostic  variables  for 
melanoma.  * Spearman test, f Pearson Chi-squared.
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Figure 4.9.1.1  Figure  illustrating the association of the  intensity of CD44v3 expression  with  Clark’s levels 
(Spearman’s correlation  p< 0.001).  The staining  intensity was scored  as negative (0), weak (1),  moderate 
(2) or strong (3).
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Figure 4.9.1.2  Figure illustrating the association between the intensity of CD44v3 expression and  Breslow 
depth  (Spearman’s correlation  p< 0.001).  Breslow depth was  grouped  according to the “T” staging of the 
AJCC  staging  classification  of  melanoma.  The  staining  intensity  was  scored  as  negative  (0),  weak  (1), 
moderate (2) or strong (3).
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165Nm23 expression was strongly correlated with Clark’s level, Breslow depth and patient age, whilst 
a trend towards an association with tumour ulceration was also observed (table 4.9.1.2)
Variable 
Clark’s level* 
Breslow Depth* 
Age1 "
Ulceration1 -  
Site of tumour1  
Male sexf
P value 
<0.001 
0.002 
0.014 
0.069 
0.551 
0.934
Table 4.9.1.2  Correlations between  nm23 intensity and  established  prognostic variables for melanoma.  * 
Spearman test, f Pearson Chi-squared.
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Figure 4.9.1.3  Histogram illustrating the association between the intensity of nm23 expression and Breslow 
depth (Spearman’s correlation  p = 0.002).  Breslow depth was grouped according to the “T” staging from the 
AJCC  staging  classification  of  melanoma.  The  staining  intensity  was  scored  as  negative  (0),  weak  (1), 
moderate (2) or strong (3).
Figure  4.9.1.3  illustrates  that  no  negatively staining  tumours were  over 4.01mm  and  most were 
less than 2.01mm in depth.  A clear positive correlation of staining intensity with Breslow thickness 
and Clark’s level was observed (Figure 4.9.1.3 and data not shown).
1664.9.2  CD44v3 and nm23: expression and clinical outcome
Figure 4.9.2.1  shows  univariate  survival  curves  in  relation  to  CD44v3  expression.  The  log  rank 
test of significance between Kaplan-Meier estimates of survival showed that those patients whose 
tumours were  CD44v3  negative  had  a significantly higher probability of poor outcome than those 
whose  tumours  were  CD44v3  positive  (x2=  7.2219,  p  =  0.0072).  The  5-year  survival  for  the 
CD44v3 negative melanoma patients (n= 20) was 43% compared with a 5-year survival of 75% for 
the CD44v3 positive melanoma patients (n= 57).
” T - - -
0.9
0.8
O)
.£  0.7 
>
£  0.6
3  0.5
O  0.4
■ ■ c
O  0.3 
Q.
2   0.2 
CL
> 4 41--H++1+•.H  + H — IH-    ll-t-i
0.0
0 20 40 60 80 100
Time to outcome (months)
Figure 4.9.2.1  Survival curves comparing CD44v3 positive and CD44v3 negative melanomas.  Log rank x2  
= 7.2219, p = 0.0072.  --------   CD44v3 negative,    CD44v3 positive.
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Figure 4.9.2.2  Survival curves comparing staining intensity of CD44v3in primary melanomas.  Log rank x2  =
12.5162, p = 0.0058.      CD44v3  negative,    CD44v3  1+  positive,    CD44v3 2+ positive,
      CD44v3 3+ positive
As with  MCAM  (Figure 4.7.2.2),  the  CD44v3 positive tumours could  be stratified  according to the 
intensity o f e xpression  (Figure 4.9.2.2).  This d emonstrated t hat  the s tronger t he e xpression o f 
CD44v3  in  the  tumour,  the  better  the  patient  outcome.  The  correlation  with  outcome  was 
statistically highly significant (x2 = 12.5162, p = 0.0058).
By contrast, the expression of nm23 was negatively associated with a favourable patient outcome. 
Figure 4.9.2.3  illustrates that the 5-year survival of patients with an  nm23-expressing tumour was 
60% (n= 47), whereas patients with tumours that did not express this marker had a 5-year survival 
rate  of 90%  (n=  29).  Furthermore,  an  even  stronger correlation  with  outcome was found  when 
patients were stratified  according to staining  intensity (Figure 4.9.2.4).  However,  neither CD44v3 
nor nm23  expression  reached  statistical  significance when  analysed  in  Cox  multivariate  models,
i.e. n either  marker was  shown t o b e i ndependently p redictive of p rognosis w hen a nalysed w ith 
established clinicopathological markers of prognosis.
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Figure 4.9.2.3  Survival curves comparing  nm23 positive and nm23 negative  melanomas.  Log rank x2  = 
5.9571, p = 0.0147.  ---------nm23 negative,    nm23 positive.
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Figure 4.9.2.4  Survival curves comparing staining intensity of nm23 in primary melanomas.  Log rank x2  = 
11.3281, p = 0.0035.----- ---------nm23 negative,    nm23 1  + positive,    nm23 2+ positive.
169Variable Hazard risk
95% Cl for the Hazard Risk 
Lower  Upper P-value
Clark’s level 3.173 1.444 6.971 0.004
Breslow thickness 1.147 1.032 1.274 0.011
CD44v3 0.528 0.191 1.465 0.220
Site 0.822 0.582 1.160 0.264
Age 1.008 0.981 1.036 0.573
Sex 0.802 0.351 1.835 0.601
Ulceration 1.082 0.442 2.646 0.863
Table  4.9.2  Cox  multivariate  analysis  including  CD44v3  expression  and  other  established  markers  of 
prognosis.  CD44v3 expression is shown not to be independently predictive of poor prognosis.
95% Cl for the Hazard Risk
Variable Hazard risk Lower Upper P-value
Breslow thickness 1.166 1.048 1.296 0.005
Clark’s level 2.665 1.186 5.988 0.018
Nm23 2.262 0.502 10.185 0.288
Male sex 0.638 0.259 1.571 0.328
Site 0.839 0.587 1.200 0.336
Age 1.014 0.985 1.044 0.343
Ulceration 1.223 0.493 3.032 0.664
Table  4.9.3  Cox  multivariate  analysis  including  nm23  expression  and  other  established  markers  of 
prognosis.  Nm23 expression is shown not to be independently predictive of poor prognosis.
4.9.3  Discussion
Patients  with  melanomas  that  did  not  express  CD44v3  had  a  significantly  poorer  outcome 
compared with those whose tumours expressed this marker.  Conversely,  patients whose tumours 
did  not express  nm23  did  much  better than  those whose tumours  did  express  nm23.  Subgroup 
analysis  showed  that  marker  expression  of  both  CD44v3  and  nm23  retained  significance  when 
stratified a ccording t o t he i ntensity of e xpression of the p rotein.  F or C D44v3, t he s tronger t he
170staining  intensity,  the  more  favourable  the  patient outcome,  whereas  for nm23,  the  stronger the 
stain, the poorer the patient outcome.
4.9.3.1  CD44v3
CD44  is  a  widely  distributed  transmembrane  glycoprotein.  Originally  described  as  a  homing 
receptor for lymphocytes (Stoolman 1989), it also appears to function in such diverse physiological 
processes  as  lymphocyte  activation,  cell-cell  adhesion,  cell-matrix  interaction  and  cell  motility 
(Underhill  1992).  Interest has focused on its possible role as an adhesion molecule involved in the 
malignant progression and  metastatic potential of certain tumours (Gunthert et al.,  1995;  Harwood 
et al.,  1996;  Saegusa  et al.,  1999;  Pirinen  et al.,  2000;  Setala  et al.,  2001;  Hefler  et al.,  2002; 
Suzuki  &  Yamashiro  2002;  Bankfalvi  et  al.,  2002).  Characterisation  of the  human  CD44gene 
demonstrated that it has at least 20 exons and  is  located  on  chromosome  11.  Multiple  isoforms 
are generated  by alternative splicing of transcripts of this gene (Screaton et al.,  1992).  The larger 
splice variants  (CD44v1-10) contain additional amino acids  positioned  in the extracellular domain 
of the molecule.  They have a more restricted pattern of expression and appear to be preferentially 
associated  with  epithelial  cell  subpopulations.  The functions  of these  isoforms  remain  relatively 
unclear (Stamenkovic et al.,  1991), however CD44 molecules containing the v3 domain are able to 
bind  growth factors  and  might  play  a  role  in  the  control  of  cellular  proliferation  (Bennett  et  al., 
1995).
There  is  increasing  evidence  to suggest that CD44  may contribute to  malignant progression and 
metastasis  formation  (Bartolazzi  et al.,  1994).  As  referred  to  in  the  introduction  to  this  chapter, 
CD44 expression  correlates with the tumour stage  in  human  colorectal adenocarcinomas (Heider 
et al.,  1993),  bladder carcinoma  (Nemec et al.,  1987) and  non-Hodgkin’s  lymphoma  (Horst et al., 
1990).  The  metastatic  capacity  of  B16  mouse  melanoma  cells  (Hart  et  al.,  1991)  and  human 
melanoma cell  lines  (Birch  et al.,  1991)  is enhanced  by CD44H  expression and this capacity can 
be blocked by anti-CD44 antibodies (Guo et al.,  1994).
The evidence relating to splice variants is conflicting, with different studies detecting widely varying 
expression  levels  of  splice  variants  encoded  by  the  metastasis-associated  exons  v5  and  v6. 
Harwood  et  al.  explored  the  immunohistochemical  pattern  of  CD44  expression  in  a  range  of 
melanocytic lesions using a panel of monoclonal antibodies raised to CD44H and the variants v3- 
v6 and v8/9 (Harwood et al.,  1996).  Skin biopsies of 106 lesions from  100 patients were assessed 
and  included  benign  and  dysplastic  naevi,  melanoma  in  situ,  melanomas  in  the  horizontal  and
171vertical  growth  phase  and  cutaneous  and  lymph  node  metastases.  The  study  found  that  the 
expression  of  CD44H  diminished  with  increasing  invasiveness  and  the  pattern  of  expression 
observed  correlated  significantly  with  the  growth  phase  of  the  lesion,  rather  than  its  Breslow 
thickness.  These results were confirmed in a later study on 292 stage I melanomas by Karjalainen 
et  al.  (Karjalainen  et  al.,  2000).  In  the  present  study  CD44v3  expression  was  significantly 
correlated with both Clark's level and Breslow thickness.  In Harwood’s study, CD44 splice variants 
were  not detected  in  any of the  lesions  using  their antibodies.  Ranuncolo  and  co-workers  also 
failed  to  detect  expression  of  CD44v3  in  their  series  of  57  primary  cutaneous  melanomas 
(Ranuncolo et al., 2002), as did Seelentag et al. in 28 melanomas (Seelentag et al.,  1997).  Both of 
these groups used anti-CD44v3 antibodies supplied by different manufacturers compared with the 
antibody used  in the present study.  Differences in the methods of antigen  retrieval and detection 
may further contribute to conflicting results in immunohistology studies.
Dome et al. analysed 46 primary melanomas with a minimum follow-up of 61  months and were the 
first to demonstrate the expression of the v3 splice variant by immunohistochemistry in melanoma 
(Dome et al.,  2001).  CD44v3 expression was only observed  in tumours thicker than  1.0mm.  The 
expression of CD44v3 was not detected in the non-metastatic group of patients.  The marker was 
detected  in  only  one  lymph  node-metastatic  tumour;  but  was  prevalent  in  the  organ-metastatic 
group.  The 5-year survival of patients with CD44v3 positive tumours was lower than those who did 
not e xpress  this  marker.  These r esults a re w holly a t v ariance w ith t hose  found i n t he  present 
study.  Dome’s  group  analysed  a  relatively small  number of tumours  (46)  and  detected  CD44v3 
using  a  different  antibody  compared  with  this  study,  which  may  have  contributed  to  the 
discrepancy in results.
This study showed  a  clear correlation  between  CD44v3  staining  intensity and  outcome,  with the 
strongest staining  being  correlated  with  the  most favourable  outcome.  Although  loss  of CD44v3 
expression  has  not  previously  been  shown  to  correlate  with  poor outcome  in  melanoma,  it  has 
been  shown  in  several  other  cancers.  Decreased  CD44v3  expression  in  oral  squamous  cell 
carcinoma  was  significantly  correlated  with  unfavourable  tumour-free  and  overall  survival 
(Bankfalvi et al., 2002).  Suzuki and Yamashiro analysed CD44v3 expression in 93 Japanese lung 
adenocarcinoma patients by immunostaining to study the relationship between marker expression 
and  invasion  in  lung  adenocarcinoma  (Suzuki  &  Yamashiro  2002).  A  significantly  reduced 
expression  of  CD44v3  was  observed  in  invasive  lesions  compared  with  non-invasive  lesions, 
suggesting  that  reduced  expression  of  CD44v3  is  associated  with  invasion  in  lung 
adenocarcinoma.  This observation supported an earlier study, which found reduced expression of 
CD44v3 to be associated with poor survival in non-small cell carcinoma of the lung (Pirinen et al.,
1722000).  Loss  of  CD44v3  has  also  been  correlated  with  poor survival  of ovarian  cancer  patients 
(Saegusa et al.,  1999).  By contrast, no relationship between CD44v3 expression and survival was 
found in vulvar carcinoma (Hefler et al., 2002) or gastric cancer (Setala et al., 2001).
The role of CD44v3 in tumour progression remains to be determined.  The v3 splice variant is the 
only CD44  isoform  able to  bind  heparin-binding  growth factors and  cytokines through  its  heparin 
sulphate  side  chains  (Bennett et al.,  1995;  Van  der Voort et al.,  1999).  Cells expressing  the v3 
variant may therefore accumulate matrix-bound growth factors.  This could improve the survival of 
cells remaining in their original environment and relieve the selective pressure to progress towards 
a  metastasis-forming  phenotype.  This  would  explain  the  findings  of  this  study,  in  which  the 
stronger the expression of CD44v3, the better the prognosis of the patient.
4.9.3.2  Nm23
The nm23 gene was originally identified by differential colony hybridisation experiments on related 
K-1735  murine  melanoma  cell  lines  of  low  and  high  metastatic  potential  (Steeg  et  al.,  1988). 
These experiments identified a gene expressed at ten-fold  higher mRNA levels in two cell lines of 
low  metastatic  potential  than  in  five  cell  lines  of  high  metastatic  potential.  Transfection  of the 
murine  nm23  cDNA  into  highly  metastatic  K-1735  murine  melanoma  cells  reduced  its  metastatic 
potential,  independent  of the  effect  on tumour  cell  growth  rate (Leone  et  al.,  1991).  Similarly, 
transfection of the nm23 gene into B16F10 melanoma cells also resulted in significant suppression 
of invasiveness and  metastatic ability and also enhanced survival of tumour-bearing mice (Parhar 
ef al.,  1995).
Nm23  protein  is  present  in  many  human  tissues  and  is temporarily  up-regulated  during  lactation 
and intestinal epithelial regeneration (Gumbiner et al.,  1992).  A major biological role of the Nm23 
protein  is  its  nucleoside  diphosphate  kinase  activity  that  transfers  a  phosphate  group  between 
nucleoside  di- and  tri-phosphates.  This  is  not considered  to  be  associated  with  a  potential  anti­
metastatic  activity.  Other  functions  attributed  to  the  nm23  gene  product  include  a  role  in  the 
activation of small  G-proteins during the initial steps of signal transduction (Kiura et al.,  1990), the 
modulation of TG F ft 1-mediated cell adhesion (Urano  eta I.,  1  993; Hsu  eta I.,  1  994) and c -myc 
transcription  (Postel  et al.,  1993).  The  exact relationship  between the various functions of nm23 
and its role in tumour progression and metastasis remains unclear.
173However,  average  mRNA  levels  of  cell  lines  derived  from  primary  and  metastatic  melanomas 
shown  no  significant  difference  (Easty  et a/.,  1996).  Previous  studies  of  nm23  mRNA  levels  in 
metastatic m elanomas h ave  shown  significantly  lower  levels  in  patients  developing  metastases 
within 2 years of diagnosis than  in those with less aggressive disease  (Florenes et al.,  1992) and 
longer survival for patients with higher levels of mRNA (Xerri et a!.,  1994).
Nm23 expression  in other cancers showed varying  results:  low levels of nm23 mRNA have  been 
found to correlate with the development of metastases in  breast cancer (Bevilacqua et al.,  1989), 
stomach  cancer  (Nakayama  et  al.,  1993)  and  liver  cancer  (Nakayama  et  al.,  1992),  whilst  in 
human  neuroblastoma  (Hailat et al.,  1991),  breast carcinoma  (Sastre-Garau  et al.,  1992), thyroid 
carcinoma  (Zou  et  al.,  1992),  colon  carcinoma  (Haut  et  al.,  1991),  cutaneous  squamous  cell 
carcinoma  and  squamous  carcinoma  of the  lung  (Engel  et al.,  1993)  high  levels  of nm23  mRNA 
have been demonstrated in more advanced and aggressive lesions.
Recent  studies  evaluating  immunohistochemical  staining  for  nm23  expression  in  melanocytic 
lesions  do  not  appear to  mirror the  findings  of earlier  mRNA  studies  with  respect to  prognosis. 
Although  Lee et al.  demonstrated  and  inverse correlation  between staining  and tumour thickness 
(Lee  et  al.,  1996),  other  studies  have  found  no  correlation  between  nm23  expression  and  the 
development  of  nodal  metastases ( Easty  et  al.,  1996;  Saitoh  et  al.,  1996)  or  survival  outcome 
(Holmes & MacKie 1996; Reichrath et al.,  1997; van den Oord et al.,  1997).  McDermott et al. have 
studied the  largest series of melanomas to date for nm23 expression  using  immunohistochemical 
techniques  (n=145)  (McDermott  et al.,  2000).  This  study found  a  strong  positive  correlation  of 
staining  intensity with survival,  in  keeping with  previous mRNA studies and the findings of Lee et 
al.  (Lee et al.,  1996).  These results reached statistical significance  in  univariate analysis,  but did 
not retain significance in multivariate analysis.
The findings of the  present study are at variance with those of McDermott and  co-workers  but in 
keeping with those of Saitoh et al.  (Saitoh et al.,  1996).  Saitoh et al.  found a correlation between 
nm23 expression and early local  recurrence,  Clark’s level and  Breslow thickness,  but not with the 
presence  of lymph  node  metastases  using  paired  primary and  metastatic lesions from  the  same 
patient.  In this study a correlation between nm23 expression, Clark's level, Breslow thickness, age 
and  poor outcome was found.  Furthermore,  the degree  of positivity of nm23 staining  correlated 
with outcome,  such that stronger staining  predicted a worse outcome.  It has been  proposed that 
melanocytes  do  not  require  a  high  level  of  nm23,  either  because  of  their  differential  status  or 
because  nm23  is  not  relevant to  melanoma -  a  theory that does  not seem  plausible,  bearing  in 
mind the results of this study.  The anti-Nm23 antibody used  in other studies may not be specific
174for  an  epitope  associated  with  metastatic  or  aggressive  potential.  Therefore, 
immunohistochemistry  results  may  depend  on  the  specificity  and  selectivity  of  antibodies  and 
methods employed.  The conflicting findings of this study and others on nm23 expression and the 
progression of melanoma and other tumours most likely reflect the multiple functions and complex 
role of this marker in tumour biology.
4.10  OTHER MARKERS INVESTIGATED
A  variety  of  other  markers  were  investigated  using  the  melanoma  tissue  microarray.  Of  the 
remaining  markers  (AP-2,  (3-catenin,  bcl-2,  ki-67  and  MG50),  only  the  intensity  of expression  of 
bcl-2 w as s hown t o c orrelate w ith p rognosis i n t his c ohort o f m elanoma p atients ( p= 0.05).  A 
summary of the results is shown in Table 4.9.
Bcl-2 is a proto-oncogene and  part of a regulatory pathway that prevents programmed cell death. 
It is involved in the 14:18 chromosome translocation observed in some follicular lymphomas, which 
leads  to  increased  expression  of the  gene  (Pezzella  et al.,  1990).  Bcl-2  is  thought to  exert  its 
effect on preventing apoptosis by protecting the cell from the oxidative stress that results from free 
radical accumulation  (Hockenbery et al.,  1990).  Previously,  Grover and Wilson investigated bcl-2 
expression  in  a  series  of  melanoma  lymph  node  metastases  using  flow cytometry  and  found  a 
correlation of high expression with a shorter survival (Grover & Wilson 1996).
Marker  Expression (univariate)  Intensity (univariate)  Multivariate analysis 
Log Rank  P-value  Log Rank  P-value  Hazard Risk  P-value
(x2)  (x2)
AP-2 1.498 0.221 4.83 0.185 0.854 0.817
(3-catenin 0.727 0.394 2.53 0.469 1.54 0.383
bcl-2 0.452 0.5 7.75 0.05 0.566 0.442
ki-67 2.62 0.106 2.89 0.409 1.21 0.743
MG50 0.361 0.548 2.31 0.511 9236 0.986
Table  4.10.1  Table  summarising  the  results  of  other  immunohistochemical  markers  examined  with  the 
melanoma  tissue  microarray.  None  of these  markers  demonstrated  correlations  with  melanoma  patient 
outcome.
175More recently, Vlaykova et al.  used immunohistochemistry to investigate 60 metastatic melanomas 
and found that the  presence of Bcl-2 immunoreactivity was associated with a  longer disease-free 
survival.  However, the study also found that focal bcl-2 expression was strongly associated with a 
worse prognosis compared to a diffuse expression or lack of Bcl-2 staining (Vlaykova et al., 2002). 
In the  present study  increased  bcl-2 expression correlated with  poor outcome,  in  agreement with 
the results of  Grover and  Wilson (Grover &  Wilson  1  996).  H owever, no correlation was  found 
between  positivity  alone  and  outcome.  The  relationship  with  the  pattern  of staining  and  patient 
outcome in the study by Vlaykova et al.  may explain why,  in the present study,  no correlation was 
found  between  the  positivity  of  bcl-2  and  survival,  whereas  one  was  between  the  intensity  of 
expression and  survival were associated  (Vlaykova et al.,  2002).  It is possible that the technique 
of tissue microarray  is  not  suitable for  the  assessment  of  bcl-2  or  other  markers,  in  which  the 
pattern of staining is more significant than the presence or absence of staining itself.
Of the  remaining  markers  investigated, only the staining  of Ki-67 was shown to correlate with the 
clinicopathological  variables  analysed.  Table  4.9.2  shows  that  ki-67  expression  is  strongly 
correlated  with  Breslow  thickness,  melanoma  ulceration  and  Clark’s  level.  Despite  this,  no 
relationship  with  patient outcome  was  found  in  either univariate  or multivariate  analysis.  Figure
4.9.2  illustrates the relationship between Ki-67 expression level and Clark's levels.  It can be seen 
that staining  intensity increased with  increasing Clark's level, such that no Clark's level  1  tumours 
were  stained  more  than  weakly  and  most  Clark's  level  5  tumours  were  stained  moderately  or 
strongly.
Variable P value
Breslow Depth* 0.001
Ulceration* 0.005
Clark’s level* 0.024
Age* 0.247
Male sex* 0.688
Site of turnout 0.945
Table  4.10.2  Correlations  between  ki-67  expression  level  and  established  prognostic  variables  for 
melanoma.  * Spearman test,1  Pearson Chi-squared.
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Figure  4.10.2  Figure  illustrating  the  association  of  the  intensity  of  ki-67  expression  with  Clark’s  levels 
(Spearman’s correlation p = 0.024).  The expression of ki-67 was scored as negative (0), weak (1), moderate 
(2) or strong (3).
Because Ki-67 is not expressed in resting cells but is expressed from the mid-G1  phase of the cell 
cycle through to the S,  G2 and  M phases,  it is considered to be a reliable marker of proliferation 
and hence possibly a useful prognostic marker.  Ki-67 has previously been studied for correlations 
of  expression  with  melanoma  clinicopathological  variables  as  well  as  outcome.  In  the  largest 
series of melanoma  specimens  studied  so far (n=  137),  Hazan  and  colleagues showed  a  highly 
significant correlation  of Ki-67  expression  and  tumour thickness,  results that mirror those of this 
study  (Hazan  et al.,  2002).  Hazan  et al.  also found  a  correlation  between  ulceration  and  Ki-67 
staining  was  found,  although  this  did  not  reach  significance  (p  =  0.09)  and  no  statistically 
significant correlation between patient outcome and  marker expression was found.  These results 
are  therefore  comparable  with  those  of  the  present  study.  Other  studies  have  also  found 
correlations  between tumour thickness,  Clark's  level  and  Ki-67 expression  (Ramsay et al.,  1995; 
Boni  et  al.,  1996;  Henrique  et  al.,  2000).  Other  immunohistochemical  studies  have  shown  a 
correlation  between  Ki-67 expression and  melanoma  patient outcome  (Korabiowska  et al.,  1994; 
Ramsay et al.,  1995; Vogt et al.,  1997;  Niezabitowski et al.,  1999; Straume et al.,  2000; Ostmeier 
et  al.,  2001).  However,  most  of  these  studies  evaluated  cohorts  consisting  of  mainly  thicker 
tumours  (Korabiowska  et al.,  1994;  Ramsay et al.,  1995;  Vogt  et al.,  1997;  Niezabitowski  et al., 
1999;  Henrique et al.,  2000).  Indeed,  Boni  et al.  found that ki-67 expression only correlated with 
survival in patients whose tumours were more than  1.5mm in depth (Boni et al.,  1996).  Similarly,
Clark's 1   Clark's 2  Clark's 3  Clark's 4  Clark's 5
Clark's level
177Sparrow  et  al.  found  no  association  between  Ki-67  expression  and  thin  metastasising  primary 
cutaneous melanomas (Sparrow etal.,  1998).
It is known that Ki-67 expression can vary even within different parts of the same tumour (Ostmeier 
et al.,  1989;  Hazan et al.,  2002).  Therefore,  it is possible that, similar to bcl-2, evaluation of Ki-67 
expression u sing t he t issue m icroarray d id n ot  provide t he s ame r esults t hat w ould h ave b een 
obtained  had  whole  tumour  specimens  been  used.  However,  the  tissue  array  validation  study 
(section 4.5;  Pacifico et al.  2003) had shown that 4 core biopsies per specimen used for the tissue 
microarray  resulted  in  a  high  concordance  with  whole  specimen  staining.  Another  potential 
explanation for the lack of a correlation with patient outcome is the size of the cohort investigated. 
However, as the results matched those of Hazan et al. closely this seems unlikely to have affected 
the outcome.  Finally,  it is  possible that the anti-Ki-67 antibody used  may not have been specific 
enough  for  cells  that  will  complete  the  cell  cycle  and  progress  to form  tumours  that  result  in  a 
poorer patient outcome (Hazan et al., 2002).
4.11  RELATIONSHIPS BETWEEN MARKERS 
INVESTIGATED
The final section of this chapter investigates the relationships between the markers studied.  Table 
4.10  summarises  the  relationships  revealed  between  pairs  of  markers.  Highly  statistically 
significant relationships are observed between various pairs of markers.  Of note is the relationship 
between  P-cadherin  and  E-cadherin  and  between  the  cadherins  and  IJ-catenin.  Relationships 
revealed  between the various adhesion  molecules  may not mean that their function  is related but 
may have arisen due to various changes in expression occurring simultaneously.  However, some 
relationships observed are supported by evidence in the literature, as discussed below.
Cell adhesion molecules do not simply  function as a  molecular  glue organising cells into  static 
structural  entities,  but  also  support  and  direct  the  exchange  of  information  between  cells 
(Klymkowsky  &  Parr  1995).  This  is  supported  by the  nature  of the  relationship  between  certain 
adhesion  molecules  and  patient  outcome  revealed  in  the  present  study.  Adhesion  molecules 
themselves actively participate in transducing signals into the cells both through interaction of their 
cytoplasmic  regions  with  kinases  such  as  focal  adhesion  kinase  (Schlaepfer &  Hunter  1998)  as 
well as through interaction with growth factor receptors mediated by extracellular regions (Johnson
1781999).  Adhesive  interactions  mediated  by  one  adhesion  molecule  can  also  influence  the 
expression or activity of a second adhesion molecule.
Disruption of E-cadherin-mediated cell adhesion facilitates tumour invasion, whereas restoration of 
E-cadherin  expression  results  in  growth  retardation  and  inhibition  of the  invasive  and  metastatic 
phenotype  in  carcinoma  cells  (Christifori  &  Semb  1999).  It  has  been  shown  that  E-cadherin- 
mediated  adhesion  with  keratinocytes  can  modulate  MCAM  expression  (Shih  et  al.,  1994). 
Melanocytes cultured  in the absence of keratinocytes express MCAM and this can be reversed by 
the  addition  of  keratinocytes.  Melanoma  cells  are  generally  resistant  to  the  influence  of 
keratinocyte  co-culture  and  this  has  been  shown  to  be  associated  with  the  lack  of  E-cadherin 
expression  by  the  melanoma  cells  (Hsu  et  al.,  1996).  In  the  present  series  no  relationship 
between E-cadherin and MCAM was found, although as expected, a close relationship between E- 
and P-cadherin was observed.  Loss of P- and  E-cadherin expression  has been previously shown 
in the earliest identifiable  malignant lesions  (Christifori  & Semb  1999).  It is a critical event in the 
development of metastatic potential, leading not only to the expression of new adhesion molecules 
but also to broad changes in gene expression which contribute to or even constitute the biological 
behaviour of melanomas.
(i-catenin was one of the markers in which no correlation with patient outcome was revealed; yet a 
highly significant relationship with both P- and E-cadherin was found (as well as with CD44v3, AP2 
and  nm23).  Formation  of the  cadherin  -  (i-catenin  complex  is  essential for  E-cadherin-mediated 
cell adhesion (Ozawa et al.,  1990), but the role of li-catenin is far more than that of a structural link 
to the cytoskeleton.  fi-catenin is a key regulatory molecule linking adhesion to the control of gene 
transcription  (Klymkowsky & Parr 1995).  (i-catenin is a multi-functional protein,  binding to several 
different  partners  in  addition  to the  classical  cadherins.  Free  (1-  catenin  can  bind  to the  cellular 
proteins  glycogen  synthetase  kinase  3  (GSK-3U)  and  adenomatous  polyposis  coli  (APC),  which 
target  it for destruction.  Pathways  triggered  by  mutations  in  the  APC,  mutations  in  fi-catenin  or 
loss  of E-cadherin  expression  all  lead  to  an  increase  in  the  pool  of free  (i-catenin.  It  has  been 
speculated  that  these  pathways  are  associated  with  the  transition  of  cells  to  more  migratory 
mesenchymal  phenotypes  in  carcinomas  (Johnson  1999).  Precursors  of epidermal  melanocytes 
arise during fetal development from the neural crest and migrate throughout the embryo to take up 
residence in a complex process, which has much in common with the metastatic process (Erickson 
1993).  The  biological  changes  set  in  motion  during  melanoma  development  may  trigger  a 
reversion  to  this  melanoblast  phenotype  and  one  of  the  critical  events  could  be  disruption  of 
keratinocyte-melanocyte  interaction.  Disturbances  in  cadherin  expression  or function,  one of the
179earliest  steps  in  the  development  of  metastases,  may  also  be  one  of  the  earliest  steps  in  the 
development of cutaneous melanoma.
Marker P- E- P-
S M-CAM CD44v3 AP-2 cadherin cadherin catenin MG50 Ki-67 Nm23 Bcl-2
Bcl-2 CC 0.371** -0.150 0.069 -0.042 0.126 0.175 .208 .191 0.470** 1.000
a 0.001 0.195 0.566 0.723 0.271 0.133 .077 .099 0.000
N 74 76 72 75 78 75 73 76 74 80
Nm23 CC 0.397** - 0.146 0.417** 0.131 0.097 0.346** 0.454** 0.450** 1.000
a 0.000 0.210 0.000 0.263 0.410 0.002 0.000 0.000 0.000
N 76 76 74 75 74 76 73 75 76
Ki-67 CC 0.098 - 0.065 0.452** - 0.077 -0.092 0.141 0.475** 1.000
a 0.402 0.576 0.000 0.509 0.428 0.228 0.000 0.000
N 75 76 73 75 76 75 74 79
MG50 CC 0.031 0.043 0.388** 0.036 0.057 0.312** 1.000
a 0.797 0.713 0.001 0.760 0.629 0.007 0.000
N 73 77 71 75 75 73 79
P-
catenin
CC
0.105 0.292* 0.287* 0.509** 0.428** 1.000
a 0.368 0.011 0.013 0.000 0.000 0.000
N 76 76 74 75 75 77
E-
cadherin
CC
a
N
0.066
0.577
74
0.180
0.114
78
0.072
0.547
72
0.356**
0.002
75
1.000
0.000
83
P-
cadherin
CC
a
N
0.099
0.398
75
0.212
0.066
76
0.133
0.262
73
1.000
0.000
77
AP-2 CC
a
N
0.101
0.393
74
0.016
0.891
74
1.000
0.000
74
CD44v3 CC
a
N
-0.112
0.333
76
1.000
0.000
84
M-CAM CC
a
N
1.000
0.000
76
Table 4.11  Summary of statistically significant relationships between markers investigated  (** p < 0.001, * p 
< 0.05).  S = Spearman Rho, CC = correlation coefficient, a = sigma(2-tailed), N = patient number evaluated.
1804.11  SUMMARY
This  chapter  has  demonstrated  the  suitability  of  using  tissue  microarray  technology  for  the 
assessment of the  prognostic potential  of melanoma-associated  proteins.  When  using four core 
biopsies  from each melanoma  represented, a  high concordance with results achieved  from  the 
whole  specimen  were  found.  A  number of  melanoma-related  cellular adhesion  molecules  were 
studied  and  significant  relationships  with  patient  outcome  was  found  for  MCAM,  P-cadherin, 
CD44v3, N m23 a nd B cl-2 ( see F igures 4.11  a nd 4.12  for s ummaries o f r esults).  F or s ome o f 
these  markers,  such as  MCAM,  although  predicted  to  be correlated with tumour progression and 
patient  outcome  from  laboratory  studies,  no  patient  outcome  studies  have  previously  been 
undertaken.  The results show that tissue array can bridge the gap from laboratory work to clinical 
use.  Implementation  of markers  in  the  routine  staining  and  assessment  of melanomas  excised 
from  patients  will  add  to  the  currently  available  armoury  of  tests  that  are  routinely  used  and 
improve the accuracy of the prediction of prognosis
By  further  investigating  the  relationship  between  the  markers,  insights  into  the  biology  of 
melanoma  development and  progression  may  be  gained.  Most studies  in  this  complex field  are 
use  cell  lines  or  melanoma  models.  By  studying  melanoma-associated  proteins  expressed  in 
humans, further advances in this area will be made.
4.12  CONCLUSION
The  tissue  array  provides  an  ideal  method  for  investigating  immunohistochemical  markers  on  a 
large n umber of p athological s pecimens s imultaneously.  11 i s n ot o nly of b enefit i n  the  field of 
cancer  research,  but  promises  to  provide  a  high-throughput  strategy  of  analysing  other  tissue 
specimens  relevant to  plastic surgery,  such  as  Dupuytren’s  tissue,  tendon  samples or burn  scar 
tissue.  This  study  identified  a  number  of  melanoma-associated  proteins  correlated  with  patient 
outcome.  These  are  valuable  prognostic  markers  for  predicting  outcome  in  melanoma  patients 
and potential targets for therapeutic manipulation.
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Figure 4.11  Cartoon  summarising the relationship of each of the markers studied with tumour depth.  The 
variation  in  the  breadth  of  the  shape  alongside  each  of  the  markers  represents  the  staining  intensity 
according to Breslow depth.
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Figure 4.12  Cartoon  summarising staining characteristics of primary melanomas predicting either good or 
poor outcome in  patients.  The markers in the middle were not correlated with patient outcome.  E-cadherin 
was the only marker shown, that is not in the middle, without a statistically significant correlation with patient 
outcome.
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SCFV COCKTAILS
1845.1  INTRODUCTION
Many  melanoma  patients  first  present  with  metastases,  which  are  often  clinically  undetectable 
(Weiss  et  al.,  1995;  Hofmann  et  al.,  2002).  With  current  diagnostic  methods,  detection  of 
metastases lacks sensitivity and specificity (Shirkhoda et al.,  1987; Takahashi et al.,  1992;  Holder 
et al.,  1998; Terhune et al.,  1998;  Hofmann et al.,  2002; Voit et al.,  2002) (for review, see section 
1.6).  Earlier detection  of metastases would  provide  opportunities for early treatment, which  may 
result in cure, not currently achievable.  As discussed in chapter 1, radioimmunoscintigraphy (RIS) 
promises to offer accurate  detection  of occult metastases with  optimal  sensitivity and  specificity. 
Ideally  it would  be  used  around  the  time  of first presentation,  in  order to  screen for metastases, 
after which appropriate management could be undertaken.
When used for in vivo tumour targeting whole monoclonal antibodies have shown limitations due to 
their  high molecular  weight.  T heir  large  size  leads  to  long  circulatory half-lives  and  prolonged 
antibody retention in the blood (Adams 1998c).  It hinders their diffusion into extra-vascular tumour 
sites and results in poor tumour penetration (Juweid  et al.,  1992).  Clearance from normal tissues 
is slower,  especially in  blood-rich  organs  such  as the  liver,  lung,  spleen  or kidneys,  reducing  the 
contrast obtained  between tumour and  normal tissue  (Yokota  et al.,  1992).  Therefore,  there  is a 
considerable delay in reaching high tumour to normal tissue ratios.  Mouse IgG has been shown to 
bind  to  human  Fc  receptors  (McCool  et  al.,  1985).  Therefore,  binding  of  IgG  to  Fc  receptors 
present  on  circulating  immune  cells  also  contributes  to  non-specific  accumulation  of  whole 
monoclonal antibodies and  reduced  blood  clearance  (Herlyn  et al.,  1983;  Buchegger et al.,  1986; 
Herlyn etal.,  1986).
Antibody fragments have therefore formed the focal point for improving the tumour to normal tissue 
contrast in  melanoma antibody localisation studies  (Kang  et al.,  1999;  Kang  et al.,  2000;  Pacifico 
et  al.,  2003).  Single  chain  (Fv)  antibody  fragments  (scFvs)  are  one-sixth  the  size  of  whole 
antibodies (27 kD) and represent the minimal portion of an antibody that can still retain full antigen 
binding.  ScFvs  exhibit  improved  biodistribution  and  blood  clearance  compared  with  whole 
monoclonal  antibodies  (Colcher  et al.,  1999).  Another  advantage  of scFvs  is  improved  tumour 
penetration  (Pluckthun  et  al.,  1997;  Adams  et  al.,  1998a;  Colcher  et  al.,  1999).  The  short 
residence time of scFvs  in the  circulation  and  in  normal tissues results in good tumour to normal 
tissue  ratios  by  reducing  the  background  accumulation  thereby  improving  tumour  targeting 
(Colcher  et  al.,  1990;  Colcher  et  al.,  1998).  However,  this  simultaneously  limits  the  maximal 
amount of scFv that can  accumulate  in the tumour.  The  lower molecular weight of scFvs allows
185rapid  plasma  clearance  and  improved  tumour  penetration,  resulting  in  higher  tumour-to-normal 
tissue ratios at early time points in vivo (Begent et al.,  1996).  The reasons for the faster dynamics 
are  not  clearly  understood  but  most  probably  relate  both  to  the  smaller  physical  size  of  the 
molecule and to the fact that they lack the Fc portion of the antibody, which promotes uptake and 
metabolism of whole monoclonal antibodies by phagocytic cells (Holliger et al.,  1997).
Despite  considerable  progress  in  the  production  of  antibodies  and  their  fragments  recognising 
human  melanoma-associated  antigens  specifically  and  in  targeting  methodology,  the  amount  of 
radioactivity that accumulates specifically in  melanoma  lesions following  injection  of radiolabelled 
anti-MAA antibody fragments remains low.  Strategies to improve this critical parameter are being 
investigated to increase the efficacy of immunoscintigraphy (Adams et al.  1999a).
Increasing the dose of monoclonal antibody or scFv does not enhance the contrast achieved with 
immunoscintigraphy.  Wahl et al.  have shown that increasing the dose of radiolabelled anti-HMW- 
MAA monoclonal antibody injected into human melanoma-bearing nude mice from 6.25 to 1,875pg 
did  not  markedly  change  the  percentage  of  relative  radioactivity  uptake  in  melanoma  compared 
with normal tissues (Wahl et al.,  1986).  Rogers et al.  have obtained  similar results with anti-CEA 
monoclonal  antibody:  an  increase  of  the  dose of  radiolabelled  monoclonal  antibody  from  16  to 
500pg/mouse  resulted  in  a  linear increase  in  the  absolute  concentration  of radioactivity found  in 
the  transplanted  tumour  with  no  detectable  change  in  the  percentage  of  radioactivity  uptake 
relative  to  normal  organs  (Rogers  et  al.,  1986).  Furthermore,  increasing  the  dose  resulted  in 
decreased  tumour  to  blood  ratios.  Similarly  Pimm  and  Baldwin  found  that  an  increase  in  the 
amount  of  radioactivity  localised  to  a  human  osteosarcoma  xenograft  was  associated  with  an 
increase  in  the  dose  of  radiolabelled  antibody  injected  up  to  500pg  per  nude  mouse  (Pimm  & 
Baldwin  1984).  When  the  dose  was  greater  than  500pg/mouse,  a  reduction  in  the  fractional 
accumulation  of  radioactivity  in  transplanted  tumour  was  observed.  In  clinical  studies,  dose 
escalation  has  been  reported  to  result  in  no  difference  in  biodistribution  or the  quality of tumour 
images (Carrasquillo et al.,  1988a; Taylor et al.,  1987) or in an  increase in detection sensitivity of 
malignant lesions (Halpern etal.,  1985; Taylor etal.,  1987; Carrasquillo etal.,  1988b; Murray etal.,
1988).  Furthermore,  blood-pool  clearance  was  prolonged  (Halpern  et  al.,  1985;  Taylor  et  al., 
1987) and an  increase  in fractional accumulation of radioactivity in some non-tumour tissues was 
observed (Taylor et al.,  1987; Carrasquillo et al.,  1988b).  Thus alternatives to increasing the dose 
of antibody administered are required to optimise tumour imaging.
Other methods that have been employed to optimise tumour targeting  have ranged from changes 
in the peri-tumoral environment to alterations in the targeting  molecules themselves.  There have
186been attempts to increase antibody uptake in tumours by using cytokines that increase blood flow 
within the tumour.  Interleukin 2 conjugated to a monoclonal antibody has been shown to increase 
tumour  blood flow,  which  has  in  turn  lead  to  an  increase  in  antibody  uptake  of  up to four-fold 
(LeBerthon et al.,  1991).  As an alternative strategy, upregulation of target antigen expression with 
interferon  administration  has  been  used  to improve targeting  (Krasagakis  et al.,  1991).  Methods 
that  would  ensure  that the  antibodies  remain  in  the  circulation  would  also  allow  higher tumour 
accumulation to occur - Adams et al.  have shown that scFv uptake is very high in mice after they 
were  subjected  to  nephrectomy  (Adams  et al.,  1998b).  Furthermore,  modifications  to  the  scFv 
themselves,  such as  making  scFvs  multimeric and  thermally stable also improves tumour uptake 
and retention (Willuda etal.,  1999; Kupsch, personal communication).
Pre-targeting  of the  tumour  involves  two  or three  step  strategies  to  improve  targeting.  The first 
step  is  followed  by  administration  of  a  second  reagent  in  a  form,  which  will  be  captured  or 
activated  by the  bound  antibody.  The  high  affinity and  tetravalency of streptavidin for biotin  has 
been exploited  to this end.  Streptavidin  has been conjugated to antibody and targeted with  ^In- 
labelled biotin for imaging (Kalofonos etal.,  1990).  Others have imaged a pre-targeted biotinylated 
antibody  with  an  avidin  chase  followed  by  a  final  step  of  radiolabelled  biotin  (Paganelli  et  al., 
1991).
5.1.1  RAFT scFvs
Three  scFvs  (B3.  B4  and  RAFT3)  have  previously  been  developed  against  distinct  and  very 
melanoma-specific cell surface antigens (Kang,  MD thesis  1997;  Kupsch et al.,  1999;  Kang et al., 
1999;  Kang  et al.,  2000;  Hamilton,  MD  thesis  2001;  Odili,  MD  thesis  2002).  However,  relatively 
low absolute  amounts  of scFv were  found  to  localise  to  the  tumour.  In  addition,  remaining  non­
specific background  accumulation was observed  in  the  kidney.  As described  in  previous studies 
above  (Rogers  et al.,  1986;  Wahl  et al.,  1986;  Pimm &  Baldwin  1984;  Carrasquillo et al.,  1988a; 
Taylor  et  al.,  1987),  increasing  the  dose  of  scFv  administered  did  not  improve  contrast  as 
background accumulation increased correspondingly.
1875.1.2 Heterogeneity and underlying mechanisms
Tumour  cell  populations  are  heterogeneous  in  various  biochemical  and  biological  properties, 
including  their  antigenic  profile  (Byers  &  Johnston  1977;  Burchiel  et  al.,  1982;  Heppner  1984; 
Natali  et  al.,  1983;  Natali  et  al.,  1985).  The  degree  to  which  melanoma  cells  within  a  tumour 
express  specific  antigens  is  not  only  of  considerable  theoretical  interest  but  also  of  practical 
importance.  Heterogeneous  expression  of  melanoma-associated  antigens  could  be  a  limiting 
factor in the usefulness of antibodies as diagnostic or therapeutic agents.
In vitro  analysis  of human  tumour cell  lines with  antibodies  to  histocompatability antigens  and  to 
tumour-associated  antigens  has  detected  three  types  of  heterogeneity:  among  cell  lines  derived 
from different patients (Burchiel et al.,  1982), among cell lines originating from different metastases 
of the same patient (Albino et al.,  1981) and  among cells within a cell  line  (Burchiel et al.,  1982). 
Albino et al.,  using cell lines derived from three metastatic masses from the same patient, reported 
a  variation  in  reactivity  with  a  panel  of  monoclonal  antibodies  (Albino  et  al.,  1981). 
Immunohistochemical  studies  of  cultured  human  melanoma  cells  by  Wilson  and  colleagues 
demonstrated that antibodies reactive with antigens of similar molecular weight were recognising a 
heterogeneous group of antigenic determinants on melanoma cells (Wilson et al.,  1982).  Burchiel 
and  colleagues studied  panels of cell lines from different patients with  monoclonal antibodies and 
flow cytometry and  found  considerable  heterogeneity with  regard  to antigen expression  (Burchiel 
et a I.,  1  982).  They found t hat  the e xpression  of m ela noma-associated a ntigens c hanged a s a 
function of the cell cycle and that the change correlated with increasing cell size.  This implies that 
tumour cell  populations with  low levels of antigens  may not bind  sufficient amounts of antibodies 
and  therefore  escape  from  therapy.  However,  using  in  vitro  experiments  it  is  not  possible  to 
conclude  whether  these  differences  reflected  distinct  cell  populations  in  vivo  or  were  due  to 
variations  related  to adaptation to tissue culture:  expression  of antigens  by established  cell  lines 
may not reflect that of the tumour cells from which they originated.  Indeed, a study by Zhang and 
co-workers  on  colorectal  cancer  cells  revealed  only  an  approximately  50%  overlap  of  genes 
expressed  by cell  lines  and  those  in situ,  i.e.  in  vivo (Zhang  et al.,  1997).  This therefore  means 
that 50% of genes expressed in cell lines are “false positives” and 50% of genes expressed in vivo 
are  “false  negatives”  when  tested  on  cultured  cell  lines.  Therefore,  only one  third  of genes are 
expressed in cell culture as they are expressed in vivo.
The expression heterogeneity observed in vitro is, however, supported by in vivo studies.  Natali et 
al.  compared  the  antigenic  profile  of  surgically  removed  primary  melanomas  with  that  of 
autologous metastases as well as multiple autologous metastases (Natali et al.,  1983).  In spite of
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differed  significantly  in  their  reactivity  with  a  panel  of  monoclonal  antibodies  in  direct 
immunofluorescence.  The authors went on to investigate antigen expression for correlations with 
tumour characteristics.  The  extent of the  antigenic  heterogeneity did  not  correlate with  melanin 
synthesis,  site  of  origin of  the  primary  tumour, sites  of  metastatic foci or  treatment.  They  did, 
however,  notice  that  the  variation  was  less  marked  in  patients  carrying  the  primary  tumour 
simultaneously  with  their  metastases.  A follow-up  study was  undertaken,  published  in  1985,  in 
which  the  extent of antigenic  heterogeneity of primary  and  metastatic  lesions from  patients with 
melanoma was characterised using a semi-quantitative method (Natali et al.,  1985).  It showed for 
the first  time  heterogeneity  in  the  distribution  of distinct  antigenic determinants  of  HMW-MAA  in 
autologous lesions.
In order to overcome the limitations of assessing antigen heterogeneity using cell lines Berd et al. 
analysed  melanoma  cells  dissociated  from  metastatic  masses  using  flow  cytometry  as  a 
quantitative assay (Berd et al.,  1989).  They found that the most consistently expressed antigen in 
the  53  metastases  studied  was  HMW-MAA.  However,  the  expression  showed  considerable 
variability, far more than that observed with cell lines.  They also found a reasonable concordance 
in  antigen  expression  on  different  tumour  masses  from  the  same  patient,  contrary  to  results 
previously reported with cell lines isolated from different metastases of the same patient (Albino et 
al.,  1981).
As  most previous work  had  been  carried  out on  nodular melanomas,  Kageshita  et al.  compared 
the  differential  expression  of  melanoma-associated  antigens  in  primary  and  metastatic  acral 
lentiginous  and  nodular  melanoma  (Kageshita  et  a!.,  1991).  Primary  acral  lentiginous  lesions 
expressed  significantly  lower  levels  of  HMW-MAA  than  nodular  lesions.  Similar  to  a  previous 
study  (Natali  et al.,  1983),  no  correlation  between  heterogeneity  and  clinicopathological features 
was found.  Thus  it is apparent that antigen or epitope  heterogeneity will  have consequences for 
the  efficacy  of  targeting  tumours  with  epitope-specific  antibodies.  Indeed,  Siccardi  found  a 
correlation between false negative radioimmunoscintigraphic images and low expression of HMW- 
MAA in biopsies form those patients (Siccardi,  1990).
5.1.2.1  Mechanisms of antigenic heterogeneity
Various  mechanisms  exist  that  result  in  antigenic  heterogeneity.  At  the  genomic  level  point 
mutations,  multiple  genetic  loci  and  multiple  alleles  at  a  single  locus  lead  to  the  appearance  of 
distinct gene  products.  At the transcriptional  level,  differential  splicing  of specific mRNA species
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contribute  to  this,  because  the  expression  of  histocompatability  antigens  and  tumour-associated 
antigens  has been found to change on cultured  melanoma cells moving through the growth cycle 
(Burchiel  et  al.,  1982).  In  addition,  altered  expression  of  transcription  factors  and  changes  in 
methylation  may  play  a  role  (Weetman,  1988;  Hietala  et  al.,  1997).  Genetic  deletions, 
translocations  and  amplification  (sometimes  leading  to  multidrug  resistance)  and  chromosomal 
alterations  have  all  been  shown  to  play  a  part i n  changing  antigen  expression  (Hayashi  et  al., 
1990;  Sedlak  et  al.,  1997;  Hulkkonen  et  al.,  2002).  Co-translational  and  post-translational 
modifications of a  protein  may occur generating  antigens with  an  identical  primary structures  but 
varying  degrees  of processing.  Examples  include  modulation  and  immunoselection,  which  have 
been  thought  to  play  a  role  if  patients  mount  an  immune  response  to  antigens  expressed  by 
melanoma cells (Ferrone & Pellegrino,  1978).
The  possibility that the antigenic phenotype of the  cell  changes continuously is supported  by the 
susceptibility of antigens  to  modulation  by various  agents,  such  as  interferons  (Giacomini  et al., 
1984b)  and  cell  cycle-related  events  (Burchiel  et al.,  1982)  as well  as  by  reports  of quantitative 
changes of melanoma-associated antigens during the serial passage of melanoma cells in culture 
(Zehngebot et al.,  1983).  Furthermore, it has been shown in murine melanoma that the stability of 
phenotypes  in  a  malignant  lesion  may  be  influenced  by  interactions  among  clonal  cell 
subpopulations (Hill et al.,  1984).  Heterogeneity has also been noted in other tumour types, such 
as  among  tumour  cells  in  primary  or  metastatic  lesions  surgically  removed  from  patients  with 
breast carcinoma (Schlom et al.,  1980).
The  antigenic  heterogeneity  of  tumours  thus  introduces  variability  in  tumour  localisation  of 
antibodies.  A given  tumour contains a  large  variety of cells expressing  different antigens,  which 
prevents antibodies  with  a  single  specificity from  completely  coating  all  the  tumour cells within  a 
lesion.  Antigenic modulation sometimes occurs between primary and secondary tumour (Natali et 
al.,  1985) and  the degree of detection  is  related to the  number of antigen-positive cells  (Siccardi, 
1990).  This represents a potentially major limitation in the development of immunodiagnostic and 
immunotherapeutic  approaches  to  melanoma.  Indeed  Siccardi  observed  a  down-regulation  of 
HMW-MAA in stage  IV melanoma patients resulting  in sub-optimal antibody images but no down- 
regulation for patients in earlier stages (Siccardi, 1990).  Since the use of radioimmunoscintigraphy 
is intended for the detection of metastatic disease, the antigenic heterogeneity of HMW-MAA and 
other MAAs is of paramount importance.
1905.1.2.2 Loss of MHC Class I and mechanisms of immune escape
Major  histocompatability  complex  (MHC)  class  I  antigens  are  polymorphic  transmembrane 
glycoproteins  non-covalently associated with  (32-microglobulin  (Ploegh  et al.,  1981).  They play a 
key  role  in  recognition  of  antigen-expressing  cells  by  T  cells  because  they  display  processed 
peptides with antigenic epitopes and expose them on the cell surface.  T lymphocytes recognise a 
cell as antigenic only when  MHC molecules and  internally processed  antigens  provide targets for 
the  immune  system  (Zinkernagel  &  Doherty  1979).  Alterations  in  MHC  expression  related  to 
normal  tissues  have  been  observed  in  several  tissue  types  (Ruiter et al.,  1982;  Gutierrez  et al., 
1987) and malignant transformation of cells is frequently associated with reduction or loss of MHC 
class  I  expression  (Tanaka  et al.,  1988).  In one study loss of MHC class  I  has been observed  in 
15% of colon carcinomas,  8% of gastric carcinomas and  11% of melanomas (Lopez Nevot et al.,
1989).  The  alterations  or  loss  of  MHC  class  I  can  be  associated  with  tumour  growth 
characteristics,  suggesting  the  influence  of  cellular  immunity  on  the  host-tumour  interaction 
(Festenstein  &  Garrido  1986).  Furthermore,  MHC  class  I  expression  exerts  an  effect  on  the 
immune response.  The underlying mechanisms are similar to those described above for antigenic 
heterogeneity.  In  addition,  defects  in  antigen  processing and transport of MHC  molecules to the 
cell  surface  contribute  to  loss  of  MHC  expression.  Loss  of  MHC  class  I  molecules  results  in 
escape from  T  cells,  but concomitantly  increases  susceptibility to  lysis  mediated  by  natural  killer 
cells (Maio et al.,  1991).
In comparison with the  primary tumours, a decrease in  HLA antigen expression  has been seen  in 
visceral  metastases of melanomas and  is generally associated  with a  poor prognosis (Brocker et 
al.,  1985).  Whether the reduction of MHC class  I expression is a critical event in the progression 
to  cancer  or  rather  a  phenomenon  that  results  from  the  genetic  instability  associated  with 
malignancy is unclear.  Nevertheless the crucial role played by MHC class  I antigens in the lysis of 
target  cells  by  T  cells  has  raised  the  possibility  that  reduction  or  heterogeneity  of  MHC  class I 
expression  by  tumour  cells  may  facilitate  their escape from  immune  destruction  by  cytotoxic  T 
lymphocytes.  This  has been suggested to underlie the significant association  between low levels 
of MHC class I antigen expression in primary cutaneous melanomas and poor prognosis (Gattoni- 
Celli  et al.,  1993).  These  effects  may be  partially antagonised  by the  use  of immunomodulators 
such as  interferon  (Geersten  et al.,  1999).  This escape from  immunosurveillance  is the result of 
several molecular events occurring at different levels of the complex interaction of melanoma cells 
with reactive lymphocytes.
1915.1.3 Antibody cocktails
In order to overcome the problem of antigenic heterogeneity it has been proposed that a cocktail of 
antibodies targeting d ifferent  antigens, or different determinants on  the same antigen, could be 
used to improve tumour targeting (Burchiel et al.,  1982; Natali et al.,  1983;  Natali et al.,  1985).  By 
using this strategy,  not only should the number of false negative  radioimmunodetection  scans  be 
reduced,  but  targeting  may  also  be  improved,  by  an  amplification  of  the  signal  as  a  result  of 
simultaneously  coating  more  of  the  tumour  cells  with  different  radiolabelled  antibodies.  The 
hypothesis that targeting  may  be  improved  by amplifying  the  signal  with  the  use of a  cocktail  of 
anti-tumour scFvs is shown schematically in Figure 5.1.3.
Other potential advantages of using a cocktail include combinations of Mabs as carriers of distinct 
components  of  a  therapeutic  system,  which  have  to  be  delivered  in  close  proximity  at  the  cell 
surface, so that they may assemble and function in selected areas of high antigen expression.  For 
example, one antibody could  mediate antibody-dependent cytotoxicity and  the other complement- 
dependent  cytotoxicity,  therefore  making  escape  less  likely.  A  similar  approach  has  been 
investigated using bispecific antibody fragments.  Holliger et al.  used bispecific antibody fragments 
to  recruit  the  whole  spectrum  of  antibody  functions  by  retargeting  serum  immunoglobulin  in 
combination  with  a  T  cell-activating  diabody  against  the  same  tumour  antigen  (Holliger  et  al., 
1997).  The bispecific diabodies were able to recruit complement,  induce mononuclear phagocyte 
respiratory burst and  phagocytosis  mediated  by one and  T cell  activation  by the other diabodies. 
Furthermore, the cocktail was shown to promote synergistic cytotoxicity towards colon carcinoma 
cells  in  conjunction  with  CD8+  T-cells at concentrations that were too  low to achieve therapeutic 
effect with the diabodies when used in isolation.
More recently Kipriyanov et al.  constructed a bispecific diabody against human CD19 (lymphoma) 
and  CD16  (natural  killer  cells)  and  combined  it  in  a  cocktail  with  another  bispecific  diabody 
targeting CD19 and CD3 (T cells) (Kipriyanov et al., 2002).  Co-stimulation by using both diabodies 
significantly  increased  the  lysis  of  tumour  cells.  Treatment  of  tumour-bearing  mice  with  the 
cocktail  resulted  in  complete  resolution,  whilst treatment with  either  diabody  alone  showed  only 
partial tumour regression.  It is possible that a similar synergy might be observed with a cocktail of 
monospecific scFvs targeting different epitopes.  Indeed, it has been shown that using a cocktail of 
monospecific  scFvs  carrying  immunotoxins  against  B-cell  lymphoma  resulted  in  complete 
regression of tumours,  whereas each component when used individually did not ( Flavell  etal., 
1997).
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Figure 5.1.3  Schematic representation of the "cocktail principle",  illustrated with the three scFvs (R3,  B3 
and  B4)  used  in  this  chapter.  The  cocktail  could  increase  contrast  if used  at saturating  antibody dose 
(estimated as  125pg  per mouse for the HER2 antigen,  which  is expressed at levels similar to HMW-MAA 
(Adams et al., 1998b)) provided that tumour accumulation is stable.
1935.1.3.1 In vitro studies using antibody cocktails
Krizan and colleagues studied both melanoma cell lines and fresh tumour biopsies with a panel of 
monoclonal  antibodies  by flow cytometry  (Krizan  et al.,  1985).  The  percentage  of labelled  cells 
and relative fluorescence intensity when stained with individual monoclonal antibodies varied with 
different  cell  lines  and  biopsy  samples  under  saturating  conditions.  Use  of  a  cocktail  of 
monoclonal  antibodies  that  recognized  different  melanoma-associated  antigens  reduced  these 
variations.  In  cell  lines  both  the  percentage  of labelled  cells  and  relative  fluorescence  intensity 
increased substantially when the cocktail prepared from five monoclonal antibodies rather than an 
individual  monoclonal antibody was used for staining.  The cocktail of monoclonal antibodies also 
increased  the  percentage  of  labelled  tumour  biopsy  cells  and  relative  fluorescence  intensity. 
These data show that a  cocktail of  monoclonal antibodies can be more effective than a  single 
monoclonal  antibody for melanoma  cell  labelling  in  vitro and  might  be  more  effective for tumour 
imaging  and  therapy.  In  a  study on  breast  carcinoma,  Tagliabue  and  colleagues  demonstrated 
significantly improved  immunodetection  in serous effusions from  breast carcinoma  by using  up to 
nine monoclonal antibodies directed against different epitopes (Tagliabue et al.,  1986).  Ziai et al. 
used  a  cocktail  of  antibodies  and  increased  the  staining  intensity  of  cultured  melanoma  cells, 
without an  increase  in  the  number of cells  stained,  whereas with  surgically  removed  specimens, 
the staining pattern  became homogeneous compared with heterogeneous when a single antibody 
was used alone and with no loss of specificity (Ziai et al.,  1987).  Similarly,  Matzku et al. observed 
an  increase  in  binding  of  antibodies  to  melanoma  cells  when  two  or  three  were  used  in 
combination (Matzku et al.,  1989).  These results suggest that use of a combination of monoclonal 
antibodies  recognising  distinct  determinants  of  HMW-MAA  may  increase  the  sensitivity  of 
immunoscintigraphy.
Another application  of a  cocktail  of antibodies  in  autologous  stem  cell  transplantation  has  been 
investigated  by a German group (Hempel  et al.,  2000).  Following  chemotherapy,  stem cells from 
twelve breast cancer patients were collected  and  incubated with antibody-coated  magnetic beads 
to remove contaminating tumour cells.  Prepared stem cell grafts were transplanted 24 hours later 
and patients were administered with the monoclonal antibody 17-1 A, an immunotherapeutic agent 
that  exerts  its  effect  through  antibody  dependent  cellular  cytotoxicity  (ADCC),  induction  of  an 
idiotypic  network  cascade  and  possibly  also  by  complement  activation  (Frodin  et  al.,  2002). 
Tumour cells were found  in five of the  12 patients prior to chemotherapy.  However, following the 
treatment regime a  consistent reduction  in tumour cells in four of the five patients was observed. 
These  four  patients  subsequently  faired  significantly  better  than  an  untreated  control  group  in
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immunotherapeutic  agents  may  considerably  further  improve  patients’  outcome  using  this 
technique.  Other  potential  in  vitro  applications of  antibody  cocktails  include  the  more  sensitive 
detection of tumour cells in biopsies (Taha et al.,  1989).  This would be especially useful in sentinel 
node biopsy in which  it could  reduce the numbers of false negative results obtained.  Cocktails of 
antibodies (polyclonal antibodies) are already used as more sensitive secondary layers in Western 
blot, ELISA and  FACS for exactly the same reason.
5.1.3.2  Previous use of antibody cocktails in vivo
Previous  attempts  to  use  cocktails  of  antibodies  to  improve  tumour  targeting  have  used 
monoclonal  antibodies.  Gaffar  et  al.  first  used  a  combination  of  two  anti-colorectal  cancer 
monoclonal antibodies in  human xenograft-bearing  hamsters and found that "the presence of [the 
additional] antibody seems to potentiate the tumour accretion of the CEA antibody, suggesting that 
the antibody mixture is more effective for tumour radioimmunodetection than either antibody given 
alone"  (Gaffar et al.,  1981).  However,  the authors did  not state the dose of the antibody cocktail 
used compared with the individual components,  nor did they demonstrate that the antibodies used 
bound  different  epitopes.  Munz  and  colleagues  found  that  adding  equal  amounts  of  iodinated 
F(ab')2 fragments targeting different epitopes resulted  in an increased maximum amount of bound 
labelled protein as compared with either component alone demonstrating an additive binding effect 
(Munz et al.,  1986).  The  biologic half-life  of the antibody mixture  in  the tumour was significantly 
greater than that of either monoclonal antibody alone.  Matzku et al. aimed to overcome the limited 
sensitivity of single monoclonal antibodies by using a cocktail of three monoclonal antibodies, each 
targeting  a  distinct  epitope  of  HMW-MAA  (Matzku  et  al.,  1989).  In  this  study,  neither  the 
combination of the three radiolabelled  monoclonal antibodies nor increasing the dose of individual 
antibodies  increased  the  amount  of  radioactivity  specifically  localized  to  the  human  melanoma 
xenografts i n n ude m ice.  H owever, S ardi  et a I.  found t hat a  mixture of m onoclonal a ntibodies 
improved tumour targeting  in a study in  nude  mice (Sardi  et al.,  1989).  In this study a hand-held 
gamma  probe  was  used  to  detect  radiolabelled  antibody  in  tumour.  In  addition,  the  individual 
organs  were  excised  and  the  radioactivity  measured  at  the  end  of  the  experiment  and  higher 
counts  were  detected  in  the  tumour,  whilst  the  counts  in  the  normal  organs  remained  relatively 
stable.
Wahl et al. argued that if saturating doses of a cocktail are given, the unbound excess antibody will 
result in a very high background (Wahl et al.,  1990).  Therefore the authors gave low doses of anti-
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saturating  doses.  Two  antibodies were  administered  intra-lymphatically to  17  patients.  Gamma 
camera  images  were  taken,  lymph  nodes  removed  and  the  presence  of tumour was  compared 
with  radioactivity  counts.  Good  contrast was  achieved  in  the  lymph  node-positive  patients  with 
little  background  activity.  However,  the  results were  not compared with  those  achieved  with  the 
individual  components  of the  cocktail.  Volpe  etal.  showed  an  improvement  in  the  detection  of 
colorectal  metastases  in  patients  using  a  cocktail  of monoclonal  antibodies when  compared with 
the  individual  antibodies  (Volpe  et  al.,  1998).  Antibody  cocktails  have  also  been  used  in 
radioimmunoguided  surgery  (de  Nardi  et  al.,  1997).  De  Nardi  et  al.  observed  an  improved 
sensitivity  using  a  cocktail  of  monoclonal  antibodies  for  intra-operative  radioimmunodetection  of 
colorectal  tumours  compared  with  a  single  antibody.  No  study  has yet  investigated  the  use  of 
scFvs  in  a  cocktail  to  improve  targeting  and  increase  the  sensitivity  of  immunodetection. 
Theoretically  using  scFvs  as  a  cocktail,  with  their  inherent  advantages  over  whole  monoclonal 
antibodies, could further enhance tumour targeting.
The work in this chapter was done by me apart from: historical control studies (work done by my 
predecessors), PCR cloning and genetic sequencing (both by Dr Jorg Kupsch).
5.2  AIMS
The  purpose of the present study was to improve in vivo tumour targeting  by using a cocktail of 
scFvs that targets three different epitopes on melanoma cells.
1965.3  METHODS
5.3.1  Production and Purification
Three scFv clones were  used for the study:  RAFT3 (Kang  et al.,  2000),  B3  (Kupsch et al.,  1999) 
and B4 (Kang et al.,  1999;  Kupsch et al.,  1999).  The production and purification of the scFvs was 
undertaken  as  described  in  chapter 2,  section  2.2.  Optimal  conditions for induction  of individual 
scFvs  in  large-scale  bacterial  culture  have  been  determined  empirically  (Kang,  MD thesis  1997). 
Briefly, scFvs were expressed  in E.  coli TOP10 and  made from a standard  1-litre induction.  A 10 
ml  culture  in  LBG a  (10  ml  Luria  Broth  +  0.5ml  40%  D-glucose  +  100pg/ml  ampicillin),  inoculated 
with  a  pipette tip  stabbed  into a  bacterial  glycerol  stock was  grown  at 30°C overnight  in a  rotary 
shaker at 250  rpm  (see chapter 2).  In the morning  overnight cultures were diluted  1:100 up to  1  
litre  in  LBG a and  shaken at 250 rpm for 6  hours at 30°C (to an OD600 of approximately  1.5). After 
approximately  6  hours,  the  bacteria  were  pelleted  and  the  supernatant  poured  off.  The  bacteria 
were  resuspended  in  1   litre  of  LB  containing  100  pg/ml  ampicillin  and  100  pM  IPTG.  Cultures 
were then shaken overnight (for 16-18 hours) at 30°C and 250 rpm.
All  scFvs  were  purified  by  IMAC  purification  on  High-Trap  chelating  sepharose  columns 
(Amersham  Pharmacia  Biotech,  chapter 2.2.6).  After elution,  scFvs were concentrated to  1   ml in 
IMAC elution buffer and aliquoted before storage at -80°C.  For the purpose of these experiments, 
the  scFvs  were  not  desalted.  They were  analysed  by Western  blot  (section  2.3.4),  SDS-PAGE 
(using  Coomassie  staining;  section  2.3.3)  and  by  cell  ELISA on  melanoma  cells  (section  2.4.3). 
Further  analysis  of  the  scFvs  was  by  low-pressure  gel  filtration  (section  2.2.7)  on  HiPrep™ 
Superdex  75  XK  16/60  columns  (Amersham  Pharmacia  Biotech).  For gel  filtration,  two  millilitre 
aliquots were collected and tested for presence of scFv by Western blot.
5.3.2  Production of the cocktail
Three separate preparations of the scFvs RAFT3,  B3 and  B4 were produced.  RAFT3 is a mouse 
hybridoma-derived  scFv  (Kupsch  et al.,  1995;  Kang  et al.,  2000),  whilst the  two  other scFvs are 
human  phage  library-derived  (Kupsch  et al.,  1999).  After appropriate testing  and  analysis of the 
preparations, the cocktail was made by combining equal amounts of each of the scFvs.
1975.3.3 Competition ELISA
In order  to d emonstrate that the three  scFv  clones bound d ifferent e pitopes, a  competition cell 
ELISA was  set  up,  essentially as described  by Stahli  (Stahli  et al.,  1983).  Melanoma  cells were 
grown  in  96 well  ELISA plates  (see section 2.4.2).  All the  ELISA plate wells were  initially loaded 
with 500ng/50pl of LHM2  IgG (parent mouse monoclonal antibody) per well and serial dilutions of 
all  scFvs  (RAFT3,  B4  and  B4)  were  carried  out across  the  plate from  500  to  1ng/50pl  per well. 
LHM2  IgG  binding was detected  using  rabbit anti-mouse  IgG-HRP conjugate  (Dako), which does 
not cross-react with scFv.  The ELISA was completed as previously described (Section 2.4.3) and 
the plate read at 490 nm.  A similar technique has been described by Giacomini et al.  in which the 
binding of radiolabelled monoclonal antibody was compared with cold antibody allowing the affinity 
to be determined (Giacomini etal.,  1985).
5.3.4  Addition ELISA
Using the method  described  by Friguet et al.  "addition" ELISAs were performed to further confirm 
the differential  binding  of the three scFvs to different epitopes (Friguet et al.,  1983).  ScFvs were 
added  to the first column  of wells  at saturating  concentrations,  as  determined from  previous  cell 
ELISAs.  An  additional  scFv  was  then  added  to  the  first  column  of  wells,  also  at  saturating 
concentrations,  and  the  combination  of  pairs  of scFvs  titred  as  described  in  section  2.4.3.  The 
maximum OD obtained was compared with those of the individual scFvs that were titred in parallel 
on  the  same  ELISA  plate.  Differential  epitope  binding  was  demonstrated  if  the  maximal  OD 
observed  was  similar to that expected  from  the sum  of the  ODs  of the  individual  components at 
saturating concentrations.
5.3.5  In vivo methods
The  scFv  cocktail  was  examined  for  its  in  vivo  targeting  properties  (sections  2.7  &  2.8)  and 
compared  with  those  of  its  individual  components  RAFT3,  B3  and  B4.  As  described  above, 
combining  equal  amounts  of  each  of  the  component  antibodies  produced  the  cocktail.  Each 
mouse  received  0.5pg  of  scFv  cocktail,  i.e.  0.167pg  of  each  component  scFv.  The  individual 
scFvs were also administered at 0.5pg per mouse.
1985.3.6  Radiolabelling
Radiolabelling  was  carried  out  using  the  lodogen™  method  (Pierce)  and  125l  as  the  radiolabel 
(Section 2.5).  Immunoreactivity after labelling was assessed by comparing equivalent amounts of 
labelled and unlabelled scFv in cell ELISA (Section 2.4.3).
5.3.7  Biodistribution
Biodistribution  data  were  obtained  in  Balb/c  nu  mice  bearing  human  melanoma  xenografts 
(Sections 2.7 & 2.8).  Half a microgram of 125l-labelled scFv cocktail in  100pl PBS was injected via 
the tail vein and the mice culled at appropriate time points.  Three to five mice were used for each 
time point.  M ice  were sacrificed at 1, 3, 6  and 18 hours after injection.  A  blood sample was 
obtained  by  cardiac  puncture  and  organs  removed  for  weighing  and  gamma  counting. 
Radioactivity in the tumour,  blood,  both quadriceps,  both femurs,  spleen,  liver,  kidneys and  lungs 
was  counted.  Results  were  expressed  in  terms  of percentage  of the  injected  dose  per gram  of 
tissue  (%ID/g) and from this tumour-to-normal tissue  ratios  (T:NT) were calculated.  T:NT values 
were  calculated  for  each  mouse  individually  and  expressed  as  the  average  for each  group  and 
time  point.  It  should  be  noted  that when  the  organs  weigh  less  than  1g  the  %ID/g  can  exceed 
100%.
1995.4  IN  VITRO  RESULTS
5.4.1  Purification of scFvs
RAFT3,  B3 and B4 scFvs were made with sufficiently good purity and yield.  Figure 5.4.1  shows an 
example of a Western  Blot and SDS-PAGE of the scFvs individually and  mixed  in equal amounts 
as  a  cocktail.  Note the  increased  yield  achieved  for the  RAFT3  scFv shown  by the  SDS-PAGE. 
The  yields  for the  three  scFvs  were  100pg/ml,  300(jg/ml  and  1000pg/ml  for  B3,  B4  and  RAFT3 
respectively,  per litre induction.
Binding  affinities  have  previously been  determined for the  scFvs  studied  and  are  shown  in Table
5.4.1  along with their respective antigen densities (Kang, thesis  1997).  The affinities ranged from 
4.96 x 10‘8 to 6.31  x 10'8 M'1  and the antigen densities ranged from 4.3 x 105  to 2.8 x 106.  All three 
clones  showed  comparable  resistance  to  serum  proteases  and  thermal  stability  when  incubated 
with  50%  mouse  serum  in  PBS for 24  hours  at 37°C  (Odili,  MD thesis  2001).  No degradation  or 
loss  of  antigen  binding  was  observed  under  these  conditions.  In  addition,  all  3  scFvs  are 
expressed as monomers (Odili, MD thesis 2002).
m
KM  B3  B4  R3  Cocktail  KM  B3  B4  R3  Cocktail  Ova 1   Ova 3  Ova 5
Figure 5.4.1.1  Western  blot and SDS-PAGE showing the purity and yield of the individual scFvs and the 
cocktail,  respectively.  The  yield  was estimated  by comparison  with  ovalbumin  standards (1,2  and  5pg). 
9E10 hybridoma supernatant was used to detect scFv in Western blot.  KM: kaleidoscope molecular weight 
marker.
200Clone
RAFT 3
B3
B4
Kd (M-1)
4.96x10-® 
6.31  x 10"® 
6.05x10-®
Antigen density 
(molecules per cell)
4.3 x 10®
1.9 x 10®
2.8 x 10®
Table  5.4.1  Binding  affinity  (dissociation  constant,  KD)  of  the  scFvs  studied  and  antigen  density  as 
determined by Scatchard plot (adapted from Kang, MD thesis 1997)
Binding  to  melanoma  cells  was tested  in  a  cell  ELISA.  Figure  5.4.1.2  shows  the  binding  of the 
individual components of the cocktail.  In addition,  it shows the predicted and observed  binding of 
a cocktail of the three scFvs.  The binding of the cocktail is similar to that predicted and is shown to 
be of increased potency at equivalent scFv concentrations.
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Figure 5.4.1.2  Cell ELISA showing binding of each individual component of the cocktail, the predicted and 
observed binding of the cocktail.  Results are  representative of 3 experiments.  The predicted OD of the 
cocktail  is  calculated  by  the  sum  of  the  OD  of  the  individual  components  at  equivalent  total  scFv 
concentration.
2015.4.2 Confirmation of epitopic specificity
Epitopic specificity was confirmed  by both addition and  competition  ELISA assays.  Table 5.4.2.1 
shows  an  example  of the  results  of an  addition  ELISA.  The  first  row  represents  the  individual 
scFvs at maximal OD.  The other rows show the results of combining two combinations of pairs of 
scFvs.  The OD reached for the combinations is approximately the sum of the maximal ODs for the 
individual components.
ADDED B3 B4 R3
NONE 0.248 0.325 0.486
B3 - 0.599 (0.573) 0.714 (0.734)
B4 0.599 (0.573) - 0.987 (0.811)
R3 0.714(0.734) 0.987 (0.811) -
Table 5.4.2.1. Table showing maximum ODs in cell ELISA using individual scFvs and combinations of two at 
saturating concentrations.  Observed  ODs a re shown with those predicted from  combining two shown  in 
brackets.  Results are representative of 3 cell ELISAs.
Inhibition of binding  of LHM2  IgG  by each of the scFvs was tested.  Figure  5.4.2.2 illustrates the 
results of a competitive ELISA using B3, B4 and RAFT3.  The OD of LHM2 (parent Mab of RAFT3) 
is seen to increase as the concentration of RAFT3 decreases, therefore demonstrating competition 
for binding  to  the  same  epitope.  No  such  competition,  however,  was  observed  for  B3  and  B4, 
showing  that  the  two  scFvs  bind  to  different  epitopes.  The  results  obtained  with  addition  and 
competition  ELISA were in agreement and showed that B3,  B4 and  RAFT3 bind distinct and  non­
overlapping epitopes on melanoma.
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Figure 5.4.2.2  Competition ELISA demonstrating shared epitope specificity for RAFT3 and LHM2 Mab but 
no inhibition with B3 (5.4.2.2a) and B4 (5.4.2.2b).  Results are representative of 3 experiments.
2035.5 IN  VIVO  RESULTS
5.4.3  Radiolabelling
Single chain Fvs  were radiolabelled and the incorporation of  125l was calculated as 1  2%.  T he 
effect of radiolabelling was assessed in cell ELISA by comparing the melanoma binding exhibited 
by equivalent amounts  of labelled  and  unlabelled  scFv.  The  results  showed  that approximately 
88% of the immunoreactivity was retained by the scFv cocktail (Figure 5.4.3).
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Figure  5.4.3  I mmunoreactivity  of the scFv cocktail  before a nd after r adiolabelling a s d etermined b y cell 
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5.4.4  In vivo studies
The in vivo melanoma targeting  by the individual  scFv components of the cocktail has previously 
been  studied  in  detail  (Kang,  MD  thesis  1997;  Kang  et al,  1999;  Kang  et ai,  2000).  The scFv 
cocktail was studied and the findings are shown here in comparison with archival data.  Results of 
the percentage injected dose of 125l-labelled scFv obtained for the individual scFvs and the cocktail 
are shown  in  Tables  5.4.4.1  - 4.  Initial  tumour uptake for  B3  scFv was  1.355%  at  1   hour post­
administration compared with 2.854% for B4 and 2.263% for RAFT3.
2045.4.4.1  %ID/g for 125l labelled B3 scFv
Tumour Kidney Spleen Liver Lung Muscle Blood
1  hour 1.355 5.704 0.627 2.704 0.953 0.381 1.598
3 hours 1.066 3.341 0.355 2.325 0.477 0.318 0.387
6 hours 0.786 1.779 0.139 0.948 0.206 0.093 0.123
18 hours 0.506 0.357 0.068 0.391 0.095 0.059 0.079
5.4.4.2  %ID/g for 125l labelled B4 scFv
Tumour Kidney Spleen Liver Lung Muscle Blood
1  hour 2.854 11.409 1.584 2.044 3.328 0.678 4.414
3 hours 2.521 5.388 1.217 0.956 1.904 0.502 2.758
6 hours 1.795 3.792 0.346 0.312 0.354 0.231 0.421
18 hours 0.509 0.356 0.076 0.068 0.064 0.053 0.074
5.4.4.3  %ID/g for 125l labelled RAFT 3 scFv
Tumour Kidney Spleen Liver Lung Muscle Blood
1  hour 2.263 16.939 1.535 1.844 2.260 0.761 3.205
3 hours 1.280 10.603 0.764 0.992 1.124 0.548 1.021
6 hours 0.680 7.828 0.196 0.174 0.234 0.123 0.135
18 hours 0.420 2.329 0.073 0.085 0.064 0.054 0.061
5.4.4.4  %ID/g for 125l labelled scFv cocktail
Tumour Kidney Spleen Liver Lung Muscle Blood
1  hour 24.220 183.710 6.350 11.930 7.807 7.820 18.167
3 hours 26.730 150.060 5.750 12.760 6.490 7.657 21.777
6 hours 22.800 115.810 3.606 10.510 5.370 4.821 13.574
18 hours 5.146 6.260 1.213 1.677 1.343 0.763 3.932
Tables  5.4.4.1  - 4  Percentage injected dose of 125l  labelled scFvs per gram of tissue.  Each data point 
represents the mean from 4-5 mice.
205The accumulation of B3 scFv then declined steadily over the remaining time points, such that at 18 
hours  post-injection  the  %ID/g was 0.506%.  The  B4 scFv showed  superior initial  uptake, with  a 
value of 2.854% at 1   hour post-administration.  However, by 18 hours the value was similar to that 
of  B3.  Similarly,  RAFT3  initially  showed  targeting  superior  to  B3,  but with  time  the  decline  in 
percentage injected dose was comparable with the other scFvs.  The blood clearance of the three 
scFvs was similar.  B3 showed an accumulation in blood of 1.598% after 1   hour, which dropped to 
0.079%  by  18  hours.  B4 and  RAFT3  both  accumulated  to a greater degree  in the  blood  after  1  
hour (4.414%  and  3.205%,  respectively)  but then  cleared  efficiently to  levels similar to  B3  by  18 
hours.
The percentage of injected dose per gram of tissue for the scFv cocktail is shown in Table 5.4.4.4 
and  Figure 5.4.4.4.  A considerably higher amount is seen to accumulate in the tumour at  1   hour 
compared  with  any  of  the  individual  components.  Similar  to  the  individual  scFvs,  the  values 
decline over time, such that at 18 hours post-injection 5.146%ID/g of cocktail is sequestered in the 
tumour.  Likewise, the amount of cocktail in all other organs is noticeably higher at equivalent time- 
points compared with individual scFvs and declines in a comparable manner.
The tumour to  normal  tissue  ratios  of the  individual  scFvs  and  the  cocktail  are  shown  in  Tables 
5.4.4.5-8 and  Figures 5.4.4.1-4.  In all four experiments an  improvement in the tumour to normal 
tissue ration is seen over time with each organ.  The kidney consistently exhibited the lowest T:NT 
ratio and the muscle the highest.  Despite the very much higher values of %ID/g observed with the 
scFv  cocktail  compared  with  the  individual  scFvs  the  T:NT  ratio  is  comparable  across  all  time 
points, as this figure is a ratio derived from the values calculated from the % I D/g.  The cocktail did 
not improve the T:NT ratio observed for the kidney compared with the individual scFvs.  A range of 
0.180 to  1.429 was observed at the  18 hour time point as the maximal T:NT ratio for the kidneys. 
At  18  hours  the  individual  scFvs  had  a  range  of 5.738  to  7.495  for the  T:NT  of the  spleen.  In 
contrast,  the  cocktail  reached  a  T:NT  ratio  of  17.081  at  18  hours  (p  <  0.05).  There  was  no 
significant difference in contrast in the liver, lung or blood between either of the individual scFvs or 
the cocktail.  The T:NT values for the muscle are approximately the same for the individual scFvs. 
The cocktail  however,  showed  a  considerably higher value  (15.982) for this tissue.  In  summary, 
therefore, the cocktail showed a very much-improved tumour to normal tissue ratios in the spleen 
and the muscle.  The %ID/g varied between different experiments but the tumour to normal tissue 
ratio remained  approximately the same,  for the same experiment repeated  twice,  a  phenomenon 
noted by others (Jackson etal.,  1998) (see Discussion).
2065.4.4.5  T:NT ratios for 125l labelled B3 scFv
Kidney Spleen Liver Lung Muscle Blood
1  hour 0.238 2.162 0.501 1.422 3.562 0.848
3 hours 0.319 3.006 0.459 2.237 3.356 2.757
6 hours 0.442 5.644 0.830 3.818 8.494 6.415
18 hours 1.421 7.495 1.295 5.355 8.632 6.444
5.4.4.6  T:NT ratios for 125l labelled B4 scFv
Kidney Spleen Liver Lung Muscle Blood
1  hour 0.250 1.802 1.397 0.858 4.208 0.647
3 hours 0.468 2.071 2.636 1.324 5.022 0.914
6 hours 0.473 5.189 5.755 5.072 7.773 4.265
18 hours 1.429 6.694 7.481 7.949 9.645 6.875
5.4.4.7  T:NT ratios for 12 5 l labelled RAFT 3 scFv
Kidney Spleen Liver Lung Muscle Blood
1  hour 0.134 1.474 1.227 1.001 2.973 0.706
3 hours 0.121 1.675 1.29 1.139 2.336 1.254
6 hours 0.087 3.468 3.906 2.905 5.526 5.035
18 hours 0.180 5.738 4.941 6.563 7.781 6.885
5.4.4.8  T:NT ratios for 12 5 l labelled scFv cocktail
Kidney Spleen Liver Lung Muscle Blood
1  hour 0.101 3.224 1.541 2.384 2.733 1.079
3 hours 0.355 5.249 2.12 4.231 4.647 1.618
6 hours 0.212 6.362 2.283 4.437 6.011 1.849
18 hours 0.983 17.081 3.235 5.493 15.982 4.949
Tables  5.4.4.5-8  Tumour to normal tissue ratios of 125l labelled scFvs per gram of tissue.  Each data point 
represents the mean of 4-5 mice.
20716 -
14 -
12
I -   10
Kidney Spleen Liver Lung Muscle Blood
1 1   hour  ■ 3 hour ■ 6 hour  □ 18 hour
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Figure 5.4.4.4  Tumour to normal tissue ratios (T:NT)  of the scFv cocktail
2095.5  DISCUSSION
5.5.1  Analysis of in vitro results
The  use  of a  cocktail  of scFvs was  investigated  as  a  strategy to  improve  tumour localisation  by 
overcoming  potential  antigen  expression  heterogeneity  in  vivo  and  reducing  the  background 
accumulation of radiation for imaging purposes.
The yield of the clones B3 and B4 was similar, but that for RAFT 3 was considerably higher (Figure
5.4.1.1).  Nevertheless,  it was possible to combine the proteins in equal amounts, such that each 
contributed to one third  of the cocktail.  SDS-PAGE and Western  blot demonstrated the  purity of 
the three clones and the cocktail.  From  previous experiments  (Kang,  MD thesis  1997;  Odili,  MD 
thesis  2001)  it  was  known  that  the  scFv  clones  were  comparable  in  properties  known  to  be 
important for the in  vivo targeting  by scFvs,  such as affinity for the antigen  (Adams et al.,  1998b) 
thermal stability and  resistance to serum proteases.  In addition, all three scFvs are expressed as 
pure monomers  (Odili,  MD thesis 2001) and all three clones bound well to melanoma cells in cell 
ELISA, as expected from the similar affinities and antigen expression levels (Table 5.4.1).  Figure
5.4.1.2  shows the expected  binding for the cocktail  in comparison with the observed values.  The 
expected  curve was  derived  from the  sum  of OD values  at each  dilution  of the  individual  scFvs. 
The actual curve obtained demonstrated excellent binding of the cocktail, superior to that observed 
for the individual scFvs and in good agreement with the expected curve.
The specificities of the 3 scFvs for different epitopes was demonstrated by both an addition ELISA 
(Friguet  et  al.,  1983)  and  a  competition  ELISA  (Stahli  et  al.,  1983)  (Figures  5.4.2.1  &  2). 
Furthermore, the addition  ELISA revealed that when B4 and  RAFT3 were used in combination the 
OD  achieved  was  slightly  better  than  predicted  (0.987  rather  than  the  predicted  0.811).  The 
possibility of a synergistic effect when both epitopes are bound simultaneously on live cells (i.e. in 
vivo)  is  raised  by  this  result.  The  addition  ELISA  clearly  demonstrated  improved  binding  of  a 
combination  of  scFvs  compared  with  the  binding  of  individual  scFv  components  at  saturating 
concentrations  (Fig.  5.4.1.2).  The  competition  ELISA further confirmed  that  RAFT3  binds to the 
same  epitope  as  its  parent  monoclonal  antibody  LHM2  and  that the  B3  and  B4  scFvs  bound  to 
different  epitopes  (Fig.  5.4.2.2).  The  combination  of  B3  and  B4  binding  at  saturating 
concentrations (Table 5.4.2.1) shows that the two epitopes are non-identical.
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kMouse  hybridoma-derived  RAFT3  binds  to  HMW-MAA,  as  does  its  parent  monoclonal  antibody 
LHM2  (Kupsch  et al.,  1995).  Although the  human  phage  library-derived  B3  and  B4  scFvs were 
shown  to  bind  epitopes  different to  RAFT3,  the  molecular  identity  of the  B3  and  B4  antigens  is 
unknown.  B3  and  B4are  nevertheless  very  melanoma  specific ( Kupsch  et  al.,  1999)  and the 
possibility  that  they  may  target  different  epitopes  on  HMW-MAA or  different antigens  altogether 
remains.  When  previously  tested  on  a  panel  of  non-melanoma  tumour  sections,  some  tissue 
cross-reactivity between the three scFv clones was observed, although the reactivity patterns were 
not identical for the three  clones.  Using  immunohistochemistry,  it was shown  that although both 
B3 and  B4 stained  basal  cell carcinoma,  B3 also stained  breast carcinoma (Kupsch et al.,  1999). 
An  attempt  was  also  made  to  characterise  the  B3  and  B4  antigens  by  Western  blot  and 
immunoprecipitation  of  melanoma  cell  extracts,  however  without  success.  The  differences 
observed  between  B3,  B4  and  RAFT3  in  tissue  section  staining  patterns,  cellular distribution  of 
antigen  and  expression Ievels  suggested that the  antigens  are  not  identical.  Furthermore, the 
phage  library from which  B3 and  B4 were derived,  was selected  on  keratinocyte sub-populations 
that expressed  HMW-MAA  antigen  without  success,  indicating  that  B3  and  B4  are  not  directed 
against this antigen (Clarke & Kupsch, unpublished).
5.5.2  Analysis of in vivo results
The  scFv  cocktail  retained  most  of  its  immunoreactivity  after  radiolabelling  (Figure  5.4.3).  In 
biodistribution studies in human melanoma xenograft-bearing Balb/c nude mice, both the individual 
scFvs and the cocktail exhibited rapid clearance.  All the individual scFvs localised to the tumours, 
reaching maximum  uptakes  of  approximately  3%  at  60  minutes following  intravenous  injection. 
These  results  are  comparable to tumour targeting  studies  of scFv  reported  by other laboratories 
(Colcher  et al.,  1990;  Milenic  et al.,  1991;  Whitlow  et al.,  1993) which  found  peak  values  in  the 
range of 3-7 %ID/g  in xenografts 30-60 minutes after injection, decreasing to about 1   %ID/g at 24 
hours.  The  value  of  24%  reached  by  the  cocktail  in  the  tumour  was  exceptional,  but  was 
paralleled  by  high  values  observed  in  the  other tissues.  The  difference  in  %ID/g  shown  for the 
cocktail  compared  with  its  individual  components  and  differences  in  %ID/g  between  different 
experiments (data not shown) are a phenomenon observed by other investigators (Jackson et al., 
1998).  Nevertheless,  the  ratios of scFv distribution  remained  the same,  resulting  in  reproducible 
tumour to normal tissue ratios.  In agreement with  published  reports,  these studies demonstrated 
that  rapid  tumour  uptake  and  rapid  clearance  from  blood  and  normal  tissues  resulted  in  high 
tumour to muscle ratios (Colcher et al.,  1998; Adams & Schier,  1999).
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spleen  and  muscle.  Despite  unambiguous  evidence  of improved  binding  by  use  of a  cocktail  of 
scFvs  in  vitro  there  was  no  improvement  in  T:NT  ratios for other tissues  nor with  the  blood.  In 
addition,  there was  no  improvement  in  renal  accumulation  of scFv.  However,  this would  not  be 
expected, as the individual scFvs were not modified (such as by charge or by size, see chapter 6).
The finding  that the  T:NT for  muscle  was  considerably  improved  should  not  be  underestimated. 
Clinically,  initial  melanoma  recurrence  usually  occurs  either  locally,  in  transit  or  in  the  regional 
lymph  nodes  (neck,  groin  or axilla)  (Balch  et al.,  2001a).  Were  a  recurrence  to occur at any of 
these sites, the background tissue would most often be muscle, especially at the periphery.  Thus, 
greater contrast in radioimmunoscintigraphy at these sites is invaluable.
There are several possible explanations why an improvement in targeting was not observed for all 
organs.  The  most  likely argument  is  that the doses  used  for the  in  vivo experiments were sub- 
saturating.  The  ELISAs  that  demonstrated  the  enhancement  in  binding  by the  cocktail  were  all 
performed  at  saturating  concentrations,  so that  all  possible  binding  sites  on  the  melanoma  cells 
were occupied.  Due to the vast number of antigens in the xenograft tumours in comparison to the 
ELISA plates,  it is  unlikely that saturation of the  binding  sites could  have occurred.  Adams et al. 
showed that a dose of 125pg scFv per mouse is required to saturate tumour xenografts expressing 
the HER2 antigen at levels similar to those of HMW-MAA on melanoma (Adams et al.,  1998b).  On 
the other hand, if saturating doses were used, an increase in background accumulation would be a 
potential difficulty, one of the very problems this strategy aimed to overcome (Matzku et al.,  1989; 
Wahl  et  al.,  1990).  Despite  this,  Wahl  et  al.  achieved  good  binding  using  a  cocktail  at  a  low 
monoclonal antibody dose that the authors claim was sub-saturating  (Wahl et al.,  1990).  Another 
reason for the lack of improved tumour to normal tissue ratios for most organs could be the limited 
heterogeneity  on  cells  from  a  cell  line  compared  with  those  found  in  patients  (Ziai  et al.,  1987; 
Natali  et al.,  1985).  The  increased  heterogeneity in  patients would theoretically not only result in 
improved contrast due to less background, but also increased sensitivity, with fewer false negative 
scans.  According to Chatal  et al.  an  increase  in the sensitivity of immunoscintigraphy in  patients 
may be obtained  by injecting  monoclonal antibodies to two tumour-associated antigens (Chatal et 
al.,  1984).
As  presented  in  the  methodology,  the  tumour  to  normal  tissue  ratios  have  been  calculated  by 
taking the mean %ID/g for the tumour at each time point and individually calculating the T:NT ratio 
for each  mouse.  The  value  presented  is the  mean  of each group at each time point.  There are 
arguments  for and  against  using  this  methodology to  calculate  the  T:NT  ratios.  The alternative
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mean  %ID/g  of the tumour.  The  latter method  may be  less  likely skewed  by a  single erroneous 
result  in  %ID/g  but  does  not  truly  represent  the  T:NT  achieved  in  each  subject  mouse.  No 
established  method  for this  calculation  is  apparent  on  review of the  literature.  Thus  the former 
method  was  used  as  it  was  argued  that  this  produced  a  more  accurate  representation  of the 
contrast achieved in each mouse.
It  is  important  to  consider  the  differences  between  investigations  performed  with  a  cocktail  of 
antibodies  recognising  distinct  antigens  from  those  that  recognise  distinct  determinants  on  the 
same  antigen  as  well  as  between  investigations  in  patients  and  nude  mice  transplanted  with 
human  tumours.  The  approach  used  with  antibodies  to  distinct  antigens  aims  to  overcome 
heterogeneity in the antigenic profile of tumour cells (Chatal et al.,  1984,).  On the other hand, the 
approach  to  use  monoclonal  antibodies  to  distinct  determinants  of the  same  tumour-associated 
antigen  aims  at  increasing  the  number of antibody  molecules  targeted  to  a  tumour  cell  and  will 
therefore  be  effective  only  when  monoclonal  antibodies  are  used  in  saturating  concentrations. 
Furthermore,  in  tumour-bearing  patients  anti-tumour  antibodies  react  not  only  with  malignant 
lesions, but also with any normal tissues expressing the same or cross-reacting antigens.  In nude 
mice transplanted with human tumours the reactivity of anti-tumour antibodies with normal tissues 
is  virtually  absent,  enabling  clearer  interpretation  of  results.  In  the  present  study  it  was  not 
determined  whether the  B3  and  B4  epitopes  are  on  entirely different antigens  or are  part of the 
HMW-MAA.  From  previous  results  it  seems  likely  that  the  three  antigens  are  non-identical 
(Kupsch etal.,  1999).
5.5.3  Comparison with other cocktail studies
As referred to in the introduction, strategies using  cocktails of antibodies have previously been 
studied  in an attempt to improve tumour targeting and with varying degrees of success.  No study 
has yet  used  scFvs  in  an  antibody cocktail.  Matzku  et al.  undertook a  similar study  using  nude 
mice  and  whole  monoclonal  antibodies  (Matzku  et  al.,  1989).  In  that  study  three  monoclonal 
antibodies targeting distinct determinants on  HMW-MAA were used.  In vitro analysis showed that 
combining two or three monoclonal antibodies induced a two- to threefold  increase in the amount 
of  radioactivity  bound  to  the  melanoma  cells,  when  each  monoclonal  antibody  was  used  at 
saturating  concentrations.  However,  only  a  “slight  increase”  was  detected  at  non-saturating 
concentrations.  In  vivo  experiments  showed  that  increasing  the  amount  of  the  individual
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antibodies.  Data  not shown,  but discussed  by the authors,  demonstrated  reduced  expression of 
HMW-MAA on  melanoma  cells once transplanted  into the  mice,  which  may have explained  or at 
least  contributed  towards  the  results  (Siccardi  et  al.,  1990).  They  went  on  to  perform  dose 
escalation  experiments  in  which  increasing  doses  of  monoclonal  antibodies  were  injected  into 
tumour-bearing  mice  that  were  then  subjected  to  semi-quantitative  autoradiography.  A  highly 
heterogeneous  distribution  was  recorded  at  low  doses  that  became  more  homogeneous  with 
increased doses.  This observation suggested that the increase in tumour uptake associated with 
the  increase  in  the  dose  of  monoclonal  antibody  injected  resulted  from  enhanced  monoclonal 
antibody  binding  in  the  central  parts  of the  xenografts  leading  to  saturation  of the  binding  sites. 
They  repeated  their  cocktail  experiment  at  saturating  concentrations  and  still  found  no 
improvement in binding and a reduction in the relative uptake of the monoclonal antibody due to an 
increase  in  background  accumulation.  These  results  suggest  that  increasing  the  dose  of  the 
cocktail  would  not  improve  the  results  of  the  present  study,  although  they  may  have  been 
improved  had their antibodies targeted  different antigens,  rather than distinct determinants on the 
same antigen.
An  investigation  by  Munz  et  al.  using  a  mixture  of  two  F(ab’)2  fragments  recognising  distinct 
tumour-associated  antigens  reported  a  significantly  enhanced  tumour  contrast  in  nude  mice 
bearing  human  colon  carcinoma  xenografts  (Munz  et  al.,  1986).  Radioimmunoimaging 
demonstrated  the  tumour  contrast  obtained  with  a  mixture  of  F(ab’)2  fragments  to  be  a 
“considerable”  improvement over that using  either component alone.  Mice  receiving  the cocktail 
showed  higher  tumour  to  normal  tissue  contrast  at  equivalent  doses  to  either  F(ab’)2  fragment 
alone,  results  that  reached  statistical  significance.  Tumour  contrast  did  not  increase  with 
increasing dose of monoclonal antibody fragments given alone; the highest contrast was obtained 
with  the  mixture  of  both  antibodies  as  increasing  the  dose  of one  simultaneously  increased  the 
background  radiation.  Kawabata  et al.  using  a  similar  model  to  Munz and  co-workers found  no 
significantly greater uptake of a mixture of F(ab’)2 fragments (Kawabata et al.,  1988).  Chatal et al. 
found  a  considerable  increase  in  the  sensitivity  of  immunoscintigraphy  in  patients  with  colon 
carcinoma  by  injecting  monoclonal  antibodies  to  two  tumour-associated  antigens  compared  with 
using a single antibody for imaging  (Chatal et al.,  1984).  Naruki et al.  used two F(ab’)2 fragments 
targeting CEA and CA 19-9 and demonstrated good tumour targeting in seven patients, but did not 
compare  the  results  with  those  obtained  with  either  antibody  used  alone,  a  limitation  they 
acknowledged  in the discussion (Naruki et al.,  1994).  Ballantyne et al.  used a similar combination 
in  a  study  aimed  at  imaging  both  colorectal  and  pancreatic  cancer  metastases  and  found
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result of an antigen expression level effect (Ballantyne et al.,  1988).
Like  Matzku  et al., Wahl et al.  used a cocktail of antibodies reactive with different epitopes of the 
same  antigen  HMW-MAA  (Matzku  et  al.,  1  989;  Wahl  et  al.,  1990).  T o  avoid  high  background 
radiation  each antibody was given  at low protein  dose to prevent tumour saturation  as well as to 
possibly  increase  tumour to  background  ratios.  Seventeen  patients with  stage  I  or  II  melanoma 
were studied using the antibody cocktail for lymphoscintigraphy.  Very low background levels were 
observed in lymph node positive tumours, and no false positives occurred.
Although  the  results  of  the  experiments  with  the  cocktail  of  anti-melanoma  scFvs  have  not 
produced in vivo results as good as those observed in vitro, the use of a combination of scFvs may 
have an advantage over individual scFvs in patients with  melanoma because of the heterogeneity 
in  the  expression  of  distinct  determinants  of  HMW-MAA  and  other  antigens  on  melanoma  cells 
within a lesion and among  lesions at different anatomic sites (Ziai et al.,  1987;  Natali et al.,  1985). 
Antibody cocktails have already been shown to be more efficacious in tumour therapy when used 
in radioimmunotherapy (Song  et al.,  1998).  The improvement in therapy may have been a result 
of  overcoming  heterogeneity  and  targeting more  cells,  or the  cocktail may  have  targeted more 
epitopes  on  individual  tumour  cells.  Furthermore,  combinations  of  scFvs  to  distinct  melanoma 
determinants  may  be  useful  as  carriers  of distinct components  of a  therapeutic system  (e.g.  two 
chains of a  toxin),  which  have  to  be delivered  in  close  proximity at the  cell  surface,  so that they 
may assemble and function in selected areas of high antigen expression.  Zhang et al. tested four 
antibodies  in  vitro against different  melanoma  and  other cancers  cell-surface  gangliosides  alone 
and  in  combination  (Zhang  et  al.,  1995).  Increased  tumour  cell  recognition  and  complement- 
dependent cytotoxicity resulting from the combination of three or four of the antibodies was found 
with  all  cell  lines  tested  and  this  was  most striking  when  each  antibody was  used  at suboptimal 
concentration.
Strategies  aimed  at  reducing  immune  escape  are  also  likely to  benefit from  the  use  of antibody 
cocktails.  Melanomas express complement-inactivating surface markers at high levels as a further 
means of immune  escape  (Gorter &  Meri  1999).  Therapeutic antibody  cocktails  may  be able to 
overcome  the  resulting  relatively  high  complement  resistance.  Melanomas  also  express  high 
levels of MHC  class  II,  but without the  B7 or CTLA-4 (co-stimulatory molecules).  Normally MHC 
class  II  plus  either  B7  or  CTLA-4  activate  circulating  T  cells.  On  the  other  hand  expression  of 
MHC class  II only induces circulating T cell anergy.  Transfection of melanoma with B7 or CTLA-4 
has  been  shown  to  convert  melanoma  cells  into  good  targets for T  cells.  If a  cocktail  could  be
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escape via  MHC  class  II  expression  (Rohrbach  et al.,  2000).  Furthermore,  scFvs fused to MHC 
class  I  have  been  used  to  confer  melanoma  an  “allo-phenotype”  in  vitro,  resulting  in  T  cell- 
mediated lysis (Willemsen et al., 2001).  With both B7 and MHC class  I fusions molecules, a scFv 
cocktail could be extremely efficient.
5.6  CONCLUSION
This study has shown  an  improvement in  melanoma targeting  by an  antibody cocktail  in vitro.  If 
expression  is  more  variable  in  vivo  than  in  vitro  this  cannot  be  easily  tested  in  mice.  LHM2 
monoclonal  antibody  and  the  scFvs  used  can  only  be  detected  using  anti-mouse  IgG 
immunoconjugates,  which  will  subsequently  result  in  high  background  in  immunohistology.  The 
data  showed  an  enhancement  in  tumour targeting  with  the  use  of a  cocktail  of scFvs  targeting 
different epitopes on human melanoma cells for both the spleen and muscle, when compared with 
the individual scFvs.
It  is  somewhat difficult to  predict any  improvement that  may  be  expected  with  a  similar study  in 
patients  as  it  is  still  unclear  whether  the  three  scFvs  used  actually  target  different  antigens  or 
different determinants  on  the  same  antigen.  However,  despite  this  a  considerable  improvement 
could be expected due to the substantially increased antigenic heterogeneity in humans compared 
with that in cell lines or human xenograft tumours.  Unfortunately,  use of human xenograft-bearing 
animals  is  the  best  model  available  for such  experiments.  Whether the  results  may  have  been 
improved  with  saturating  doses  is  open  to  debate,  as  this  would  probably  have  concomitantly 
increased  background  levels  of  radioactivity  (although  this  could  be  counteracted  by  the  rapid 
clearance  of  scFvs).  Nevertheless,  as  discussed  above,  a  cocktail  of  scFvs  is  likely  to  be  of 
benefit in  immunotherapy,  especially when  two agents  need to  be delivered  in  close  proximity to 
one another.  In  conclusion  the  results of this  study  revealed  moderate  improvements  in  tumour 
targeting  with  the  use  of a  cocktail  of scFvs,  which  may further  be  improved  upon  by  using  the 
same strategy in humans.
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SCFV MULTIMERS
2176.1  INTRODUCTION
A  variety  of  strategies  have  been  adopted  to  improve  the  in  vivo  tumour  targeting  of  scFvs. 
Increasing  the  valency and  molecular weight  have  been  identified  as  key features for optimising 
the  design  of  antibody  fragments  for  tumour  targeting.  ScFv  multimers  (60-120  kDa)  are 
significantly  larger  than  monomers  (-30  kDa)  and  have  the  advantages  of  improved  tumour 
targeting  and  rapid  tumour  penetration,  but  not  the  fast  renal  clearance  time  and  high  renal 
accumulation  typical for scFv monomers  (Hudson  &  Kortt  1999).  Multimerisation  leads to higher 
functional  affinity  (avidity)  by  increasing  the  number  of  binding  sites  (valency)  of  the  antibody 
fragment.  The  molecular  weight  is  also  increased  and  has  been  thought  by  some  authors  to 
extend the serum half-life of the molecules in the circulation, as they would  not be filtered through 
the glomeruli  (Pack et al.,  1992;  King  et al.,  1994).  The  prolonged  blood  residence would  allow 
higher tumour accumulation  but with  reduced  contrast to normal organs.  However,  this theory is 
probably  too  simplistic  as  more  recent  studies  have  shown  that  scFv  multimers  as  large  as 
tetramers are still retained in the kidneys (Schultz et al., 2000).  Previous studies have shown that 
multimers  exhibit  improved  tumour  targeting,  as  measured  by  tumour-to-normal  tissue  ratios, 
compared to monomeric scFvs (Adams et al.  1998a; Adams et al. 1998b; Fitzgerald et al.  1997).
Monomeric scFvs are small  monovalent molecules, which  are  rapidly cleared from the circulation 
(Colcher  et  al.,  1989;  Begent  et  al.,  1996).  Unfortunately,  the  monovalent  nature  confers  a 
disadvantage to scFvs,  resulting  in limited  uptake and  retention  in tumour xenografts and this can 
render  tumour  images  sub-optimal  (Larson  et  al.,  1997).  In  contrast,  the  whole  monoclonal 
antibody  is  a  bivalent  molecule with  relatively  improved  avidity when  compared  with  monovalent 
Fab fragments and scFvs.  A similar increase in avidity is therefore possible when scFv fragments 
are combined i nto I arger m ultimers  (i.e. d imers, t rimers a nd tetramers)  (Pluckthun  et a I.,  1997; 
Willuda  et al.,  2001).  An  inverse  relationship  between  molecular weight and  tumour penetration 
does  exist,  however,  as  seen  with  whole  monoclonal  antibodies  and  a  compromise  is  therefore 
required  between  molecular weight, valency and tumour penetration.  Also of importance in these 
multimeric molecules is the flexibility between antigen-binding sites allowing effective cross-linking 
of target antigen molecules (Wu et al.,  1999).
The ideal multimer would  exhibit slow blood  clearance allowing  adequate time for tumour uptake. 
Higher valency and avidity provide multiple antigen-binding sites, effectively reducing the off-rates, 
thereby  allowing  increased  antibody  retention  by  the  tumour.  A  multivalent  protein  capable  of 
binding more than one antigen molecule will bind with a greater free energy than one that can only
218bind  a  single  antigen  site  (Pluckthun  et al.,  1997).  Many scFv fragments  have  been  reported  to 
form  dimers to  some  extent,  where the VH   domain  of one  chain  is  paired  with  the  VL  domain  of 
another chain and vice versa (Essig et al.,  1993; Holliger et al.,  1993; Whitlow et al.,  1993; Whitlow 
et al.,  1994;  Desplancq et al.,  1994).  Various strategies have been investigated to modify the size 
and valency of antibody fragments in attempts to improve tumour targeting.  These designs have 
included  alteration  of  scFv  peptide  linkers  to  form  diabodies  (Holliger  et  al.,  1993;  Kortt  et  al., 
1997) and triabodies (lliades et al.,  1997), disulphide linkage of scFvs through C-terminal cysteine 
residues (Cumber et al.,  1992; Adams et al.,  1993; Kipriyanov et al.,  1994) and covalent linkage of 
two scFvs  in  tandem through  an  additional  peptide  linker (Gruber et al.,  1994;  Mallender & Voss 
1994; Kurucz et al.,  1995; De Jonge et al.,  1995; Mack et al.,  1995; Schmidt et al.,  1996).
6.2  MULTIMERISATION STRATEGIES
6.2.1  Shortening of the ScFv Peptide Linker
The  scFv  is  composed  of the  heavy  chain  variable  domain  (VH)  and  light chain variable  domain 
(VL ) joined  by a  short  polypeptide  linker (typically  15 amino acids),  which  is designed to facilitate 
the association of the VH  and the VL  domains from the same chain.  Multimers can be produced by 
altering the  length  of the  peptide linker between the V domains of the scFv fragment.  The linker 
region  can  be  shortened  to  5  amino  acids  or  less  to  prevent  refolding  of the  molecule  into  the 
normal,  paired  orientation  of  the  V  domains,  thus  forcing  the  spontaneous  formation  of  stable 
dimers (so-called  diabodies) with two antigen-binding sites via non-covalent bonds (Holliger et al., 
1993).  Reducing  the  linker length to  less than  3 amino acid  residues can force scFv association 
into trimers  (triabodies,  -90  kDa)  or tetramers  (120  kDa)  (Dolezal  et  al.,  2000).  This  produces 
molecules with increased avidity as well as increased size.  In theory this should create molecules 
with a size  above the threshold  for renal  re-absorption  (Rennke et al.,  1978),  thus  reducing  renal 
clearance and accumulation.
The fraction of dimer formed is dependent on linker length (with short linkers between five and ten 
amino  acid  residues  forcing  the  almost  quantitative  formation  of  dimers),  but  also  on  external 
parameters such as ionic strength, pH and the presence or absence of antigen (Arndt et al.  1998).
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formed,  but  the  details  of  this  phenomenon  are  yet  to  be  fully  understood  (Kortt  et  al.,  1997). 
Diabodies  can  be  constructed  to  be  bivalent and  either  monospecific or  bispecific.  In  the  latter 
case these  heterodimeric scFvs target two different antigens  (Atwell  et al.  1996) and  have  been 
shown to be effective in  retargeting cytotoxic T cells to kill lymphoma cells (Holliger et al.  1996) or 
breast cancer cells  (Zhu  et al.  1996).  In  principle,  any lymphocyte  can  be  re-targeted  to tumour 
cells  using  bivalent  scFvs.  Diabodies  therefore  possess  considerable  potential  for 
immunotherapeutic applications.
6.2.2  Chemical cross-linking
ScFvs can be engineered with unpaired cysteine residues to allow dimer formation via a disulphide 
bond.  Antibody fragments with  unpaired  cysteines  have  been  produced  in  E.  coli  (Cumber et al. 
1992;  Rodrigues et al.  1993;  Hu et al.  1996;  Fitzgerald et al.  1997) by fusing these residues onto 
the C-terminus of the VH  chain  (Kipriyanov et al.  1994).  The presence of the sulfhydryl group can 
allow site-specific chemical  cross-linking for dimer formation  (King  et al.,  1992).  Dimer formation 
can  also  occur  spontaneously  under  some  conditions,  allowing  not  only  the  formation  of mono- 
specific  dimers  for  immunodetection,  but  facilitating  the  creation  of  bivalent  dimers  for 
immunotherapy (Norton et al., 2001).
Dimer formation usually occurs after secretion from bacteria into an oxidising environment.  Whilst 
the formation of disulphide bonds is not normally spontaneous, an unpaired cysteine can be used 
to g enerate d isulphide  bonds d uring r efolding a nd c hemical c ross-linking a fter s cFv p urification 
(Cumber  et  al.  1992).  Such  dimers  can  have  improved  thermal  stability  as  well  as  enhanced 
tumour  targeting  (Cumber  et  al.  1992;  FitzGerald  et  al.  1997).  Good  results  have  also  been 
obtained with cysteines engineered at the V domain interphase of an Fv, which has resulted in the 
production of molecules with  improved stability and yield  (Glockshuber et al.  1990; Webber et al., 
1995).  However, other this strategy requires knowledge of the three dimensional structure of the 
recombinant  protein,  can  have  variable  success  (Fitzgerald  et  al.  1997)  and  can  result  in  a 
reduction of expression yield (Pluckthun et al.  1997; Waibel et al.  1999).  Disulphide-linked dimers 
can also be made in non-E.coli expression systems including mammalian cells (Sibler et al., 2003) 
and the yeast, P. pastoris (Gukan et al., 2003).
2206.2.3 Naturally Evolved Multimers
A simple alternative multimerisation strategy is to use a combination of the “rational” approach and 
“directed  evolution”  to  isolate  scFvs  with  a  natural  tendency  to  multimerisation.  The  rational 
approach involves aligning the antibody sequence to well-expressing clones (Knappik & Pluckthun 
1995),  together  with  exchanging  exposed  hydrophobic  residues  (Nieba  et  al.  1997)  and  the 
possibility  of grafting  complementarity-determining  regions  (CDRs)  directly  onto  very  stable  and 
well expressed  frameworks  (Jung  et al.  1997).  Alternatively,  the  evolutionary approach  may be 
used,  where  selection  pressures  place  a  bias  towards  selection  for  improved  expression  and 
stability (Proba et al.  1998; Jung et al.  1999).  Antibodies undergo cycles of genetic diversification, 
followed  by  selection  and  screening  for  a  desired  property  such  as  yield.  The  evolutionary 
approach  can  be  adapted  such  that  selection  pressures  place  a  bias  towards  selection  for 
multimerisation.  Antibodies  undergo  cycles  of  genetic  diversification  followed  by  Darwinian 
selection  for a  desired  property.  Selection  for  multimerisation  could  be  one  of these  properties 
(Odili, thesis 2002; Kupsch, personal communication).
6.2.4  Other multimerisation strategies
Other  methods  of  multimer  formation  have  consisted  of  fusions  of  scFvs  to  additional  protein 
domains  such  as  streptavidin,  Ig  kappa  constant  regions  and  leucine  zippers,  which  have  been 
used  to  produce  multimers  by  fusion  to  scFv  fragments  isolated  from  phage  display  libraries 
(Kostelny  et  al.  1992;  Pack  et  al.  1992;  McGregor  et  al.  1994;  Dubel  et  al.  1995;  de  Kruif  & 
Logtenberg  1996) with varying  degrees of success.  Other strategies employed  have been:  helix- 
turn-helix d omains ( Pluckthun &  P ack e t a I.  1  997); theCH 1  andCLd omain o f t he F ab c an b e 
replaced  with  a  heterodimeric-coiled  coil,  the  so-called  helix-stabilized  Fv fragment  (Arndt et al.
2001);  the  formation  of  disulphide  bonds  (Hu  et  al.  1996)  and  the  fusion  of  self-associating 
peptides to the carboxyl  terminus (Willuda et al.  2001).  Disulfide-bonded scFvs and  scFv dimers 
have  been  made with  improved  stability  (Reiter et al.  1996).  Some  examples of multimerisation 
strategies are shown in Figure 6.1.
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Figure 6.1  Diagram of Recombinant Antibody Fragments (see references in section 6.2.4)
It  may  be  possible  to  combine  these  multimerisation  strategies  to  produce  a  large  array  of 
multimers with  differing  properties for imaging  and  therapy.  However,  a  risk of combining these 
strategies  is  of  producing  toxic  “daisy-chains”.  These  are  large  molecular  assemblies  of  scFv 
molecules  linked  by alternating  covalent and  non-covalent  bonds.  Such  large complexes cause 
“jamming” of the secretion  apparatus  (Hayhurst et al.,  2000),  expression  toxicity and  low protein 
yield.  In  the  laboratory  at  RAFT  this  has  been  seen  with  non-covalent  and  disulphide-linked 
dimers  (Kupsch,  personal  communication).  Furthermore,  to date there  have  been  no  published 
papers on the successful combination of these strategies.
6.2.5  RAFT multimers
Odili  previously  investigated  the  advantages  of  multimeric  scFvs  over  monomeric  scFvs  (Odili, 
thesis  2002).  A  comparison  was  made  between  the  RAFT3C4  monomer  with  the  RAFT4A4 
multimer.  Significant improvements  in  tumour targeting were demonstrated with  much  improved 
tumour to  normal  tissue  ratios for clone 4A4.  The  results  of this work are  shown  in  the  results
222section  of  this chapter for  comparison.  The  4A4  multimer,  however,  consisted  of  a mixture  of 
monomers,  dimers  and  trimers  and  it was  uncertain  which  of the  components  contributed  to the 
overall enhancement in targeting.
Wu et al.  produced  an scFv with a linker length of 14 amino acids.  In much the same way as the 
RAFT 4A4  multimer  (15  amino  acid  linker),  this  scFv was  expressed  as  a  mixture  of monomers 
and  multimers  (Wu  et  al.,  1996).  After  purification  with  size-exclusion  chromatography 
biodistribution studies of purified monomers vs dimers showed that the non-covalent dimers clearly 
demonstrated  superior  tumour  targeting  (Wu  et  al.,  1996).  Follow-up  studies  with  dimers 
constructed  with  linkers  of 8  amino  acids  supported  those findings,  with  improved  targeting  over 
the monomers (Wu et al.,  1999).  However,  Siccardi et al.  used a (Fab’)2 preparation, that was in 
reality a  mixture  of (Fab’)2  and  Fab fragments,  and  demonstrated  good  patient  imaging  with  the 
mixture (Siccardi et al.,  1990).  For the diagnostic application of scFvs,  it would be preferable that 
these  molecules  have a  defined  oligomerisation state, which would  allow gel filtration to be  used 
for  purification.  Therefore,  clarification  of  the  extent  to  which  multimerisation  of  RAFT  scFvs 
improves tumour targeting is required.
6.2.6  The RAFT-3A11  scFv
The  RAFT-3A11  clone  used  for  the  following  experiments  has  been  extensively  studied  as  a 
monomer  (Hamilton,  thesis  2001).  Affinity  maturation  by  chain  shuffling  was  used  to  produce 
3A11   from the  LHM2-derived  parent scFv.  The  resulting  scFv was then analysed  in  vitro and  in 
vivo.  Chain shuffling  is the term for the  replacement of heavy or light chains of a scFv molecule 
and  has  previously  been  used  as a  means to improve  affinity for the target antigen  (Clackson  et 
al.,  1991;  Ohlin  et al.,  1996;  Schier et al.,  1996;  Park  et al.,  2000).  In  the thesis  of Hamilton,  a 
combinatorial  library of VK   segments was  used  to  produce  scFvs  consisting  of the  parent mouse 
VH   and  a  large  variety  of  human  VK s (Hamilton,  thesis  2001). This  library  was  screened  using 
antibody phage display techniques.  Filamentous bacteriophage “displaying” the different scFvs on 
their  surface  were  selected  on  melanoma  cells  to  identify  scFvs  with  increased  affinity  for  the 
antigen. These scFvs were produced as recombinant protein in E.coli and then assessed.  RAFT- 
3A11  was one of the best  of approximately 10,000 different binders isolated.
SDS-PAGE d emonstrated t hat a round 0.5  -  1  mg of p ure 3 A11   s cFv was p roduced p er I itre  of 
bacterial  supernatant.  T he  epitopic  specificity was  the  same  as  that of  the  parent monoclonal
223antibody LHM2.  The scFv showed rapid blood clearance with a t1/2a of 7-9min and a ti/2p of 175- 
206 minutes.  In biodistribution studies RAFT-3A11  scFv achieved 4.071 %ID/g localising to tumour 
at 1   hour dropping to  1.186% at 18 hours and good tumour to normal tissue ratios were achieved 
(e.g.  55.236 for muscle  and  46.694 for  bone), considerably  higher than  those  achieved  by  the 
parent  scFv.  The  3A11  results  will  be  detailed further  in  the  results  section  of this  chapter for 
completeness and comparison.
The work in this chapter was done by me apart from: historical control studies (work done by my 
predecessors), PCR cloning and genetic sequencing (both by Dr Jorg Kupsch).
6.3  AIMS
The  aim  of  this  study  was  to  investigate  a  possible  improvement  in  tumour  targeting  with 
increasing  multimerisation  of  scFv.  To  this  end  a  series  of  3A11  scFv  pure  diabodies  and 
triabodies was  constructed.  The  multimeric 3A11  scFvs  were  analysed  in  vitro and  in  vivo and 
compared  with  the  properties  of the  3A11   scFv  monomer and  the  spontaneous  multimer,  clone 
4A4.
6.4  IN VITRO METHODS
The m ultimerisation  strategy  used  for  3A11   was  to  shorten  the  scFv  peptide  linker.  However, 
using traditional techniques of splicing  by overlay extension  (SOE) (Horton et ai,  1989) and  PCR 
resulted  in  contamination  with  the  original  scFv  peptides,  i.e.  in  re-isolation  of the  original  scFv 
monomer clones,  thought to  be  due  to  contamination  with  the  PCR  template  (Kupsch,  personal 
communication).
Therefore,  an  alternative  tactic was  adopted:  domain  swapping  was  used  in  order to prevent  re­
isolation  of the  original  clone  and  guarantee formation  of multimers with  short  linkers after PCR. 
The  3A11   diabody  (DB)  and  triabody  (TB)  scFvs  were  made  by  PCR with  appropriate  primers. 
The diabody linker consisted of a 5 amino acid linker (alanine, serine, glycine, glycine, glycine) and 
the  triabody  had  a  2  amino  acid  linker  (alanine  and  serine).  Both  clones  have  the  VL -linker VH  
domain orientation and were sequenced to ensure the correct scFvs had been produced.
2243A11   d iabody (DB) a nd t riabody (TB) s cFvs w ere e xpressed i n E . c oli T OP10 a nd m ade  from 
standard  1-litre  inductions  (Section  2.1).  Briefly,  a  10  ml  culture  (LBG a)  containing  a  pipette  tip 
stabbed  into bacterial glycerol stocks was grown at 30°C overnight in a  rotary shaker  (250 rpm). 
The following  morning  overnight cultures were made up to  1   litre in the same medium and grown 
with  shaking  at 250  rpm for 6  hours  at 30°C  to an  OD6o o  of approximately  1.5.  At 6  hours,  the 
bacteria were pelleted and the supernatant poured off.  The bacteria were resuspended in 1   litre of 
LB containing 100 pg/ml ampicillin and 100 pM IPTG.  Optimal conditions for induction of individual 
scFvs  in  large-scale  bacterial  culture  have  been  determined  empirically  (Kang,  MD thesis  1997). 
Cultures were then shaken overnight (for 16-18 hours) at 30°C and 250 rpm and the supernatant 
harvested the following morning.
All  scFvs were  purified  by  I MAC  purification  on  HiTrap chelating  sepharose  columns  (Amersham 
Pharmacia  Biotech;  Section  2.2).  ScFvs  were  concentrated  to  1   ml  in  IMAC  elution  buffer and 
aliquoted  before  storage  at -80°C.  For the  purpose  of these experiments the  scFv  preparations 
were  not  desalted.  The  scFvs  were  analysed  by  Western  blot (section  2.3)  and  by  ELISA on 
melanoma cells  (section  2.4.3).  Further analysis of the scFvs was  by gel filtration  (section 2.2.7) 
using  the  AKTA  FPLC™  system  (Amersham  Pharmacia  Biotech,  Uppsala,  Sweden).  Two  ml 
aliquots were  collected  and  the  samples  corresponding  to the  peaks were  subjected  to Western 
blot analysis to confirm the presence of scFv.  The molecular weights were then calculated  based 
on a previously determined calibration curve.
6.5  IN VIVO METHODS
The  scFv m ultimers were examined  for their i n  vivo targeting p roperties.  The  monomeric 3A11  
scFv and 4A4 scFv (a  mixture of monomers, dimers and trimers) have previously been examined 
in  vivo  (Hamilton,  MD  thesis  2001;  Odili,  thesis  2002).  These  results  are  included  here  for 
comparison.
2256.4.1  Radiolabelling
Radiolabelling  was  carried  out  using  the  lodogen™  method  (Pierce)  and  125l  as  the  radiolabel 
(Section 2.5).  Immunoreactivity after labelling was assessed by comparing  equivalent amounts of 
radiolabelled  scFv  to  unlabelled  scFv  in  cell  ELISA.  Ultrafiltration  after  radiolabelling  was 
performed  using  VectaSpin  Micro™  centrifuge  tube  filters  (Whatman,  Maidstone,  Kent)  to 
concentrate the radiolabelled scFv to the original volume used for radiolabelling.
6.4.2  Biodistribution and Pharmacokinetics
Biodistribution  data  were  obtained  in  Balb/c  nu  mice  bearing  human  melanoma  xenografts 
(Section 2.7).  Half a  pg  of 125l  labelled  scFv in  100  pi  PBS was  injected via the tail vein and the 
mice culled at appropriate time points.  Four to five mice were used for each time point.  Mice were 
sacrificed at 1, 3, 6 and 18 hours after injection.  A blood sample was obtained by cardiac puncture 
and organs  removed for weighing  and  gamma counting.  Radioactivity in the tumour,  blood,  both 
quadriceps,  both femurs, spleen,  liver,  kidneys and  lungs were counted.  Results were expressed 
in terms of percentage of the  injected dose  per gram of tissue  (%ID/g).  From this the tumour-to- 
normal tissue ratios (TNT) were calculated  individually for each mouse.  The average TNT value 
for each organ and the time-point was then calculated.
2266.6 IN  VITRO  RESULTS
As discussed in section 6.2.6,  previous  results for the 3A11  monomer showed that 0.5 -  1  mg of 
pure scFv was produced per litre of bacterial supernatant.  The epitopic specificity was confirmed 
as the  same  as the  parent  monoclonal  antibody,  LHM2,  and  the  scFv  showed  good  melanoma 
binding.  Figure 6.6.1.1  shows a Western  blot of the 3A11  preparation and comparing  it with the 
3C4  monomer  and  4A4  multimer,  both  of which  were  studied  extensively  by  Odili  (Odili,  thesis
2002)  and will be further discussed below.
The  3A11  diabody  and  triabody  were  tested  in  Western  blot  and  SDS-PAGE  and  then  in  cell 
ELISA to test for melanoma  binding.  Western  blot  analysis  was  performed  under reducing  and 
non-reducing conditions.  The results revealed pure protein, which, under non-reducing conditions, 
migrated  faster  and  produced  a  better  signal,  as  the  disulphide  bonds  of  the  protein  are  not 
disturbed.  SDS-PAGE analysis showed both the diabody and triabody to be produced with good 
purity and yields of 1  mg/ml (Figure 6.6.1.2).  Figure 6.6.1.3 shows a Western blot including a 3A11 
monobody.  The  different  mobilities  are  due  to  linker  lengths  of 25  amino  acids  (monobody),  5 
amino  acids  (diabody)  and  2  amino  acids  (triabody).  All  the  modified  clones  are  in  the  VL -VH  
orientation and the original  (15 amino acid  linker)  in  a VH -VL  orientation.  The  3A11  diabody and 
triabody  showed  improved  expression  and  binding  over  the  monomer  and  monobody,  the 
monobody binding melanoma only weakly in spite of reasonable expression.  It is possible that the 
long  linker  in  the  monobody  clones  caused  folding  problems  that  affected  binding  but  not 
expression.  Both  the  3A11  multimers  bound  melanoma  strongly,  as  demonstrated  in  Figure 
6.6.1.4, which shows the results of the cell ELISA.
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Figure 6.6.1.1  Western  blot of scFv clones 4A4 (lane 2),  3C4 (lane 3)  and  3A11  (lane 4) (Odili, thesis 
2002).  The molecular weight marker is shown in lane 1.
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Figure 6.6.1.2  Western  blot (left)  and  SDS-PAGE  (right) demonstrating  purity of the 3A11  diabody and 
triabody under non-reducing (lanes 3 & 5) and reducing (lanes 2 & 4) conditions. Lane 1: molecular weight 
marker, lanes 2 & 3: 3A11  triabody, lanes 4 & 5: 3A11  diabody.
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Figure  6.6.1.3  9E10-stained  Western  blot of small  scale  induction  supernatants  from  clones  in  E.  coli 
TOP10 under reducing conditions.  Lane 1:  3A11,  lane 2: 3A11  monobody,  lane 3:  3A11  diabody,  lane 4: 
3A11  triabody.
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Figure 6.6.1.4  Cell ELISA showing the titration curves for both 3A11  diabody and triabody.  Both curves are 
the mean of three experiments.
6.7  IN VIVO RESULTS
6.7.1  Radiolabelling
Incorporation of 125l with the 3A11   diabody and triabody was 10.46% and 8.14%, respectively.  The 
effect  of  radiolabelling  on  immunoreactivity  was  assessed  in  cell  ELISA  by  comparing  the 
melanoma  binding  exhibited  by equivalent amounts of labelled  and  unlabelled  scFv.  The results 
indicated  that  approximately  90%  of the  immunoreactivity was  retained  by  both  scFvs  (data  not 
shown).
2296.7.2  In vivo studies
Biodistribution  results  in  tumour  and  normal  organs  are  shown  as  %ID/g  in  Tables  6.7.2.1-3. 
Maximal tumour accumulation at the time-points measured was found at 1   hour for 3A11   monomer 
and diabody, whilst maximal tumour accumulation for 3A11   triabody was at 3 hours.
6.7.2.1  3A11 scFv (monomer)
RAFT3A11   monomer scFv achieved 4.071 %ID/g localising to tumour at 1   hour, which was cleared 
steadily over time to  1.186%  at  18  hours  post-injection  (Table  6.7.2.1).  The  highest %ID/g  was 
found in the kidney at 1   hour (22.950%), which decreased to 2.894% at 18 hours.  Values for other 
normal  organs  showed  a  range of  1.320%  - 3.930%  at  1   hour and  decreased  steadily with time. 
The 3A11   monomer showed  tumour to normal tissue  ratios  rapidly increasing with time to values 
much in excess of one except for the kidney (Table 6.7.2.4).  By 18 hours T:NT ratios ranging from 
4.120 for liver to  55.236 for muscle were  observed.  It should  be  noted that the values for bone 
may have been subject to considerable experimental error since very small samples of bone were 
obtained  and  very low counts were  measured,  compounding any sampling  error.  In addition, the 
very high  muscle value achieved was somewhat skewed  by one  mouse with a very low %ID/g  in 
muscle  (almost  zero)  which  almost  certainly  represented  a  sampling  error.  If  that  mouse  is 
excluded, the tumour to muscle ratio is slightly greater than 17 at this time-point.
6.7.2.2  3A11  diabody
The percentage of the injected dose of 3A11   diabody that localised to the tumour was 0.584% at 1  
hour.  Accumulation did  not clear rapidly and the amount at 18 hours was still 0.489%  ID/g (Table
6.7.2.2).  The amount that localised  to the  normal organs at  1   hour ranged from 7.035%  ID/g for 
the lung to 0.829%  ID/g for the  muscle.  For the  normal organs 3A11  diabody showed  a general 
trend  of steady decrease  with  time.  However,  a  higher than  expected  amount was  observed  in 
many  organs  at  the  6  hour  time-point.  The  tumour  to  normal  tissue  ratios  showed  rapidly 
increasing values with time (Table 6.7.2.5).  Excluding the kidney, these ranged from 7.005 for the 
spleen to 32.583 for the muscle.  The kidney showed a maximal T:NT ratio of 0.390 at 18 hours.
2306.7.2.3  3A11  triabody
Similar  to  the  diabody,  3A11  triabody  accumulation  remained  stable  in  the  tumour,  initially 
achieving a %ID/g of 0.919% at 1   hour and only decreasing slightly to 0.829% at 18 hours (Table
6.7.2.3).  In  the  other organs  %ID/g  values  from  0.253%  in  the  muscle  to 4.836%  in  the  kidney 
were  observed  at  1   hour.  In  most  organs  a  steady  clearance  of  the  radiolabelled  scFv  was 
observed with %ID/g values of less than 0.29% reached for all organs apart from the kidney at 18 
hours.  At this time point reasonable tumour to normal tissue ratios were achieved of up to 18.896 
in  the  spleen  and  14.686  in  the  lung  (Table  6.7.2.6).  As for the  other scFvs  in  the  series,  poor 
contrast was observed for the kidney, even at 18 hours (0.432).
2316.7.2.1  %ID/g for 125l Labelled 3A11   scFv (monomer)
Pi Tumour Kidney Spleen Liver Lung Muscle Bone Blood
1   hour 4.071 22.950 2.490 2.718 2.974 1.320 1.411 3.930
3 hours 3.153 9.147 1.012 1.186 1.203 0.547 0.461 1.419
6 hours 2.959 5.866 0.933 1.040 0.870 0.211 0.553 0.687
18 hours 1.186 2.894 0.168 0.288 0.060 0.066 0.026 0.112
6.7.2.2  %ID/g for 12 5 l Labelled 3A11  diabody
Pi Tumour Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 0.584 4.556 0.762 3.270 7.035 0.829 0.719 1.105
3 hours 0.094 1.230 0.478 0.726 0.375 0.061 0.148 0.211
6 hours 0.385 2.009 0.298 0.217 0.663 0.115 0.282 0.414
18 hours 0.489 1.406 0.110 0.448 0.178 0.017 0.101 0.086
6.7.2.3  %ID/g for 125l Labelled 3A11  triabody
Pi Tumour Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 0.919 4.836 2.004 3.237 1.720 0.253 0.587 0.981
3 hours 1.274 6.276 1.053 1.812 1.375 0.272 0.376 1.352
6 hours 0.401 4.771 0.271 0.837 0.511 0.117 0.139 0.230
18 hours 0.829 2.025 0.066 0.283 0.065 0.088 0.130 0.073
Tables  6.7.2.1-3  Percentage  injected dose  per gram  (%ID/g) values  achieved  withthe3A11 monomer, 
diabody and triabody, respectively,  pi: post-injection.
2326.7.2.4 T:NT ratios for 125l Labelled 3A11   scFv (monomer)
Pi Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 0.184 1.677 1.536 1.405 3.164 2.961 1.063
3 hours 0.345 3.115 2.658 2.622 5.762 6.845 2.222
6 hours 0.571 3.372 2.982 3.712 16.401 5.350 5.437
18 hours 0.426 7.152 4.120 24.106 55.236 46.694 11.697
6.7.2.5 T:NT ratios for 1 2 5 l Labelled 3A11  diabody
Pi Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 0.156 1.198 0.408 0.207 1.612 0.860 0.572
3 hours 0.141 1.588 1.105 0.739 5.604 1.012 1.389
6 hours 0.271 2.443 1.908 1.125 9.372 1.764 1.517
18 hours 0.390 7.005 8.181 7.735 32.583 18.594 7.114
6.7.2.6 T:NT ratios for 12 5 l Labelled 3A11  triabody
Pi Kidney Spleen Liver  Lung Muscle Bone Blood
1  hour 0.255 0.634 0.305  0.801 3.986 1.745 0.990
3 hours 0.284 2.771 2.117  1.064 7.224 6.548 1.601
6 hours 0.087 3.841 2.286  0.981 8.470 6.906 3.330
18 hours 0.432 18.896 4.079  14.686 9.531 8.257 12.702
Tables 6.7.2.4-6  Tumour to  normal tissue ratios  (T:NT) achieved with the 3A11  monomer,  diabody and 
triabody, respectively,  pi: post-injection.
2336.7.2.4 Summary and analysis of results
All three scFvs in the series exhibited good tumour targeting and good contrast for all organs apart 
from  the kidney.  Nevertheless,  there  was  no  improvement  in  tumour targeting  with  increasing 
multimerisation of the 3A11   scFv.  The gene sequences of the scFv multimers confirmed that the 
diabody and triabody had the intended 5 and 2 amino acid linkers, respectively.  Excellent binding 
of pure preparations of the multimers in vitro and good yields suggested that production problems 
were  unlikely to explain  these  unexpected  results.  Therefore,  the  proteins were analysed further 
by gel filtration, in collaboration with researchers at The Royal Free Hospital.
6.7.3  Analysis of multimers by Gel Filtration
Since  the  results  did  not  show  the  expected  improvement  in  tumour  targeting  with  increasing 
multimerisation,  the  scFv  multimers  were  subjected  to  analysis  by  gel  filtration  (Section  2.2.7). 
Access to suitable gel filtration equipment was generously granted  by Dr.  Kerry Chester’s team at 
The  Royal  Free  Hospital.  The  results  were  strikingly  different  to  those  expected  from  the 
sequencing analysis.  Figure 6.7.2.5 shows the results of the gel filtration for the 3A11  triabody at 3 
different concentrations.  All  experiments  generated  artefact  peaks  at around  38  minutes,  which 
are  routinely  observed  with  the  equipment  at  The  Royal  Free  Hospital  (Lee,  Y-C,  personal 
communication).  The  reason  for  the  far  larger  peak  seen  at  170pg/ml  was  the  very  sensitive 
detection  settings  required  to visualise the  specific peak.  The gel filtration  experiments  revealed 
elution  peaks  at approximately 60  minutes for high  concentration  scFv  (1 mg/ml)  and  69  minutes 
for lower concentrations  (both  run  at  a  flow  rate  of 2ml/min).  Comparison  with  molecular  mass 
standards  showed  that  the  first  peak  corresponded  to  an  apparent  molecular  mass  of  about 
60kDa,  while  the  second  corresponded  to  about  28kDa.  These  were  assigned  as  dimer  and 
monomer,  respectively.  A  small  shoulder  observed  to  the  left  of  the  main  peak  at  high 
concentrations  (52  minutes)  corresponded  to  a  molecular weight  of around  110kDa,  which  may 
have represented  some  3A11   tetramer formation as specific bands were observed when aliquots 
from  this  peak  were  tested  in  Western  blot  (see  Figure  6.7.2.5  top).  The  same  pattern  of 
monomers  and  dimers  was  observed with  the  3A11  diabody  at  the  same  protein  concentration 
(data not shown).  Thus, monomers and dimers were observed, but no trimers, even with the 3A11  
“triabody”.  The  results  showed  that  multimerisation  was  concentration-dependent.  At  the 
concentrations tested no mixture of monomers and dimers formed.
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Figure 6.7.2.5  Examples  of the  results of gel  filtration  at different concentrations of 3A11   triabody.  The 
pink lines correspond to the fractions collected and the yellow shaded areas correspond to those fractions 
that were positive for scFv in Western Blot. mAU: milli-absorbance units.
2356.7.4 Change of protocol
After the  gel  filtration  revealed  that the  ‘diabody’  and  ‘triabody’  were  in  fact  both  concentration- 
dependent dimers, the experimental protocol was revised.  Radiolabelling is typically carried out at 
scFv concentrations of around  1  mg/ml.  The radiolabelled scFv is then desalted on a PD10 column 
to remove any unbound radiolabel.  This results in the dilution of the radiolabelled scFv by nine- to 
twelve-fold.  The dilute radiolabelled scFv is then tested in cell  ELISA and stored overnight at 4°C 
prior to testing in vivo on the following day.  This would allow the now dilute radiolabelled scFv to 
equilibrate,  allowing  dissociation of the dimer into monomers.  Therefore,  it was reasoned that by 
re-concentrating  the  radiolabelled scFv to  1  mg/ml after desalting, the dimers would  be prevented 
from  dissociating.  The  radiolabelled  scFv  was  reconcentrated  by  ultrafiltration  to  the  original 
volume  that it  had  prior to  radiolabelling  (section  2.5.3).  The  reconcentrated,  radiolabelled  scFv 
was then  tested  in  cell  ELISA and  stored  overnight at 4°C for subsequent testing  in  mice on the 
following day.
6.8  POST-CONCENTRATION IN VIVO RESULTS
6.8.1  Post-concentration 3A11  “diabody” scFv (dimer)
The  re-concentrated  3A11  diabody  localised  well  to the tumour.  The diabody did  not clear from 
the tumour but accumulated over the first 6 hours,  prior to clearance.  This resulted  in a  maximal 
accumulation  in  the  tumour  of  7.598%  ID/g  at  6  hours  (Table  6.8.1).  In  the  normal  organs  a 
pattern  of  high  initial  antibody  accumulation  followed  by  steady  clearance  was  observed. 
Excluding the kidney, the scFv accumulation at 18 hours was reduced to values between 0.109 (in 
muscle) to 0.484 (in liver) % I D/g.  Rapidly increasing T:NT ratios were observed for all organs and 
most  of these  reached  high  values  (Table  6.8.5  and  Figure  6.8.2).  At  18  hours  T:NT  ratios  of 
69.770  were  reached  in  muscle,  34.649  in  bone,  29.644  in  lung  and  28.409  in  liver.  The  high 
tumour to blood contrast of 23.787 at  18 hours is the most likely reason for the good T:NT values 
in the blood-rich organs analysed.
2366.8.2 Post-concentration 3A11  “triabody” scFv (dimer)
The 3A11   triabody showed a very similar biodistribution pattern to that of the diabody, which would 
have been expected after the gel filtration revealed that they actually were both dimers.  The scFv 
remained  in the tumour for all the time-points, whilst in the normal organs initial accumulation was 
followed  by  clearance  of the  scFv.  The  %ID/g  in  the  normal  organs were  not as  high  as those 
observed  with  the  diabody,  but  the  pattern  observed  was  similar  (Table  6.8.2).  Despite  this, 
excellent tumour to normal tissue ratios were reached at 18 hours (Table 6.8.6 and  Figure 6.8.4). 
The highest T:NT value was observed for muscle (83.832), whilst in the bone 22.505, in the spleen 
26.693 and in lung 20.771  were reached.  The blood contrast at 18 hours was 16.941  similar to the 
diabody.
6.8.3  4A4 (multimer) results
For completion and further comparison, the results obtained with the 4A4 scFv are included here. 
4A4 is a mixture of monomers, dimers and trimers and previously demonstrated improved tumour 
targeting compared with 3 scFv monomers tested,  including  3A11   (Odili, thesis 2002).  4A4 scFv 
showed good biodistribution properties with high tumour uptake, which persisted for 6 hours (Table
6.8.3).  Initial  tumour  uptake  of 4A4  was  4.586  %ID/g  at  1   hour following  administration,  stayed 
high at 6h (3.961  % I D/g) and the scFv remained in the tumour at relatively high levels even at  18 
hours  post-injection  (2.608  %ID/g).  4A4  scFv  localised  very well  to  the  tumour xenografts,  and 
activity in normal organs and blood cleared rapidly,  resulting in high tumour to normal tissue ratios 
at  18  hours  (44.968  in  muscle,  6.610  in  blood)  (Table  6.8.7  and  Figure  6.8.3).  The  kidneys 
showed  high  initial  activity,  which  cleared  rapidly.  Kidney activity  reached  peak  levels  at  1   hour 
following injection (24.337 % I D/g) and declined rapidly to 5.947 %ID/g at 3 hours and 0.517 %ID/g 
at  18  hours.  Blood  clearance  was  also  rapid  from  7.668  %ID/g  at  1   hour to  0.398  %ID/g  at  18 
hours.  The  main  differences  between  4A4  and  3A11   diabody  and  triabody were  its  lower renal 
accumulation and slower blood clearance.
2376.8.1  %ID/g for 125l Labelled 3A11  “diabody” scFv (dimer) post-concentration
Pi Tumour Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 2.698 14.919 7.512 7.526 8.167 0.396 1.110 1.274
3 hours 0.780 14.042 4.914 4.696 4.937 0.660 0.798 0.584
6 hours 7.598 11.935 2.885 4.069 3.850 0.697 0.825 0.943
18 hours 6.127 4.929 0.422 0.484 0.383 0.109 0.322 0.345
6.8.2 %ID/g for 125l Labelled 3A11  “triabody” scFv (dimer) post-concentration
Pi Tumour Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 1.679 17.406 0.768 1.414 0.851 0.430 1.342 2.805
3 hours 1.117 9.179 0.432 1.022 1.594 0.344 0.583 1.186
6 hours 2.741 7.908 0.844 1.194 0.720 0.248 0.618 0.924
18 hours 2.096 3.986 0.156 0.463 0.173 0.027 0.106 0.131
6.8.3  %ID/g for 12 5 l Labelled 4A4 multimer scFv (mixture of multimers & monomers)
Pi Tumour Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 4.586 24.337 3.259 2.976 3.885 0.867 1.732 7.668
3 hours 4.098 5.947 1.699 1.408 1.903 0.430 1.044 3.291
6 hours 3.961 1.967 0.887 0.921 1.045 0.204 0.415 1.701
18 hours 2.608 0.517 0.308 0.238 0.266 0.058 0.088 0.398
6.8.4 %ID/g for 125l Labelled 3A11  scFv (monomer)
Pi Tumour Kidney Spleen Liver Lung Muscle Bone Blood
1  hour 4.071 22.950 2.490 2.718 2.974 1.320 1.411 3.930
3 hours 3.153 9.147 1.012 1.186 1.203 0.547 0.461 1.419
6 hours 2.959 5.866 0.933 1.040 0.870 0.211 0.553 0.687
18 hours 1.186 2.894 0.168 0.288 0.060 0.066 0.026 0.112
Tables 6.8.1-4  Percentage injected dose per gram (%ID/g) values for the 3A11  diabody and triabody post 
concentration, in comparison with the (unconcentrated) 4A4 multimer and 3A11  monomer,  pi: post-injection.
2386.8.5  TNT ratios for 125l 3A11   “diabody” scFv (dimer) post-concentration
Pi Kidney Spleen Liver Lung Muscle Bone Blood
1   hour 0.190 1.136 0.952 1.341 7.877 2.770 3.556
3 hours 0.120 2.487 1.099 3.731 9.314 1.526 6.326
6 hours 1.045 4.000 6.031 5.028 18.379 10.487 12.026
18 hours 1.834 18.371 28.409 29.644 69.770 34.649 23.787
6.8.6  TNT ratios for 125l Labelled 3A11 “triabody” scFv (dimer) post-concentration
Pi Kidney Spleen Liver Lung Muscle Bone Blood
1   hour 0.193 2.762 1.268 3.138 6.972 2.155 0.861
3 hours 0.249 7.494 2.080 4.135 10.589 6.033 1.636
6 hours 0.379 5.564 2.997 5.197 15.005 5.685 4.500
18 hours 0.536 26.693 5.676 20.771 83.832 22.505 16.941
6.8.7  TNT ratios for 125l Labelled 4A4 multimer scFv (mixture of multimers and monomers)
Pi Kidney Spleen Liver Lung Muscle Bone Blood
1   hour 0.190 1.408 1.545 1.178 5.297 2.648 0.596
3 hours 0.689 2.412 2.911 2.153 9.530 3.925 1.245
6 hours 2.060 4.562 4.477 3.927 21.593 9.954 2.424
18 hours 5.069 8.735 11.023 9.837 44.968 30.081 6.610
6.8.8 TNT ratios for 125l Labelled 3A11   scFv (monomer)
Pi Kidney Spleen Liver Lung Muscle Bone Blood
1   hour 0.184 1.677 1.536 1.405 3.164 2.961 1.063
3 hours 0.345 3.115 2.658 2.622 5.762 6.845 2.222
6 hours 0.571 3.372 2.982 3.712 16.401 5.350 5.437
18 hours 0.426 7.152 4.120 24.106 55.236 46.694 11.697
Tables 6.8.5-8  Tumour to normal tissue ratios (T:NT) for the 3A11   diabody and triabody post-concentration, 
in comparison with the (unconcentrated) the 4A4 multimer and 3A11   monomer,  pi: post-injection.
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Figures 6.8.1-4  Graphical representations of tumour to normal tissue ratios of 3A11   monomer (1), 
3A11   “diabody”  post-concentration  (2),  4A4  multimer (3)  and  3A11   “triabody”  post-concentration 
(4).  Error bars represent 1   SD.
2406.8.4 Summary and comparison of results
The results show that by re-concentrating the radiolabelled 3A11   scFv multimers tumour targeting 
improved,  i.e.  higher tumour to normal tissue  ratios were observed.  The tumour to normal tissue 
ratios  for  the  “diabody”  and  “triabody”,  which  were  in  fact  both  dimers,  were  superior  to  those 
achieved  with  the  3A11   monomer.  This was especially clear,  when  the  one  mouse that skewed 
the 3A11   monomer data was removed, which changes the T:NT of the muscle from over 55 to 17 
(see  section  6.7.2.1).  Augmentations  of  the  contrast  to  blood  were  observed  in  the  re­
concentration experiments.  It is interesting to compare the values achieved after re-concentration 
with  those  of  the  4A4  scFv,  a  mixture  of  multimers  with  monomer.  The  3A11  dimers  show 
improved results over those obtained for the 4A4 with a tumour to blood ratio of at least twice that 
of the 4A4.  Other improved values include those for the spleen, liver,  lung, muscle and bone.  On 
the other hand,  the T:NT values of 4A4 for the kidney were superior to both  3A11  monomer and 
dimers.
2416.9  DISCUSSION
The purpose of these experiments was to produce and assess, in vitro and in vivo, a series of pure 
anti-melanoma  scFv  multimers  of varying  size  and  valencies for their targeting  efficiency of high 
molecular weight melanoma-associated antigen (HMW-MAA).  Multimerisation strategies are used 
to improve tumour targeting, to reduce background accumulation  (for imaging applications) and to 
reduce exposure of normal organs to toxic agents (for therapeutic applications).  The experiments 
examined  two  clones  derived  from  the  3A11  monomer  that  were  initially  considered  to  be  a 
diabody and a triabody after sequence analysis.
In  vitro  experiments  showed  that  the  scFvs  were  produced  with  good  purity  and  yields  (around 
1  mg/ml).  E xcellent melanoma binding was demonstrated in  cell ELISA for both  the  multimeric 
clones.  The expression yield and  in  vitro melanoma  binding of the 3A11   multimers  is superior to 
the 3A11   monomer whereas a similar series with the 4A4 scFv showed  no improvement (Kupsch, 
personal  communication).  The  3A11   multimers  were  therefore  chosen  for testing  in  the  mouse 
model.
6.9.1  In vivo results
Radioimmunopharmaceuticals typically display a biphasic pattern of clearance from the circulation 
(Milenic et at.,  1991).  The primary phase represents the development of an equilibrium in all bodily 
tissues.  This first phase has a  half-life designated  ty2 a and  is  usually rapid  (Adams,  1998b).  The 
secondary  phase  is  less  rapid  and  reflects  the  gradual  release  of  intact  radiopharmaceuticals 
dissociating  from  the  antigen  and  clearance  of  non-specifically  accumulated  scFv  from  normal 
tissues.  The half-life of the secondary phase is termed ty2(3.  The data in the present study confirm 
the rapid pharmacokinetics of the RAFT 3A11   series of scFvs.
The  in  vivo  results  with  the  diabody and  triabody  in  athymic  mice  bearing  melanoma  xenografts 
were initially disappointing.  The expected  improvement in tumour targeting and tumour to normal 
tissue  ratios  were  not  observed.  Repeated  experiments  confirmed  this  to  be  the  case. 
Subsequent  analysis  of  the  scFvs  by  gel  filtration  revealed  unanticipated  results.  The  3A11 
diabody and triabody both showed concentration-dependent multimerisation.  Both proteins formed
242dimers  at  high  concentration  and  monomers  at  lower  concentrations.  In  fact,  their  molecular 
weights were identical at equivalent concentrations, suggesting that notwithstanding their different 
genetic sequence,  they were very similar scFvs.  Further experiments were  aimed  at preventing 
the  scFvs  from  reaching  an  equilibrium  that  favoured  monomers  at  dilute  concentrations  after 
radiolabelling.  The  radiolabelled  scFvs  were  re-concentrated  to  their  original  pre-radiolabelling 
concentrations  and  volume.  Subsequent  in  vivo  testing  of  the  re-concentrated  scFvs  showed 
superior  targeting  with  scFv  dimers.  Overall  improvements  in  tumour  targeting  and  tumour  to 
normal tissue ratios were seen for the dimers compared with the monomer.  The results observed 
were  better than  those  achieved  with  the 4A4  clone,  which  is a  mixture  of monomer,  dimer and 
trimer at  concentrations  of around  4mg/ml  (Odili,  MD  thesis  2002).  The  tumour to  blood  ratios 
were  extremely  good  as  were  the  tumour to  muscle  ratios.  These  two  values  are  of  particular 
significance  to  melanoma  targeting,  as  most  initial  recurrences  are  loco-regional  recurrences 
around the site of the primary tumour or in the draining lymph node basin (Balch et al., 2001b).  In 
humans,  these sites tend tobeonthe limbs  for the local recurrences  and around surrounding 
muscle and bone (such as the axilla or inguinal region) for the regional recurrences.
Despite the rapid clearance, all the scFvs localised to the tumours, reaching maximum uptakes of 
approximately  1.6  -  4.6%ID/g  at 60  min  following  intravenous  injection  (Tables 6.8.1-4).  These 
results are comparable to tumour targeting studies of scFv reported by other laboratories (Colcher 
et al.,  1990; Milenic et al.,  1991; Whitlow et al.,  1993).  The tumour accumulation of the 3A11   scFv 
of 1.186 %ID/g at 18 hours is similar to the values reported  in other similar studies.  For example, 
Adams  et  al.  achieved  a  value  of  1.42%ID/g  at  24  hours  (Adams  et  al.,  1998a).  The  tumour 
accumulation  of the  reconcentrated  3A11  dimer was  2.096  -  6.127  %ID/g  for the “triabody” and 
“diabody”,  respectively  at  18  hours  post-injection.  Therefore  both  dimer  preparations  showed 
stable tumour retention to a greater extent than that reported for other dimers in the literature.  For 
example,  when  Goel  et al.  tested  scFv dimers  in  athymic mice  bearing  human  colorectal  cancer 
xenografts,  accumulation  declined  rapidly  from  the  tumour  after  4  hours  (Goel  et  al.,  2001). 
Tetramers were stably retained  in the tumour for 6  hours.  Others  have  also found that although 
multimerisation  into  dimers  or  trimers  improves  initial  tumour  accumulation,  the  retention  of 
antibody fragments did not remain stable in vivo (King et al.,  1994; Viti et al.,  1999).  For example, 
King  et al.  tested  a  F(ab’)2 antibody fragment and  observed  a  maximum tumour accumulation  of 
approximately 3%ID/g at 6 hours post-injection, which then decreased to 1.5%ID/g and 0.25%ID/g 
at  24  and  72  hours,  respectively.  The  tumour  accumulation  in  the  study  by  Viti  et  al.  was 
7.32%ID/g  at  4  hours  which  decreased  to  1.29%ID/g  at  24  hours.  In  comparison,  the  %ID/g 
observed  in  the  present  study  was  2.698%ID/g  at  1  hour  and  6.127%ID/g  at  18  hours  for the
243diabody.  For the triabody 1.679%ID/g at 1   hour and 2.096%ID/g at 18 hours for the triabody were 
observed.
The dimers had a  rapid  blood clearance.  Several groups have observed  rapid  blood clearance of 
dimeric scFvs that was slightly prolonged compared with the monomer (Adams et al.,  1993; Wu et 
al.,  1996).  The  clearance  of  the  dimer  and  monomer  in  the  present  study  was  similar  and, 
combined  with  the  stable  tumour  retention  observed,  resulted  in  good  T:NT  targeting  values. 
These were superior to previous studies with antibody multimers that did  not show stable tumour 
retention over time (see section 6.9.4 below).
6.9.2  scFv localisation to the kidney
Renal accumulation of small tumour-targeting molecules reduces the efficacy of both imaging and 
therapeutic  studies.  Significant  renal  accumulation  is typical  with  antibody fragments,  especially 
those  small  enough  to  be  freely  filtered  in  the  kidney  (below  approximately  60kDa)  (Silbernagl,
1988).  Whilst  renal  localisation  may  represent  only  a  minor  nuisance  in  diagnostic  imaging,  in 
therapeutic studies nephrotoxicity becomes a possibility and may represent the dose-limiting factor 
(although  other studies  have  suggested  that the  bone  marrow would  be  the  dose-limiting  organ; 
Behr et al.,  1998).  Indeed,  whilst a  great  many  imaging  studies  using  antibody fragments  have 
now  been  published,  relatively  few  in  vivo  studies  using  therapeutic scFv  constructs  have  been 
seen  in  the  literature.  Moreover,  nephrotoxicity  has  been  a  serious  concern  in  many  of those 
published so far (Behr et al.,  1997; de Jong et al.,  1997;  Reubi,  1997).  Strategies to reduce renal 
accumulation  are  therefore  of  critical  importance  if  the  superior  tumour  to  normal  tissue  ratios 
achieved  using  antibody fragments  compared  with  whole  immunoglobulins are to  be exploited  in 
cancer therapy.
The  renal  accumulation  of  antibodies  and  small  peptide  molecules  is  thought  to  be  largely  a 
function  of the  kidney’s  ability to filter and  reabsorb  peptides falling  below a  threshold  of around 
60kDa  in  size  (Rennke  et al.,  1978;  Silbernagl,  1988).  These  molecules are filtered  through  the 
glomerular basement  membrane  and  then  actively  reabsorbed  in  the  proximal  convoluted  tubule 
by pinocytosis.  Under physiological conditions,  little or no protein or peptide material is lost in the 
urine.  Evidence  supporting  this comes from studies such as that by Viti et al. who demonstrated 
improved  tumour to  kidney  ratios  with  a  dimer over a  monomer  (Viti  et al.,  1999).  However,  in 
other studies  multimerisation  actually led  to increased  renal accumulation.  King et al. found that 
renal  accumulation  was  worse  with  a  trimer  than  a  dimer,  which  in  turn  was  worse  than  the
244monomer  (King  et  al.,  1994).  Furthermore,  in  the  study  by  Goel  et  al.,  the  tetramer  studied 
reached  a  maximal tumour to kidney ratio of only 3.4  (Goel  et al.,  2001).  This value is similar to 
the  T:NT  ratio  of  5.069  at  18  hours  observed  with  the  4A4  scFv  (mixture  of  monomers  and 
multimers;  see  Table  6.8.7),  supporting  the  view that  kidney  retention  is  not determined  by size 
alone.
The  data  from  other  studies,  therefore,  suggest  that  size  alone  does  not  determine  renal 
accumulation.  The  renal  accumulation  of the  3A11  scFv  series  was  considerable  at early time- 
points and consistent with the renal accumulation typically seen with molecules of this size (Maack 
et al.,  1979;  Silbernagl,  1988).  No  significant difference  was  seen  between  the  clones  studied. 
The slightly higher renal accumulation seen with the 3A11  scFv monomer at the  1-hour time-point 
was not evident at 18 hours.  This is in contrast to what would have been predicted if size were the 
sole determinant of kidney accumulation  (Maack et al.,  1979).  If size alone were the determinant 
of  kidney  accumulation  of  the  RAFT  scFvs,  the  following  order  of  renal  clearance  would  be 
expected:  3A11DB/TB  > 4A4  > 3A11  monomer.  This order is not observed;  in fact,  the order is: 
3A11DB/TB  >  3A11   monomer  >  4A4.  The  observed  pattern  is  more  consistent  with  size  and 
charge both being important for renal accumulation.
The  kidney  is  an  organ  rich  in  membranes  with  negative  surface  charge,  which  suggests  the 
possibility of binding to the positively charged 3A11   (pi = 8.6).  The 4A4 multimer demonstrated a 
faster renal  clearance than the 3A11   dimers.  It has a  pi of 7.8,  almost neutral, which  supports a 
hypothesis that charge  may  be  more  important than  size for renal  clearance.  Another clone,  B3 
(Kupsch  et al.,  1999;  J.  Odili,  unpublished data),  a  monomer with a pi  of 6.7 also has a relatively 
low kidney accumulation  (T:NT 0.442 at 6  hours and  1.42 at  18  hours -  see  Chapter 5) and  like 
4A4, a relatively slow blood clearance (tumour to blood ratio of 6.444 at 18 hours) suggesting that 
charge could play a role in kidney filtration or clearance.
As  well  as  altering  the  charge  of  scFvs  in  an  attempt  to  improve  renal  accumulation,  other 
strategies  have  been  suggested.  T hese  have  included  the  co-administration  of cationic  amino 
acids such as lysine to block reabsorption of radiolabelled scFv by renal cells (Behr et al.,  1998b; 
Hamilton  et  al.,  2002).  Another  strategy  is  the  interposition  of  a  cleavable  linker  between  the 
antibody fragment and the site of radiolabel,  so that the radiolabel  is excreted from the lysosomal 
compartments of renal cells into the urine after lysosomal proteolysis of the radiolabelled antibody 
fragment  in  the  renal  cells  (Arano  et  al.,  1999).  However,  the  latter  strategy was  not tested  in 
tumour-bearing mice and its effect on tumour targeting has yet to be shown.
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2%ID/g at  18  hours)  might hinder therapeutic approaches  using the 3A11  scFv dimers but would 
not prevent imaging studies.
6.9.3  ScFv Localisation to Other Organs
The  distribution  of  the  3A11  dimer  to  other  organs  differed  between  the  diabody  and  triabody 
preparations,  although  the  tumour  to  normal  tissue  ratios  were  comparable.  The  diabody 
preparation  demonstrated  better  tumour  localisation  initially  (Table  6.8.1),  but  by  18  hours  the 
%ID/g for both  preparations was very similar (Tables 6.8.1  & 6.8.2).  This was to be expected as 
both preparations consisted of 3A11   dimers at the time of injection.  The two preparations may still 
differ  in  their thermal  stability or their tendency to dissociation  into  monomers  in  vivo  (neither of 
which  were  tested).  Compared  with  the  diabody,  the  tumour to  liver  ratios  were  lower for the 
triabody after concentration, which could  be due to lower stability and  possibly degradation in the 
liver.
The  other  discrepancies  could  have  been  due  to  differences  in  radiolabelling,  differences  in 
administration of the radiolabelled scFvs or possibly sampling errors.  The stability of the radiolabel 
in vivo for each scFv and the inherent resistance of the constructs to proteolysis were not studied 
specifically and  could  play a  part in  the overall  targeting  efficiency.  In agreement with published 
reports,  the  data  demonstrated  that  rapid  tumour  uptake  and  rapid  clearance  from  blood  and 
normal tissues resulted  in high tumour to muscle ratios.  In addition, the present study and that of 
Odili  (Odili,  thesis 2002) are the first to show a further improvement of in vivo targeting  by stable 
tumour retention of scFv multimers.
6.9.4  Tumour to Normal Tissue Contrast
Tumour  to  normal  tissue  ratios  are  shown  in  Tables  6.7.2.4-6  and  Tables  6.8.5-8.  A  striking 
improvement  in  tumour  to  normal  tissue  (T:NT)  contrast  is  seen  with  dimerisation.  This 
improvement should  result  in  both  increased  imaging  contrast  and  therapeutic efficiency.  Since 
the  normal  tissue  accumulation  remains  similar  to  the  3A11  monomer,  the  increase  in T:NT  is 
almost entirely a function of increased tumour retention.  Adams et al.  compared scFv monomers 
and  dimers  in  scid  mice  bearing  tumour xenografts  and  found  slower clearance with  the dimers,
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affinity of the original monomeric scFvs or the dimers themselves (Nielsen et al., 2000).
As noted previously, the tumour to muscle ratio for the 3A11   monomer at 18 hours (of 55.236) was 
skewed by a very low %ID/g value in one mouse.  This potential error, however, demonstrates the 
effect of 2  methods of calculating T:NT values.  The tumour to  normal tissue ratios can either be 
calculated for each  mouse  individually and then  the  mean T:NT is derived for the group of mice. 
Alternatively,  it can  be calculated for each organ from the mean %ID/g of the group of mice.  The 
latter method would be less likely to be skewed by a single erroneous result in %ID/g but does not 
truly represent the T:NT achieved in each subject mouse.  A review of published papers using the 
nude  or  SCID  mouse  xenograft  model  revealed  no  detailed  description  of  the  exact  methods 
employed for calculating T:NT ratios.  It can be reasoned that the former method produces a more 
accurate representation of the contrast achieved mouse by mouse and, therefore, it was used in all 
the present studies.  Although the mean %ID/g in tumour at the  18 hour time-point is  1.186 and in 
muscle 0.066, the accurate T:NT is 55.236 (taken as a mean of T:NTs) rather than a value of 17.9 
which one might expect (i.e.  1.186/0.066).  Excluding the apparently erroneous value obtained with 
one mouse gives  a tumour to muscle  ratio of almost  18  in this  instance.  Even with the  potential 
vulnerability of this method to experimental error,  it appears to present a more accurate reflection 
of the situation in vivo.
The  results  are  most  encouraging  and  demonstrate  the  improvement  that  can  be  achieved  by 
dimerisation.  In  comparison  to  other  published  studies,  the  T:NT  ratios  achieved  are  highly 
promising.  Results for the 3A11   dimers are superior to those obtained by King et al.  using F(ab’)2  
fragments (King et al.,  1994) and those of Verhaar et al.  using an anti-CEA scFv in mice (Verhaar 
et al.,  1996) which  was  subsequently  used  to  produce  impressive  patient  images  (Begent et al.,
1996).  Furthermore, the tumour to blood ratios in the present study are better than those achieved 
by Viti et al.  (1999)  (23.787 at  18  hours vs.  10.33 -  see Table 6.8.5) who did  not observe stable 
tumour retention.
The fact that the scFv dimers tended to persist in the tumours for a considerable period  in these 
experiments  is the  main  explanation for the  improvement in  tumour to  normal  tissue  ratios.  The 
increased t umour  targeting a nd retention o bserved i n the p resent study  for the a nti-HMW-MAA 
dimers is likely to be due to higher valency and  avidity,  rather than  increased serum persistence. 
A  comparison  of  the  terminal  half-lives  of  two  versions  of  anti-CEA  diabody  with  half-lives 
determined for monomeric scFvs  in  mice and  humans,  revealed that all exhibit terminal half lives 
within  the  range  of  about  3-5  hours  (King  et  al.,  1994;  Begent  et  al.,  1996;  Wu  et  al.,  1999).
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clearance)  of an  anti-HER2/neu diabody constructed with a five amino acid  linker (Adams et al., 
1998c).
6.9.5  Other explanations for improved results
While the  major factor in  the  increase  in  tumour localisation  is  likely to  be avidity for the antigen 
and  hence  prolonged tumour retention, other possible factors merit consideration.  The studies in 
this chapter have attempted to standardise as many variables as possible, including target epitope, 
labelling  technique  and  immunoreactivity.  However,  as  discussed  in  section  6.9.2,  molecular 
charge  can  play  a  part  in  the  pharmacokinetics  of  targeting  molecules  and  cannot  be  easily 
standardised  in experiments of this type.  Previous studies have demonstrated that increasing the 
pi  by  chemical  cationisation  of  Fab’  fragments  can  markedly  increase  renal  excretion  without 
affecting tumour localisation  (Tarburton et al.,  1990).  Conversely,  increasing the isoelectric point 
(pi) of a whole antibody from 8.9 to >9.5 has  been shown to increase cellular uptake and  reduce 
residence  time  in  the  systemic  circulation  (Pardridge  et  al.,  1995).  Interaction  of  the  charged 
protein molecules with negatively charged surfaces of vascular endothelial cells and proximal renal 
tubular cells have been proposed as the explanation of these findings (Maack et al.,  1979; Sumpio 
& Maack 1  982).  A Iteration of the isoelectric point may therefore be a  strategy for tackling  the 
problem  of renal  accumulation  (Odili,  MD  thesis  2002)  as  the  present study and  others  suggest 
that multimerisation strategies seem to be ineffective in achieving more than a modest reduction of 
kidney  accumulation  of  antibody  fragments.  In  previous  studies,  the  primary  effect  of  charge 
modification  has  been  on  renal  clearance  rather  than  cellular  uptake  (Tarburton  et  al.,  1990; 
Pardridge et al.,  1995).
6.9.6  Method of multimerisation - altered linker length
A number of research groups  have shown that single chain  Fv fragments, depending  both on the 
VhA/l interface and the linker length, can spontaneously dimerise or form higher multimers (Essig 
et al.,  1993; Whitlow et al.,  1993;  Holliger et al.,  1993;  Griffiths et al.,  1993;  Schodin  et al.,  1993; 
Odili, MD thesis 2002).  A more systematic investigation of this phenomenon (Holliger et al.,  1993; 
Whitlow et al.,  1994; Desplancq et al.,  1994) then demonstrated that the percentage of monomer is 
directly proportional to the linker length connecting the two variable domains.  Molecular modelling 
and subsequently the determination of the crystal structure of a dimeric scFv (Perisic et al.,  1994)
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molecule, to create two VH /VL  assemblies in one molecule, termed a diabody (Holliger et al.,  1993). 
In some  cases,  the  monomers and  dimers are  in a concentration-dependent equilibrium  (Kortt et 
al.,  1994; Lee etal., 2002).
Alteration  to  the  peptide  linker  is  known  to  promote  multimerisation.  Hence  it  was  used  to 
construct the 3A11  multimers (Alfthan et al.,  1995).  Shortening the linkers to less than  12 amino 
acids  tends  to  promote multimerformation (Kortt  et  al.,  1997)  whilst  longer  linkers  (>17  amino 
acids) tend to  result in  the  production  of monomeric scFv (Whitlow et al.,  1993;  Desplancq  et al., 
1994; Wu et al.,  1996).  However, linker engineering can have a number of drawbacks.  The nature 
of the multimers formed seems rather unpredictable and a property of the combination of antibody 
and the linker used.  In addition,  reducing the linker length from 3 to 2 residues does not precisely 
dictate  the  transition  from  dimers  to  higher  multimers.  Instead,  a  mixture  of multimers  (dimers, 
trimers and tetramers) may form, and the tetramers may be unstable, reverting back to the dimeric 
or monomeric state  (Dolezal  et al.,  2000).  Short  linkers  of length  less than  12  residues tend  to 
stabilise the diabody or triabody forms of the scFv molecule, as these prevent the association of VH  
and  VL   domains  in  monomeric  scFv.  The  reversibility  of  dimerisation  is  dependent  on  buffer 
conditions  and  the  scFv  (Arndt  et al.,  1998).  HPLC  gel  filtration  of the  scFv  3A11  diabody and 
triabody  showed  peaks  with  the  molecule  existing  as  a  monomer  or  dimer  depending  on  the 
concentration.  Both clones formed dimers at high concentration, despite differing linker lengths (2 
amino acids for the triabody and 5 for the diabody).  It is possible that by reducing the linker length 
to zero and/or changing  the  domain  orientation  form  VL -VH  to VH -VK ,  more  stable  (concentration- 
independent) dimers or higher multimers could be made (Pluckthun & Pack,  1997).
The linker can also affect the affinity, stability and expression  levels of scFvs (Alfthan et al.,  1995; 
Tang  et  al.,  1996), factors  that  are  critically  important for  patient  studies.  Although  simple  and 
effective  in  principle,  the  diabody  approach  may  not  always  produce  molecules  with  properties 
suitable  for  patient  studies.  Various  other  strategies  such  as  the  fusion  of  leucine  zippers  or 
streptavidin  have  been  used  to  produce  scFv  multimers  but  it  is  not  uncommon  that  problems 
similar to those  observed  with  diabodies  are  reported  (Pluckthun  &  Pack,  1997).  This suggests 
that there may be  no universal approach to multimer formation and the optimal strategy will have 
to be established for each antibody empirically.
Diabodies  can  possess  some  of  the  properties  required  for  immunoscintigraphy  and 
immunotherapy and can be constructed in either monospecific or bispecific formats.  However, the 
two  chains  of  the  diabodies  are  capable  of  dissociating,  as  has  been  the  case  at  low
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disulphide  bonds  at the  VH -VL   interface,  covalently  locking the two  chains  together (Fitzgerald  et 
al.,  1997).  This has been shown to improve thermal stability and could favour the correct pairing of 
the two different chains  in  bispecific diabodies.  Previously published work has also indicated that 
the introduction of inter-chain disulphide bonds can reduce binding affinities and expression yields 
(Reiter et al.,  1994;  Reiter et al.,  1996b; Pluckthun & Pack,  1997) but this is not a universal finding 
(Fitzgerald et al.,  1997).
6.9.7  Concentration-dependent multimerisation
Based  on  the  literature  (Kortt  et  al.,  2001),  the  intended  multimerisation  of  3A11  was  initially 
assumed as a result of the genetic sequence.  Multimer formation was subsequently characterised 
by submitting the 3A11   diabody and triabody to size-exclusion gel filtration chromatography.  The 
results  suggested  a  concentration-dependent  multimerisation.  High  concentrations  of  protein 
favoured  dimer (and  possibly tetramer) formation,  whilst lower concentrations favoured  monomer 
formation.
Concentration  of  protein  samples,  typically  to  1  mg/ml,  has  previously  been  shown  to  increase 
multimer  formation  (Todorovska  et  al.,  2001).  Thus  the  monomer/dimer  equilibrium  in  scFvs 
becomes biased towards dimers.  Similarly, concentration can increase the proportion of triabodies 
and  higher multimers  in  scFv diabodies  (linkers  between  3  and  12  residues)  (Todorovska  et al., 
2001).  This phenomenon s uggests that  the V h /Vl i nterface i n the F v molecule can d issociate, 
enabling V-domains to shuffle and re-associate.  The rate of Fv dissociation will be unique to each 
antibody.  Several  methods  have  been  suggested  to  increase  the  stability  of  scFvs,  including 
storage as antibody-antigen  complex (Lawrence  et al.,  1998),  the addition  of buffer components, 
adjusting pH and ionic strength (Arndt et al.,  1998), design of “knobs-into-holes” mutations (Zhu et 
al.,  1997;  Dall’Acqua  &  Carter  1998),  or  the  introduction  of  inter-domain  disulphide  bonds 
(Brinkmann et al.,  1997).  All  these  methods  have  been shown to  be effective for scFv multimer 
stabilisation in vitro.
Without  any  stability  engineering  it  is  possible  that  after  injection  into  the  mouse  the  initially 
concentrated  scFv  may  reach  a  new  monomer-dimer  equilibrium  in  the  circulation,  resulting  in 
dissociation  into  monomers.  If this  was  the  case,  in  vivo targeting  could  be further improved  by
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could become trapped and unable to equilibrate further (Arndt et al.,  1998).
6.9.8  Other factors influencing dimer to monomer transition
As discussed, the extent of dimerisation depends upon a number of factors including linker length, 
amino acid sequence, as well as other external factors such as pH and temperature.
The presence or absence of the antigen may also play a role in favouring monomeric or multimeric 
states.  It  has  been  suggested  that  a  dynamic  equilibrium  exists  between  monomer  and  their 
dimers, which  is influenced  by external factors (Arndt et al.,  1998).  It has been shown for dimeric 
variants  of streptavidin  that  monomers  are the  more  thermodynamically stable forms and  that in 
the  absence  of  biotin,  dimers  can  revert to the  monomeric form  (Sano  et al.,  1995;  Sano  et al.,
1997).  Ionic strength  and  pH  have  also  been  shown  to  influence  the  rate  of dimer to  monomer 
conversion.  For some monomeric species this conversion is faster under physiological conditions 
(Arndt et al.,  1998) and the conversion will depend on the VL -VH  interface energy.
A range  of dissociation  constants for the VL -VH   association  has  been  observed for Fv fragments 
derived from antibodies and they can be as low as 10‘7 M (Polymenis & Stollat,  1995; Mallender et 
al.,  1996).  Thus in some cases where the VL -VH  interface is intrinsically stable, the re-equilibration 
of dimer to monomer may be incomplete or minimal, even in the absence of the antigen.  Different 
scFvs  may be trapped  in  the dimer state to different degrees.  One study has demonstrated  that 
human scFv fragments with  high  specificities of binding to human self-antigens selected from the 
same  phage  library  consisted  of a  mixture  of monomers  and  dimers  (Griffiths  et al.,  1993).  The 
binding  kinetics  were  determined  by  surface  plasmon  resonance  and  whilst  the  kinetics  of 
association  were  typical  of  known  Ab-protein  interactions,  the  kinetics  of  dissociation  were 
relatively fast.  The  development of useful  dimeric scFvs  thus  requires  the  understanding  of the 
conditions more likely to favour dimerisation rather than monomeric states.
6.9.9  Size of scFv multimers and its effect on pharmacokinetics
ScFv multimers such  as diabodies  (~60kDa) and triabodies  (~90kDa) are significantly larger than 
scFv  monomers  (~30kDa)  and  thereby  can  have  an  advantage  for  in  vivo  applications  by
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increased  size and  moderate clearance rate  is offset by decreased tumour penetration,  since the 
distribution  rate through the vascular network into the tumour is inversely correlated to the size of 
the protein in  vivo.  Indeed,  some of the most recent in vivo data using  radiolabelled diabodies in 
three different xenograft models show that diabodies have a significant advantage over monomeric 
scFvs  (Wu  et al.,  1996;  Wu  et al.,  1999;  Adams  et al.,  1998;  Adams  &  Schier,  1999;  Viti  et al., 
1999).  Similarly,  the  small  size of the diabodies should  have advantages for tumour penetration 
over the  larger multimeric  Fab chemical  conjugates and  intact whole  Ig,  although this  remains to 
be  demonstrated  experimentally  (Casey  et  al.,  1996).  Previous  investigations  with  anti-CEA 
diabodies (Wu et al.,  1999) and anti-HER2Ineu diabodies (Adams et al.,  1998) reported tumour to 
blood ratios considerably higher than those achieved for F(ab’)2 (Pedley et al.,  1993 ; Casey et al., 
1999).  This is the result of the rapid beta phase clearance from the blood.
The fast clearance  of smaller molecules from  the  kidney reduces  tumour accumulation  (Dillman,
1989).  S cFvs n ormally h ave a  p ositive n et c harge t hat  may a Iso contribute  to  their h igh  renal 
accumulation.  Increasing  their surface  negative  charge,  or modifying  the  radionuclide chemistry 
can achieve improvements in the biodistribution and pharmacokinetics of these small recombinant 
antibody  fragments,  both  strategies  reducing  the  renal  uptake  (Arano  et  al.,  1999).  Other 
strategies  include  pre-treatment  or  co-administration  of  cationic  amino  acids  such  as  D-Lysine 
(Behr etal.,  1997; Carrasquillo etal.,  1998; Arano etal.,  1999; Hamilton etal., 2002).
Interestingly, Adams et al.  showed that diabodies had  improved tumour targeting when compared 
with  scFvs  that  had  been  dimerised  via  disulphide  bonds  and  this  might  reflect  higher  in  vivo 
stability  of  the  diabodies  (Adams  et  al.,  1998c).  The  linkers  in  diabodies  and  triabodies  are 
relatively  inaccessible to  proteases  compared with  the  long  linkers  required for monomeric scFv. 
Although covalent dimers continue to be produced (Beresford et al.,  1999; Pavlinkova et al.,  1999), 
diabodies  (made  by  shortening  the  linker  length)  could  be  more  stable  than  dimers.  Since 
diabodies provide  more  rapid tumour penetration and  clearance than  (Fab’)2 (100kDa) they seem 
most  promising  as  reagents  for  radioimaging  using  radionuclides  with  short  half  lives  such  as 
" m Tc.
2526.10  CONCLUSIONS
The use of scFv molecules  in a wide range of biological and  medical applications will be affected 
by whether the scFv possesses a stable monomeric structure with a single antigen-binding site or 
a stable dimer structure with two antigen-binding sites.
If it  is  assumed  that  3A11   dimer  is  applied  to  humans  in  500pg  aliquots,  in  a  volume  of around 
3.5ml, it will be diluted to 0.0001 mg/ml if the total adult blood volume is  five litres.  The same 
calculation  in  mice, assuming a  blood volume of 2mls and 0.5pg scFv is injected, demonstrates a 
similar result.  Local  concentration  effects  may arise  in  tumours,  where  3A11   will  accumulate by 
binding  to cell  surface-expressed  HMW-MAA,  where this  is abundant.  However,  once 3A11   has 
bound to HMW-MAA, it may be trapped in its monomer structure and be unable to form a dimer.  A 
dimer or diabody structure would  probably  not therefore  be  expected  to form  in tumours even at 
high local concentrations of 3A11.
The  present  work  has  demonstrated  the  concentration-dependent  nature  of  the  RAFT  3A11 
multimers and therefore the need to be wary of this when considering multimerisation strategies for 
future  use  in  humans.  Despite  this,  clearly  improved  targeting  of the  3A11  dimer was  revealed 
compared with not only the parent monomeric scFv, but also the mixture of monomers, dimers and 
trimers formed by the 4A4 clone.  Thus dimerisation promises to be a useful strategy for improving 
radioimmunodetection  of  metastatic  melanoma.  Further  improvements  in  melanoma  targeting 
could  be  achieved  by  diabody  engineering  such  as  alteration  of  the  V  domain  orientation, fine 
tuning  of  the  linker  length  or  the  introduction  of  stabilising  disulphide  bonds.  Diabody  re­
concentration proved a simple and effective strategy to improve in vivo targeting.
253CHAPTER 7
SUMMARY AND FUTURE DIRECTIONS
2547.1  SUMMARY
The  incidence  of  melanoma  is  continuing  to  increase  despite  greater  public  awareness  and 
advances in prevention and treatment (see Chapter 1   for review).  This thesis has addressed three 
problems  faced  when  dealing  with  this  disease.  It  has  examined  secondary  prevention  (early 
detection),  estimation  of prognosis and  the early detection  of metastases.  Advancements in any 
one of these areas will serve to improve the lot of the melanoma patient.  The following paragraphs 
summarise the findings in this thesis and put forward suggestions for addressing questions raised.
7.2  PIGMENTED LESION CLINIC
Despite the existence of rapid-access pigmented lesion clinics for over a decade, no study has yet 
examined their impact on  melanoma  patient outcome.  However, early detection has been shown 
to be an effective strategy for improving  patient outcome in breast and colorectal cancer (Moss et 
al.,  1994;  Niv  et  al.,  2002).  Other  PLC  studies  have  examined  the  efficiency  of  the  clinics, 
compared PLC patients with data from other studies (O’Connor & Barnes 1994) or looked at trends 
in melanoma patients presenting to PLCs over time (Bataille et al.,  1999; Duff et al., 2001).
The  work  done  on the PLC  study  in  this thesis  has  shown  that the  strategy  of  early  detection 
improves  overall  melanoma  patient  survival  and  improves  disease-free  interval  in  those  patients 
that  develop  regional  recurrences.  Although  it  may  be  assumed  that  an  efficiently  run  early- 
detection  PLC  will  have  the  effect  demonstrated  in  this  thesis,  there  are  pitfalls  and  dangers  in 
making  assumptions that  have  not  been  based  on  scientific analyses.  An  example of this  is the 
very wide margins  (>6cms) that were once used when resecting  primary melanomas, which have 
since been shown to be unnecessary for local disease control (Veronesi et al.,  1988).  Therefore it 
was important that a study such as the  present one was undertaken.  This thesis has shown that 
the strategy of early detection,  by means of reducing the inherent delays incurred in the system of 
GP referral and the bureaucracy of hospital administration, directly affects patient outcome.  This is 
achieved  without the  need  for additional  publicity  campaigns  to  run  in  conjunction with  the  PLC.
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otherwise  be  treated  as  unsuspicious  by  the  GP.  This  has  been  shown  to  be  a  factor directly 
relating  to  the  thickness  of  melanomas  presenting  (Ibbotson  et  al.,  1995).  The  reduction  in 
thickness  of  melanomas  presenting  to  the  PLC  should  also  reduce  the  need  for sentinel  lymph 
node  biopsy,  a  procedure  with  considerable  associated  morbidity  and  cost  implications 
(Hettiaratchy  et  al.,  2000;  Jakub  et  al.,  2003).  The  improvement  in  survival  and  disease-free 
interval conferred on patients by the PLC will also reduce the numbers of patients undergoing toxic 
(and currently ineffective) chemotherapeutic regimes.  Finally,  in the present healthcare system of 
budgetary constraints, the efficiency a nd effectiveness of a  P LC d oes  not only i mprove patient 
outcome, but considerably reduces the financial burden on the NHS.
7.2.1  Future directions
It is hoped that following  publication of the results of the investigation into the PLC, other hospitals 
will  be  encouraged  to  establish  similar  clinics.  By  using  this  simple  strategy  nationally,  the 
morbidity and mortality from melanoma may be significantly reduced.  With the annual increases in 
incidence of melanoma, the importance of this cannot be overstated.
7.3  TISSUE ARRAY
Accurately  predicting  the  prognosis  of  melanoma  patients  is  crucial  for  making  correct 
management decisions,  the  planning  of follow-up  regimes and for the  psychological well being of 
melanoma patients.  Currently it may be possible to inform a patient that they have an 80% chance 
of having no recurrence,  but it is not possible to inform them if they will be within that 80%.  With 
the  discovery  of  novel  prognostic  markers,  adding  to  the  battery  of  established  indicators  of 
prognosis,  the  accuracy  of  the  predictions  made  is  improving.  After  relying  on  the  Breslow 
thickness,  Clark’s  level,  presence of ulceration,  patient age, tumour site and  patient sex, the next 
most important determinant of prognosis  is the  nodal  status of the  patient.  Sentinel  lymph  node 
biopsy (Morton et al.,  1992) is now widely practiced as a means of accurately staging patients and
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(Hettiaratchy  et al.,  2000;  Jakub  et al.,  2003) and  has  not yet been  shown  to  have  a  bearing  on 
overall patient survival.  Non-invasive approaches to predicting prognosis are therefore desirable.
The  employment  of  high  throughput  tissue  microarray  analysis  on  480  core  biopsies  form  120 
melanoma patients has permitted the identification of several novel prognostic melanoma markers. 
These  markers  will  be  applicable  to  use  alongside  routine  staining  that  is  performed  on  lesions 
suspected  to  be  melanomas,  without  incurring  any further morbidity to the  patient.  In this thesis 
MCAM,  P-cadherin,  CD44v3  and  nm23  were  shown  to  be  effective  in  predicting  outcome  in 
primary cutaneous melanoma.  In addition,  MCAM was shown to predict prognosis independent of 
other established clinicopathological variables.
7.3.1  Future directions
The  use  of tissue  array  as  an  efficient tool  to  study  large  numbers  of specimens  simultaneously 
has  opened  up  the  possibility of screening  for many further  potential  markers.  This  applies  not 
only t o t umour s pecimens, b ut a Iso t o o ther t issues, s uch a s c onnective t issue i n t he s tudy o f 
Dupuytren’s disease,  tendon  research  and  burns  scar tissue.  Furthermore,  improvements  in the 
efficiency  of  tissue  array  analysis  are  continually  being  developed,  including  computer-aided 
analysis of array staining.  The  use  of computerised  image analysis to aid  scoring  of cores on  a 
tissue array will increase the objectivity of the results.
In  terms  of  melanoma  research,  many  more  avenues  remain  to  be  explored,  even  with  the 
markers  studied  in  this  thesis.  Tissue  microarrays  may  be  constructed  purely  of  melanoma 
subtypes,  such  as  acral  lentiginous  or  nodular melanomas to  determine  any specific trends and 
peculiarities  within  melanoma  subtypes.  Arrays  of  intermediate  depth  melanomas,  of  which 
Breslow thickness does not predict outcome, could be made which would assist in the discovery of 
other  markers  that  will  improve  the  accuracy  of  the  prediction  of  patient  outcome.  Another 
possibility is a tissue microarray of lymph node metastases.  Indeed, if an array was constructed of 
lymph node metastases, it would be possible to study correlations between staining  for certain 
markers and the effectiveness of chemotherapeutic regimes in clinical trials.  In this way,  it would
257be possible to delineate sub-groups of patients who respond well to particular regimes, which may 
then  be started  at the  earliest  possible opportunity after sentinel  lymph  node  biopsy.  This could 
lead  to  improved  response  rates  and  possibly  even  remission  from  metastatic  disease,  not 
currently possible.
The tissue microarray also provides an opportunity to investigate other tumours.  Of interest is the 
study of prognostic markers in relation to cutaneous squamous cell carcinoma (SCO).  Cutaneous 
SCC is a tumour within the plastic surgeon’s remit that has not been extensively studied, despite of 
having an age-adjusted incidence of 100-150 per 100,000 persons per year (Alam & Ratner 2001). 
High  risk  cutaneous  SCCs  are  defined  by  their site,  diameter,  depth,  histological  differentiation, 
host  immunosuppression  and  previous  treatment  modality  (Motley  et  al.,  2002).  On  the  other 
hand, SCC of the head and neck has been studied for various prognostic markers, but these have 
not yet been studied  in  cutaneous SCC.  Examples of markers with an association with head and 
neck  SCC  are:  CD44  splice-variant  isoforms,  which  may  be  down-regulated  (Assimakopoulos et 
al.,  2002);  epidermal growth factor receptor;  transforming growth factor alpha and  cyclin  D (Quon 
et al., 2001; Smith et al., 2001).
The identification of a  cellular marker correlated with early metastasis and an aggressive disease 
course would be invaluable in the management of cutaneous SCC.  If such SCCs were identifiable 
at the time of first excision, surgical management could be altered in an attempt to improve patient 
outcome.  Currently  it  is  recommended  that for clinically well-defined  low-risk tumours  less than 
2cm  in diameter,  surgical  excision  with a 4mm  margin  is appropriate, whereas  in  larger or higher 
risk  tumours,  margins of at I east 6 mm a re advised ( Motley  et a I., 2002).  V arying  the width of 
excision  margins  is  one  example  of  how  an  aggressive  SCC  may  be  locally  controlled  at  the 
earliest  opportunity.  If  more  accurate  identification  of  high-risk  tumours  was  possible,  some 
patients may be spared potentially unnecessary aggressive surgical treatment.
2587.4  RADIOIMMUNOSCINTIGRAPHY
Several  melanoma-specific  monoclonal  antibodies  and  anti-HMW-MAA  monoclonal  antibodies  in 
particular have been used successfully for radioimaging of melanoma patients (Herlyn et al.,  1988; 
Siccardi et al.,  1990).  Most of the problems encountered with antibody radioimaging (human anti­
mouse  response,  slow  blood  clearance,  accumulation  in  normal  organs)  are  caused  by  the 
relatively large size of the monoclonal antibodies.  ScFv fragments are the smallest functional units 
of antibodies that contain the complete antigen-binding  site.  Their relatively small size, the ability 
to  produce  them  in  functional  form  in  the  bacterial  periplasm,  as  well  as  their  potential  use  in 
immunoscintigraphy  and  immunotherapy  makes them  an  interesting  tool for protein  engineering. 
Whether  cloned  from  hybridomas  or  obtained  from  phage  libraries,  scFvs  can  show  poor 
production  yields  and  exhibit  low thermodynamic stability,  thereby  limiting  their usefulness for in 
vivo applications even if they have excellent affinities and tumour specificity (Willuda et al., 1999).
Limited  stability remains  one  of the drawbacks,  preventing  the everyday use of scFvs  in  medical 
and biotechnological applications.  Whilst the qualities required for in vitro stability are beginning to 
be elucidated,  those for in  vivo stability remain to be defined  more  clearly.  In  humans stability is 
not  only  influenced  by  thermal  aggregation,  but  also  by  blood  clearance,  proteolysis  and  other 
effects.  The  optimal  functional  parameters  of  these  molecules,  such  as  the  required  stability, 
molecular  weight  and  affinity  are  not  fully  understood  and  have  to  be  optimised  empirically 
depending  on  the  diverse  clinical  requirements.  It will  therefore  be  important to  understand  the 
molecular basis  of these factors  to enable  the  routine  use  of scFvs  in  melanoma  patients  in the 
future.
7.5  ANTIBODY COCKTAIL
The  use  of  a  cocktail  of  single  chain  (Fv)  antibody  fragments  directed  against  three  different 
melanoma-specific  antigens  holds  much  promise  for  improving  tumour  targeting.  The  present 
study demonstrated  improvements  in  melanoma  binding  in  vitro  and  improvements  in  tumour to
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antigenic heterogeneity  in  patients.  However,  the  in vivo results did  not improve on those of the 
individual  components  of  the  cocktail  as  much  as  was  hoped.  This  was  most  likely  due  to 
insufficient quantity of scFv used for the experiments, which did not allow saturation of the tumour 
binding sites.  Nevertheless this strategy promises to be one that may prove useful for therapeutic 
applications.
7.5.1  Future directions
The cocktail strategy could  be used for therapeutic applications in several ways.  Combinations of 
scFvs to distinct determinants of HMW-MAA may be useful as carriers of distinct components of a 
therapeutic system (e.g. two chains of a toxin), which have to be delivered in close proximity at the 
cell surface, so that they may assemble and function in selected areas of high antigen expression. 
Another example would  be the use of two different scFvs with appropriate molecules attached that 
would  in-turn stimulate complement-mediated cytotoxicity and  cell-mediated cytotoxicity and/or an 
immune response.
Other advantageous properties of scFvs also need to be further exploited.  Increasing the yield of 
RAFT scFvs  in an  attempt to produce saturating quantities could  be achieved  by the use of large 
fermenter-based  production  systems.  Recently,  improved  yields  have  been  reported  using  heat- 
inducible  vectors,  which  may  further enhance  scFv  expression  (Power  &  Hudson  2000).  Other 
authors have described  the  successful  employment of yeast cells for markedly increased  protein 
production (Freyre et al., 2000).
7.6  SCFV MULTIMERS
ScFv multimers have been used as a strategy to improve tumour targeting by means of improving 
tumour retention  and  blood  clearance as well as a  means of reducing  kidney accumulation.  The 
study undertaken for this thesis  has shown  them to be effective for the former,  but not the latter. 
The bi-valency of the dimers resulted in excellent tumour accumulation resulting in good tumour to
260normal  tissue  contrast.  However,  the  problem  of renal  accumulation  remained.  From this work 
and the work of others,  it seems likely that size alone can therefore not be the only reason for the 
high kidney accumulation of scFvs.
7.6.1  Future directions
Alternative strategies aimed  at reducing  renal accumulation were discussed  in chapter 6.  One of 
the most promising  strategies is to alter the electric charge of the scFvs.  By creating a series of 
scFvs with similar properties, such as thermal stability and size, but with different isoelectric points, 
it will  be  possible  to determine the  influence  of charge on  renal  accumulation.  It is  possible that 
the “ideal scFv”  is a  multivalent molecule of low isoelectric point that will exhibit excellent tumour 
retention,  rapid  blood  clearance  and  little  kidney accumulation.  This  might open  the way for the 
development  of m ore t herapeutic  constructs,  which  should  cause  little  nephrotoxicity  due  to  its 
short kidney residence time.
Most scFvs  are  positively charged  and  are difficult to convert into  negatively charged  constructs, 
although Ronda et al.  have demonstrated that it can be done (Onda et al., 2001).  However, Onda 
et al.  did  not  look  at  biodistribution,  only  at  toxicity  in  mice.  Goel  et al.  also  used  a  negatively 
charged scFv with a  c-terminal  (glu)5 tail and  did  look at biodistribution  but this scFv did  not have 
reduced  renal  accumulation.  Nevertheless,  these effects  merit further study in the context of the 
RAFT scFvs.
Bispecific multimeric  scFv  molecules  capable  of recruiting  T-cell  or complement  responses  have 
been developed in other tumour  models  (Holliger  etal.,  1  993;  Kipriyanov  etal.,  1998).  These 
molecules are relatively simple to design and could be applied in the setting of melanoma.  Finally, 
one group has recently reported successful tumour eradication in a colon carcinoma mouse model 
by the  combination  of an  anti-vascular agent and  an  iodine-131  labelled  antibody  (Pedley et al., 
2001).  Such  combinatorial  treatments  may  represent the way forward  in  antibody-based  tumour 
therapy.  It is clear that many potential therapeutic approaches are available and the versatility of 
scFvs is a particular strength in this regard.
2617.6.2  Pretargeting Strategies
Another  approach  would  involve  pretargeting  strategies  in  which  an  unlabelled  bispecific  scFv 
(with one binding site targeting melanoma and the other binding site reacting with a small hapten) 
is administered  first (Goodwin &  Meares 1  997).  A t a  later point  when  the circulating unbound 
antibody  levels are low  and tumour targeting is optimal, a  radiolabelled hapten is administered 
which localises to the antibody bound to the tumour, thereby reducing the radiation dose to normal 
tissues.  This pretargeting approach can be modified further by conjugating streptavidin or biotin to 
the  pre-administered  antibody,  followed  by  the  injection  of  radiolabelled  biotin  or  streptavidin, 
respectively  (Paganelli  et  al.,  1995).  More  recently  a  three-step  regime  has  been  developed, 
where biotinylated antibody is given first, followed by an avidin and/or streptavidin chase (2n d  step), 
and  finally  by  radiolabelled  biotin  (3rd   step).  This  multistep  approach  has  yielded  impressive 
results  in  pre-clinical  studies  in  animal  models,  when  compared  to  conventional  one-step 
radioimmunotherapy,  and  has  been  tested  in  clinical  trials  (Paganelli  et  al.,  1999). 
Radioimmunotherapy would be of great value for melanoma patients with a high risk of developing 
distant metastases.
7.6.3  PEGylation of ScFvs
It  has  been  shown  that  chemical  modification  of  scFvs  with  PEG  (PEGylation)  can  result  in 
molecules with properties similar to Mabs that allow delivery of much higher doses to tumours (Lee 
et  al.,  1999).  mPEG  (Shearwater  Polymers)  has  a  molecular  weight of 20-40  kDa  and  can  be 
cross-linked  to scFvs  (King  et al.,  1994).  This strategy should  prolong the serum  residence time 
and thus increase the  initial tumour dose, with only a moderate increase in the antibody fragment 
size.  As a  result  it would  be expected  that the  %ID/g  in the tumour is  increased.  PEGylation  in 
combination  with  tumour pretargeting  with  the  biotin/streptavidin  system  could  therefore  confer a 
therapeutic potential to scFvs.
2627.6.4  Immunotherapy
Antibody  fragment-based  therapy  for  melanoma  is  still  in  its  infancy.  Several  animal  studies  in 
other tumour  models  have  been  highly  promising.  For  example,  combining  scFv with  immuno- 
active  agents  such  as  interleukin-2  (Melani  et  al.,  1998)  or  radiotherapeutic  nuclides  such  as 
iodine-131  (Goel et al., 2001) has been encouraging.  The potential of gene therapy in cancer has 
received much attention recently yet the problem of efficient targeted delivery has still to be solved. 
RAFT scFvs  have  been  used  to target retroviral vectors to  melanoma  cells in  vitro (Martin et al., 
1999) and in vivo (Chowdhury et al., 2004).
The  project is now working on a clinical imaging trial,  using  radiolabelled  3A11   monomer.  A pilot 
trial will  initially be conducted  on  20 patients with stage  III  melanoma.  Radioimmunoscintigraphic 
scans will be compared with CT scans and other imaging modalities to determine the effectiveness 
of radioimmunoscintigraphy with  RAFT  scFvs  as  an  imaging  mode  to  be  introduced  into  routine 
practice.
7.7  CONCLUSION
In  conclusion,  this  thesis  has  shown  that  secondary  prevention  is  a  successful  strategy  for 
improving  melanoma  outcome,  several  novel  markers  of  melanoma  progression  have  been 
identified and the work on scFvs has enhanced the targeting of melanoma in the animal model and 
brought the  clinical  trial  significantly  closer.  Further improvements  in  targeting and  reduced  renal 
accumulation  will  hopefully  unlock  the  potential  of  these  exciting  molecules  for  the  therapy  of 
metastatic melanoma.
263ABBREVIATIONS
ADCC Antibody Directed Cell Mediated Cytotoxicity
AJCC American Joint Committee on Cancer
ATCC American Tissue Culture Collection
CDR Complementarity-Determining Region
Cps counts per second
Cpm counts per minute
EDTA Ethylene diaminetetra-acetic acid
ELISA Enzyme Linked Immunosorbent Assay
ELND Elective Lymph Node Dissection
F(ab')2 100 kDa antibody fragment
F(ab) 50 kDa antibody fragment
Fc Constant region fragment
Fv Variable region fragment
(His) 6 6 Histidine amino acid residues at the C-terminus of scFv for IMAC
HMW-MAA High Molecular Weight Melanoma-Associated Antigen (proteoglycan)
HPLC High Pressure Liquid Chromatography
ig Immunoglobulin
igGi Immunoglobulin (isotype G Class 1)
I MAC Immobilised Metal-lon Affinity Chromatography
ISG Immunoscintigraphy
Ka Association constant for equilibrium binding of antibodies
Kd Dissociation constant for equilibrium binding of antibodies
KDa Kilodalton
KeV Kilo-electron Volt
MAA Melanoma Associated Antigen
Mab Monoclonal Antibody
PCR Polymerase Chain Reaction
PEG Poly-Ethylene Glycol 6000
PET Positron Emission Tomography
Pi Isoelectric point
264rPL  Recombinant Protein-L column
rpm  Revolutions per minute
RAFT  Restoration of Appearance and Function Trust
RIS  Radioimmunoscintigraphy
RIT  Radioimmunotherapy
RT  Room Temperature
ScFv  Single-chain Fv Antibody Fragment
SDS-PAGE  Sodium Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis
SLNB  Sentinel Lymph Node Biopsy
SPECT  Single Photon Emission Computerised Tomography
T  ris  T  ris(hydroxymethyl)aminomethane
Tween 20  Polyoxyethylene-sorbitan monolaurate
t1/2a  Distribution half-life
t1/2p  Elimination half-life
VH   Heavy chain variable  region
VK   Kappa chain variable  region
VL   Light chain variable region
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